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Abstract 
 
Primary total knee arthroplasty (TKA) for end-stage osteoarthritis (OA) is a surgical 
procedure with a long history of successful outcomes. However, one fifth of patients 
report dissatisfaction with the outcome of surgery which results from a combination 
of factors including poor functional improvement. This research examined the 
functional elements of recovery, with a focus on the role of skeletal muscle. The pain 
of OA normally limits activity; if the pain is relieved by TKA, any disuse atrophy 
associated with the OA has been reported in some patients to improve 
postoperatively with an eventual strengthening. Quadriceps muscle group strength 
is correlated with activities of daily living (ADLs). Myogenesis is complex but 
facilitated by muscle precursor stem cells; mainly muscle satellite cells. An 
individual’s skeletal muscle phenotype contributes to their physical recovery 
following surgery. Many factors have been reported as individually influencing 
skeletal muscle phenotype, but patient specific clinical data is lacking to evaluate 
these. In this study, these factors were examined in a primary TKA population to test 
the hypothesis that specific preoperative and perioperative muscle factors and 
patient background characteristics affect outcome, with the aim of indicating which 
patients might benefit from targeted treatment. 
 
Seventy-two patients listed for primary TKA were recruited to a single centre 
longitudinal observational cohort study. The participants underwent preoperative 
interview and assessment, provided a quadriceps skeletal muscle sample at time of 
surgery and completed a range of functional assessments and outcome reports 
during their recovery until 12 months following their operations. 
 
Muscle biopsies were analysed to determine morphometric and gene expression 
levels for each patient. Immunofluorescence histology identified muscle fibre type 
profiles, and quantitative real-time polymerase chain reaction (qPCR) determined 
relative translational profiles for myogenic, inflammatory, and senescent gene 
markers. GeNorm methodology identified 3 reference targets as optimal, and EIF4A2, 
UBC, and GAPDH were noted as the most stable (M=0.55) within the target superficial 
vastus medialis skeletal muscle tissue in the TKA cohort population. Patient 
functional performance was evaluated in outpatient hospital research clinics using a 
battery of functional tests in tandem with patient reported outcome measures 
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(PROMs) tools. Patient function was also evaluated in a sub-cohort in the community 
setting using activity monitoring devices. 
 
Different temporal trends were observed between functional measurements. 
Substantial variation was observed in the response trajectory of functional metrics. 
Patients perceived that they meaningfully improved earlier than was observed 
through directly measured functional performance. Compared to preoperative 
values, by 12 weeks post-op, patients had achieved 82% of final (12 months post-op) 
PROM score, 63% of final leg power, 63% of final ADL performance, and 5% of final 
daily step count. The values further increased by 6 months post-op with PROM score 
increase at 92% of final score, leg power at 94% final, ADL at 116% final, and daily 
step count at 110% of final value. These findings highlighted the utility of using a 
combination of diverse metrics to evaluate patient functional outcome and showed 
that patient evaluated outcome alone may not fully represent early functional 
outcome. They also emphasise the critical nature of the follow up time points chosen 
for clinical trials. 
 
Patient background characteristics (demographic, health, and lifestyle factors) were 
contrasted with patient functional performance and skeletal muscle phenotype using 
univariate and exploratory multivariate regression modelling. Relationships were 
identified between patient preoperative baseline factors and post-surgical outcomes, 
with an observed R2 range of 0.14-0.31 (p≤0.05). Associations were found between 
background characteristics and physiological phenotypes at time of surgery (R2 0.11-
0.29, p≤0.06). Influences were identified from perioperative physiology on early or 
primary end-point surgical outcomes, with distinct contributions from certain 
molecular profiles and skeletal muscle fibre phenotypes (R2 0.09-0.24, p<0.05). 
Models constructed using patient preoperative function combined with preoperative 
PROMs parameters provided the strongest prediction of surgical primary functional 
outcomes (R2 0.28-0.73, p≤0.006). 
 
The results provided new insights into the relationship between functional metrics 
during early recovery post-TKA. The study identified a variety of demographic and 
muscle related factors which significantly affect patient early surgical outcomes in 
primary TKA populations. 
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Lay Summary 
 
Total knee replacement for osteoarthritis (OA) is a surgical procedure with a long 
history of successful outcomes. However, one fifth of patients report dissatisfaction 
with the outcome of surgery which results from a combination of factors including 
poor functional improvement. This research examined the functional elements of 
recovery, with a focus on the role of skeletal muscle. The pain of OA normally limits 
activity; if the pain is relieved by joint replacement, the muscle wastage associated 
with OA has been reported in some patients to improve postoperatively and 
eventually strengthen. Quadriceps muscle group strength is correlated with activities 
of daily living (ADLs). The formation of muscle is complex but facilitated by stem cells; 
mainly muscle satellite cells. An individual’s skeletal muscle type contributes to their 
physical recovery following surgery. Many factors have been reported in laboratory 
research as influencing skeletal muscle type, but there is a lack of clinical evidence to 
confirm this in human patients. In this study, these factors were examined in a knee 
replacement population to evaluate if the factors found before or at the time of 
surgery affect patient outcome, with the aim of indicating which patients might 
benefit from targeted treatment. 
 
Seventy-two patients listed for knee replacement were recruited to a cohort study 
where they would be observed over time at a single hospital site. The participants 
were interviewed and assessed before surgery, had a muscle sample taken at time of 
surgery and completed a range of functional assessments and questionnaire reports 
during their recovery until 12 months following their operations. 
 
Muscle samples were analysed to determine structural and genetic characteristics 
for each patient. This included the muscle sub-types and sizes, genetic markers of the 
level of muscle turnover and repair, and genetic markers of the levels of inflammation 
and cell ageing. Patient functional performance was evaluated in outpatient hospital 
research clinics using a battery of functional tests in tandem with patient 
questionnaires. Patient function was also evaluated in a sub-cohort in the community 
setting using activity monitoring devices. 
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Different trends were observed between functional measurements over time. 
Substantial variation was observed in the rate of change of functional metrics. 
Patients perceived that they meaningfully improved earlier than was seen through 
directly measured functional performance. These findings highlighted the usefulness 
of a combination of metrics to assess patient function following knee replacement 
and show that questionnaires alone may not fully represent patient function. They 
also emphasise the importance of the choice of follow-up time-points in clinical trials. 
 
Patient background characteristics (demographic, health, and lifestyle factors) were 
contrasted with patient functional performance and muscle type using statistical 
modelling. Relationships were found between certain patient characteristics before 
surgery and how patients recovered. Associations were discovered between 
background characteristics and muscle sample characteristics at time of surgery. 
Influences were identified from time of surgery muscle characteristics and how 
patients recovered. Statistical models made with patient functional performance and 
questionnaire answers before surgery predicted up to 73% of how they recovered 
from their operation. 
 
The study results provided new insights into the relationship between patient 
functional metrics during early recovery following knee replacement surgery. The 
study identified a variety of demographic and muscle related factors which 
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One in five patients that undergo knee replacement surgery are dissatisfied with the 
outcome, amounting to 15,000 dissatisfied patients annually in the UK alone (1),. 
Dissatisfaction with surgery is largely attributed to unmet preoperative expectations, 
a lack of pain relief, and a disappointing hospital experience (2). A patient’s recovery 
from surgery and their resulting functional ability are central themes in these factors. 
Developing further understanding of these areas can eventually allow for a reduction 
in dissatisfaction. 
 
Short term recovery focuses less on joint health and articulation but instead on the 
ability of the patient to mobilise, regain independence and gain competence in 
activities of daily living. The anatomical driver of this function is the level of 
neuromuscular recovery of the supporting musculature around the operated joint. 
This research focuses on the muscular aspect of this recovery. Effective recovery of 
the major weight bearing muscles of the lower limb is key to this recuperation. These 
muscles have to overcome both wasting from immobility and damage from surgery 
(3). The focal time of muscular recovery after total knee arthroplasty (TKA) is 
between six weeks and six months. Effective muscular recovery in this time frame 
can mean the return to a level of function not achieved for many years. This is 
frequently seen in osteoarthritic patients who have undergone knee arthroplasty 
surgery (4). 
 
An influence on this early time within routine clinical practice is that of clinic-based 
and take-home physical therapy regimes. However even these do not always result 
in a guaranteed recovery of function (5). The function and power of the quadriceps 
muscle group are associated with Activities of Daily Living (ADLs) performance during 
recovery following knee surgery (6,7). The failure of this muscle group to recover 
function following TKA can result in an inability to perform ADLs and be termed poor 
surgical outcome. This poor outcome has previously been partially predicted using 
social, psychological and clinical estimations (8). However, the ability to predict poor 
outcome may also be improved with a deeper understanding of a patient’s muscle 
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physiology by using quantified physiological markers of muscle regenerative ability. 
Examples of these markers include growth factors, cytokines, immune responses, and 
other cell metrics (9). Some of these promising markers relate to the muscle 
precursor cell, the muscle satellite cell. 
 
Muscle satellite cells are the precursors to myoblasts, myocytes, and myotubes. 
Much investigation into the cell type in recent years has been performed through in 
vitro study and in vivo rodent modelling. Though allowing for high volume of 
experiments, relatively low research costs and tight control of variables, it is 
acknowledged that all findings do not directly translate into human physiology (10). 
 
The muscle research that has taken place in humans is largely split between young 
elite sporting (11) and muscular dystrophy populations (12). These groups have 
multiple factors that are unconnected to the average primary knee arthroplasty. For 
example, the sporting population have a clear training history and ongoing training 
regime, and the dystrophic populations have a clear genetic nature. 
 
With a healthy muscle satellite cell population linked to superior regeneration and 
performance in mouse models and performance sporting cohorts, substantial 
investigation of the concept has yet to be performed in a geriatric lower limb 
arthroplasty population. 
 
Within the population regularly seen for knee arthroplasty surgery, there are lifestyle 
choices and patient demographics that are closely linked to recovery patterns 
(13,14). Examples are smoking, high levels of alcohol consumption, a sedentary 
lifestyle, and obesity. Pre-emptive rehabilitation, or prehab, where strengthening 
exercises are performed prior to surgery, is widely performed but lacks evidence (15). 
These factors are yet to be looked at in relation to their effect on muscle satellite cells 
in a human post-total knee arthroplasty population.  
 
While not routinely an acute life or death scenario, a poor functional outcome 
following TKA can result in a patient’s reduced ADL capability to the point of extreme 
disability. By identifying patient background characteristics or muscle physiological 
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targets for therapeutic intervention or clinical care optimisation, the incidence of 
these outcomes can be reduced in future clinical practise. 
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Study Overview 
 
This thesis centres around a longitudinal cohort study of osteoarthritic patients who 
underwent primary total knee replacement surgery. The study aimed to investigate 
factors affecting surgical outcome, focussing on patient demographics and patient 
thigh muscle and physiology at time of surgery. Key analytical tools to assess outcome 
included patient reported outcome measures (PROMs) and direct functional tests. 
The cohort’s muscle samples were also analysed in the laboratory using a battery of 
investigations. 
 
116 patients were screened for eligibility, 92 patients were approached, and 72 
patients agreed to take part in the study. There were 3 cohorts within the study with 
varying levels of follow-up interaction and data collection. Study data were examined 
with a focus on patient background characteristics, their relationship to patient 
muscle physiology, and the physiological relationship of muscle with patient 
functional outcomes. 
 
Overview of Collected Study Data 
 
Data collection time-points: Surgical Pre-assessment Clinic (PAC: 2-6 weeks pre-op), 
6 weeks post-op, 12 weeks post-op, 6 months post-op, 12 months post-op. The 
categories of collected study data are represented in Table 1. 
 
Table 1 – Overview of collected study data categories. 
Data Category Measurements 
Direct Measurements Leg Power, ALF Score, BMI, BEI, ROM, Daily step 
count, HR, Sleep quality. 
Patient Reported Assessments OKS, EQ-5D, KOOS, FJS, Pain scores, Complications, 
Rehabilitation, Experience, Satisfaction. 
Muscle Biopsy Laboratory 
Assessments 
Histological (IF): Fibre type, fibre size. 
Gene expression (qPCR): Myogenesis, inflammation, 
and senescence groupings. 
Patient Baseline Factors Basic demographics, Vocational history, current and 
historic activity levels (Tegner), smoking history, 
alcohol history, orthopaedic treatment history, 
SIMD quintile, Dominant side, K&L radiographic 
score, CCI, blood results. 
ALF – Aggregated Locomotor Function, BMI – Body Mass Index, BEI – Bioelectrical Impedance, ROM – Range of movement, OKS – Oxford 
Knee Score, EQ-5D – EuorQol 5 Dimension, KOOS – Knee Injury and Osteoarthritis Outcome Score, FJS – Forgotten Joint Score, IF – 
Immunofluorescence, qPCR – quantitative polymerase chain reaction, SIMD – Scottish Index of Multiple Deprivation, K&L – Kellgren and 
Lawrence, CCI – Charlson Comorbidity Index. 
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Chapter 2: Literature Review 
 
Scientific 
Muscle Development and Repair 
 
The musculoskeletal system enables human mobility and autonomy in activities of 
daily living (ADLs). The failure of skeletal muscle tissue, whether from acute local 
trauma or systemic chronic pathology, is detrimental to the affected individual. 
 
Early Muscle Development and Repair 
Prenatal myogenesis basics 
 
Human skeletal muscle first develops from the dermomyotome within the somite 
during embryonic development. Precursor cells react to signals from surrounding 
tissue and commit to the muscle lineage in their anatomical niche (16). 
 
Foetal myogenesis is driven by the Wnt, sonic hedgehog (Shh), and bone 
morphogenetic proteins (BMP) pathways which regulate the expression of the 
myogenic regulatory factor transcription factors (MRFs). These initial embryonic 
muscle precursor pathways and cells differ to the pathways in postnatal muscle tissue 
(17). Prenatal muscle precursor cells are named myogenic precursor cells (MPCs) and 
postnatal cells are muscle satellite stem cells (MuSCs). 
 
The MRFs consist of myogenic regulatory factor 5 (Myf5), myogenic determination 
factor 1 (MyoD), myogenin (MyoG), and herculin also known as myogenic regulatory 
factor 4 or myogenic regulatory factor 6 (Myf4/Myf6). These factors share functions 
and govern the process from developmental lineage commitment to proliferation 
and differentiation. Paired box transcription factor 3 (Pax3), paired box transcription 
factor 7 (Pax7), sine oculus (Six), and eye absent (Eya) signalling proteins are also 
involved in the prenatal myogenesis process (18). 
 
This combined pathway transforms MPCs into embryonic and foetal myoblasts that 
combine to form skeletal muscle fibres, with MuSCs appearing at the end of 
embryonic development. 
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Postnatal myogenesis, hypertrophy, and repair is governed by different pathways, 
with MuSCs and related signalling pathways playing the most important roles in the 
processes of skeletal muscle tissue construction and repair (19). 
 
Skeletal muscle is the most abundant type of muscle in the body. It is structured into 
groupings of hierarchical bundles, built up from the basic unit of the myofilaments 
eventually into groups (Figure 1). Myofilaments perform the voluntary contractions 
that defines skeletal muscle function in the body. They are grouped into myofibrils, 
which are grouped into myofibres, which are clustered into fascicles, which make up 
a muscle. Extensive connective tissue matrices surround each of these groupings, 
comprised mostly of collagens. 
 
 
Figure 1 - Hierarchical structure of skeletal muscle. Figure adapted from The Netter Collection of Medical 
Illustrations(20). 
Skeletal muscle tissue is extensively vascularized and innervated to allow for efficient 
respiration and nervous control. 
 
Nerve action potentials in the somatic peripheral nervous system cause 
neuromuscular junction depolarization at the motor end plate where the nerve and 
muscle tissue interface. The depolarization of the neuromuscular junctions is relayed 
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via the t-tubules and the sarcoplasmic reticulum along the length of each myofibril 
to allow for simultaneous contraction within each sarcomere unit of myofilaments. 
 
The classical process of contraction, described as the sliding-filament or cross-bridge 
model is facilitated by several steps, beginning with the depolarization causing 
calcium ion release which bind to troponin on thin filaments. The thin filaments are 
anchored to the Z-bands which border each sarcomere. When troponin is bound it 
reveals neighbouring tropomyosin which allows adenosine tri-phosphate (ATP)-
bound myosin heads on thick filaments to bind to actin on thin filaments. Next, 
ATPase severs ATP into adenosine diphosphate (ADP) and phosphate, with the 
resulting energy moving the position of the myosin heads. These pull on the actin 
causing a shortening of the sarcomere unit. The binding of a new ATP molecule to 
the bound myosin head group releases the actomyosin complexes and allows 
relaxation. 
 
However, there are some anomalies in the cross-bridge theory of eccentric skeletal 
muscle contraction and recent findings have identified the prominent role of titin 
protein in active and passive contraction. The three-filament model helps to explain 
residual force enhancement, where isometric contraction force is larger following a 
muscle stretch. This is particularly observed during eccentric contractions. Titin 
exhibits elastic properties which contribute energy into the sarcomere contraction 
process in addition to the actomyosin cycles (21–23). 
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Adult Muscle Development and Repair 
Postnatal Myogenesis Basics and Healthy Turnover 
 
Postnatal human skeletal myogenesis is facilitated in the vast majority of 
circumstances by Muscle Satellite Cells (MuSCs). Myogenic regulatory transcription 
factors (MRFs) continue to mediate the process of skeletal muscle repair and 
hypertrophy in reaction to physical conditioning, damage, or environmental stimulus 
(19). 
 
MuSCs exist in several states depending on these signals. They can be quiescent and 
mitotically dormant, they can proliferate, and they can differentiate to fuse into 
myofibers (24). Figure 2 shows the large heterogeneity of states and expression 
profiles and lineages of MuSCs.  
 
Figure 2 - Muscle satellite cell state variation and lineage progression with corresponding transcription factor 
expression profiles. Figure adapted from Bentzinger et al 2012 (25). 
 
When proliferating, the cell division axis and polarity determines whether the 
outcome is two daughter MuSCs, or one daughter MuSC and one cell committed to 
myogenic differentiation (26–28). Symmetric division serves to replenish the MuSC 
pool and asymmetric division serves to repair or grow the myofibers. Along with the 
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MRFs: Myf5, MyoG, MyoD, and Myf4/Myf6, the Pax7 transcription factor plays a 
major role in the postnatal myogenesis pathway. 
 
Adult MuSCs’ can be identified by their transcription factor expression. MuSCs in the 
quiescent state express Pax7 and Myf5 but not MyoG or MyoD. MuSCs that are 
proliferating into myoblasts express Myf5 and MyoD. A myogenically committed cell 
can be identified through the process of fusion and expressing less Pax7, and 
upregulation of MyoD and MyoG. This myocyte phenotype allows fusion to occur in 
order to repair the myofibre. Newly formed myofiber segments can be identified by 
their centrally located nuclei. In healthy muscle, the nuclei migrate to the edge of the 
fibre and are identical to surrounding undamaged fibres (29). 
 
Thus, markers and molecular analysis techniques can be made to identify MuSCs in 
their specific states. Pax7 can be used to identify MuSC abundance, MyoD and Myf5 
can be used to identify early myogenesis, and MyoG can be used to identify late 




Myonuclear domain theory describes how each myonucleus can cover a finite muscle 
fibre cytoplasmic volume for effective protein transcription. Previously, this volume 
was thought to be fixed (>25% cross sectional area (30)) beyond which MuSC activity 
such as nuclear donation was required. However, there is now thought to be more 
flexibility depending on the nature of the muscle hypertrophy or atrophy (31). 
 
Muscle fibre type is a classification that characterises the composition, phenotype 
and function of a muscle cell. It is mostly based upon the myosin heavy chain 
composition that makes up the myosin filaments of the fibre. In humans, the major 
classifications of fibres are type 1 or type 2, of which there are distinct subtypes 
(32,33). Type 1 fibres, known as slow-twitch fibres for their relatively slower 
contraction time, have low glycolytic, high oxidative properties, and are known for 
their aerobic endurance capacities. Contraction time variances exist due to 
differences in the time that actin is bound to myosin. Type 2 fibres, known as fast-
twitch, contrastingly have high glycolytic and low oxidative characteristics, though 
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subtypes express variation. Type 2 subtypes include 2A, 2B, and 2X, and overlapping 
combinations exist resulting from hybrid isoforms of the myosin heavy chain protein 
(34). Unstained visual differences can be discerned between the two major types due 
to the difference in myoglobin content, with type 1 fibres having a darker red 
appearance. There are known differences in force generation between the fibre 
types; Type 2 fibre types contract with greater force per cross-sectional-area (35). 
 
Fibre hypertrophy can occur without the presence of MuSCs, as demonstrated in 
some Pax7 knock-out rodent model studies (36). This has reported to be fibre-type 
dependent and is only witnessed in type-II fibres. Extensive fibrosis was observed in 
tandem with the fibre hypertrophy. However this has yet to be observed in human 
studies (36). Current observations indicate that type-I fiber hypertrophy can only 
occur with differentiated MuSC fusion. This highlights the complexity of the role that 
MuSCs play within local extracellular matrix (ECM) regulation in coordination with 
fibroblasts and other cell types. 
 
The muscle fibre type is determined based on developmental processes. Much 
understanding of the processes has recently been developed through fish models. 
They are discussed in Rossi’s review from 2014 (37), however many of these 
pathways have yet to be confirmed in humans. Generally, fibre type is based upon 
developmental regulation involving Sox6, Pbx and Prdm1a transcription factors. 
Processes also exist to ensure heterogeneity in a muscle grouping for functional 
purposes. The majority of this occurs during embryonic stages based on genetics and 
maternal nutrition, but also continues through childhood in response to external 
stimuli. Fibre typing can also occur to some extent through a fibre plasticity response 
to specific stimuli during adult life (38). A typical example is the transition from type 
1 to type 2X in response to a resistance exercise program, and also from type 2 to 
type 1 in limb lengthening (39). The signalling pathways for the remodelling process 
in adulthood are outlined in Bassel-Duby’s review from 2006 (40). Innervation is 
required for plasticity changes, and muscle fibres default to type 1 in response to 
denervation. A muscle group typically has more than one fibre type but different 
muscle groups are comprised of different fibre type ratios due to their varied 
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functions (41). A group involved in holding body posture will have a greater 
percentage of oxidative fibres. 
 
Differences in the molecular composition of each fibre type can help to identify each 
isoform. Type 1 fibres express myosin heavy chain type 7 (MyH7) protein, type 2A 
express myosin heavy chain type 2 (MyH2), and type 2X express myosin heavy chain 
type 1 (MyH1) (34). 
 
Historic studies have shown that elderly individuals show reduced muscle mass and 
changes in their fibre compositions (42). This typically takes the form of a reduction 
in the size and percentage of type 2 fibres. This has been used as a marker of aged 
muscle compared to young, however it does not correlate with all humans once a 
certain age is reached. For example, not all individuals over 50 years old display the 
same phenotype, but the average at age 70 shows reduced mass, particularly 
amongst type 2 fibres, compared to the average 20-year-old (43). Other factors are 
therefore thought to contribute, such as genetics and lifestyle choices, leading to 
differences in chronological and biological age at this stage in life (44). 
 
Myogenic Progenitors – A more complex picture 
 
Other cell types (as well as MuSCs) have recently been identified as playing direct and 
indirect roles in the adult skeletal myogenesis. These include pericytes, PW1+ 
interstitial progenitor cells (PICs), fibroadipogenic (FAPs) also known as mesenchymal 
progenitors (MPs), CD133+ cells, muscle side population cells (MPs), and 
myoendothelial cells. Some of these have been suggested as having potential in cell 
therapeutics as the properties of MuSCs change ex-vivo which limits their use (45). 
Additional endogenous cells such as myeloid cells, endothelial cells, and fibroblasts 
also can contribute towards related signalling pathways (46). 
 
Pericytes have been observed playing a role in the myogenesis process. A pericyte 
subpopulation expressing tissue non-specific alkaline phosphatase (TNAP) has been 
observed contributing to skeletal muscle in mice (47). These pericyte-derived 
mesoangioblasts have been observed contributing to the satellite cell pool during 
regeneration in vitro (48). However, when investigated with human clinical trial cell 
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transplantation, they had low efficacy with the cell lineage failing to manifest (49). 
The contributions of these pericytes in humans is yet to be directly observed. 
 
FAPs or MPs are different to mesenchymal stem cells (MSCs). They can contribute 
under certain circumstances to myogenesis. They have been termed “promyogenic” 
as their function in controlling the extra-cellular matrix is also key to the repair 
process (50). In vitro FAPs have been observed to change into myoblasts, but this has 
not been observed in humans (50). 
 
PICs stand out amongst the other promyogenic cell populations as also contributing 
directly to the satellite cell pool. They originate from a different lineage from 
embryonic MuSCs and can differentiate into MuSCs and adipocytes (48). 
 
The resulting interactions between each of these cell populations and the exact role 
each plays in myogenesis still requires much elucidation. However, as the diverse 
nature of signal expression amongst and between these groups is further 
determined, the accepted cross-over between distinct cell types and differently 
described subpopulations of MuSCs themselves may change as further 
understanding is gained (48). 
 
Despite variations in lineage, the vast majority of myogenesis is accepted as 
facilitated by MuSCs. 
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Muscle Damage, Disease and Ageing 
 
Muscle damage can be due to trauma or acute pathology, resulting in abrupt losses 
of muscle mass and function. Slower muscle atrophy can occur from other pathology 
or simply from disuse. Overall, muscle atrophy occurs due to greater muscle protein 
breakdown than protein synthesis. This imbalance can result from a variety of 
scenarios. 
 
It is thought that the down regulation of transcription signalling pathways are the 
main cause of disuse atrophy (51). Key pathways are the insulin-like growth factor 1 
– protein kinase B – mammalian target of rapamycin 1 (IGF-1-Akt-mTOR) pathway 
and the focal adhesion kinase – protein kinase B – mammalian target of rapamycin 1 
(FAK-Akt-mTOR) pathway. The mechanical chronic unloading of muscle leads to the 
reduced activation of both synthesis pathways leading to a reduction in protein 
generation (51).  
 
Increased muscle degradation is a component of this negative balance of cell and 
protein turnover. The ubiquitin protease system is the most proteolytic, with 
calpains, caspase-3, and the autophagy-lysomal system also contributing. The 
ubiquitin E3 ligase muscle RING-finger protein-1 (MuRF1) and muscle atrophy F-box 
(MAFbx/atrogin-1) are both strongly expressed during muscle atrophy and are 
frequently used as molecular markers to detect this (51). 
 
Trauma and Muscle Tissue Breakdown 
 
Traumatic musculoskeletal damage has a range of causes. These range from chronic 
overexertion to acute mechanical force damage (52), which in the extreme can lead 
to complications culminating in tissue necrosis and amputations (53). In these 
circumstances, grafting muscle tissue from one body are to another can help to 
salvage viability (54). 
 
Additional factors that cause muscle damage include chemical toxin exposure, 
extremes of temperature, infection, and autoimmune disorders (55). Even electrolyte 
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imbalances such as phosphates, potassium, and sodium in the blood can lead to cases 
of rhabdomyolysis or striated muscle breakdown (56). 
 
Autoimmune idiopathic inflammatory myopathies, with an annual incidence of 1 in 
1,000,000 have been reported to occur when environmental exposure is combined 
with a defective immune response (57,58). This leads to self-recognising 
immunogenicity through a variety of mechanisms (59). Resulting myositis causes 
muscle weakness and, in some subtypes, necrosis of muscle fibres. 
 
Orthopaedic procedures cause damage in the process of intervention. For example, 
arthroplasty operations by nature cause trauma to the target joint. Surgical 
approaches have been developed to minimise collateral tissue damage but the 
nature of accessing a joint makes this unavoidable. For total knee arthroplasty, a 
variety of approaches exist for differing reasons (60). The medial parapatellar 
approach is popular in the UK. It involves cutting into the joint capsule along the 
patellar ligament and quadriceps tendon to access the joint (61). This approach has 
been compared to the theoretically less invasive subvastus knee arthroplasty surgical 
approach as it avoids the knee extensor mechanism, however both have the same 
functional outcomes following the initial few post-operative days.  This has been 
shown in both a randomised controlled trial with patients undergoing single leg total 
knee arthroplasty operations, and in patients undergoing bilateral procedures with 
one knee randomised to each approach (62,63). Understanding the muscle 
physiological changes caused by TKA trauma are relevant to contextualising the post-
operative recovery process. 
 
Muscle injury and repair has multiple stages. Initially, the broken myofibers and 
ensuing inflammatory response form a hematoma. Any dead tissue is digested by 
phagocytic cells and myofibre repair is facilitated by MuSC-derived myoblast 
integration. New capillarisation may take place depending on the extent of injury, 
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The Ageing Process: Elderly Skeletal Muscle 
 
Comorbidities such as cancer, hypertension, obesity, and organ failure are more 
prevalent in the older population and are found in the elective arthroplasty 
population. 
 
Cachexia and Sarcopenia 
 
Cachexia is defined as weight loss, inflammation, and emaciation due to chronic 
disease. In patients, it may also present as weakness and fatigue. Frequently, this is 
from cancer, organ failure or rheumatoid arthritis (65). At least 50% of cancer 
patients show symptoms of cachexia, of which 80% are dead within one year (66,67). 
Historically, cachexia has been the greatest cause of death in cancer patients (68,69). 
Tumour growth leads to protein degradation in skeletal muscle as alenine and 
glutamine are used by the tumour. The increased quantities of lactate production 




Sarcopenia develops in the elderly due to a range of factors (67). These include 
anabolic signalling blocks, muscle breakdown through the calpain, UPS, and 
autophagy pathways, mitochondrial functional turnover blocks, and redox 
homeostasis. Sarcopenia is thought to be the biological mechanism behind elderly 
physical frailty (71). Past the age of 50 years old, annual skeletal muscle wasting 
occurs at roughly 1.5% per year. Once a level of reduced mass and function is 
reached, as defined by clinical scores, a diagnosis of sarcopenia can be made (72). 
 
A factor thought to contribute to sarcopenia is reduced MuSC number in old age as 
demonstrated in Kadi’s study from 2004 (73). The study’s sample size was robust 
(young n=31, elderly n=27) but the single muscle group choice (tibialis anterior) may 
have limited these findings. Some transgenic mouse models have shown hypertrophy 
in MuSC null elderly mice, but the question of translatability from these mouse 
studies to the human remains (74,75). Hypertrophy typically occurs here through 
expansion of the myonuclear domain, which may not be sustainable. Elderly mice are 
defined as roughly 2 years old compared to human studies where the average patient 
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is several decades older. Additionally, criticisms have been made that mice confined 
to a cage do not represent normal physiological conditions (76), and of 
methodological problems with the models’ selection of the tiabialis anterior muscle 
group to study (77). 
 
Circulating myostatin, which inhibits myogenesis, is a controversial cause of 
sarcopenia. Opposing studies measuring levels following bouts of resistance exercise 
have disagreed: though Snijders’ study used more robust modern laboratory 
techniques (78), Ratkevicius’s study was more robust with a sample size three times 
larger (79). The larger study showed no difference in levels between young and old, 
however Snijders’ study showed delayed expression of MuSC content. Other 
biomarkers have been proposed such as, IL-6, SOCS3, and potentially TNF-, but due 
to the phenotypic variation there is no consistent panel for diagnosis of sarcopenia 
(71,76). 
 
More recent findings seem to indicate that rather than the raw number of the MuSCs, 
or even the number of MuSCs per fibre or fibre type, that it is the MuSC state 
regarding propensity to activate or self-renew that may differ in old age (80). Change 
in the local milieu can dictate polarity and therefore the division criteria (81). 
 
The effect of diet on patient MuSC function is poorly understood, but some evidence 
points to supplementary amino acid ingestion increasing function (82,83). Certain 
aspects of diet have been observed (primarily in animal models) to affect both the 
immune system as well as the musculoskeletal system (84). Particularly seen in 
studies focussing on training regimes but may have future potential to aid recovery 
in the orthopaedic clinic. 
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Figure 3 – Diagram of cell signalling pathways leading to sarcopenia with demonstration of the interventional 
effect of exercise. Figure from Angulo et al  (85). Nrf2 - nuclear factor erythroid-2-related factor 2, SIRT – Sirtuin, 
mitoch – mitochondrial. 
 
The physiological response to exercise is frequently used in research to compare 
these variables. The influence of exercise on the nuclear factor erythroid-2-related 
factor 2 (Nrf2), sirtuin (SIRT), and klotho is thought to counteract the natural decline 
of the expression of these factors due to ageing and sedentary lifestyles (85). 
Increasing exercise reduces oxidative stress and increases mitochondrial biogenesis 
through the upregulation of these factors (Figure 3). 
 
The elderly have smaller skeletal fibre cross-sectional-area (CSA) compared to 
younger individuals, particularly in type 2 fibres (86–88), as well as lessened response 
to hypertrophic stimuli. They also have less fibres, once again particularly type 2 
fibres (89,90). These aspects of atrophy and hypoplasia are well established. High-
intensity resistance exercise in osteoarthritic elderly men has been found to be more 
effective than in women, but still more effective than moderate-intensity resistance 
exercise (91). The ability of individuals with OA to undertake hypertrophic exercise 
programs is limited by kinesiophobia (avoiding movement due to fear of pain) (92). 
Following TKA, this has been observed to continue to be a relevant factor in return 
to activity (93,94). The exact mechanisms continue to be investigated with cognitive 
and behavioural factors as likely candidates (95). In this context, the exact fibre-
specific changes following TKA are yet to be explained. 
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Oxidative capacity is related to the vascularisation of the tissue. Therefore, the extent 
of capillary networks of skeletal muscle can indicate the endurance capacity of an 
individual. A correlation between reduced capillarisation and normal ageing has 
proved contentious. Some studies show lower capillarisation in the elderly in 
conjunction with hypertension and sarcopenia (96,97), but others show similar 
capillarisation in the elderly compared to young controls (98). Barnouin’s study, 
examined very active elderly individuals which may well have skewed the findings 
and does not represent a typical arthroplasty population. 
 
Overall, telomere shortening, where chromosomes are mitotically truncated 
resulting in replicative senescence, does not occur in skeletal muscle ageing, and is 
likely not a factor in sarcopenia as reviewed by Lorenzi et al (99). However, the 
current studies have methodological limitations concerning the nature of a clinical 
frailty group, the invasiveness of biopsies and the heterogenous cell content of 
typical patient samples. As a result of these shortcomings, it has been recommended 
that single whole fibre investigations are performed to confirm the findings of a lack 
of telomere shortening. Thus, the effect on MuSCs has been hard to quantify in 
elderly and frail individuals (100). Murine models with induced shortened telomeres 
have been shown to have no detrimental effect on MuSC function (101). 
 
Pathology: Osteoarthritis and Muscle 
 
End stage osteoarthritis (OA) is the primary indication for total knee arthroplasty 
(TKA). Primarily affecting older individuals, osteoarthritis has different pathogenic 
causes and stages, as highlighted in Figure 4. Initial risk factors for developing OA 
include demographic and biomechanical factors. These include sex, race, obesity, and 
joint injuries, and can be metabolic or post-traumatic. The incidence of some risk 
factors naturally increases with age resulting in a higher prevalence of OA in the 
elderly. Typical disease progression begins with damage to joint cartilage past the 
point of possible repair leaving subchondral bone exposed (102). Osteophytes grow 
at the edge of joint surfaces, and changes can lead to thickening of the joint capsule. 
This leaves a narrowed joint space which typically causes discomfort and pain to the 
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individual. OA is more prominent in weight bearing joints such as the knee and hip 
compared to upper limb joints. 
 
Figure 4 – Summary flow-chart showing the pathogenic causes and phenotypes of the three subtypes of 
osteoarthritis. Figure from Bruyère 2015 (103). 
 
Cartilage repair is facilitated by chondrocytes. Trauma, hormonal changes, and 
genetic predispositions can change their phenotype and accelerate the detrimental 
effects leading to OA (103). Biomechanical factors such as increased weight can also 
contribute to this, with early clinical treatment commonly including weight 
management and physical activity advice. 
 
OA is a complex condition with no current cure (104). Much research is currently 
ongoing to target the pathogenic causes and to elucidate mechanisms further (105). 
TKA is the primary treatment for end-stage OA once early conservative interventions 
have been exhausted. 
 
It has previously been suggested that selective atrophy of hamstrings lead to the 
quadriceps becoming dominant and that this can lead to OA. However, the 
techniques used to investigate this lacked depth (106), and did not take the 
confounding factors of age and BMI criteria into account in the analysis (107). Greater 
muscle atrophy has been linked to OA severity and, similarly, atrophy of quadriceps 
has been observed in those with patellofemoral joint OA (108). However, these study 
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results seem to indicate disuse atrophy could be mostly accounted for by reduced 
joint movement because of pain. 
 
With a projected ageing population, and a mean age for primary TKA of 68, the UK is 
poised to see a rise in OA and similar age-related musculoskeletal diseases over the 
coming decades (Figure 5) (109). Anticipating this potential rise in incidence, research 
into these diseases and conditions is pertinent to improving healthcare. 
 
 
Figure 5 - UK population historic breakdown and projection over the next 80 years. Adapted from UN DESA 2015  
(110,111). 
 
As an interventional procedure in response to a disease, it is important to determine 
if arthritic processes have any paracrine effects on skeletal muscle functions, or vice-
versa. The cross-talk interactions are discussed in depth in Krishnasamy’s review from 
2018 (112). She identified potential relationships include myokines blocking 
inflammatory pathways of chondrocytes, where disruption of secretion leads to 
inflammation and increased pain from neurotrophins such as brain derived 
neurotrophic factor (BDNF) (113). The release by muscle cells of pro-chondrogenic 
IGF-1 may regulate cartilage development and upkeep. On the other hand, OA and 
associated symptoms may impact on skeletal muscle function. For example, the 
adipose infiltration of skeletal muscle reduces strength and fibre recruitment in OA 
patients (114,115). An overview of the levels of signalling is presented in Figure 6. 
 
 
Figure 6 - Overview of the levels of intercellular and inter-tissue signalling related to skeletal muscle. Figure 
adapted from Yin et al 2013 (24). 
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These signalling effect levels span (a) the immediate niche, (b) the local milieu and (c) 
the systemic milieu. Cell-to-cell signalling of growth factors can direct MuSCs into 
mitosis in the immediate viscinity of muscle fibres. Within a muscle fascicle, the 
interactions between more diverse cell types occur at a slower rate but with different 
purpose. The systemic milieu includes endocrine hormones and the wider immune 
system, all of which can impact upon MuSC activity (24). This range highlights the 
diversity of the MuSC local and wider environments, and the complexity regulating 
their activity. 
 
A recent investigation into disease specific effects on skeletal muscle function 
targeted clusterin protein expression in osteoporotic (OP) and osteoarthritic human 
populations (116). Clusterin, a protein related to inflammation and senescence, was 
found to have high expression in OP patients but not in OA patients. However, other 
published studies have previously shown mixed results regarding clusterin 
correlation with OA (117–119). In these, clusterin deposits have been found to 
correlate with muscle fibre degradation, and clusterin protein immunoreactivity has 
been found to associate with muscle denervation atrophy (120). 
 
The use of some pharmaceuticals associated with pain management of OA has been 
known to impact upon MuSC function. Non-steroidal anti-inflammatory drugs 
(NSAIDs) impair the function of MuSC through blocking of prostaglandins and growth 
factors which prevent the fusion of myoblasts (121). However, it seems the effect 
may be more pronounced in young cohorts as observed in young athletes (122). 
Differences have additionally been observed between oral and intramuscular 
infusions, with the effect only being seen in oral doses (123). A small but bilaterally 
controlled cohort was used in the infusion study, which may have impacted results 
due to sample size. Nevertheless, this may suggest more complex factors are 
involved. The exact influence of NSAIDs on MuSC function has yet to be clinically 
confirmed. 
 
Concern has been raised about the inability to activate musculature surrounding the 
operated joint after an arthroplasty procedure (3,124). Rather than a pain related 
issue, this effect is mostly attributed to joint effusions affecting sensory nerve 
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receptors and is termed arthrogenic muscle inhibition (AMI) (125,126). AMI is 
associated in OA knee patients with increased pain and decreased bone marrow 
legions (127). The loss in muscle strength loss has been postulated to be more 
influenced by denervation than by muscle autophagy (128). 
 
The rehabilitation post-joint-replacement can take different forms ranging from an 
immediate post-op assessment along with a self-guided exercise sheet, to regular 
post-hospital-discharge outpatient appointments. A study examining the differences 
between patients who made use of the two extremes in TKA and THA populations 
found that those attending regular sessions post-discharge performed worse than 
those who did not (129). Some of those making use of the latter service had self-
referred and others had been referred by their General Practitioner, though the 
proportion is not specified. Despite the therapeutic benefit of physiotherapy 
intervention, results indicate that a skewing may have occurred towards those 
already with poor outcomes. It was not possible to pre-operatively predict 
physiotherapy need. The results indicate that patients struggling with function are 
referred by themselves or by a clinician to physiotherapy, however most patients 
without issue do not make use of the service. While a patient’s MuSC content cannot 
directly influence PROM response or hospital satisfaction, the compounding effects 
on muscle phenotypes and resulting function within an outcomes window may have 
a modifiable effect on these headline outcome parameters. 
 
Diabetes mellitus is a comorbidity present in at least 10% of the knee arthroplasty 
population (130). While acknowledged as being at larger risk of infection post-surgery 
due to circulatory factors (131), little consideration is given to the condition’s effect 
on MuSCs and related muscular recovery following arthroplasty. Recent type 2 
diabetes murine model studies have been conflicted, some showing no-effect, as well 
as some showing delayed or reduced MuSC function (132). This reduced function 
presented in content or proliferation rate. More research is required with an 
emphasis on translational studies to understand this issue further. 
 
Across all pathology, negative impact on MuSC and skeletal muscle function may be 
impacted by inflammatory and senescence pathways (133,134). Identification of the 
Chapter 2: Literature Review 
  23 / 309   
presence of these markers can be compared to the presence of functional 
impairment and potential causative factors. Once senescence MuSC pathways are 
activated and systemic, they can be irreversible with fatal consequences. This can 
occur through the de-repression of as CDK2NA (also known as p16INK4a) locus 
resulting in pathway upregulation as investigated in a model study by Sousa-Victor 
(135). Markers of senescence can therefore be identified by analysing expression of 
CDK2NA and of tumor necrosis factor alpha (TNF-), an inflammatory cytokine. 
Markers of inflammation can be investigated through identification of interleukin 6 
(IL-6), an inflammatory cytokine. However, analysis is complicated due to its co-role 
as a myokine with controversial evidence pitting a reported positive impact on MuSCs 
against its role as a promotor of atrophy (136). Despite this controversy, it is well 
used as a marker of negative inflammatory function in molecular analysis of muscle 
samples (137). 
 
The nuclear factor κ-light-chain enhancer of activated B cells (NFB) transcription 
factor has also been identified as playing a role influencing myogenesis at various 
stages(138). TNF- and IL6 can induce NFB signalling which can lead to muscle 
wasting, especially in the presence of inducible nitric oxide signalling (i-NOS) (139). 
The Monocyte enhancement factor 2 (MEF2) grouped factors have been implicated 
in muscle remodelling in ageing (140). They therefore can be said to cooperatively 
increase the activity of myogenic transcription factors in models. 
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Muscle Physiology Research Models and Human Studies 
 
Research modelling skeletal muscle factors in vitro and in vivo does not always 
translate to human clinical relevance (10,141). Bareja’s 2014 flow cytometric species 
comparison study showed the differences in mechanisms well (142). Specifically, they 
found differences in genetic myogenesis, in cytokine sensitivity, and in cell 
interactions. Mouse MuSCs differentiate more readily than human MuSCs, and to a 
different lineage of daughter cells. The mouse MuSCs also reacted positively to some 
inflammatory cytokines whereas human MuSCs responded negatively. 
 
Human musculoskeletal research is typically focussed in three areas: namely 
congenital and developmental areas, young active populations (11), and muscular 
dystrophy patients (12). The clinical niches are quite distinct. However, skeletal 
muscle is an important component to consider in orthopaedic patients. Orthopaedics 
research has focussed upon surgical technique, bone biology, and biomechanics to 
optimise the implant components for function and longevity. The muscle recovery 
component of arthroplasty is under-researched. 
 
Sporting populations have a clear training history and ongoing programs, and the 
dystrophic populations have a genetic nature with a physiological focus different to 
the normal population. Additionally, particularly with Duchenne’s muscular 
dystrophy, patients show a satellite cell population favouring stemness. This is the 
reverse of that seen in an aged population, typically seen in arthroplasty cohorts, of 
increased differentiation and a scarcity of stem cells (27). 
 
The training history of elite sporting individuals, particularly that including resistance 
exercise, biases them towards contemporaneous fibre type profiles and towards 
hypertrophy in later life. Skeletal muscle myonuclei acquired from training persist 
long after the stimuli have been removed (143). This long term effect is also seen in 
doping cases with performance enhancement agents, such as anabolic steroid use, 
where benefits are seen for decades following initial use (144). A recent model has 
attempted to disprove this finding, but the methodology of the study contained very 
few mice (minimum 6 per experimental group), chose a muscle group known for 
lacking translatability (145), and took place over only a few months (146), making the 
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results unconvincing. The exact effect of life-long exercise on elderly MuSC content 
is yet to be elucidated but the mid-term effects following a short resistance exercise 
program suggested that MuSC changes are unsustained (30). 
 
As humans age, the skeletal muscle physiological response to exercise becomes 
dampened (147). In parallel, the dietary effect of reduced protein absorption and 
muscle-protein synthesis can compound the weakened effects of strengthening 
exercises (148,149). However, the state of MuSCs has been hypothesised to influence 
the response rate to these exercise stimuli and may be used to identify those that 
respond better to exercise rehabilitation programs (150). Comparison of these 
phenotype data with recording of individuals’ historic exercise and activity habits 
may identify behavioural patterns that are linked to favourable functional recovery 
post-TKA. 
 
With a healthy muscle satellite cell population linked to superior regeneration and 
performance both in mouse models and performance sporting cohorts, there 
remains to be substantial investigation of the related physiology in an elderly lower 
limb arthroplasty clinical population. 
 
The use of a pneumatic tourniquet to control blood loss during surgery has been 
postulated to influence quadriceps function. Routinely used in the UK during TKA, 
though global use varies, it has been associated with elevated risk of distal deep vein 
thrombosis (151). The effect from applying this pressure during surgery in theory can 
affect the MuSC niche and function during the very early recovery phase. A study 
with a primary end point of 48 hours post-surgery found no difference in leg strength 
(152), however this time-point is may be too early to determine the full effect on 
functional outcome. Another study investigated the effect until 12-months post-op 
found quadriceps inhibition and greater pain during the first 6-months of recovery in 
their tourniquet study group (153). However, the exact effect on the MuSC niche is 
yet to be elucidated. Perhaps an analogous scenario is that of blood-flow restriction 
exercise training, where an artificial anaerobic environment is created to enhance 
the training stimulus. This has been shown in a small cohort to enhance short term 
MuSC function following training in this manner (154), however the ischemia 
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reperfusion injury from a pneumatic tourniquet may be to a greater magnitude. 
Blood-flow restriction exercise enhances the MuSC proliferation through the increase 
in phosphorylation of p70S6KThr389 and elevated p38MAPKThr180/Tyr182. The 
transcriptional profile of vastus lateralis muscle following TKA using tourniquet was 
compared to that from a non-tourniquet group and found to show upregulation of 
cell stress pathways (155). 
 
Patient Background and Osteoarthritis 
 
Patient background characteristics have previously been associated with OA onset 
and with surgical outcomes post-TKA to varying extents. These characteristics range 
from associations with demographic factors to lifestyle choices. 
 
Retrospective studies have shown associations between certain occupations and OA 
onset (156–158), however concern has been raised about publication bias, with a 
resulting recommendation for inclusion as a research metric in future prospective 
cohorts (159). Occupations involving high-load manual labour and kneeling are 
closely associated with knee OA, however evidence suggests genetic inheritance 
involvement when evaluating frequently hereditary manual occupations such as 
farming and fishing (160). 
 
Overall, the evidence for some of these attributes conflicts, with more research 
required to determine full relationships and underlying causes.  
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Clinical 
 
Introduction to Orthopaedic Surgery and Recovery 
 
Joint replacement, also known as arthroplasty, as a treatment for osteoarthritis is an 
elective operation with incredibly successful outcomes. Diseased or damaged bone 
joint surfaces are removed and replaced with articulating synthetic components. In 
2017, 90,000 total knee arthroplasties were performed in England and Wales (109). 
Arthroplasty of the hip and knee joints in particular can lead to pain relief and large 
improvements in quality of life for patients (161). However, knee replacement 
components are susceptible to wear and tear deterioration. Current clinical 
techniques and prosthetic designs for total knee arthroplasty have been reported to 
have a 95% survival at 20 years with 82% of replacement operations lasting 25 years 
or more (162). Inevitably, components or their fixtures break down requiring revision 
surgery to replace the components (163). This is typically more complicated and 
variable than a primary arthroplasty due to the variety of causes, wear patterns, and 
failure methods (164,165). 
 
Total knee arthroplasty is a surgical procedure requiring a major incision, arthrotomy, 
bone resection, and substantial endoprosthesis fixation. The surgery itself seeks to 
ease pain and increase function in a patient. While the observed end surgical 
outcome at 1-2 years post-operation is typically positive, short term recovery can be 
variable. One in five patients that undergo the surgery are dissatisfied with the 
outcome at 12-months post-op (1), amounting to over 18,000 dissatisfied patients 
annually in the UK alone. Dissatisfaction with surgery is largely attributed to unmet 
preoperative expectations, a lack of pain relief, and a disappointing hospital 
experience (2). The preoperative expectations aspect of dissatisfaction includes 
patients’ own expectations of functional outcome following surgery alongside other 
elements such as subsequent pain levels. 
 
Short term recovery focuses on the ability of the patient to mobilise, regain 
independence and achieve competence in activities of daily living (ADLs). Which is 
largely dependent on the musculature around the operated joint. 
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Effective functional improvement of the major weight bearing muscles of the lower 
limb is key to this recovery. These muscles – mostly of the hamstrings and quadriceps 
groups (3) – may have to overcome both wasting from recent immobility and damage 
from surgery. The main period of muscle recovery after total knee arthroplasty 
surgery is between six weeks and six months (166). Effective muscular recovery in 
this time frame can mean the return to a level of function not achieved for many 
years (4). 
 
Recovery from Total Knee Arthroplasty 
 
Immediate post-op ward care is aimed at facilitating a safe and speedy discharge. 
These approaches are different from the historical post-arthroplasty clinical pathway 
of prolonged bedrest (167,168).  
 
The current early rehabilitation within routine clinical practice is that of clinic-based 
and take-home physical therapy regimes. However these do not always result in a 
good recovery of function (5). The function and power of the quadriceps muscle 
group are associated with ADLs performance during recovery following knee surgery 
(6,7). The failure of this muscle group to recover function following TKA can result in 
an inability to perform ADLs and be termed poor surgical outcome. This poor 
outcome has previously been partially predicted using social, psychological and 
clinical estimations (8). However, the ability to predict poor outcome may also be 
improved with a deeper understanding of a patient’s muscle physiology, given the 
phenotypic variation in this area, by using quantified physiological markers of muscle 
regenerative ability. Examples of these markers include growth factors, cytokines, 
immune responses, and cell metrics (9). Some of these promising markers are related 
to the functional status of the muscle precursor cell, the muscle satellite cell (MuSC). 
 
In 2013, Hamilton et al found that the number of satellite cells found in a patient’s 
quadriceps muscle group were more predictive of outcome than preoperative lower 
limb power measurements (169). Intra-operative muscle satellite cell count was 
identified as a better predictor of post-operative leg power improvement than pre-
operative leg power. This pilot followed two separate cohorts containing 17 and 11 
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patients who underwent total knee replacement for osteoarthritis. Methods used for 
analysis were an evaluation of satellite cell content with immunohistochemistry and 
qPCR, and power assessment with a Nottingham Leg Extensor Power Rig. The 
laboratory analyses limitations included a small sample size, lack of replication, and 
at times unclear results. 
 
The cells identified by Hamilton et al (2013) as the best predictors of functional power 
improvement were the muscle satellite cells which are the precursors to myoblasts, 
myocytes, and myotubes. They can be defined as muscle stem cells, though show 
some variation in phenotype. Discovered in the early 1960s (170,171) and named 
based on their anatomical location at the periphery of muscle fibres sandwiched 
between the basal lamina and sarcolemma. They form a heterogeneous population 
with differing propensity to remain quiescent, mitotically proliferate, or differentiate 
into terminally differentiated daughter muscle cells. Recent summary reviews of the 
satellite cell niche evaluate many aspects of current understanding of the physiology 
of the cell type and the role they play (29,172–174).  
 
Investigating their function in human knee arthroplasty populations can could be of 
benefit in optimising patients’ recovery post joint replacement. 
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Clinical Research Outcomes Measurements 
 
Clinical outcomes are measures of patient health status used within clinical practice, 
clinical research, and in service quality processes (175,176). They range from a simple 
note of a patient symptom or laboratory result to other measurements and can be 
based upon psychometric and statistical analyses. Measurements can include 
technical recordings, patient interviews, or direct observations. 
 
These can be clinician or researcher led evaluations, known as Observer Reported 
Outcomes, usually recorded in physical or electronic Case Report Forms (CRFs) in 
clinical research or Medical Notes in routine clinical practice. The measurements can 
alternatively be recorded by patients themselves, termed Patient Reported 
Outcomes (PROs) (177). 
 
Most human evaluated methodologies, excluding the operation of certain technical 
apparatus, have elements of subjectivity. However, technical equipment data retains 
elements of operator variation. Variation can be reduced through appropriate 
training, standardisation by standard operating protocols, and consistency in the 
same individual recording data where possible (178). 
 
To allow comparative assessment between cases or of recovery progression, data 
must be succinctly documented. Evaluations of physical assessments, and charting 
progression of physical ability contemporaneously in the clinic environment can 
provide clear information into this (179–181). However, overly frequent onsite 
assessment of patients within Research Hospital settings can quickly become a 
burden to both patients and facilities (182,183). 
 
When patient data collection is planned more frequently than local routine clinical 
appointment schedules, other data collection methods must be utilised. Research-
specific clinical departments or remote data acquisition is necessary. Frequent repeat 
visits to a hospital site can create patient burden, leaving remote acquisition as more 
suitable. Modern techniques allow for various methods for collecting this (184). 
These methods include implantable and wearable devices, alongside other 
traditional patient contact methods. Device recorded data can be uploaded at 
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intervals during clinic visits, or with constant wireless data transmission back to a 
computer server at the research hub. Patient contact methods, traditionally via 
postal letter or phone call, now include options such as batch emails, text messages, 
web portal data entry, and video calls. All these data collection methods have security 
considerations and strict confidentiality policies which must be understood and 
adhered to (185). 
 
The standardised recording of patient data in clinical cohort research creates ease of 
analysis and comparisons. Analytical methods exist for comparative analysis of 
qualitative metrics, though they can present complex limitations in large cohorts. 
Semi-quantitative or quantitative data are preferred as they can be easily collated 
and interrogated with direct statistical analyses (186). Choosing data categories for 
collection can be challenging during study design. Clinical trials or cohort studies can 
take place over many years and the chosen metrics must be set at the study outset. 
To aid selection, many established direct and surrogate measurements exist across 
various categories within the musculoskeletal research literature (187). 
 
When assessing post-operative function, similar metrics can provide different levels 
of sensitivity and insight. While the validation process for different outcome 
measurements determines these factors, the use of multiple types of assessments 
can help to complete the clinical picture. Where possible, this can be achieved 
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Patient Reported Outcome Measurements (PROMs) 
 
Patient reported outcome measures (PROMs) are subjective reports of a patient’s 
health or experience provided by the patient themselves and without interpretation 
by a health professional (189). Routinely collected within the UK’s National Health 
Service (NHS) since 2009, they are now a core component of both routine clinical 
practice quality assurance and in clinical research (190). 
 
PROMs encompass subjective experiential feedback from patients. Relevant topics 
within musculoskeletal research include clinical care experience, functional 
experience such as activities of daily living (ADL) competence, and activity specific 
pain levels.  
 
Methods for recording PROM data are varied. They encompass many responses to 
enquiries regarding their symptoms and clinical concerns. PROMs can be recorded 
face-to-face with patients in a clinic scenario as part of a consultation interview or 
remotely in several ways. In both scenario types, a standardised format must be 
followed to ensure reliability. Some methods require more researcher input than 
others, and comparisons of recording methods show variation in patient preference 
and response rates (191). For example, phone calls are individual and require patient 
convenience, mailed questionnaires are efficient with time but have low response 
rates, and web database input forms have low response rates but remove the latter 
need for analogue to digital response conversion pre-analysis (191). The most 
consistent recording method is in-clinic where possible. Participant focus is ensured, 
with the ability to provide clarity or context if necessary. 
 
A transition from paper-based to electronic PROMs format has recently become 
preferred due to increased efficiency and reliability in recording (192). Care is taken 
in the transferral to electronic versions to ensure equivalence is demonstrated 
between formats (193,194). While the format of electronic PROMs tools have 
previously been confined to proprietary tablet devices linked to a centre or study, the 
recent emergence of application-based reporting mechanisms that work from any 
internet-connected device has opened new avenues for academic research (195). 
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Assessment of the Knee Osteoarthritis Patient Population with PROMs 
 
The use of PROM tools in the assessment of total knee arthroplasty populations is 
well established (196). These vary in length, dimension scope, target audience, 
language, and history. Some are proprietary, some are free to use.  
 
A list of prominent PROMs related to total knee arthroplasty are listed in Appendix 
A: Clinical Study Documentation from adapted information in published reviews 
(197,198). 
 
Recent research using PROMs tools in TKA populations has investigated factors 
ranging from health status, to satisfaction, to work status, to the changes in ability to 
perform activities of daily living following surgery (199–201). The tools are utilised to 
examine aspects of routine TKA outcome to determine how current clinical 
procedures or service provision affects patients, and could be adapted (190). They 
are also used to determine differences between existing surgical treatments and 
novel endoprosthetic designs in clinical trials (63,202). 
 
Variation in comorbidities, patient biometrics such as body mass index and in patient 
demographics have been shown to affect Oxford Knee Score (OKS), a PROM tool 
specific to evaluating knee symptoms and function, following TKA (203,204). The 
comorbidities data originated from over 2700 patients, making them very robust for 
a single study site. 
 
Case mix describes the range of patient background and health status of those being 
admitted for a surgical procedure. This can include patient age, sex, comorbidities, 
and other factors. The range of patients admitted to a hospital can identify “cherry 
picking” of favourable cases and therefore affect the overall rate of positive 
outcomes for a department or hospital. Previous research in the United States 
identified that TKA outcomes are consistent for low-risk patients across all types of 
hospital settings, but high-risk patients have better outcomes at smaller speciality 
centres (205). However, they also identified elements of “cherry picking” in the case 
selection at those centres.  International comparisons of TKA case mix outcomes have 
found national differences in outcomes, pointing to potential differences in 
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physiology and in cultural context during recovery from TKA (206,207). The suggested 
cultural contextual factors included differences in routine intervention time-point in 
late stage OA and ranging positions during post-operative recovery. 
 
Examination of outcome using PROM tools has identified the importance of baseline 
scores of some metrics in relation to post-operative outcomes. The EuroQol Five 
Dimension PROM tool (EQ-5D), measuring health-related quality of life, has been 
shown to increase post-operatively by similar amounts for each clinical BMI category 
(204). Patients showed worse pre-operative scores with increasing baseline BMI. 
Patient PROM scores improved post-operatively, but each category showed similar 
increases resulting in similar variance in post-operative outcomes. 
 
Just as surgical case mix can confer different outcomes for surgeons’ individual 
annual lists, the case mix of study recruitment can influence outcomes in research. 
While inclusion and exclusion study criteria help to narrow variation and control for 
confounding factors, recruitment has inherent variation due to the factor of case mix. 
 
Patient hospital experience has been shown to affect outcomes following TKA. 
Outcomes measured using the OKS and the Short Form-12 (SF-12) PROM tools 
showed that those with poor hospital experience had outcome scores less than half 
of those who described their experience as excellent (208). However, the assessment 
of hospital experience was assessed at 6-months following operation and may have 
been influenced by patient early outcome when retrospectively evaluating hospital 
experience. This is addressed in the study paper’s discussion as recall bias. 
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Observer Reported Outcomes 
 
Observer reported outcomes are based upon a variety of factors. Examples of these 
include raw biometric measurements, discussions with patients, data from 
specialised instrumentation, and physical assessments. The latter two categories can 
be targeted to specific clinical groups. 
 
They are distinct from PROMs as they must be recorded by a clinical or research 
professional to record them. Elements of subjectivity can still exist within these 
outcomes. 
 
Functional Assessment of the Knee Osteoarthritis Patient Population 
 
To measure functional outcomes following TKA, there are bodies of validated, well-
used tests in the literature (Table 2). Functional assessments exist that are validated 
for specific clinical populations (209). These are known as performance-based 
measures and can target both OA patients and those recovering from major surgical 
knee operations. 
 
For a functional test to be considered robust, it must be assessed for accuracy and 
reproducibility. This includes inter- and intra-operator reliability, test interpretability, 
and test responsiveness, amongst other criteria (210). The composition of validation 
tests varies. 
 
Published comparisons and best practice recommendations for OA functional 
outcome assessment tools are intermittently published by OARSI, the Osteoarthritis 
Research Society International, from the consensus of a large number of experts in 
the field. Some of these focus on tests specific to knee OA function. A seminal 
publication recommended a timed up-and-go test, a walk test, a stair climb test, a 
chair to stand test, and a duration walk test as a best practice combined testing 
battery to assess post-TKA function (211). These tests do not require specialised 
expensive equipment or require large amounts of space to be conducted. Another 
publication assessed intra- and inter-operator variability of these tests with a large 
patient population and found them to be robust (212).  
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Table 2 - List of example functional performance-measures for assessing lower limb osteoarthritic patients. 
Adapted from OARSI (211). 
Identified activity themes Identified tests 
Walking short distances Fast-paced walk test – 50 ft 
Fast-paced walk test 40 m (4 × 10) 
Fast-paced walk test 40 m (2 × 20) 
Fast-paced walk test 80 m (8 × 10) 
Self-paced 13 m 
ALF battery 
Self-paced walk test 8 ft 
Multi-paced 5 m 
Walking long distances Six MWT 
Getting in/out of a chair Timed up and go test 
Get up and go test 
ALF battery 
Chair-stand test – 30 s 
Chair-stand test – five repetition 
Rising from a stool 1-leg rising 
Getting in and out of bed Steultjens battery 
ILAS battery 
Rolling over in bed ILAS battery 
Turning whilst walking (ambulatory transitions) TUG 
Walking down/down stairs Stair-climb test −12-step 
Stair-climb test – nine-step 
Stair-climb test – four-step 
Hopping 1-leg hop test 
Kneeling 
 
Standing up from sitting on floor 
 
Full squat on two legs Maximum squat test 
Semi squat on one leg 1-leg squat test 
Static standing balance FAS battery 
Reaching in standing Functional reach test 
Putting on socks/footwear Sock test 
Getting in/out of a car PAR battery 
Running Fig 8 running test 
Zig–zag run test 
Lifting and carrying objects PAR battery 
Steultjens battery 
Walking on different surfaces 
 
Walking around/over obstacles 
 
Stair negotiation Nine step stair test 
Twelve step stair test 
Four step stair test 
ALF battery 
FAS, Functional Activity Scale; PAR, Physical Activity Restrictions; ILAS, Iowa Level of Assistance Scale; ALF, Aggregated Locomotor Function 
Score. 
 
Recognition has also been made of the differences between PROMs and directly 
measured functional data (213). While only evaluated at 1-month and 12-months 
post-op in Mizner et al.’s study, his observations indicate they may follow differing 
trajectories. Further research from his group indicated that in the first month 
following surgery, patients perform better in PROM scores than in functional scores 
but subsequently follow a collinear trend (188,214). The exact improvement rate 
during early outcome time-points following TKA is yet to be fully understood. 
Concerns have previously been raised about using PROMs measurements alone, 
however the use of stronger psychometric evaluation techniques and the flexibility 
of electronic PROMs technology have improved data quality (215). When well-
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constructed, PROMs tools can be as robust as objective, directly measured functional 
measurements to determine patient outcome (216). 
 
Biometric measurements include the range of movement of a joint, body mass index 
(BMI), and bioelectrical impedance (BEI). Measurements of the limb circumference 
such as a thigh can be used to assess muscle mass, however evidence for validity of 
this metric is mixed (217,218). While a non-invasive quick measurement, aspects of 
body fat and identifying a reproducible anatomical location on the patient’s thigh 
create uncertainty. Unreliability has been reported in obese patients (219), and the 
measurement has also been reported as susceptible to sex differences (217). The 
technique is not as accurate as magnetic resonance imaging (MRI) to determine 
muscle mass (220), but can provide a quick and cost effective in-clinic measurement 
that can comparatively assess atrophy and indicate potential underlying sarcopenia 
(221). 
 
Dual energy X-ray absorptiometry is considered reliable for the assessment of muscle 
mass but exposes a patient to a very low ionising radiation dose, which may be 
deemed an excessive burden within research by an ethical review board. Bioelectrical 
impedance analysis can be used non-invasively to assess muscle mass and is 
frequently used to assess sarcopenic populations (222–225). Body mass index 
assesses weight to height ratio. A study of early outcomes found BMI had no 
influence on functional recovery following TKA, however it was conducted in a 
relatively small sample size and patients were evaluated at a maximum of 12 weeks 
following surgery (226). The impact of pain could still be a major factor in some 
patients at this stage of recovery. Another study showed those with obese BMI 
ratings had significantly reduced functional recovery compared to those with lower 
BMI scores (227). Separately, higher BMIs have been shown to influence some 
PROMs scores but not others, with patient surgical satisfaction most susceptible to 
negative influence from high BMI (204).  
 
Wearable Electronic Health Monitoring Devices 
 
New technological approaches to remote data capture provide interesting and novel 
avenues for data collection. 
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Wearable technology is a trend developing with increasing speed over the past 
decade. It is a fast-paced competitive commercial area which provides incredible 
opportunity to healthcare research (228). Areas of clinical relevance which occur 
away from the clinical environment can now be remotely and constantly monitored. 
Insight which previously required specialised and cumbersome equipment can now 
be obtained from discreet wearable devices. Concerns about privacy are rightly 
placed, but, with appropriate oversights and regulation, the use of such devices 
provides valuable insight going forward in both clinical practice and clinical research 
(185,229–231). These regulations include considerations to ensure appropriate 
confidentiality when using and transferring patient data, and related accountability 
to the hospital or NHS trust’s patient data authority. 
 
Take-home health monitoring devices have a history spanning decades with several 
notable categories of relevance. These include cardiovascular, activity, body 
temperature, galvanic skin response (conductivity), and blood oxygen saturation 
monitoring devices (228). Some aim to cover multiple categories of these in a single 
device. The creation of micro-electronic-mechanical systems (MEMS) has allowed for 
the miniaturisation of health monitoring instrumentation, with what began in 
aerospace industry now transitioned to consumer devices in the community 
(232,233). 
 
Activity Monitoring Devices for TKA Clinical Research 
 
There are now a large variety of styles and functions to choose from when selecting 
a wearable electronic health monitoring device. 
 
The use of health monitoring devices for monitoring TKA outcomes dictates desired 
device attributes. The average TKA patient is 68 years old and has pain and mobility 
issues. While comorbidities are frequently present, examining mobility as a primary 
assessment characteristic is relevant when assessing function. Within the health 
sensor sector, these instruments are known as activity monitoring devices. They 
collect data primarily on user movement and can range from simple accelerometer-
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based step-counters, to GPS-connected devices with activity-specific insights that 
incorporate a large number of sensors into a single compact system.  
 
Metrics are based upon distinct sensors, which rely on algorithmic analysis to 
categorise raw data into defined class intervals or bins (234). Examples of sensor 
categorisation include step cadence, heart rate, workout ‘zones’, estimations of 
calorific expenditure, and sleep times, quality and depth (231). Activities 
categorisation ranges from time spent sitting, to the number of steps taken, to the 
smoothness of  a swimming stroke (235). 
 
Activity monitoring device systems can attach to the body of the subject in different 
ways. Some are wrist-based, others are placed in a garment pocket, attached to the 
waistband, or fixed directly to the skin and wrapped in a dressing to secure them. 
Each style balances accuracy with convenience.  The popular clinical research device 
ActivPal requires gluing to a subject’s thigh (236). The devices are validated for a 
variety of clinical study uses, however the collected data is limited, and the devices 
are inconvenient compared to other application methods (236). The developers have 
recently introduced a pocket-based device, however this application method is 
susceptible to missing data due to garment removal (237). Wrist-based devices 
provide similar accelerometer data to those previously used on the waist or thigh, 
and can also provide further patient information through additional sensors such as 
heart-rate monitoring (238,239). 
 
Previous research by Luna et al utilised wrist-based activity monitoring devices as 
part of an outcomes tools battery to assess TKA patients in the three weeks following 
surgery (240). The study identified that during the first month of recovery, TKA 
patients reported perceived improved function prior to a measured increase in 
activity. However, methodologically, they only retrieved 80% of their target activity 
monitoring data, and only recorded activity for 14 hours per day, which may have 
skewed their findings. The devices also measured generic proprietary activity (in 
actigraphy units unique to the device which lacked definition), and a direct surrogate 
to step count could not be made, as the readings could have been confounded by 
upper limb movement (241). 
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The measurement of patient daily step count in the community provides useful 
insight, but the relationship with health status is yet to be defined. It has been stated 
that a routine daily count over 1000 steps is beneficial compared to a completely 
sedentary lifestyle of under this amount, however the subsequent higher categories 
and their health implications remain contested (242). Factors such as age and 
comorbidities vastly change observations as a healthy target for a 20 year old is 
expected to be greater than an 80 year old individual post-TKA (243). Suggestions for 
healthy step count targets range from 3000-10000 steps. However, after lower limb 
arthroplasty or in patients with a comorbidity, the target is roughly 30% lower (242). 
The levels and duration of moderate-to-vigorous physical activity are also important 
for cardiovascular health, however this metric is more relevant to younger individuals 
(244). In addition, walking cadence is a relevant metric which provides further 
context to daily step count. An observational study focussing on these metrics by 
Webber et al found similar step counts and cadences between patient post-TKA and 
those awaiting surgery (244). However, counts for the TKA patients were lower 
compared to accepted numbers for healthy individuals. The comparisons were 
performed in separate cohorts and only at one time-point for each cohort, averaging 
34 participants each. The use of literature healthy control data instead of collected 
study data devalued this secondary comparison, however the recordings were made 
over 7 days and the device was reliable which made the measurements in their study 
robust. 
 
Many activity monitoring devices have graphic displays which present a live tracking 
of their activity. The ability to observe these numbers has been assessed a 
motivational tool during early recovery post-TKA and post-THA. In a study of 163 
patients with 5% loss to follow-up, greater step count was observed in the first 6 
weeks post-op and at 6-months post-op in those who were not blinded (245). KOOS 
and EQ-5D scores were similar between the cohorts at 6-months post-op. The study 
design and combined TKA and THA cohort provided potentially confounding factors, 
as the proportion of TKA:THA patients was not identical in the blinding and unblinded 
cohorts. In addition, there were other demographic discrepancies between the 
cohorts. The conflation of set step count targets and blinding to progress also 
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combined two potentially influential factors. The motivational factors relating to 
unblinded activity monitor provision without stated step targets remains unclear. 
 
Additional activity categories can be recorded by monitoring devices such as heart 
rate, sleep quality, and metabolic energy expenditure. Wrist-based heart rate 
measurements, taken once every minute with optical photoplethysmography, are 
accepted as reliable at rest (246). However, concern remains over the effect of 
stimulants such as caffeine as an uncontrolled variable when measuring resting heart 
rate in a study population (247). Measurement of sleep qualities result from 
algorithmic binning of accelerometer data during defined evening, nighttime, and 
morning time periods. They provide insight into duration of sleep, and proportions of 
light or deep sleep. Lighter sleep is defined as restless, encompassing relatively more 
movement (e.g. turning in bed). Patient pain and comorbidities are known to 
influence sleep quality and duration (248), which are known to vary in a post-TKA 
cohort (249). The data category of metabolic energy expenditure, usually recorded in 
calories is based upon large assumptions made on fitting primary step count and 
heart rate data into formulae based on average general population biometrics (250). 
As a result, it is not a reliable wrist-based activity monitor metric for use in clinical 
research. 
 
Preoperative Prediction of TKA Outcomes 
 
The identification of associations between pre-operative baseline data and patient 
outcomes following TKA provides an opportunity to identify at-risk groups of patients 
prior to their operations (251). Factors predicting outcome, provide important 
targets for pre-operative optimisation and can facilitate targeted recovery-care 
planning. 
 
Previous research has attempted to predict patient surgical outcomes with a 
combination of preoperative measurements. These predictions are estimated with 
PROM tools, functional scores, patient background factors, or other combinations of 
pre-operative metrics. Regression statistical modelling or correlation coefficients are 
typically used to evaluate predictive relationships (252). Some research groups have 
attempted to develop individual pre-op tools that try to predict early outcome post-
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TKA, for example the Prediction Rule by Lungu et al which identifies at risk patients 
(8).  
 
Several studies have investigated predictive factors of 6-month outcome following 
TKA. One study identified that surgical outcomes at 6-months post-op could be pre-
operatively predicted by the Oxford Knee Score PROM tool, pre-op chronic pain level, 
pain expectations, and coping abilities (253). Similarly, factors such as poor pre-
operative function and social isolation have been shown to predict poor 6-month 
outcome (254). In another study, a prominent finding was the relationship between 
pre-operative and post-operative function (255). The results inferred that the 
optimisation of the identified factors prior to surgery would improve outcomes. It 
was suggested that the post-op outcomes could be improved by preoperative activity 
modification or by reducing the progression of OA and its associated decline in 
function. Some believe that prehabilitation can overcome negative effects by 
improving a patient’s functional strength and performance before an operation, but 
recent findings indicate the limited potential of prehabilitation regimes in TKA 
patients (15,256). Neuromuscular electrical stimulation has also been examined as a 
recovery tool for TKA patients (257). Study results showed short-term quadriceps 
activation improvement but no long-term effects. 
 
Functional elements have been extensively discussed in the literature as direct 
predictors of functional outcome following TKA, however there is not a consistent 
relationship, with different factors identified depending on primary outcome or time-
point (255,258–260). For example, those with higher surrogate ADL functional 
performance pre-op do not always perform the best in similar tests post-op, with 
psychosocial elements previously identified as negative influences on outcomes post-
TKA (261–263). 
 
Pain levels pre-op have been shown to be predictive of post-op pain scores, however 
these have mostly been performed during very early time-point in the first few days 
after surgery (264). 
Chapter 2: Literature Review 
  43 / 309   
Patient background factors such as side dominance, historical activity preference, 
and use of tobacco and alcohol have been examined to determine associations with 
outcome post-TKA. 
 
The side preference of leg dominance is associated with superior fine motor control 
and biomechanical stability in certain tasks compared to a non-dominant side (265). 
The factor has been investigated in the OA arthroplasty literature but not conclusively 
due to small cohorts (266,267). In these studies, the superior motor control, stability, 
and confidence in a dominant leg has been reported to translate into marginally 
improved functional outcomes compared to TKA in a non-dominant leg. 
 
The correlation between an individual’s sporting history and OA is varied, with recent 
evidence pointing to high intensity and high frequency sports being a potential 
causative factor of OA (268,269). The inferred mechanism includes a higher 
propensity to traumatic joint injury and a likelihood to return to activity prior to full 
recovery, thereby compounding damage. However, the quality of evidence across 
many studies in this area has been evaluated as poor (270). 
 
Amongst the population regularly seen for knee arthroplasty surgery, there are 
lifestyle choices that are closely linked to negative surgical recovery patterns (13,14). 
Examples are smoking, high levels of alcohol consumption, a sedentary lifestyle, and 
obesity. These factors are yet to be looked at in relation to their effect on satellite 
cells in a human arthroplasty population. 
 
A recent retrospective study in over 100000 patients examined the effect of smoking 
on surgical outcome post-TKA and found that it was associated with a higher rate of 
complications, use of analgesia, and mortality, but PROMs remained similar to non-
smoking groups (271). Consumption of alcohol and use of tobacco has been shown 
to reduce in OA patients following TKA (272), however those continuing to drink 
alcohol or smoke tobacco showing higher levels of periprosthetic joint infection 
(273). No link was found between hospital length of stay or readmission rates for 
those with an alcohol use history, however greater readmission rates were found 
within 1 month post-op for tobacco smokers (274). 
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These studies highlight how certain lifestyle choices increase the risk factors for OA 
progression and also affect the outcome following TKA. Examining these factors in 
relation to muscle physiological profile may provide important context to underlying 
mechanisms of poor outcome. 
 
As studied previously, preoperative symptom severity, is a relevant predictive factor. 
However, arthritis severity and its relationship with knee extensor power or strength 
is conflicted. Many studies show the factors are inversely related (as reviewed by 
Zwart et al in 2018 (275)), with higher OA severity and progression linked to weaker 
knee extensor torque, particularly in women. However, when adjusted for knee 
compartment alignment, this effect disappears (276). 
 
Few studies have evaluated the associations and predictive effect of physiological 
markers on surgical outcomes. Perioperative synovial fluid examination identified 
higher TNF- concentration levels were correlated with subsequent lower pain and 
better function at 6-weeks post-op. It was postulated that the TNF- levels were 
associated with inflammation in the joint capsule. Arthroplasty was considered to 
remove this stimulus resulting in a reduction in pain (277). Conversely, another study 
investigated the outcomes 2-years post-TKA. They found that lower TNF- levels in 
synovial fluid were associated with better outcomes (278). The latter study only 
evaluated outcome with the WOMAC index and did not use direct functional tests. 
The evaluation of stress hormones in patients’ urine prior to surgery was investigated 
as a predictor of 3-month post-operative pain. Higher catecholamine and cortisone 
levels pre-op were found to be predictors of lower post-op pain, in opposition to the 
study’s initial hypothesis (279). The observations are described as complex due to 
changes in pre-operative activity such as a reduction due to fear of pain, and to 
varying levels of anticipatory stress. 
 
A recent study investigating post-TKA muscle atrophy and the effect of essential 
amino acid supplementation found that diet in the week prior to surgery was 
associated with the levels of inflammatory markers as a prediction of atrophy in the 
immediate two weeks following the operation (280). Previous pilot work by the same 
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group had identified pre-op diet to be associated with stronger performance in 6-
week post-op functional tests (281). However, a longer outcomes measurement 
window is required to confirm if the effects persist. In addition, the laboratory 
techniques require additional quality steps to improve data robustness. 
 
Associations with gender and preoperative activity score have been used to predict 
post-operative activity levels by Turnbull et al (282). Additional observations included 
an observation that higher social deprivation predicted lower post-op activity, health 
status, and patient reported outcome. They additionally found that younger patients 
were more likely to be dissatisfied with surgery.  
 
Expanding the scope of pre- and peri-operative factors to include physiological 
factors related to the musculature surrounding the target joint of the TKA procedure 
may help to improve the models for predicting outcome. 
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Aims and Research Hypotheses 
 
The study’s Primary Hypothesis was: 
 Preoperative and perioperative muscle factors in conjunction with patient 
background characteristics predict early functional outcome following 
primary total knee arthroplasty. 
 
Patient characteristics and peri-operative muscle physiology were compared to their 
early functional surgical outcomes following primary total knee arthroplasty. The 
study’s Primary Aim was therefore: 
 To identify preoperative and perioperative muscle factors and patient 
background characteristics affecting early functional outcome following 
primary total knee arthroplasty. 
 
The study methodological structure required laboratory and clinical investigations of 
an observational longitudinal patient cohort. As such, the primary aim required 
several steps to examine the concept within a total knee arthroplasty population. 
Initially, background characteristics and baseline factors were defined. Then, the 
functional outcomes were measured at various time-points. Finally, relationships 
between background, baseline and outcome factors were examined. The patient 
characteristics and factors were defined from distinct categories of demographic, 
biometric, comorbidity, and lifestyle choices. 
 
An observational longitudinal cohort study was established with five time-points to 
evaluate temporal trends in functional outcome. Once established, the factors 
affecting early functional outcome were examined using sequential comparisons to 
understand the relationships. Initially, individual factors and outcomes were analysed 
to establish correlations. Following this, multivariate analysis was used to provide 
insight into the complex associations between background characteristics, muscle 
physiology, and surgical outcomes: 
 
1. Patient characteristics was first compared to early surgical outcomes. 
2. Patient skeletal muscle physiology to surgical outcomes. 
3. Patient background characteristics to patient skeletal muscle physiology. 
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4. Finally, multivariate modelling of patient skeletal muscle and physiology 
factors was compared to surgical outcomes to identify combined 
relationships.  
 
The study’s Secondary Hypotheses are therefore: 
 Patient background characteristics correlate with functional surgical 
outcomes following primary total knee arthroplasty. 
 Patient muscle physiology at time of surgery correlates with functional 
surgical outcomes following primary total knee arthroplasty. 
 Patient background correlates with patient muscle physiology at time of 
surgery in patients undergoing primary total knee arthroplasty. 
 
While ultimate final recovery is the lasting impact of the surgical intervention, large 
variance is observed within patient populations during the very early recovery stage, 
up until 6-months following the surgical intervention. The rate of recovery does not 
always correlate with final functional outcome.  
 
The study’s Tertiary Hypotheses were therefore: 
 
Tertiary hypotheses: 
 Patient background characteristics and muscle factors affect very early 
functional recovery following primary total knee arthroplasty. 
 The pattern of recovery of different categories of outcome metrics vary 
during the early recovery stage in primary total knee arthroplasty 
population. 
 
The same statistical stepwise methodology was used to examine both very early 
functional outcome and primary outcome at the study’s final time-point. Temporal 
trends were examined and the relationships between the categories of outcome 
measures were assessed. The time-point at which the different outcome 
measurements plateau was also defined. 
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A longitudinal clinical cohort study of patients soon to undergo primary total knee 
arthroplasty were prospectively recruited to a study including the sharing of clinical 
data, collection of a muscle tissue biopsy, multiple questionnaire completion, and a 
series of research data collection clinics where functional tests and clinical outcomes 




A maximum follow-up time-point of 12 months post-surgery was set. As many data 
collection points as reasonably possible were used. Subjects were consented to the 
study, assessed prior to surgery, had a skeletal muscle biopsy taken during surgery, 
and then assessed at numerous time-points up until 12 months. 
 
Routine Clinical Context 
 
To aid observational surgical cohort study design, routine procedural steps were 
established. The patient protocol stages for total knee arthroplasty in the local 
university hospital are displayed in Table 3. 
 
Variations in this protocol occur if a patient becomes medically unwell. Additionally, 
during recovery, variation occurs between patients who are referred for 
physiotherapy intervention in the community, those who self-refer, and those who 
do not undertake any intervention at all. 
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Table 3 – Time-points for routine clinical protocol for total knee arthroplasty patient at the Orthopaedic Surgery 
Department, Royal Infirmary of Edinburgh, NHS Lothian. Protocol correct as of August 2017 at study outset. 
Time-point Patient Activity 
Surgery -2 weeks  Attend outpatient pre-assessment clinic for preoperative baseline health and 
social checks. 
Day of Surgery  Patient fasting solid food from night before. 
 Day of surgery health checks at Orthopaedic admissions clinic. 
 Wait in waiting area until set place on surgical list. 
 Anaesthetic administration. 
 Elective total knee arthroplasty surgical procedure. 
 Initial monitored anaesthetic recovery in theatre recovery area. 
 Transfer to in-patient recovery ward. 
Surgery +1 day  Standing, mobility, and functional status assessments performed by 
occupational and physical therapy teams. 
Surgery +3-5* days  Discharge from hospital into community once able to perform appropriate 
activities of daily living independently. 
*This step varies based on the strength and pain tolerance of the patient, and 
may be longer if the patient becomes medically unwell. 
Surgery +2 weeks  Removal of surgical clips by nurse practitioner in the community. 
Surgery +6 weeks  Attend hospital outpatient department for clinical assessment by arthroplasty 
practitioner or surgical team. 
Surgery +12 months  Attend hospital outpatient department for clinical assessment by arthroplasty 
practitioner or surgical team. 
 
The clinical protocol identified patient hospital visits. Connecting research data 
collection with these time-points was beneficial for both the research team and for 
potential participants, due to a reduced time and travel burden. Major data collection 
time-points were therefore linked to the routine clinical protocol. However, this did 
not allow a patient’s recovery trajectory to be measured, therefore a sub-cohort of 
patients was established who could attend extra appointments in the early post-op 
phase. Creating these time-points for all participants would not have been logistically 
possible and would have served to dissuade some individuals from participating at 
all. 
 
Data Collection Time-points 
 
The study time-points were selected to coincide with the routine clinical 
appointments and to access meaningful and insightful data. Initial post-arthroplasty 
functional recovery progression occurs at a faster rate (213). The typical functional 
difference between 1 and 2 months after surgery shows more improvement than the 
difference between 3 and 6 months, however there is individual variation. Capturing 
the nuances of this recovery trajectory were important, so more early recovery 
appointments were chosen, with decreased frequency closer to the final 12-month 
time-point. The data collection time-points were selected as Pre-Surgery and then at 
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6 weeks, 12 weeks, 6 months, and 12 months-post-operation. Additionally, two of 
the post-operative data collection time points coincided with the local NHS protocol 
at the time. Patients would routinely return to a clinic for assessment by an 
arthroplasty practitioner at roughly 6 weeks and 12 months after surgery. 
 
The collection of functional data at the surgical pre-assessment clinic (PAC) 
attendance was not thought to influence physiological data in the surgical biopsy due 




As an explorative study to determine relevant factors, no formal power calculation 
was performed. The recruitment target was determined by surgical list access and 
the recruitment time window and set at 100 patients within a 4-month window based 
upon patient availability.  
 
The cohort comprised of patients from the local area who were to undergo primary 
total knee replacement following diagnosis of end stage osteoarthritis. The annual 
operating rate at the local hospital site is roughly 700 primary TKA operations per 
year. This workload is divided between approximately 15 consultant orthopaedic 
surgeons. While potentially a variable controlling factor, recruiting study participants 
from the surgical list of only one consultant surgeon would have limited recruitment 
potential. As such, 11 surgical teams participated in biopsy collection. The nature of 
the standardised arthroplasty procedure, similar training background of all the 
surgical teams, and the diagrammatic explanation of requested biopsy location, all 
served to reduce concern about variation. The target recruitment for the study was 




Core criteria were established for the screening of potential participants. They 
allowed for careful selection of patients to prevent approaching anyone who had any 
confounding conditions.  
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Inclusion criteria were to include elective surgery listing, ability to consent, and an 
agreement to attend follow-up research clinics. The study exclusion criteria were to 
include comorbid factors that would directly affect function, TKA procedures 
performed solely for pain relief, and factors limiting data collection such as a lack of 
fluency in English. 
Formalised criteria are tabled in the Methodology section. 
 
Clinical Research during Routine Clinics 
 
To arrange clinic access to approach patients and collect data, setting agreed access 
times to routine facilities were a key part of the research project. Access is 
coordinated in the United Kingdom (UK) as Site Specific Approvals with the local 
hospital facilities. This was organised with the NHS Lothian Research and 
Development Office who considered the proposed research plan and how it would 
affect local routine practice. 
 
Permission to conduct a Clinical Research Study 
 
In order to perform research using human participants, ethical review and permission 
was sought for the proposed protocol. In general, the ethical review process serves 
to safeguard their rights, dignity, and safety (283,284). 
 
A system exists to streamline the process of applying for Research Ethics Committee 
and NHS Research and Development study permissions, named the Integrated 
Research Application System (IRAS) (285) (BGO Software, Sofia, Bulgaria). Once 
complete, the application forms are automatically generated in PDF format for each 
authority to review. 
 
Muscle Assessed Knee Replacement Outcome – The MAKRO Study 
 
All local clinical studies are provided an acronym for reference purposes. The study 
acronym was created and styled as the Muscle Assessed Knee Replacement Outcome 
study, or MAKRO study. The study was also given a longer study title of ‘Intrinsic 
muscular physiological factors contributing to early outcome status after primary 
total knee replacement’. 
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Ethical approval was granted by South East Scotland REC (REC:17/SS/0088) in July 
2017 and NHS Lothian agreed to act as research sponsor (R&D:2017/0189). The study 
was registered on the NHS Health Research Authority website database (286). The 
approval documents and the summary study overview can be found in the Clinical 
Study Approvals, Notices appendix.  
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Recruitment Documentation Development 
 
The patient information sheet (PIS) was used to inform the patient about what would 
be required of them to participate in the study. The consent form was used to 
explicitly state the necessary permissions for when the patient was agreeing to study 
participation, and to collect their signature. 
 
The PIS content informed the patient about several legal aspects of the study. The 
confidentiality aspects whereby all identifiable data were subject to the Caldicott 
Guardian controls (287). That all samples would be eventually discarded in line with 
the Human Tissue (Scotland) Act 2006. Additionally, it included the details of the 
study organisers, sponsors, ethical approval details, and contact information 
regarding requesting any further information or making a complaint. 
 
The consent form explicitly asked for permission for the research study to access their 
medical records, collect a tissue biopsy sample, for analysis to be performed on the 
sample, for their GP to be contacted, and for the waiver to any financial gain from 
participating. They also confirmed that they had read the PIS, considered all the 
information, and had asked all questions that they had.  Lastly, they were aware they 
could withdraw from the study at any time and without the need to provide a reason. 
 
The PIS was designed with lay accessibility and reading age in mind. The Flesch 
reading ease score evaluates average word and sentence length to provide a widely 
used approximation of readability (288). The document attained a Flesch reading 
ease score of 60.7. The majority body of the text achieved a score above 70, but the 
necessary inclusion of technical aspects lowered this overall. The scores achieved 
ensured ease of document comprehension for the patient demographic. The Tegner 
has a low Flesch reading ease score due to its listicle structure (289). As such, it was 
discussed with every participant in detail (Appendix A: Clinical Study Documentation). 
 
Patient study data were handled in line with local policies and all legal requirements. 
Identifiable physical data were stored in locked areas accessible only to study 
approved personnel on within NHS facilities.  Digital identifiable data were located in 
NHS servers with similar access controls. For analysis purposes, all data leaving these 
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areas were pseudonymised to allow transport and use with University areas and 
computers for study purposes. 
 
During the study, the General Data Protection Regulations (EU 2016/679) came into 
effect via the Data Protection Act 2018. The patient informed consent process as part 
of study participant enrolment covered all aspects of required data use during the 
study. Patients were also reminded of this and their rights as research study 
participants during follow-up clinic visits followed this change in law. 
 
Baseline Participant Data Selection 
 
Patient identifiers and relevant background data were initially collected during initial 
appointments. These data served to categorise patients demographically and to 
ascertain background characteristics. Data included are listed in Table 4. 
 
Table 4 - Data collected as part of the study baseline interview with study participants. 
Study participant baseline data collection 
Criteria Additional information 
Occupation(s) Sedentary / Labour 
Other lower body arthroplasty Previous lower body joint replacements 
Bloods Haemoglobin, Urea, Potassium, 
Creatinine, Alkaline Phosphatase, 
Gamma-glutamyl transpeptidase, 
Alanine aminotransferase, Bilirubin. 
Comorbidities Discussion following Charlson 
Comorbidity Index questionnaire 
European (Scottish) Tegner Score Peak fitness, last year, currently 
X-ray Kellgren & Lawrence Score 
Dominant side (Left / Right / Ambidextrous) 
Smoking Current, history, when stopped. 
Alcohol Current, history, when stopped. 
 
Case Report Form Data Selection 
 
The study case report forms (CRFs) were used to record data at each study time-point 
visit. Multiple patient identifiers were included to confirm participant identity. These 
were provided linked anonymised identifications for later analysis. 
 
Each CRF recorded time-point biometric information and functional performance 
data. These were separately obtained from functional assessment instruments and 
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battery tests. Patient general health state and relevant recent information was also 
recorded.  
 
Functional Assessment Selection 
 
Several methods for evaluating functional outcome assessment of TKA patients were 
evaluated. These were based upon OARSI recommendations and local constraints. 
 
Existing pieces of equipment were independently evaluated as to whether or not they 
would provide valuable insight into the assessment of the patient group. Some pieces 
of equipment were discounted due to risk assessment conclusions such as weighted 
tests or tests that may result in a patient fall or stranding. All tests had to be 
performed within or adjacent to an allocated research space embedded in the Royal 
Infirmary of Edinburgh’s (RIE) orthopaedic outpatient department. While the 
potential existed to pursue these in other locations, a combination of limitations 
including the existing available space, support facilities such as waiting areas and 
administrative staff, and the whether an area was appropriate for the evaluations to 
take place in were taken into consideration. Additionally, while some clinical research 
appointments could take place during flexible windows, others were constrained by 
NHS clinic frameworks. The clinics set appointments to 20 minutes which directly 
limited the volume of data that could be obtained. 
 
The Aggregated Locomotor Function (ALF) score, and the Nottingham Leg Extensor 
Power Rig were chosen alongside biometric measurements (290,291). The ALF score 
provides a composite timed score representing many of the recommended OARSI 
performance test criteria and utilised department facilities as best possible. The 
Nottingham Leg Extensor Power Rig directly assessed quadriceps power strength and 
provided a comparison to body weight (7,124,292,293). All tests are considered valid, 
reliable and responsive functional outcome assessments within a TKA population. 
 
When studying recovery, a patient appropriate control is used. This can be age and 
sex matched, however leg strength and functional performance will still significantly 
vary when this is performed. A potential control to a limb intervention is the 
contralateral joint. While controlling for many aspects, a reality of the OA TKA 
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population is frequent presence of bilateral symptoms. The variation and progression 
of these symptoms can therefore change per assessment time-point and confound 
results (128,294,295). To prevent these discrepancies, when assessed as non-
symptomatic, the contralateral results at baseline can be used as control for the 
duration of the study, however the bilateral symptoms may still impact this. For 
example, in a patient awaiting staged arthroplasty on the contralateral knee. 
 
Output data from the Nottingham Leg Extensor Power Rig included raw power 
generation in Watts and a normalised value controlling for body weight. This controls 
for sex and stature of subjects (291). Data were recorded for both the operated leg 
and the control leg at each time-point. They were displayed as a ratio. Both raw 
output and power-to-body-weight ratio were recorded to provide a range of metrics 
from the assessment. 
 
Activity Monitoring Device Criteria 
 
Community-measured activity levels were a chosen metric for participant 
assessment. The selection of an economic and reliable device was necessary. 
 
A sample of ActivPal devices were trialled for this study but frequently detached from 
their leg placements on departmental volunteers, and reported patchy data when 
analysed. 
 
The factors of price, availability, features, and reliability were considered while 
creating a short-list of replacement devices. A wearable device was necessary to 
reflect the full depth of activity data. On consultation with a patient group, the 
undesirable connection was made between potential ankle-based research activity 
monitors and similar devices used by the criminal justice system (296,297). 
Comments were made that such devices would likely be removed by study 
participants, resulting in missed data capture. As such, the social context much 
favoured a watch-like wrist-based activity monitored for protocol adherence. 
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Factors dictated a device that would be provided to study participants during clinic 
visits, to be worn for a period of time following the clinic, then returned via postal 
mail, and synchronised upon return to capture the data from the time period. 
 
Activity Monitor Selection and Data Collection 
 
The Mi Band 2 device (Xiaomi, Beijing, China) demonstrated multi-test reliability of 
features compared to other devices and possessed a reasonable price point (235). 
Functions include step count, heart rate, approximations of calorie expenditure, 
sleep duration and depth, long battery life, and a IP67 waterproof rating (298). It 
additionally had the flexibility to interact with third party applications in order to 
divulge raw device data. 
 
Several applications were evaluated for suitability, with the expansion to virtual 
machine providing greater application flexibility. The VirtualBox desktop hypervisor 
(Oracle Corp., CA, USA) allowed for emulation of the Androidx86 Marshmallow 6.0 
operating system (Google LLC, CA, USA). A bridge was created to Bluetooth hardware 
to allow device synchronisation to the machines. 
 
The applications Mi Band Master and Notify and Fitness for Mi Band were established 
as the third-party applications of choice. Both are available on the Google Play 
application listings. They allowed for fine control of the data capture alongside 
facilitating the export of raw data via the Dropbox cloud repository (Dropbox Inc., CA, 
USA) in SQLite database file format. Files are accessed through the DB Browser for 
SQLite open source software application and exported to comma separated value 
(CSV) files for analysis. Raw data time-points use Unix timestamps which count the 
number of seconds elapsed since the start of January 1st, 1970. Having established a 
working protocol, an additional 9 devices were ordered, each of which had a cloned 
virtual machine created to unify the device settings and recording instructions. 
 
The duration of data collection was decided based upon the device battery life and 
the interval between research data collection points. A number of devices had to be 
ready at all times for data collection, while others may be in use. With daily patient 
recruitment expected at the start of the study, a reasonable compromise was made 
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between data collection and device readiness. As such, a period of four whole days 
was set for data collection. This allowed both for representative data capture and for 
reasonably prompt device return, especially in time for the latter time-points’ weekly 
research clinics. This duration also reduced the patient burden. 
 
Regarding the collected data an evaluation was made of the hierarchy of data quality. 
The step count showed strong reliability considering the limitations mentioned 
earlier. Any periods of waking at night, defined by movement level, were recorded 
separately. Patient pain and comorbidities may influence sleep data, but are factors 
which are very relevant to the target investigational cohort.  
 
Reporting of activity tracking data was therefore average daily step count taken from 
midnight to midnight over 4 days, average resting heart rate between 02:00 and 
04:00 over 4 days, and average nightly sleep duration taken over 4 days. The devices 
collected walking vigorousness, and walking cadence, however there was a lack of 
clear defining boundaries between device defined categories. 
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Care must be taken with questionnaire selection as each questionnaire or PROMs 
tool has been developed for a specific target audience. This includes specific patient 
groups, population demographics, or specific international classification of disease 
(ICD) audiences. 
 
PROMs tools are subjected to analysis during development to prevent suggestive 
scenarios, narrow or confusing answer ranges, floor or ceiling effects, validity, 
sensitivity, responsiveness, or other non-representative scenarios leading to 
anomalous data (299). Many PROMs questionnaires provide a numerical output for 
each dimension or as a total through their scoring rules. The majority of these are 
scored through two styles of question; numerical rating scales (NRS) and visual 
analogue scales (VAS). NRS can be binary or Likert scales. Likert scales comprise an 
odd number of usually ordinal categories as answers to a question. The odd number 
of categories allows for a central neutral category; however, this is not always used 
for this purpose. VAS are used to measure subjective attributes that are hard to 
directly assess. They have continuous line with stated book-end descriptions at the 
edges where the subject selects a single point on the scale that reflects their answer 
(300). In hard copy questionnaires, recording of answers is performed by NRS tick 
boxes and indicating VAS with a drawn vertical line. 
 
Scores are generally cumulative for each PROM dimension and may at times all be 
combined for a tool total. For each of these cumulative scores, a rubric specific to the 
tool applies. 
 
While prominently useful in remote data collection, the use of PROM questionnaires 
allows for time saving within a clinic as they can be filled out by patients in waiting 
areas or remotely by postal questionnaire. As such hard copy questionnaire batteries 
were chosen for recording the bulk of this style of clinical outcome data. 
 
Patient questionnaire burden is a factor to be minimised so the dovetailing of existing 
required departmental questionnaires with study specific batteries was vital (301). 
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The consideration of burden was also central to selecting the group of questionnaires 
to be used with the study participants. 
 
The frequently unsupervised nature of PROMs data collection can lead to missing 
data such as a skipped question. In best practice, patients can be contacted to fill in 
missed data points, but this is not always possible. Many PROMs tools account in 
their formulation for this occurrence but it must be acknowledged as a potential 
factor in the selection of PROMs as a data collection method. For example, in the use 
of algorithms to retain a comparable outcome score. 
 
During PROM tool selection, all of these criteria must be considered to ensure 
collected data is reliable and appropriate to the study. 
 
PROMS for Knee Osteoarthritis and Total Knee Arthroplasty 
 
There have been many PROMs tools developed for use the target study population. 
Considered examples relevant to the study cohort are listed in the Study 
Methodology Development appendix. The aim was to use a group of questionnaires 
that would encompass a range of functional, symptomatic, and lifestyle criteria. 
 
A general health and activities of daily living assessment was included as part of the 
battery. The 36-Item Short Form Survey (SF-36) is a prominently used example of this 
but takes a relatively long time to complete (302–304). It was established that the 
Knee Injury and Osteoarthritis Outcome Score (KOOS), Oxford Knee Score (OKS) and 
EuroQol Five Dimensions Questionnaire (EQ-5D) questionnaires would cover similar 
ground while retaining a desired knee joint focus in the KOOS and OKS. 
 
MAKRO Study – Chosen PROMs 
 
Having considered the desired data and the nature of each candidate PROMs tool, a 
final group were chosen to move forward with. PROMs tools selected for the study 
are listed in Table 5. 
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Table 5 - PROM tools used within questionnaire groups during the MAKRO study. 
PROM tool description PROM focus Reference(s) 
Charleson Comorbidity Index (CCI) Comorbidities (305) 
EuroQol Five EuroQol Five 
Dimensions Questionnaire (EQ-5D) 
Health related quality of life 
index measure 
(306,307) 
Forgotten Joint Score (FJS) Joint specific tool (308) 
Knee Injury and Osteoarthritis 
Outcome Score (KOOS) 
Joint specific activities 
assessment 
(309) 
Oxford Knee Score (OKS) Joint specific tool (310) 
Patient Satisfaction (Edinburgh) Surgical satisfaction (311) 
Tegner Activity Score (TAS) 
(modified for Scotland based on 
Scandinavian version) 
Work and sporting activities. (312–314) 
Visual Analogue Scale Pain Scores 
(VAS) 
Pain levels (315) 
 
The CCI was included to cover aspects of relevant comorbidities that may not be 
overtly present in the patient’s notes. A modified version known as ‘Complications’ 
was included for post-operative answering to identify any important health issues 
resulting from or relating to the surgery. For example, a surgical complication leading 
to a prolonged hospital stay following surgery would influence the physical functional 
decline (316). Similarly, the presence of pain in a lower limb unrelated to the knee 
replacement operation would affect functional measurements. This was recorded 
separately in the Case Report Forms (CRFs). 
 
The EQ-5D, OKS and aspects of the KOOS covered quality of life and ADLs. Knee 
function was covered by OKS, KOOS, and FJS. Wider activity factors were covered by 
the KOOS and the Tegner. The chosen tools offered differing and complementary 
psychometric properties. The whole battery was of reasonable length to be 
manageable and not a burden as evaluated by an informal consultation with local 
patient group. 
 
The chosen range of questions covered self-care, acute symptoms, mental health, 
activities of daily living (such as washing or shopping), recreational activities, surgical 
satisfaction, and complications. This wide range allowed insight into many relevant 
aspects of patient recovery. 
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Tissue Samples and Biopsy Location 
Biopsy sampling techniques 
 
The biopsy was taken from the quadriceps muscle group. Both punch biopsy and 
open biopsy techniques were considered: 
 
Punch muscle biopsies were originally pioneered in 1868 by Duchenne and are taken 
percutaneously (317). Modern popular muscle punch techniques include the 
Bergström needle (318) and Tru-Cut needle (319). They are performed using basic 
sterile considerations and do not require a specialised environment.  They allow 
repeat sampling with relative ease, unlike open biopsies, and carry less risk of 
infection, however they do require specialist training. 
 
Open biopsies of muscle groups require an incision and surgical operating theatre to 
provide the necessary infection controls and anaesthesia. This has a greater staffing 
requirement and cost. 
 
Primary total knee arthroplasty is an open procedure and enabled an open biopsy to 




Due to the expected finite and scarce nature of the proposed study’s biopsies, the 
optimisation of laboratory techniques took place where possible on non-study tissue 
samples. Other skeletal muscle tissue was collected locally for this purpose through 
tissue defined as discard material from similar local limb orthopaedic surgeries in an 
anonymous route akin to internal biobanking (320). This tissue is routinely excised 
during procedures and is normally destined for clinical waste incineration. Following 
an informed consent process with the patients prior to surgery, and with the 
permission of the local consultant surgeons, this tissue could be retrieved. The 
research was conducted under local ethical permission (LREC number: 2002-1-22; 
R&D study number: 2002/R/OST/02). 
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The procedures where the tissue was collected from were anterior cruciate ligament 
(ACL) repair operations that used hamstring tendon. Hamstring tendon, usually 
semitendinosis tendon, is harvested and grafted to the native ACL insertion loci (321). 
The skeletal muscle attached to the tendon at time of harvest is removed and 
destined for clinical waste incineration in routine practice. With the patients’ 
informed consent, this allowed for tissue collection for research optimisation use. 
 
Local hospital Total Knee Arthroplasty technique and biopsy location 
 
All local consultants and their teams used the medial parapatellar approach to access 
the knee joint during total knee arthroplasty operations. This approach routinely 
disrupted and exposed the vastus medialis muscle along the medial border with the 
quadriceps tendon and the patella. This exposure allowed for collection of the 
skeletal muscle biopsy without meaningful procedure alteration or an additional 
procedure. The approach, exposure, and biopsy sample site are shown in Figure 7. 
 
The image was shown to all surgeons involved in the tissue biopsy procedures for 
study patients. All were given the chance to ask questions and instructed to retrieve 




Figure 7 - Peripatellar approach to total knee arthroplasty. Images from Hoppenfeld et al (61); Swann Morton. 
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The ‘pea sized’ biopsy sample were collected consistently between surgeons. The 
biopsies were transferred via dry-swab from the surgeon’s scalpel to outside of the 
operative field, the biopsy was then placed into a sterile universal tube containing 
woven-gauze slightly dampened with saline. This method was included to prevent 
drying of the sample (322). Full immersion in saline or other solutions as an 
alternative would have created large sample artefact from osmotic pressure 
differences. Immersion in a fixative at this stage would have limited subsequent 
laboratory processing and analysis, so the decision to keep the samples fresh prior to 
processing was made. The biopsies were transported back to the research laboratory 
on an ice pack inside two sealed boxes. This took place within a maximum of 30 
minutes from the harvesting of the biopsy.  
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Methodology 




Patients fitting study participation criteria (Table 6) were initially approached during 
their surgical pre-assessment clinic (PAC) hospital appointments. These occurred 
roughly two weeks prior to surgery. The clinic lists were screened by members of the 
clinical team for exclusion criteria, leaving a white-list of potential participants. 
Patients were asked if they would consider participation in a clinical research study 
and, if amenable, would be provided with a copy of and an explanation of the patient 
information sheet, and given the opportunity to ask any questions. They were then 
given the rest of their clinic visit to consider their participation. If happy to participate 
in the research study, they were provided with a consent form to sign, allocated a 
study identification number, and provided with the PAC study questionnaire. All 
aspects were performed by the researcher. Following the clinical aspects of their PAC 
appointment, baseline physical study measurements were taken. Study 
documentation are located in the Clinical Study Approvals, Notices, and 
Documentation appendix. 
 
Not all patients who were listed for primary total knee replacement surgery in the 
hospital were approached. The main factor in these instances was the dates and 
times of appointments not coinciding with the researcher’s attendance. This 
occurred due to clinic and surgery, or clinic and laboratory time-conflicts. 
 
Table 6 - Inclusion and exclusion criteria for the MAKRO study at time of study design. Notable is the 5th inclusion 
criterium which was subsequently adjusted. These were subsequently amended as discussed due to further 
logistical and clinical considerations. 
MAKRO Study Population 
Criteria Inclusion Criteria Exclusion Criteria 
1 Adult osteoarthritic patients undergoing 
primary knee replacement surgery. 
Don't meet all inclusion criteria. 
2 Willing and able to consent to and comply 
with the protocol. 
Planned bilateral procedures within the 
study period. 
3 Ability to consent. Procedures done solely for pain relief 
(e.g. as part of end-of-life pathway). 
4 Aged at least 16 years old, there is no upper 
age limit. 
Activity blocking pain in their hip/knee. 
5 Ability to attend follow up assessment clinics 
at RIE site, where they may otherwise attend 
satellite clinics. 
Those not fluent in English. 
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The location of follow up assessments (inclusion criterium 5) was changed due to 
repeated requests from potential participants and became reflected in the study sub-
cohorts. The second exclusion criterium, of staged bilateral procedures, was strictly 
adhered to at time of surgery. However, one of the participants had bilateral 
procedures during the one operation which provided an opportunity to assess 
bilateral recovery rates. No other participants had planned procedures at time of 
recruitment, however within 12 months of initial surgery, some were subsequently 
listed and underwent a contralateral procedure. It would have been unethical and 
not feasible to prevent this from happening. Their early functional data was still of 
use, and any subsequently collected PROM data was specified to the study knee.  
 
Study co-enrolment was allowed however no individuals were co-enrolled in 
research studies during the duration of the study to the knowledge of the researcher, 
outwith the ongoing local department research database. Full notices and contact 




Participants were provided with sub-cohort options for taking part in the study. These 
had different levels of interaction with the researcher during TKA follow-up. The 
stratification into cohorts was necessary to achieve the maximum possible 
recruitment in the given timeframe. A trade-off was made between the depth of the 
functional data and the number of potential biopsies to be collected, and subsequent 
physiological data. To collect the full data set on all participants would have both 
been an excessive burden on the research and clinical departments but would also 
have served to deter participants. This was confirmed by patient feedback. 
 
The study recruitment was initially divided into two cohort participation options. 
One, named the Routine cohort, would attend their normal routine clinical post-
arthroplasty appointments and spend some time during these appointments with the 
research team.  The other, titled Enhanced cohort, would attend these plus two 
additional post-operative appointments. The Enhanced cohort additionally was the 
focus of the activity tracker data collection. This cohort was also provided with 
reasonable travel expenses for the two extra appointments as these were not within 
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NHS clinic frameworks. The pathways of participation are displayed in Figure 8 which 
was provided during potential participants’ PAC visits. 
 
 
Figure 8 - The MAKRO Study participant cohort pathway options of Routine and Enhanced cohorts with activity 
details. This was provided to potential participants during their surgical pre-assessment appointments for their 
consideration as part of the requesting informed consent process. 
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Latterly, an additional cohort formed where participants could opt to participate in 
the Routine framework but elect to take their follow-up appointments at regional 
clinics due to their living circumstances. The nature of the catchment and 
demographic for the orthopaedic surgery department at the Royal Infirmary of 
Edinburgh encompassed many patients from the surrounding counties. These 
patients were glad to take part but felt overly burdened to make a journey lasting for 
some several hours to attend subsequent appointments. They were still content to 
provide baseline measurements, provide a biopsy for analysis, and to fill in post-
operative postal questionnaires, but were unable to attend for follow-up functional 
assessments. These participants became known as the West and East Lothian cohort, 
named after the neighbouring district counties, shortened to the WEL cohort. 
 
The three study cohorts can be summarised as follows. The base level ‘WEL’ cohort 
provided base-line measurements, had a muscle sample taken during their knee 
replacement surgery, and filled out post-op postal PROM based questionnaires. The 
‘Routine’ cohort provided a sample, had functional measurements taken at all 
routine NHS follow-up time points, and filled in postal questionnaires at the other 
time-points. Lastly, the ‘Enhanced’ cohort provided a sample, had functional 
measurements taken in the clinic at all time points, and were additionally assessed 




The chosen clinical outcome measurements, and patient reported outcome 
questionnaires were arranged into a machine-readable document format and printed 
(see MAKRO Study – Chosen PROMs section in Methodology Development). 
 
For the study specific data, in addition to the time-point questionnaire groupings and 
case report forms (CRFs), baseline measurements of participants were recorded. The 
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Research Clinic Format 
 
The research clinic assessments of study participants were standardised across all 
time-point. For the initial pre-operative assessment, additional baseline 
measurement and details were also recorded. These were recorded in Case Report 
Forms (CRFs) and in the Baseline Report Form for the initial details.  
 
All assessments were conducted in or next to a clinical assessment room designated 
for research purposes within a hospital outpatient department. 
 
Patient details were recorded by name, date of birth, unique hospital patient 
identifier (UHPI) number, community health index (CHI) number, along with details 
about surgery date and operated knee details. 
 
Patient complications, anecdotal functional issues or activity milestones were initially 
recorded at the start of each clinic assessment. Patient height and weight were then 
recorded with calibrated NHS Lothian stadiometer and mechanical scales (Seca 
GmbH, Hamburg, Germany). Patient bioelectrical impendence was recorded with a 
handheld body composition monitor (Omron BF306, OMRON, Kyoto, Japan) and 
computed internally via combined algorithms (323–325). Current medication and 
mobility aid use was also recorded. The range of movement of each knee was 
recorded with the patient allowed to apply light pressure to manipulate their leg into 
position. Measurement was made of the passive position that they could comfortably 
hold their knee at. 
 
Using a Nottingham Leg Extensor Power Rig, patients were asked to perform warm 
up exercises on the machine to ensure they were comfortable in the assessment 
position. This encompassed leaning slightly forward in the seat and for the seat to be 
adjusted to allow full extension of the assessed leg. Maximal extension actions were 
requested with the instruction given to push as hard and fast as possible. Operated 
legs were assessed first followed by contralateral legs. Three consistent repetitions 
were recorded per leg, with reasonable breaks given between them. If a notably 
lower measurement was recorded, due to a slip or similar, another repetition was 
measured. 
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Patients next performed the Aggregated Locomotor Function timed test battery 
beginning with a timed up-and-go from a seated position containing a walk to a line 
2m from the seat, then turn around, walk back, and sit down again. The second part 
of the test was a timed stair-set ascent and descent. Three steeper stairs were 
ascended, followed by a 90 degree turn at a landing following by a descent of four 
shallower stairs. Once down, the timer was reset, and the patient retraced their 
steps. An average of the two stairs exercises was recorded. Patients were advised to 
the use the dual bannisters for balancing purposes only, with a test repeat performed 
if they noticeably swung on them. This was required due to the ALF test validation 
representative of a “natural comfortable pace” (290).  Lastly the patient’s eight-
meter-walk-test was recorded in an adjacent corridor comprised of a straight line 
walk to the instruction of at a comfortable pace equivalent to that on the street 
pavement. The marked distance was slightly longer to allow for acceleration and 
deceleration. 
 
Finally, average and maximum reported knee pain on a numerical rating scale was 
recorded. Additionally, at the 6-month post-op time-point, a measurement of knee 
and thigh circumference was made. This was measured either over tight clothing or 
against the skin. The patella mid-point marked the knee measure point, and the thigh 
was measured one third of the distance up the thigh to the hip. All circumference 
measurements were performed while the patient was standing. 
 
Patient Reported Outcome Measures (PROMs) questionnaire batteries were filled in 
while in the waiting area or following assessment before leaving. If the time-point 
and cohort did not coincide with a research clinic visit, these were completed by 
return-post instead. 
 
Activity monitors were provided to participants of the Enhanced sub-cohort to be 
worn for 4 days and returned by post in a supplied prepaid padded envelope. Step 
count, heart rate, and sleep duration and quality were measured by internal sensors.  
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Patient Reported Outcomes Measurements (PROMs) 
 
The study PROM tools were the EuroQol 5 dimension 3 Likert tool (EQ-5D(-3L)), the 
Forgotten Joint Score (FJS), the Knee Injury and Osteoarthritis Outcome Score 
(KOOS), and the Oxford Knee Score (OKS). 
 
The EQ-5D(-3L) questionnaire determined patient generic health status through 5 
dimensions resulting in an output index representing quality adjusted life years 
(QALY). The dimensions are mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Two visual analogue scales (VAS) representing overall health and 
pain level are also reported. Index health status values below 0 are termed ‘worse-
than-dead’. 
 
The Forgotten Joint Score (FJS) comprises 12 questions covering different activities 
where a patient may or may not be aware of their joint. Forgetting a joint is 
representative of successful clinical treatment and normality in activity. 
 
The Knee Injury and Osteoarthritis Outcome Score (KOOS) assesses patients’ opinion 
of their knee across 5 dimensions; symptoms, pain, activities of daily living, sports 
and recreational activities, and quality of life. 
 
The Oxford Knee Score (OKS) examines patients’ recent pain and functional 
experience of their knee. 
 
The PROMs tools were used at each of the study time-points. Each study 
questionnaire battery was coordinated with the existing departmental 
questionnaires where required. The existing departmental forms remained unaltered 
and the study questionnaires were supplementary at those time-points. 
Departmental PROM questionnaires, for input into the Edinburgh Orthopaedic 
Research Database, were filled out by patients at their surgical pre-assessment clinics 
(PAC), and then sent by mail to their home addresses at 6- and 12- months post-
surgery. The three questionnaires varied in contents at each time-point. The 
coordination of each time-point in order to cover all PROMs tools with each repeated 
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aspect of the PROM battery is highlighted in Appendix A: Clinical Study 
Documentation. At 6- and 12-weeks after their operations, study participants were 
only given the study-specific questionnaires. 
 
For the PAC time-point, patients were given both departmental and study-specific 
questionnaires. Taking roughly 15 minutes to fill out, the hospital visit lasts a few 
hours and contains many breaks between seeing healthcare professionals when 
patients remain in a waiting room area. 6-week, 12-week, 6-month, and 12-month 
post-operative study PROM questionnaires were distributed in person where 
relevant to those from the cohorts who attended hospital clinic. Otherwise they were 
sent by post to their home addresses, with a coversheet and a pre-paid and 
addressed return envelope included. Where necessary, those who failed to return 
posted questionnaires within a reasonable time-frame were contacted by phone to 
make sure that it had arrived and that they had not encountered problems with the 
questions. 
 
The final arrangements of the questionnaires were submitted as part of the study 
ethical review process. This ensured, alongside estimations of reasonable length to 
avoid questionnaire fatigue, that the quantity, frequency, and length of study 
questionnaires would not be excessive. 
 
Once verified by the REC and the R&D Office, the questionnaires were formatted into 
their final form. A computer form and text recognition program owned by the 
department was used for this purpose. Formic Fusion (Formic Ltd, Uxbridge, UK) 
allowed for creation of the grouped questionnaires for each time point as approved. 
This software package also allowed for scanning and automated input of the 
completed questionnaires into .CSV format. The formatting process created single 
documents for each time-point which contained designator barcodes to allow for 
computer recognition of document item positioning. This allowed the program to 
identify the time-point and question ID. Scanning of the completed forms allowed for 
identification of which question box category had been ticked alongside other the 
information contained in the forms.  
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PROM Data Processing and Digital Input 
 
All PROMs questionnaires were digitally scanned and inputted into the Formic Fusion 
software. Questionnaire return-rate varied by cohort, PROM tool, and time-point. 
The very occasional skipped answers that occurred during questionnaire completion 
were chased where possible. 
 
After quality checks, the data was exported for processing. Due to the presence of 
identifiable data, NHS data governance policy dictated that this was removed before 
transfer from an NHS system. Subjects names, dates of birth, CHI (Community Health 
Index) numbers, and UHPI (Unique Hospital Patient Identifier) numbers were 
removed from the data. The remaining identifying characteristic was an allocated 
study number which was determined based on the individuals order of recruitment 
to the study. The collected patient reported outcome measure tools were processed 
and analysed in accordance with their stated algorithms.  
 
Once exported in this manner, data were processed using Microsoft Excel software 
(Microsoft Corporation, WA, USA). For each PROM tool, the relevant scoring rubric 
was used. The final score of each tool total or tool subscale allowed for various 
analyses and comparisons. 
 
Activity Monitoring Data Processing and Digital Input 
 
Activity monitors were synchronised with virtual machines for data capture. Physical 
devices were sterilised with Distel (Tristel Ltd, Suffolk, UK) and Virkon (Lanxess AG, 
Cologne, Germany) before synchronisation, charging and reallocation. Raw data was 
exported and categorised into daily step count, heart rate averages, and sleep 
duration and depth. Step count data were averaged over 4 days, and sleep data from 
3 nights. For ease of analysis, and comparability, sleep depth was calculated as a ratio 
of minutes of light sleep to minutes of deep sleep. 
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Tissue Samples 
 
A quadriceps sample was taken at time of surgery from the patient’s leg undergoing 
total knee arthroplasty. Samples were taken from vastus medialis at a single 
standardised location. 
 
The majority of the samples were transported directly to the laboratory for 
processing immediately upon retrieval. The simultaneous surgical procedures of 
some patients, for example for those enrolled in the study who were operated upon 
at the same time in neighbouring theatres, caused the time window variation. 
However, all samples were transported to the laboratory within 30 minutes of 
retrieval, prior to preservation processing. 
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Chapter 4: Laboratory Methodology 
 
Methodology Development 
Sample Processing and Preservation Methodology Development 
 
Samples were to be fresh-frozen and fixed in tandem to provide back-up options. 
Sample fixation was performed using 4% buffered formaldehyde prior to wax 
embedding. Multiple options were evaluated for the fresh- or snap-freezing method. 
 
Multiple cooling methods have been used in the literature to freeze preserve muscle 
tissue for clinical or research purposes (322,326). These include dry ice, liquid 
nitrogen, isopentane, and other alkane family chemicals. 
 
Freezing through slow cooling or through snap freezing in liquid nitrogen create 
freeze artefact thereby disrupting histological analysis (327). This occurs due to the 
slow cooling facilitating local tissue gaseous content expansion, and from local water 
freezing in a crystalline manner (328). Despite being colder than the isopentane, 
relatively hot objects immersed in LN2 are momentarily insulated from the 
temperature differential because of vapor film formation due to the Liedenfrost 
effect (329–331). Isopentane thermal conductivity is greater than that of nitrogen 
and therefore cools a tissue biopsy sample more rapidly (Table 7). 
 
Table 7 - Thermal properties of nitrogen compared to isopentane as candidates for study protocol snap-freezing 
liquid (332–335). 
Material Melting Point Boiling Point Thermal Capacity 







Nitrogen -210°C (63K) -196°C (77K) 70 (77K) 0.138 (77K) 
Isopentane 
(2-methylbutane) 
-160°C (113K) 28°C (301K) 29 (113K) 0.171 (113K) 
 
Cooled propane or hexane were alternative frequently used options for snap-freezing 
tissue. However, due to their flammable properties, higher freezing point for hexane, 
and a boiling-point of -42C for propane, they were excluded during protocol risk 
assessments. 
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Snap freezing with isopentane cooled in liquid nitrogen was therefore selected as the 
snap-freezing sample preservation method. 
 
Histological Methodology Development 
 
Where possible, a number of sections are used to enhance reliability of the histology 
findings. Variables of the sectioning technique, including temperature, static 
electricity controls, and section thickness can affect results. 
 
Cryosectioning and Slide Mounting  
 
Samples needed to be cut into sections to undergo histological processing and 
analysis. Cutting samples into thin sections in this way allowed for visualisation of 
internal structures and for effective penetrative diffusion of the staining materials. 
Due to the more versatile nature of the snap frozen samples, these were used for all 
histological procedures. 
 
Continued preservation of the sample architecture integrity was paramount at this 
stage. As such, samples needed to be sectioned at low temperature using a cryostat 
– a microtome within a freezer. A low temperature of -20C, a 20-degree cut angle, 
and 8m thick sections were evaluated as optimal through experimentation with the 
discard muscle tissue obtained from patients for technique optimisation. 
 
Initial cryostat chuck mounting required careful arrangement to prevent the 
development of freeze artefact. The use of Optimal Cutting Temperature (OCT) 
compound (VWR – 361603E) aided this process. OCT allowed for thin sectioning and 
ease of slide mounting due to the increased surface area compared to the sample 
alone, reduced section rolling propensity, washed away easily during the staining 
process, and did not dull the microtome blade. Stored as a colourless liquid at room 
temperature, OCT became a white solid once cooled below -10˚C which provided its 
favourable properties. Once set, excess OCT was trimmed with the blade before 
sample sectioning. 
 
Chapter 4: Laboratory Methodology 
  79 / 309   
Once cut, the sections were mounted on Superfrost Plus Gold Adhesion slides. The 
glass slides slides were coated and statically charged to aid their tissue binding 
properties. Initial optimising run use of basic, non-charged, non-coated slides led to 
frequent tissue loss during the staining protocols. This necessitated the use of 
specialised adhesion slides. 
 
Sections were mounted two, three, or four to a slide for each patient sample 
depending on the destined staining protocol. 
 
Histochemical Staining Optimisation 
 
Initial histological analysis utilised a simple Haemotoxylin and Eosin stain to identify 
microscopic anatomy for purposes of orientation. Haemotoxylin to stain nucleic acids 
and eosin to stain protein and highlight cytoplasm. The protocol utilised classic 
immersion rack and jar staining technique, tap water wash outs, dehydration steps 
and clearing with histochoice (as an environmentally friendlier alternative to xylene). 
The full protocol and materials list can be found in the Histology appendix. 
 
The tissue was consistent with the expected anatomy of skeletal muscle and there 
was a mix of muscle fibre orientations (Figure 9). The biopsy’s proximity to tendon 
interface suggested there may be connective tissue amongst the tissue sample. 
Samples were visually trimmed of any tissue other than muscle prior to processing, 
which was confirmed as successful by the histological staining. 
 
Staining to identify sample fibre-types was initially performed through the 
histological adenosine triphosphatase (ATPase) stain (materials and protocol in 
Histology appendix). The ATPase stain visualisation functions through the chemical 
process of cobalt replacing captured calcium in the presence of phosphate. This 
process is able to differentiate the fibre classes from their defining glycolytic 
properties resulting in different levels of phosphate and calcium (20,322). The varying 
use of pH leads to different coloured attributes. Usually, Type 1 slow-twitch skeletal 
muscle fibres stain light and type 2 fast-twitch fibres stain dark. However, the stain 
was found to be sufficiently inconsistent in the optimisation tissue that other options 
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were explored. Examples of successful and poor staining with this method are given 
in Figure 10. Immunohistochemical stains were found to be more reliable for the 
purposes of skeletal muscle fibre type identification (336). 
 
 
Figure 9 - Haematoxylin and eosin staining of human skeletal muscle tissue during the optimisation process. Some 
freeze artefact is present.  A) Transverse orientation. B) Longitudinal orientation.In order to quantify the desired 
muscle fibre characteristics and identify structures such as muscle satellite cells, transverse orientation would yield 
the greatest information. The mixed orientation present amongst the histological sections meant that 
reorientation was seldom necessary, and with all sections allowing for at least some staining in the transverse 
plane. To be sure of this, and particularly with the later cryo-sectioning, care was taken to orientate samples 
transversely when mounting them for sectioning. 
 
 
Figure 10 - ATPase histological staining of skeletal muscle tissue. A) Successful staining with type 1 fibres light grey 
and type 2 fibres dark grey. B) Patchy and inconsistent staining was found to be common despite protocol 
alterations. 
 
Elimination of freeze artefact 
 
Freeze artefacts were present in the initial histological staining runs. These were 
defined as the gaps opening up in the honeycomb structure of the natural skeletal 
muscle (322). They frequently occur due to the expansion of water within the tissue 
freezing in a crystalline manner, rather than the preferred amorphous freezing which 
would preserve structure. The expansion of the tissue in this way disrupted the 
natural tissue form and rendered measured results unreliable. 
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While the snap freezing process controlled for artefact during the preservation step, 
more care was required during the mounting step prior to cryo-sectioning. As OCT is 
stored as a liquid at room temperature, it is much warmer than the cryostat 
environment when poured onto sample chucks. To allow for dispensing this cannot 
be avoided. A change in the protocol to introduce careful layering and the use of a 
fast-cooling cryospray (Cell Path; KNA-0173) provided the needed adaption to 




An overview of immunohistochemistry and immunofluorescence can be found in the 
Histology appendix. 
 
Identification of Muscle Satellite Cells (MuSCs) 
 
Muscle satellite cells (MuSCs) can be identified through their transcription factors or 
through combinations of surface membrane proteins (Figure 11). Not all are 
expressed in all MuSCs at any one time but will vary depending on mitotic state and 
the subpopulation of MuSCs. 
 
 
Figure 11 - Muscle satellite cell markers divided by identifying transcription markers and membrane proteins. Not 
all are expressed in all muscle satellite cells due to population diversity. Figure from Yin 2013 (24). 
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As described in the literature review section, discussion of the optimal MuSC 
identifying methodology and associated factors for laboratory analyses are covered 
in depth in several reviews and study articles (76,172,338–340). Paired box gene 7 
(Pax7) and paired box gene 3 (Pax3) are recognised markers for MuSCs along with 
NCAM1 (also known as CD56). Not all MuSCs express these markers, with some 
expressing all and some expressing only one. Pax3 is much more prominent 
embryonically, and NCAM may also identify a subpopulation committed to myoblast 
differentiation (341). 
 
Muscle fibre types can be histochemically identified through their protein isoform 
expression as previously discussed (in the Muscle Physiology Research Models and 
Human Studies section). When identifying major type categories, the labelling of type 
1 fibres with MyH7 combined with general morphometry allows for clear distinction 
between type 1 and type 2 fibres. 
 
Labelling laminin can highlight basal lamina which can allow differentiation between 
myonuclei and MuSCs. A useful additional anatomical marker is 4ʹ,6-diamidino-2-
phenylindole (DAPI) which labels nuclei. 
 
The anatomical target structures for the study were muscle satellite cells and muscle 
fibres. The target antigens for these were selected as anti-paired box gene 7 (-Pax7) 
and anti-myosin heavy chain 7 (-MyH7). As a nuclear stain, Pax7 required a slightly 
different protocol than the surface membrane marker MyH7. 
 
Immunofluorescence Methodology Development 
 
The laboratory protocols for the IF staining were based upon a variety of published 
protocols (46,169,340,342–348). Rigorous optimisation runs with control skeletal 
muscle tissue were performed for all staining panels to ensure optimal conditions 
were established. 
 
For each staining panel, a variety of methods were trialled. Different fixatives, 
incubation temperatures, incubation times, and antibody concentrations were 
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examined to optimise the techniques. Formaldehyde based fixatives created 
inconsistent staining patterns which were attributed to protein cross-linking. 
Subsequent antigen retrieval techniques were non-effective. As fixatives, ethanol 
was too gentle, and acetone was too harsh, in addition to causing damage to 
laboratory staining apparatus. 
 
Core concentrations were established using published protocols, manufacturer 
recommendations, and a series of dilutions. The lowest possible concentration of 
antibody was used to preserve stocks and to prevent tissue artefact, particularly from 
secondary fluorophores. 
 
Incubations times and temperatures ranging from 1 hour at +37C, to 3 hours at room 
temperature, to overnight at +4C in a refrigerator were tested. Any longer or shorter 
at each of these temperatures provided insufficient or excess staining. Though a 
shorter protocol, primary antibody incubations at higher temperatures led to high 
background staining. Secondary antibodies were unaffected by this. 
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Muscle Satellite Cell Immunofluorescence Panel Development 
 
To visualise muscle satellite cells (MuSCs) within sections, a combination 
immunofluorescence (IF) staining panel was to be used. The panel stained for nuclei 
(DAPI counterstain), MuSCs (-Pax7), and basal lamina (Laminin 5 alpha-3). This 
allowed for visualisation of MuSCs nuclei compared to assumed myonuclei, with a 
confirmatory reference of the basal lamina to differentiate MuSCs based on their 
differing anatomical location to myonuclei. Initial IF runs also investigated CD56 as a 
MuSC marker but were unsuccessful. A latter panel combining MuSC and muscle fibre 
type staining was also evaluated. 
 
Considering antibody selection, factors encompassed primary host species, 
secondary host species, and fluorophore. Suggestions were made in published 
research journal articles, but these were not always available from the suppliers. 
 
The list of utilised IF and IHC antibodies for the MuSC panels are listed in Table 8. 
 





Host Brand Product 
code 








CD56 MuSCs Mouse BD 347740 Primary n/a 
 





Pax7 MuSCs Mouse DSHB Pax7-s Primary n/a 1:6 

















































DNA Nuclei n/a Vector
labs 
H-1200 Counterstain DAPI Stock 
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Initial runs identified a lack of antibody reliability which did not equate to the success 
found in the literature. Antigen retrieval techniques, such as Heat Induced Antigen 
Retreival (HIAR) were utilised to enhance epitope prominence to improve staining 
(349,350), however this is not routinely described for frozen muscle sections (351). 
The use of HIAR frequently disrupted mounted tissue sections but was utilised with 
the aim of improving immunostaining. 
 
Slide mounted sections were post-fixed in methanol at -20C for 6 minutes. Heat 
Induced Antigen Retrieval (HIAR) at 100C took place in antigen retrieval buffer 
(Vector 3300; 1:10) for 10 minutes within a microwave and pressure cooker (Nordic 
Ware Tender Cooker). Sections were ringed with a hydrophobic ‘Pap’ pen (Vector 
ImmEdge) and washed three times with phosphate buffered saline with 0.05% 
Tween20 (PBST) for 3 minutes. Sections were protein blocked (DAKO Protein Block 
x090930) for 15 minutes at room temperature to prevent non-specific antibody 
binding to the tissue. Incubation of primary antibody mouse-anti-Pax7 (1:6; DAKO Ab 
Diluent s202230) took place at +4C overnight. Slide trays included damp paper 
towels during incubation periods to prevent slide drying. Following this, sections 
were washed three times with PBST, blocked for 15 minutes, and incubated with the 
secondary antibody donkey-anti-mouse TRITC (1:500 ; DAKO Ab Diluent s202230) for 
1 hour at +37C. Slides were washed three times with PBST, once with PBS, and then 
mounted with Vectashield with DAPI (H-1200) and coverslips were placed on the 
slides. These were sealed at the edges with colourless, clear nail polish and dried 
before imaging. The full protocol and materials list can be found in the Histology 
appendix. 
 
Microscopy imaging of the slides followed, and subsequent image processing initially 
indicated positive and distinctive staining for Pax7 and therefore MuSCs. 
 
Additionally, a separate protocol expansion was created that also incorporated a 
fluorescence triple stain for Pax7, Myh7, and DAPI. It would identify MuSC fibre type 
affiliation. The imaging results from the protocol replicated those displayed in the 
literature for similar panels. A raw merged and a merged channel image adjusted for 
channel brightness from the protocol are displayed in Figure 12. 
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Figure 12 - Images of immunofluorescence staining for DAPI (blue), Pax7 (TRITC – red), and Myh7 (FITC – green). 
Both images are of the same section with different levels of digital processing. A) Raw image colour channel merge. 
B) Image channel merge adjusted for brightness. Positive muscle satellite cells are located at muscle fibre 
periphery and positively stained for both DAPI and Myh7. Though convincing, the FITC expression contained a 
large amount of autofluorescence which raised questions as to the reliability of the staining. 
 
Instances of colocalised expression between DAPI and Pax7 were prominent and the 
protocol was initially deemed successful. However, further investigation and 
confirmatory controls determined that it was likely a false positive and was 
prejudiced by confirmation bias (categorising visually borderline results as fitting the 
predetermined positive category). 
 
Auto-fluorescing of skeletal muscle section negative controls was observed under 
certain fluorescence microscopic wavelengths; primarily FITC, but also TRITC. This 
contravened published research where frequent use was made of FITC, Alexa Fluor 
488, Green Fluorescent Protein (GFP), and TRITC fluorophore tags for small 
anatomical targets in skeletal muscle (352). The phenomenon is well documented 
within the cardiac muscle literature (353) but not abundantly so in the skeletal 
muscle literature. For example, the utilised secondary wavelengths were extensively 
utilised in the published literature on which the protocols were based. The 
autofluorescence is most present within these wavelengths. 
 
Despite the existence of autofluorescence in these channels, with strongly expressed 
targets and high antibody concentrations, identification of anatomical landmarks was 
still possible. However, this was not the case with low expression of targets and could 
have provided false positives. 
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The autofluorescence was likely to be due to the innate presence of flavins and 
flavoenzymes in skeletal muscle tissue (354). Endogenous autofluorescence was hard 
to control for, with the exception of differentiating intensity of fluorescence, 
however distinct spot artefacts were also found during imaging. While each planned 
immunofluorescence staining run included negative controls, these were for the 
primary and secondary antibodies respectively. Due to the identification of this 
artefact and the presence of discussion surrounding the topic in the literature (355), 
in depth control panels were run for all aspects of the proposed protocol to minimise 
autofluorescence (Table 9). 
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From these investigative runs to identify and potentially eliminate the 
autofluorescence in the FITC channel, there unfortunately was no clear candidate for 
the artefact. Though slightly higher background autofluorescence was found in the 
Pax7/FITC-antibody-tagged IF runs, it also existed in all of the control runs. Examples 
of the extremes of control from images of the full Pax7 runs, to control slide A (Table 
9), and control slide H are shown in Figure 13. 
 
Chapter 4: Laboratory Methodology 
  88 / 309   
 
Figure 13 - Investigative controls for autofluorescence artefact in the Pax7 immunofluorescence staining example 
images. Autofluorescence is present in all images. Of note is the bright spot autofluorescence from the basement 
membranes and perimysium in the borders between muscle fibres. 
Camera exposure or brightness variation may have played a part in the distinct visual 
differences. The imaging apparatus was automated in this element and self-adjusted 
based on its internal software algorithms. Standardisation of these elements was not 
possible. 
 
The Pax7 IF staining protocol was further interrogated. True IF expression labelling 
was assumed to be inherently brighter than autofluorescence. A manual method to 
differentiated between the autofluorescence and the positive staining for Pax7 with 
the image processing software ImageJ (NIH, USA) was created. Colour channel 
isolation was used to separate and distinguish the intensity of fluorescence within 
candidate anatomical locations (Figure 14). Each distinct channel was separately 
processed using ImageJ. This allowed reasonable identification of positive staining for 
presence of Pax7. Examples images of the method compared to negative control 
slides are shown in Figure 15. Image autofluorescence across both FITC and TRITC 
channels was compared for fluorescence point intensity. Distinct superior brightness 
in the FITC channel and colocalising with DAPI fluorescence was identified as positive 
staining for Pax7. White arrows represent positive staining for both Pax7 and DAPI. 
Green arrows represent eliminated false positives. 
 
Figure 14 – Colour channel isolation and merging of a single field of view example for manual identification and 
differentiation between positive and false positive staining. 
Chapter 4: Laboratory Methodology 
  89 / 309   
 
Figure 15 - Examples of the Pax7 immunofluorescence staining panels and connected negative control slides. 
White arrows show colocalised DAPI and TRITC (Pax7) positive staining. Green arrows show eliminated false 
positives attributed to autofluorescence. Images A and B show Panel slides (immunofluorescently stained for DAPI 
and TRITC anti-Pax7), images C and D show negative control slides, with only DAPI staining. 
The differentiating image sorting method was reproducible but identified a high rate 
of nuclei belonging to MuSCs. The method was not standard and accepted image 
analysis technique. Due to the challengeable aspect of its subjectivity, borderline 
nature of many of its classifications, the large time burden per image, it was forfeited 
as a image processing technique. 
 
The utilisation of alternative fluorophores, careful HIAR, and microscopes with a 
wider range of mirror cubes for imaging may allow for clearer identification of MuSCs 
in future. 
 
Despite multiple protocols, antibodies, reagents, and creative image analysis to 
optimise the staining, no reliable protocol was identified to label and identify MuSCs 
immuno-fluorescently. Alternative methods were subsequently pursued to identify 
the MuSCs within the study biopsy samples, notably molecular gene expression 
analysis. However, not all initial hypotheses could be tested with these alternative 
investigative methods. Namely the local anatomical associations of the MuSCs such 
as fibre type affiliation and proximity to vasculature. 
 
The study’s findings during technique optimisation raise serious questions about the 
validity of published literature using this Pax7 MuSC immunolabelling and imaging 
methodology due to the false positives resulting from multiple channel auto-
fluorescence in skeletal muscle tissue.  
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Muscle Heavy Chain 7 Immunofluorescence Panel Development 
 
An immunofluorescence (IF) histological staining panel was developed to identify 
skeletal muscle fibre type within sections. This utilised IF targeting of Myosin Heavy 
Chain 7 (MyH7), a gene coding for the β-myosin heavy chain protein. This protein is 
a component of both cardiac and type-1 skeletal muscle. Given the location of the 
biopsies, this targeting allowed for identification of type-1 fibres within skeletal 
muscle tissue. The list of utilised IF antibodies for the MyH7 immunofluorescence 
panel are details in Table 10. 
 





Host Brand Product 
code 
















MyH7 Type 1 
muscle 
fibres 
Mouse DSHB A4.951-s Primary n/a 
  
MyH7 Type 1 
muscle 
fibres 
Mouse Santa  
Cruz 





PA128625 Secondary TRITC * 1:750 
Primary Donkey-
anti-mouse 
Donkey Santa  
Cruz 
sc-2300 Secondary TRITC 
  
DNA Nuclei n/a Vector 
labs 
H-1200 Counterstain DAPI * Stock 
 
Reliable primary and secondary antibodies were identified within a viable staining 
protocol detailed in the Methodology section. 
 
Imaging Microscopy Optimisation 
 
A Nikon E800 fluorescent microscope (Nikon Corp., Tokyo, Japan) was used to image 
all slides. The microscope was set-up to perform light and fluorescence microscopy 
(356,357), and contained fluorescence filter cubes for the following fluorophore 
wavelengths: cyanine 5 (Cy5), 4ʹ,6-diamidino-2-phenylindole (DAPI), tetra-methyl-
rhodamine (TRITC), and fluorescein (FITC). Excitation and emission wavelengths for 
these dyes are listed in Table 11 and in Figure 16. 
 
Mirror cube excitation and emission spectra possessed sufficiently distinct ranges to 
prevent leakage across channels. 
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Table 11 – Study fluorescent dye excitation and emission wavelengths.(358,359) 




Visual Colour Range 
Cy5 646 664 Far-Red 
DAPI 358 461 Blue 
TRITC 557 576 Yellow/Orange 
FITC 495 519 Green 
 
 
Figure 16 - Study fluorophore excitation and emission wavelengths. Adapted from Abcam Fluorochrome Chart 
(359). 
 
Optical imaging was performed with a 10X eyepiece with 10X and 20X objective 
lenses. Working magnification was therefore 100X and 200X. This provided sufficient 
detail for visualising target anatomical structures. 
 
Digital Image Processing Optimisation 
 
Digital image processing was to be conducted within ImageJ software (NIH, USA). 
Muscle fibre type and muscle fibre lesser diameter are identified from Myh7 IF 
staining. Raw microscopy images were divided by fluorescence channel and varied in 
brightness. This utilised the ‘split/merge channels’ and ‘adjust’ functions to normalise 




The analysis of the images was performed using ImageJ functions. Initial scale 
calibrations were set from ingrained metadata that was digitally etched by the 
imaging camera system. Predominantly, the ‘measure’ and ‘multi-point’ tools were 
used to record the desired measurements. This allowed for accurate measurement 
of anatomical structures.  
 
For some desired analyses within ImageJ, automated functions exist to process large 
numbers of images at once. These functions can perform complex image processing 
and analyses, and ultimately are very time-saving for researchers. 
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(A plugin macro named MuscleJ has been developed which could have allowed for 
this to happen with the study image analysis (360). While still in beta development, 
the authoring team from Institute Pasteur (Paris, France) directly shared the 
unpublished macro for use with this study image data set. Despite local attempts to 
optimise the programming elements, the beta plugin was found to have a high error 
rate when used on the study data set. The plug-in undoubtedly has promising 
potential for future use in anticipated newer versions. All images for the data set 
were therefore manually processed.) 
 
Manual digital image processing and analysis allowed for clear labelling of distinct 
fibre and their diameters. Examples of the fibre classification analysis are displayed 
in Figure 17. The labels ‘1’ and ‘2’ refer to the skeletal muscle fibre types. 
 
 
Figure 17 - Examples of the analysis method on ImageJ software for fibre type categorising. ‘1’ represents Type 1 
skeletal muscle fibres. ‘2’ represents Type 2 skeletal muscle fibres. 
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Confirmatory Analysis Techniques 
 
Further laboratory techniques were explored to provide a larger depth of data than 
that from the histological analyses alone. The methods sought to include quantified 
sub-population cell counts for entire biopsies, rather than representative sections. 
 
Flow cytometry and quantitative real-time polymerase chain reaction analyses were 
evaluated due to their prominence in the literature (339,361). 
 
A representative frozen biopsy sample stored at -80C for four months was chosen 
to evaluate a preliminary flow cytometry protocol based on a published MuSCs 
isolation publication (362). Investigations of the biopsy cell flow viability was 
performed at the Shared University Research Facilities’ (SuRF) with propidium iodide 
to establish a “live/dead” count (363). Out of 80,000 events, 289 whole cells were 
gated (0.4% of total), of which 271 cells were alive (93.8% of whole cells; 0.3% of 
total). The full protocol and materials list can be found in the Cytometry appendix. 
This low percentage of intact cells indicated that the digestion methodology was 
unsuitable for the study biopsies. The biopsy collection and storage procedure, 
including ultra-low temperature storage, may also have influenced the whole cell 
integrity. While whole cell analysis was not appropriate, the tissues were suited to 
alternative genetically based analyses as molecular nucleic acids were unaffected in 
this way. 
 
Quantitative real-time polymerase chain reaction (qPCR) analysis was utilised to 
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Genetic Expression Analysis Methodology 
 
Quantitative real-time polymerase chain reaction (qPCR) allowed investigation of 
myogenic marker profiles within patient biopsies. These would provide data on the 
genetic expression levels of target markers at time of surgery. 
 
Previous departmental work had investigated similar markers within an oncological 
population using quantitative real-time polymerase chain reaction analysis (qPCR) 
(137). Applying this technique to analyse the TKA cohort biopsy samples allowed for 
the quantification of target markers of both myogenesis and senescence as discussed 
in the literature review. 
 
RNA Extraction Method Choice 
 
Methodology options for RNA extraction included commercial kits and a Trizol 
method. The RNeasy Plus Universal Mini Kit (Qiagen, Hilden, Germany) was 
compared to a Trizol extraction method (364–366). The full protocols and materials 
list can be found in the Molecular appendix. 
 
Initial results from the kit indicated contamination and poor extraction. To determine 
whether the results were reflective of cohort sample quality or due to the extraction 
method, extraction was run in parallel with two cohort samples using the two 
extraction methods. Each patient sample was split equally in two, with one half of 
each sample per method. 
 
Results from the tandem run showed a much higher purity and yield from the Trizol 
method compared to the Qiagen kit (Table 12). This was measured using the 
NanoDrop ND-1000 machine (NanoDrop Technologies Inc., DE, USA), protocol 
available in the RNA Analysis appendix. The two yield ratios provided information on 
the purity of the extract. The 260/280 and 260/230 ratios compared the ultraviolet 
light absorbance of the samples at the specified wavelengths in nanometres. For 
extracted RNA, desired purity ratios values are ~2.00. This optimal number were 
found from the averaging of the absorbance values of all four nucleotides. Each 
nucleotide taken separately has differing values, from guanine providing a ratio of 
1.15 to adenine’s ratio of 4.50. Depending on which bases were present, the true 
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ratio can be affected. The values can additionally vary by 0.2 from this due to 
differences in pH, with acidity reducing the value and alkalinity increasing the value 
(367). A low value of the 260/280 ratio can indicate contamination of the sample with 
protein. When seen in the 260/230 ratio, it can be due to the presence of phenol or 
ethanol. Contamination affects the values due to contaminants strong absorption 
properties at the focus wavelengths (368). 
 
Table 12 - Comparison of purity and yield data between extraction methods. 
Sample Extraction 
method 
260/280 260/230 RNA yield 
(ng/l) 
A Trizol 1.91 1.97 475.6 
A Qiagen kit 1.88 0.75 64.5 
B Trizol 1.90 1.34 213.5 
B Qiagen kit 1.50 0.44 20.0 
 
The Trizol method was therefore chosen for the cohort’s skeletal muscle biopsy RNA 
extraction due to the larger yield and purity potential. 
 
Trizol is a monophasic solution of phenol and guanidine isothiocyanate that disrupts 
cells and dissolves cell components while maintaining RNA integrity. The steps 
include the lysing of cells, separation of cellular material into distinct phases, the 
precipitation of RNA from an isolated component of this, and finally the washing of 
the isolated RNA pellet to remove contaminants. 
 
RNA Quality Analysis 
 
The Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines state that RNA quality must be stated in experiment 
methodology, and further quality assessments are desirable. The quality and purity 
was to be assessed by the NanoDrop spectrophotometer, and integrity was next 
investigated (369).  
 
RNA integrity represents the quantity of the extracted total RNA that is intact. It is 
measured through a calculated ratio between two molecularly weighted peaks of 
ribosomal RNA (rRNA) identified through electrophoresis; 28S and 18S (370).  28S 
represents part of the large subunit and 18S represents the small subunit. 
Electrophoresis uses a porous gel and an electric current to separate electrically 
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charged nucleic acids based on size. For intact total RNA, clear and distinct bands 
should be observed at these locations following electrophoresis analysis. With 
fragmented RNA, the result is dispersed and indistinct. Locations, based on size 
differences, can be identified through the use of a molecularly weighted control 
ladder. While a qualitative indication of RNA integrity can be evaluated using gel 
electrophoresis, quantitative data can be established using instrumentation. 
Automated electrophoresis can calculate the quantitative RNA Integrity Number 
(RIN) from algorithmic analysis of the generated data (371). 
 
The TapeStation 2200 (Agilent Technologies Inc., CA, USA) was used to provide 
automated electrophoresis and analysis of extracted sample RNA for this purpose. 
The machine set protocol was followed. The full protocol and materials list can be 
found in the RNA Analysis appendix. 
 
A selection of optimisation samples were analysed for RIN with results showing 
inconclusive values (Figure 18). This was due to control ladder values also were 
inconclusive indicating a machine or consumables malfunction. The ScreenTape 
machine consumables are all-in-one reagent chips in which all samples are run by 
electrophoresis. While repeat freeze-thaw cycles can increase the degradation of 
RNA (372), if this was the error source the controls and ladders would have had 
positive results. High integrity can be identified from values close to 10, however the 
originating tissue type is known to lead to reduced RIN when assessing extracted RNA 
(370). However, the machine fault across the preliminary experimental runs 
indicated an issue with the chips. 
 
Figure 18 - Tapestation preliminary experimental results showing machine malfunction. The ladder (far left) should 
shown clear banding with a high RIN value.  
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In line with the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines, the Nanodrop quality and purity analyses were 
sufficient for identifying nucleic acid properties for study samples during initial 
extractions. 
 
Real-Time Polymerase Chain Reaction Optimisation 
 
The quantitative real-time polymerase chain reaction technique allows for target 
genes of unknown expression levels to be compared against consistent and relatively 
highly expressed known reference genes in a quantitative manner. The reference or 
housekeeping genes were first identified using representative samples from the 
cohort. They were identified by performing optimisation qPCR runs using commercial 
kits of likely gene candidates that were known to show stable high express. From 
these, an algorithm can select the best combination of genes that were stable in the 
cohort tissues. 
 
The comparison between the target experimental genes and the reference genes was 
performed by comparing cycle threshold (Ct) or quantitative cycle (Cq) values. These 
represent the PCR cycle at which the detected quantity of PCR product cross a pre-
set level on the thermal cycler machine. The quantity was calculated by the 
fluorophore expression strength, which is replicated, and in-theory doubled, per 
cycle. The amplification past the Cq at an earlier cycle represents a higher starting 
quantity of the gene of interest (GOI), and therefore a higher expression of that GOI 
in the sample. As all mastermixes, the starting content in each well in the instrument, 
are identical in volume, the expression levels can be compared. For each sample, the 
resulting comparative cycle threshold difference (Cq) between the experimental 
GOIs and the reference GOIs values were then able to be quantitatively calculated. 
The Cq values were then able to be compared between genes, and subsequently to 
other patient cohort factors. 
 
Reference Gene Selection 
 
The quantitative value of qPCR lies in a normalisation procedure. Genes of interest 
(GOIs) expression levels are measured relevant to reference or housekeeping genes. 
As such, the initial step required justification for the normalisation procedure and 
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identification of which reference genes were best for the tissue. The perfect 
reference genes should be consistently expressed across all the samples with high 
expression stability. The MIQE guidelines recommend using more than one reference 
gene, with a geometric mean of those used to normalise the GOI fold expression. 
 
To determine the best reference genes, a panel of 12 common qPCR reference 
targets (Human geNorm kit; ge-SY-12-hu; Primerdesign Ltd, Southampton, UK) were 
analysed. The reference gene candidates are listed in Table 13. 
 
Table 13 – The 12 qPCR reference gene candidates. 
Gene Name Gene Function (373) 
SDHA 
Succinate dehydrogenase complex 
flavoprotein subunit A. 




Role in cell proliferation. 
18S 
18S ribosomal RNA 
Eukaryotic cytoplasmic ribosomal subunit. 
TOP1 
DNA topoisomerase 1 
Encodes a DNA topoisomerase, an enzyme that 
controls and alters the orientation of DNA during 
transcription. 
ATP5F1B 
ATP synthase F1 subunit beta 
Encodes a subunit of mitochondrial ATP synthase. 
UBC 
Ubiquitin C 
Encodes a polyubiquitin precursor. 
GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase 
Product catalyses a step during carbohydrate 
metabolism, also has uracil DNA glycosylase activity in 








Encodes one of six different actin proteins, involved 
in cell motility, integrity, structure, and intercellular 
signalling. 
RPL13A 
Ribosomal protein L13a 
Eukaryotic cytoplasmic ribosomal subunit. 
EIF4A2 
Eukaryotic translation initiation factor 4A2 
Regulates lipid metabolism, and translation factors. 
YWHAZ 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta 
Encodes mediator of signal transduction. 
 
A representative selection of 12 study samples were used to evaluate the reference 
gene candidates. These represented a quarter of samples and were chosen based 
upon widely representative criteria to encompass several participant sub-cohorts. 
These included: sex, BMI, age, arthritic severity, and lifestyle choices. All samples 
were run in triplicate against all reference primers. 
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The supplied kit protocol was followed. The qPCR master mix was created for all 
genes and plated into a 96-well plate before the addition of each chosen sample. 
Pipette tips were changed for every triplicate to remove potential carry-over. The 
qPCR program was run on the LightCycler 96 Instrument (F Hoffman-La Roche AG, 
Basel, Switzerland) with the protocol displayed in Table 14 and Figure 19 - Graphic 
representation of qPCR protocol for the geNorm reference gene data collection.. 
Fluorometric data was collected through the detection of the intercalated dye SYBR 
Green, with greater fluorescence indicating greater presence of qPCR product(350). 
The full protocol and materials list can be found in Appendix B: Laboratory Protocols. 
Table 14 - qPCR protocol for the geNorm reference gene data collection. 
Step Temperature (°C) Duration (seconds) Number of Cycles 
Preincubation 95 120 1 
Amplification 95 5 45 
60 20 
Melting 95 10 1 
65 60 
97 1 
Cooling 37 30 1 
 
 
Figure 19 - Graphic representation of qPCR protocol for the geNorm reference gene data collection. 
Non-template controls (NTCs) were run on all plates and for all genes to control for 
non-specific amplification. An amplification signal in a NTC well would indicate a 
potential contamination issue or an issue with the primer. Following collection of 
data, processing and subsequent selection of references genes was performed using 
the GeNorm algorithm to assess the stability of each gene for use as a reference 
value(374–376). The fifth generation of the algorithm was used as incorporated into 
qBase+ software (Biogazelle, Gent, Belgium). The software excluded blank qPCR plate 
wells and removed anomalies (defined as outliers within a sample triplicate). Results 
from the GeNorm analysis are displayed in Figure 20, Figure 21, and Table 15.  
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Figure 20 – GeNorm V analysis results: Determination of the optimal number of reference targets. The green line 
represents the algorithmic threshold, with a desired result below the line. From the results, the optimal number of 




Figure 21 – GeNorm M analysis results: Average expression stability of remaining reference targets. A lower value 
indicates less variation across samples and greater stability. From the results displayed in Figure 20, the selection 
was then made of the 3 reference targets exhibiting the greatest stability, namely GAPDH, UBC, and EIF4A2.  
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Table 15  - GeNorm V interpretation results for qPCR reference gene evaluation for study samples. Output 
generated from qBase+ software. 
geNorm V Interpretation 
Data Interpretation 
Input geNorm analysis was initiated on 12 samples and 12 reference targets. 
Missing values The following reference target(s) contain missing data and were excluded for 
geNorm analysis: None. 
Experiment 
design 
Not all samples were measured in the same run for a given reference target. As 
inter-run variation might contribute to decreased expression stability, a proper 
geNorm analysis requires that all samples are measured in the same run for a given 
target (i.e. sample maximization strategy according to Hellemans et al., Genome 
Biology, 2007 (377)). The built-in inter-run calibration procedure in qbase+ does 




The optimal number of reference targets in this experimental situation is 3 
(geNorm V < 0.15 when comparing a normalization factor based on the 3 or 4 most 
stable targets). As such, the optimal normalization factor can be calculated as the 
geometric mean of reference targets GAPDH, UBC and EIF4A2. 
Reference target 
stability 
Medium reference target stability (0.5 < average geNorm M ≤ 1.0). This is typically 
seen when evaluating candidate reference targets on a heterogeneous set of 
samples (e.g. treated cultured cells, cancer biopsies, or samples from different 
tissues). More reference values in Table 1 in Hellemans et al., Genome Biology, 
2007 (377). 
 
The algorithm, as summarised in Table 15, evaluates different aspects of the 
candidate reference gene data. The main two factors are the coefficient of variation 
(geNorm V or CV), allowing identification of the optimal number of reference genes 
by the reliability of the normalisation, and the medium reference gene cross-sample 
stability (geNorm M). Homogenous sample panels should show values of less than 
0.25 for CV and 0.5 or below for M, whereas heterogenous panels should show 
respective values less than 0.50 and 1.0 (377). The sample panel showed a CV value 
of 0.133 and ~0.55 for M. Despite M being marginally outside the recommended 
threshold for homogenous samples, it was within tolerance compared to the 
heterogenous suggested values. The low CV value reassured this assessment as it was 
much lower than that for the recommended homogenous panel threshold. 
 
From these experimental results, GAPDH, UBC, and EIF4A2 were selected as the 
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After transfer from theatre, biopsies were rapidly processed. The laboratory 
apparatus for processing was set-up prior to attending the surgical theatre for sample 
collection. Two pathways were established for sample preservation. These were 
necessary to enable sample protection before subsequent laboratory analysis. 
Separate processing routes were established to provide back-up options and to allow 
differing analyses to be performed. However, the robust back-up preservation 
method limited certain analyses being used. The fixed tissue could not be analysed 
for enzyme activity, but the primary snap-frozen tissue would allow this. 
 
The samples were initially divided into multiple smaller pieces using a scalpel. This 
allowed for multiple sub-samples from the outset and was necessary for efficient 
sample preservation. At this stage, they were also trimmed of any remaining 
connective tissue or fatty tissue as this was not the target tissue. The muscle pieces 
were separated before preservation processing, with the majority going towards the 
snap freezing route and the remainder into formalin fixation and paraffin wax 
embedding destination. The snap freezing laboratory set up is demonstrated in 
Figure 22. The formalin fixation route similarly began with steps A and B but 
continued with 24-hour immersion in 4% buffered formaldehyde. This is pictured in 
the bijou on the left of Figure 22, image A and is described in further detail later. 
 
 
Figure 22 - Snap freezing of muscle biopsies in the laboratory. A) Bench set-up with sterile equipment and container 
with biopsy fresh from theatre. B) Cutting of biopsy into smaller pieces to aid sample preservation, remove other 
tissue types, and allow multiple analyses per sample. Size 22 Swann Morton scalpel blade for scale. C) Cooling of 
isopentane beaker in dewar of liquid nitrogen. D) Beaker of frozen isopentane on bench. Biopsy samples were 
immersed immediately as the isopentane thawed and allowed to snap-freeze for 20-30 seconds. Extraction fan 
present to prevent respiratory tract irritation from vapor exposure 
 
Snap freezing of the muscle samples was performed using isopentane (2-
methylbutane) that was cooled in liquid nitrogen (LN2). Isopentane was cooled until 
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it changed to solid state indicated by a distinct visual change to opacity. It would then 
be removed from the LN2 and be allowed to warm up on the lab bench until it thawed. 
At this temperature of around -160C muscle samples pieces would be dropped in to 
the liquid for 20-30 seconds while they snap froze (322,326,327,343,378). The 
freezing process changed the muscle colour from red to pink. The snap freezing 
method in isopentane preserved the samples in a fresh state whilst also preserving 
sample architecture (378). 
 
The snap frozen samples were then transferred to subject-specific bijous containers 
cooled on dry ice and subsequently stored in a -80C ultra-low temperature freezer. 
Samples preserved and stored in this way were to be used for the majority of 
laboratory analyses.  
 
The remainder of the samples were submerged in 4% buffered formaldehyde for 24 
hours for fixation. They were then transferred to 70% ethanol (30% dH2O) prior to 
embedding in histological paraffin wax blocks. This final step of wax embedment was 
performed by the local Shared University Research Facility (SuRF) histological service. 
A request was made for transverse muscle fibre orientation in the wax blocks to aid 
with later imaging and analysis. Though limiting certain analytical techniques from 
being used on samples stored in this way, this storage method allowed for a back-up 
biopsy component to be retained. Examples of excluded potential analyses included 
metabolic tests, cytometry, some genetic work, and some immunological targets due 
to confounding protein cross-linking. These samples could then be stored reliably at 
room temperature within the laboratory environment until further analysis. 
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Histochemical analysis 
 
Histological analysis to determine anatomical structure and protein expression was 
performed with a variety of assays. Initial histological staining targets allowed for 
determination of sample anatomical and structural orientation, supplemented with 
immunological myogenic determinant and structural markers. 
 
Cryo-sectioning and slide mounting 
 
Frozen samples were cut into section using a Bright Cryostat (Standing Refrigerated 
Microtome – OTF/AS/MRID/MGII). The cryostat was set to -20C, 20 degree cut 
angle, 8m thick sections, and a fresh blade was used from the start of the project. 
As the area of the blade became used, the blade was moved sideways to keep the 
cutting-edge location sharp. 
 
Samples were transferred from -80 freezer storage to the cryostat on insulated dry 
ice. A chosen sample would be placed on top of a cryostat chuck block and encased 
in OCT.  
 
Sections were cut using the manual function of the machine, and serial sections were 
cut where possible. Occasional readjustment of the machine or a poorly cut or rolled 
section prevented this in all cases. At times a deep cut was made into the tissue to 
provide a chance to cut sections from a different part of the biopsy and provide a 
wider representation of the sample. Due to the variable thickness of the samples, this 
was not always possible. The use of the built-in ‘Easi-set anti-roll plate’ component 
aided successful sectioning by controlling for static. 
 
All slides were mounted with four sections on Superfrost Plus Gold Adhesion slides. 
With analyses planned in triplicate, this extra section allowed for a margin regarding 
mounting errors or staining protocol disruptions. 
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Histochemical Staining Analysis 
 
Haematoxylin and Eosin stain was used to identify microscopic anatomy for purposes 
of orientation. This pre-empted staining with the further targeted 
immunohistological panels. 
 
Immunofluorescence staining for fibre type 
 
Muscle Heavy Chain 7 Immunofluorescence Panel 
 
Immunofluorescence staining was utilised to determine patient skeletal muscle fibre 
type compositions from their biopsy tissue samples. 
 
Biopsy slide sections were fixed for 6 minutes in methanol at -20C. Sections were 
washed 3 times using phosphate buffered saline with Tween20 0.05% (PBST) for 3 
minutes per wash. These steps permeabilised the sections and removed remaining 
fixative. Slide sections were ringed with hydrophobic PAP pens (Vector ImmEdge) to 
aid with liquid retention during the incubation steps. Sections were blocked using 
DAKO Protein Block (x090930) for 15 minutes to reduce background staining from 
endogenous proteins, before primary antibody (MyH7 (Santa Cruz – SC53090)) 
incubation at 1:500 concentration in DAKO Ab Diluent (s202230) at +4C overnight. 
 
Sections were washed in PBST three times for 3 minutes per wash, followed by 
another blocking step, before secondary antibody (donkey-anti-mouse TRITC 
(Fischer-Scientific – PA128625)) incubation at 1:750 concentration in DAKO Ab 
Diluent (s202230) for 1 hour at +37C. 
 
Following secondary antibody incubation, sections were washed 3 times with PBST, 
and once with phosphate buffered saline (PBS). Sections were mounted and 
counterstained with Vectashield Antifade Mounting Medium with 4ʹ,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, CA, USA – H-1200), then coverslips were 
applied and sealed with nail polish. 
The full protocol and materials list can be found in the Histology appendix. 
 
  
Chapter 4: Laboratory Methodology 
  106 / 309   
Microscopy, Image processing and analysis 
 
Microscopy System and Slide Imaging 
 
Microscope imaging was performed using a Nikon E800 fluorescence microscope at 
100X and 200X magnification. Microscopy was completed within 24 hours of an 
immunofluorescence staining. Slides were kept at +4C when this could not be 
completed same-day. This was performed to prevent fluorescence fading. 
Digital imaging was performed with a Nikon DS-L4 microscope camera control unit 
tablet and a Nikon DS-Fi3 camera. Images were taken across all channels and later 
digitally merged with separate software. While invisible to the naked eye, the camera 
allowed detection of Cy5 where used. The microscopy imaging apparatus was 
regularly serviced by a Nikon technician who calibrated the system for the desired 
panel. All images were transferred from the tablet to a separate computer for 
processing. 
 
Imaging was performed in the FITC channel alongside the target DAPI and TRITC 
channels. Despite the lack of labelled fluorophore in this wavelength, the 
autofluorescence of structures assisted with subsequent muscle fibre border 
distinctions. 
 
Digital Image Processing 
 
Digital image processing was conducted within ImageJ software (NIH, USA). Muscle 
fibre characterisation was clearly identified by the immunofluorescence staining of 
the structures. Type 1 skeletal muscle fibres, as expressers of MyH7 were labelled 
brightly in the chosen TRITC fluorophore channel. Type 2 fibres remained darker as 
they do not express the fluorescently labelled protein. Fibre boundaries were marked 
with identifiable nuclei, sarcolemmata and basement membranes. 
 
All measurements were performed in triplicate. This occurred for each patient 
sample and for each section. During slide mounting, four sections were initially 
located on each slide and labelled ‘A’-‘D’. Where a section remained and there was 
strong reason to believe staining was successful, sections ‘A’, ‘B’, and ‘C’ were 
analysed. ‘D’ was included when there were issues with one of the first three 
Chapter 4: Laboratory Methodology 
  107 / 309   
sections, such as section detachment during staining. This ensured uniform triplicate 
section analysis across all samples. 
 
Measurement of the lesser diameter of the muscle fibre prevented any distortion 
artefact from influencing analysis (Figure 23). This was identified by creating the 
largest possible circle within a fibre, and then measuring the circle diameter. For each 
section, three fibres of each type were measured to deduce a reliable average. 
Visually typical examples spanning the range of sizes from each section were selected 
to provide representative values. This provided nine measurements of fibre lesser 
diameter per patient. 
 
 
Figure 23 - Demonstration of lesser diameter measurements and the impact of oblique sections and fibre kinking. 
Figure from Muscle Biopsy - Dubowitz 2013 (322). 
 
The number of each fibre type were totalled and recorded. This provided three 
measurements of each type of fibre per patient. Due to the fixed nature of the 
standardised size of the field of view, a larger fibre diameter resulted in a lower 
number of observations overall. To allow meaningful and straight forward 
comparison of the data, the number of fibres observed in each type was therefore 
reported as a ratio (type 1: type 2) and separately as percentages where relevant. 
The metric provided insight into the metabolic phenotype of the patients’ muscle 
samples. Where necessary, the FITC channel image was used to contribute to the 
merged image to provide clear fibre border distinctions (Figure 24). 
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Figure 24 - Merged immunofluorescence Myh7 panel. Top images show only DAPI and TRITC channels. Bottom 
images show additional third channel merge (FITC autofluorescence from connective tissue) which was used to 
aid in distinguishing fibre boundaries. 
Collected data were analysed further using the Microsoft Excel software (Microsoft 
Corp., WA, USA). Measured data from the ImageJ analyses were inputted to 
spreadsheets and processed to calculate averages and ratios to be later used in 
results analysis. 
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Quantitative Real-Time Polymerase Chain Reaction (qPCR) analysis 
 
The quantity of mRNA for each target gene were analysed in each sample. This 
provided insight into the protein synthetisation and expression of each 
representative genetic marker. Higher expression of a representative gene signified 
activity that could be contextualised in terms of patient muscle physiology and 
selected systemic physiology. 
 
The Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
Guidelines 
 
The Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines provide a standardised list of experimental detail to 
be included in quantitative real-time PCR experiments publication data (379). The 
desired information seeks to improve transparency of experimental design, quality 
of laboratory results, and to improve study reproducibility. This study followed the 




Each skeletal muscle sample was lysed followed by isolation of its RNA with the Trizol 
method (364–366). To improve stability of the product, RNA isolate was reverse-
transcription synthesised to cDNA. With this product, the use of primers targeting 
the relevant genes of interest (GOIs) could be used to identify the relative quantities 
of expression of each gene using the qPCR technique. The RNA extraction, reverse-
transcription, and qPCR full protocols are listed in the Molecular Protocols appendix. 
 
NanoDrop analysis  
 
Before running sample analyses on the NanoDrop ND-1000 instrument, a blank test 
was run using DEPC/RNase free water. This was repeated every 10 samples. Between 
every sample, the measurement surfaces were wiped with lint-free laboratory tissues 
(Kimwipes, Kimberley-Clark, TX, USA). 1l of sample was loaded onto the pedestal 
for each measurement. The instrument was regularly tested to ensure appropriate 
hydrophobic properties were present to allow the samples to bead on the 
measurement platform and allow reliable analysis.  
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Trizol RNA Extraction Method 
 
The Trizol RNA extraction method followed the included kit protocol (TRIzol reagent 
- Invitrogen, CA, USA; 15596026). All consumables were certified molecular grade 
(Human DNA, DNase, RNase, PCR inhibitor-free) and all surfaces were cleaned with 
Trigene (Tristel, UK) or RNAseZap surface wipes (Thermo Fisher Scientific, MA, USA). 
All possible consumables and instruments were autoclaved before use. Fresh filter 
pipette-tips were used, and personal protective equipment (PPE) gloves were 
frequently changed. 
 
Biopsy samples were transferred on dry ice from freezer storage to the laboratory 
benchtop. Samples were transferred from storage bijous into a cooled sterile 
container. Samples were cut into uniform size of approximately 3mm3 and 40mg. All 
remaining sample was transferred back to the storage container. While frozen, the 
samples were minced using a scalpel, with care taken to contain the process. Samples 
were transferred to 2ml Eppendorf tubes on wet ice. 
 
1ml of Trizol reagent was added to the Eppendorf tube where the mixture was 
homogenized using a pellet pestle cordless motor (Sigma Aldrich; Z359971) for 2 
minutes on wet ice. Samples were then incubated and triturated 20X for 5 minutes 
at room temperature. At this stage, 200l of chloroform was added to the Eppendorf 
tubes, which were vigorously shaken for 20 seconds. They were then incubated at 
room temperature for 3 minutes, followed by centrifugation at 12000g for 15 
minutes at 4C. 
 
The samples separated into their three phases; aqueous phase (containing RNA), 
inter-phase (containing DNA), and organic phase (containing protein). The aqueous 
phase, roughly 600l, was carefully removed by pipette to a 1.5ml Eppendorf tube, 
to which 500l of isopropanol (Fisher Scientific; BP2618) was added. The sample was 
incubated for 10 minutes at room temperature. The inter-phase was also removed 
and stored at -80C for later potential analysis. 
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The sample RNA mixture was then centrifuged at 12000g for 10 minutes at 4C to 
concentrate a pellet of RNA at the tube base. The suspension was removed by a quick 
inversion over a waste container, while the pellet remained in the tube. 1ml of cold 
75% ethanol (25% RNase free-dH2O) was added, prior to vortexing and centrifugation 
at 7500g for 5 minutes at 4C to wash the pellet of contaminants and re-concentrate 
the pellet. The suspension was removed via inversion after which the pellet was air-
dryed for 15 minutes to allow remaining ethanol to evaporate. 
 
Finally, 30l of DEPC/RNase free cold water was added to the tube which was 
triturated and vortexed to dissolve the pellet. RNA analysis was performed with a 
NanoDrop to record absorbance ratios and yield. Storage until the next 
methodological stage occurred at -80C. The full protocol and materials list can be 
found in the Molecular Protocols appendix. 
 
Genomic DNA Elimination 
 
The extracted sample RNA was treated to remove of remaining genomic DNA (gDNA) 
from the sample. Without the removal of gDNA, the qPCR results may have provided 
false positives by showing higher amplification during earlier cycles. While not an 
explicit wash for removing phenols or alcohols, the buffering process provided some 
control for pH values. Later steps addressed the issue of potential contamination of 
that kind. 
 
To remove potential gDNA contamination, a Precision DNase kit (Primer Design, UK; 
DNASE) was used. Sterile equipment was used for all steps. Initially, as samples were 
thawed on wet ice, the kit buffer and enzyme components were combined. Then 4l 
of the kit solution was added to each sample, triturated briefly, and vortexed. 
Samples were then incubated for 15 minutes at 30C on a heat block to activate the 
DNase enzymes and degrade any remaining gDNA, followed by incubation at 55C for 
5 minutes to inactivate the DNAse. Samples were transferred to wet ice and 
subsequently were stored at -80C. The full protocol and materials list can be found 
in the Molecular Protocols appendix. 
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Measurement of NanoDrop ratios and yield was performed for all samples. The RNA 
extraction yield ranged from 113ng/µl to 797ng/µl, however the purity of the 
samples was found to range from 1.30 to 1.97 for the 260/280 ratio. A sample 
without genomic DNA contamination would record a NanoDrop 260/280 ratio of 2. 
RNA Quality Analysis 
 
The Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines require the adherence to one quality control (QC) 
step(379) during initial extractions, which was covered by the reproducible 
NanoDrop analyses. Further quality steps were subsequently performed throughout 
the qPCR experimental process. 
 
RNA to cDNA 
 
Synthetic complementary DNA (cDNA) was created from the extracted sample RNA. 
This was made to stabilise the extracted nucleic acid product due to the fundamental 
quality threat to the extracted RNA from the abundance of RNases. RNases are 
difficult to eliminate from the laboratory environment despite extensive routine 
cleaning Subsequent experimental analysis steps would expose the nucleic acid to 
harsher conditions which could damage their integrity and impact results. 
 
Synthesising of cDNA was performed with a High Capacity cDNA Reverse 
Transcription kit (Thermo Fisher Scientific, MA, USA; 4368814). All study samples 
were diluted to 100ng/l concentration using molecular grade water prior to 
performing the synthesis. The included product kit protocol was followed. Kit 
reagents and components were combined, 10l of kit master mix was added to each 
sample, and the samples were run on a thermal cycler in 4 steps. Initially samples 
were brought to 25C for 10 minutes, then 37C for 120 minutes, then 85C for 5 
minutes, and finally down to 4C to finish the program. The thermal cycles were 
completed on a Veriti Dx 96-well machine (Thermo Fisher; 4452300). NanoDrop 
analysis for ssDNA was performed following the reverse transcription protocol. 
260/280 values were all >1.77, 260/230 values >2.16, and yields >1580ng/µl. Due to 
the different nucleic acid composition of the cDNA compared to RNA, the ratio 
benchmark values are slightly higher. The values observed represented consistency 
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and quality across all samples. At this stage, further dilutions were made to ensure 
consistency alongside conformity with the required starting concentration for the 
qPCR technique of 5ng/l of cDNA. This was performed in two dilutions by a factor 
of 10, followed by assessment of values with the NanoDrop instrument, and a final 
dilution of 1 in 4. At every stage appropriately calculated dilutions were made for 
uniform concentration across the samples. Samples were then stored at -20C. The 
full protocol and materials list can be found in the Molecular Protocols appendix. 
 
Real-Time Polymerase Chain Reaction: Genes of Interest 
 
With stable cDNA generated, the qPCR technique could now be used to analyse the 
study samples(380) by comparing expression of genes of interest again the 
established reference gene target of EIF4A2, UBC, and GAPDH. Having identified the 
reference gene targets, these were now run against all 59 study samples. The 
amplification thermal cycle protocol remained the same as that used for the 
reference genes, displayed in Methodology Development Reference Gene Selection 
(Table 14). Once again, non-template controls (NTCs) were run on all plates. Samples 
were run in triplicate. The LightCycler 96 instrument detailed program methodology 
output and settings are displayed in the Molecular appendix section. 
 
Following the collection of reference gene data, the protocol was run once more for 
each of the experimental GOIs. Plates were run for the myogenesis marker panel of 
Pax7, MyoD1, Myf5, and Myog, and for the senescence (CDK2NA) and inflammatory 
marker panel of IL6, and TNF. 
 
During the qPCR experimental runs, the instrument detected the fluorescence of the 
amplified PCR product, providing a representation of the quantity present. With each 
PCR cycle, the quantity of primer-bound target DNA sequence doubled. The lower 
the number of cycles it required to amplify the product to a quantitative cycle 
threshold value (Cq), the larger quantity of the GOI was present in the initial sample. 
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qPCR Data Processing 
 
The data output from the Roche LightCycler 96 required several processing steps to 
contextualise the raw output and to ensure results quality. Initial proprietary file 
formats were analysed using LightCycler 96 Application Software (F Hoffman-La 
Roche AG, Basel, Switzerland) giving access to both raw data and pre-generated 
results graphics. These integrated analysis steps aided in identifying any confounding 
results generated during the process. Dissociation melting curve analysis was a key 
quality step to determining correct product amplification. Finally, exported data were 
further processed using Excel software (Microscoft, WA, USA). 
 
The quality of the qPCR results was carefully assessed. Melting curve data were 
examined for non-specific amplification and to ensure that the desired product was 
present. This also ensured that the previous DNase genomic DNA elimination step 
was effective. 
 
Following this, sample triplicate outliers were excluded, with a threshold of 0.5 
cycles, to reduce PCR replicate variation. The non-template controls (NCTs) were 
examined for amplified product which would indicate contamination of the master 
mixes or primer-dimer amplification. Following these steps, the Cq levels could be 
calculated using the following formula: 
 
Cq = 𝐶𝑞̅̅̅̅ 𝐺𝑂𝐼 − 𝐶𝑞̅̅̅̅ 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝐺𝑒𝑛𝑒𝑠   
 
Relative expression values (Cq) are calculated by determining the difference in cycle 
number between the target gene expression level and the average expression level 
from the housekeeping (reference) genes. Each housekeeping mean was unique to 
each sample. This was performed due to small variation in the starting quantities of 
sample RNA. Despite the standardisation of biopsy size that was lysed in the protocol, 
this subsequent step provided further control. 
 
Following the qPCR program, a thermal ramping program was run to identify the 
melting temperature of the PCR product. The melting curve of the products showed 
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the temperature when the double stranded product separated into single stranded 
DNA. The exact temperature for each target Gene of Interest (GOI) PCR product 
varied depending on the contained quantity of GC complexes; with more resulting in 
a higher melting temperature(381). Anomalous qPCR results were identified and 
eliminated based upon outlying melting temperatures which are usually lower than 
the main GOI PCR product. Supplier primer validation was performed on a variety of 
tissues, however specificity was assured. For example, anomalous qPCR results may 
include intramolecular ‘hairpin’ amplification of primers to themselves which have a 
lower melting peak. An example of the identification and exclusion of these data 




Figure 25 - Identification and elimination of the outlier qPCR products using melt curve analysis. Graphs represent 
data from the UBC gene qPCR experimental runs. A) Pre-processing with 83 positive wells. B) Post-processing with 
66 positive wells remaining. The excluded 17 samples were instead correctly classified as having non-detected PCR 
product confirmed by Cq values. 
This process was performed for all qPCR results and functioned as a backstop check 
to counteract the issues encountered with earlier RIN analysis. It also identified any 
issues with primers created during this specific technique.  
 
While cycle threshold quantification (Cq) values provided quantitative data, this was 
not the final step. A series of processes were used to clean the results from each qPCR 
run. These eliminated anomalous values which could not be deemed reliable. The 
exclusion criteria were primer quality issues (as evaluated by melting peak analysis), 
and triplicate outlier exclusion (indicating possible manual pipetting variation error). 
The latter steps were performed using exported data within Excel software. As 
stated, these were performed with a 0.5 cycle threshold. 
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NTC well data were examined using the same protocol and were all found to have no 
detected expression, showing that all positive experimental sample data was 
showing true amplification of GOIs and that there was no contamination. 
 
The quality control protocol steps were rigorous and resulted in multiple exclusions 
with each quality control step. Some samples were excluded on the basis of having 
no viable housekeeping reference data, and therefore no normalising data, while 
others were excluded on a per gene target basis due to melt data anomalies or 
negative results. 
 
qPCR Data Analysis 
 
Following data processing, they could now be analysed. Mean Cq data were 
calculated from remaining values for each sample GOI. 
 
Next, the differences of expression levels between the experimental target GOIs and 
the reference GOIs were calculated. The Cq values were calculated from a 
subtraction of the reference gene mean Cq value from that of the experimental GOI 
Cq value. A lower value indicated higher expression of the target gene. The Cq value 
provided the relative quantitative level of expression of each gene which was then 
incorporated into wider cohort comparisons. 
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Data Presentation and Statistical Analyses 
 
The study results of individual variable measurements are presented in several 
formats. Univariate evaluation of temporal trajectory is performed. The relationship 
within each metric group category is also examined. While all metrics were analysed 
for their total response rate, some were collected in the full cohort, and some were 
collected only in a sub-cohort. This is reflected in the stated sample number. A 
snapshot cohort overview is presented in Table 16, with a fuller breakdown displayed 
in the following chapter. 
 
Table 16 - Summary data for study sub-cohort recruitment and participation numbers. Full data capture for the 
study is detailed in the Results sections. 
Characteristic  Cohort 
All Enhanced Routine WEL 
n 63 30 13 20  
m (SD) m (SD) m (SD) m (SD) 
% Female 51 50 31 65 
Age pre-op 65 (10) 64 (9) 65 (12) 67 (12) 
BMI pre-op 32.4 (5.9) 32.7 (5.3) 31.9 (6.7) 32.4 (6.0) 
Biopsy samples taken 58 27 11 20 
 
Individual study variables measured over time are visualised using boxplot and Loess 
(local regression) smooth fit curves in figures to show trends. The variables were also 
statistically interrogated with omnibus One-way ANOVAs and, if found to show 
significant differences (alpha 0.05), were further examined with inter-time-point 
post-hoc pairwise comparison using t-tests with pooled standard deviations and 
Bonferroni-Holm (Holm) corrections for multiple comparisons (382,383). 
 
These statistical tests and graphical figures were chosen based on the repeated 
measurements of the variables in the same sample population. Boxplots visualise the 
data distribution and the Loess regression accounts for differing sample size and the 
distribution of testing intervals. Pair-wise t-tests with corrections were chosen over 
Tukey pairwise comparisons due to sample size differences, and family-wise error 
rates were chosen for the same purpose. As the number of time-point comparisons 
was 5, the step-wise Holm corrections method was chosen over the Bonferroni alone 
corrections method to avoid overly conservative correction of p-values potentially 
resulting in type II errors. The tests assume homogeneity of variance, which was 
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confirmed with Levene’s tests. Data normality was assessed with Anderson-Darling 
tests. 
 
Physiological data were analysed to establish relationships using linear regression 
equations and Pearson and Spearman Rho correlation coefficients where 
appropriate. Correlation strengths are stated and are also defined by the r brackets: 
0-0.2 “very weak”, 0.2-0.4 “weak”, 0.4-0.6 “moderate”, 0.6-0.8 “strong”, 0.8-1 “very 
strong” (384,385). Alpha was defined as 0.05. 
 
Univariate and multivariate regressions modelling was used to examine the complex 
relationships between preoperative and perioperative factors and characteristics on 
study outcome measures. Variables were initially compared using Linear Regression 
Analysis and Best Subset Regression models however missing values created overfit 
bias with the latter technique. Instead, General-to-Specific multivariate regression 
modelling techniques were used (386). Sequential steps initially remove collinear 
variables before filtering out non-significant variables to arrive at a best-prediction 
model. Collinearity was assessed with variation inflation factors (VIFs) indicating how 
collinear factors served to artificially inflate R2 values resulting in biased, overfit 
models. Non-significant variables were removed in stages with progressively 
conservative alpha values. The progressive method was used as missing values in 
different variables can result in models decreasing sample number as the general-to-
specific modelling technique progresses. Overcorrection too early in the process 
could have led to an incorrect model erroneously omitting a key independent 
variable(s). The whole model alphas were set as 0.05. 
 
Data were processed using Microsoft Excel 2016 (v16.0) and R Studio (v1.1.463). 
Graphics were created using the R package ggplot2 (v3.1.0). Statistical analyses were 
performed within Minitab 17 (v17.1.0) and R Studio. 
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Chapter 5: Results - The MAKRO Study 
 
Overview: The Muscle Assessed Knee Replacement Outcome (MAKRO) Study 
 
Study Flow and Demographics 
 
Study recruitment occurred during a 17-week time window between August and 
December 2017. 116 patients listed for primary TKA were screened by members of 
the clinical team for study eligibility. Exclusions and logistical constraints left a 
remainder of 92 patients to be approached, of which 72 consented to study 
participation. 
 
Participants cohort breakdown comprised of 35 for the Enhanced cohort, 17 for 
Routine, and 20 for the WEL cohort. Initial cohort numbers were marginally reduced 
due to several reasons such as cancellations due to hospital bed capacity. 4 patients 
were delayed by more than 6 months to outside of the study time-window and were 
therefore unable to be followed up. 
 
Of those initially consented, 63 patients proceeded with total knee arthroplasty (30 
Enhanced, 13 Routine, and 20 WEL participants). The surgical operations took place 
between September 2017 and February 2018. Follow-up research appointments 
occurred between October 2017 and March 2019. 
 
The screening and recruitment processes are summarised as a CONSORT-style (387) 
clinical study flow chart in Figure 26. 
 
Across the duration of the study, 2 participants withdrew, some were deemed lost to 
follow-up, and others were incorrectly withdrawn. Details for these are listed later in 
this section. Attempts were made to contact those lost in all cases. 
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Figure 26 - MAKRO Study CONSORT-Style Screening and Recruitment Flow Chart. Initial ineligibility criteria were 
stated in the study protocol, discussed in the methodology of this thesis, and excluded by clinical research staff as 
part of initial screening. * = Exclusion of withdrawal criteria for each cohort are listed and described separately 
per cohort later in this section. 
 
Whole Study Demographics 
 
The patients recruited to the study broadly reflected the typical total knee 
arthroplasty population observed within the department and across the United 
Kingdom as represented in the National Joint Registry (200,388). For example, with 
female percentage (NJR 56.8%; MAKRO 50.8%), age (NJR 70 (IQR 64-76); MAKRO 65 
(IQR 58-70)), and BMI (NJR 30.9; MAKRO 32.4). 
 
For the purposes of full study cohort composition, the 9 patients who were 
subsequently excluded from data collection due to withdrawal, cancellation or 
deferral of operations were not included in this analysis. Therefore, cohort 
demographics represent the 63 patients who took part in the study. The 9 patients 
who were recruited to the study but did not participate had only provided very basic 
demographic data which was retained for the purpose of identifying bias. These 
patients had mostly elected to participate in the Enhanced cohort (5 participants), 
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were 44% female, were aged between 54 and 88 at time of recruitment, and had a 
mean age of 70. They had a mean BMI of 31.6 and a mean Kellgren & Lawrence 
osteoarthritic severity score of 1.8. This was broadly representative of the remaining 
cohort showing no inadvertent exclusion bias. No data from these comparative 
categories was available on the screened and excluded individuals due to ethical data 
access restrictions. 
 
The summary data for the full cohort and sub cohorts are displayed in Table 17. 
 
Table 17 - Summary data for full MAKRO cohort compared to sub-cohorts. Category means and standard 
deviations are displayed where relevant. 
Characteristic  Cohort 
All Enhanced Routine WEL 
n 63 30 13 20  
m (SD) m (SD) m (SD) m (SD) 
% Female 51 50 31 65 
Age pre-op 65 (10) 64 (9) 65 (12) 67 (12) 
BMI pre-op 32.4 (5.9) 32.7 (5.3) 31.9 (6.7) 32.4 (6.0) 
Kellgren and Lawrence Osteoarthritis Score 
for Op-knee 
1.8 (0.8) 1.9 (0.8) 1.8 (1.0) 1.8 (0.5) 
Scottish Index of Multiple Deprivation 
Quintile 
3.0 (1.3) 3.4 (1.3) 2.9 (1.4) 2.5 (1.0) 
 
Comparison of headline demographic categories showed comparability. The routine 
cohort comprised of less female participants than the other sub-cohorts, while the 
WEL cohort had more. The Enhanced cohort included participants with least 
deprivation and the WEL contained the most, as measured by the Scottish Index of 
Multiple Deprivation (SIMD) (389). 
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The major baseline demographic categories represented in the full study cohort are 
displayed in Table 18. 
Table 18 – Full cohort demographic factor frequency table for the MAKRO study. 
Characteristic  n (%) 






Male 31 (49)  




40-50 4 (6)  
50-60 15 (24)  
60-70 24 (38)  
70-80 15 (24)  




20-24.9 6 (10)  
25-29.9 15 (24)  
30-34.9 21 (33)  
35-39.9 14 (22)  
40-44.9 6 (9.5)  




10-14.9 1 (2)  
15-19.9 1 (2)  
20-24.9 2 (3.5)  
25-29.9 7 (12.5)  
30-34.9 7 (12.5)  
35-39.9 14 (25)  
40-44.9 10 (18)  
45-49.9 8 (14)  
50+ 6 (11) 
Kellgren and Lawrence Osteoarthritis Score for Op-knee  
1 22 (35)  
2 33 (52)  
3 5 (8)  
4 3 (5) 
Lifestyle 
 
Scottish Index of Multiple Deprivation Quintile (2016) 
 
 
1 8 (13)  
2 19 (30)  
3 12 (19)  
4 14 (22)  




Sedentary desk work 20 (32)  
Manual labour work 41 (65) 
Alcohol intake per week (units) 
 
 
Nil 16 (26)  
Consumption within NHS guidelines (1-14) 31 (51)  
Consumption above NHS guidelines (15+) 14 (23) 
Tobacco Smoking History 
 
 
Current 3 (5)  
Previous 18 (29)  
Never 41 (65) 
Peak previous regular physical activity (Tegner) 
 
 
Low (level 0-3) 15 (25)  
Medium (level 4-6) 16 (26)  




Diabetes 9 (10)  
Hypertension 22 (35) 
Long term pharamaceutical use pre-op 
 
 
Paracetamol 46 (73)  
NSAIDs 16 (25)  
Opiates (including cocodamol and other minor and major opiates) 27 (43) 
Previous Lower Limb Arthroplasty 
 
 
Contralateral Knee 35 (56)  
Contralateral Hip 8 (13)  
Ipsilateral Hip 7 (11)  
Contralateral Ankle 3 (5)  
Ipsilateral Ankle 4 (6) 
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The cohort displayed a normal distribution across the majority of biometric factors. 
Exceptions were observed in two instances. Firstly, in the bioelectrical impedance 
values, where the instrument classified all values over 50 as the same, and secondly 
with the Kellgren & Lawrence (K&L) osteoarthritic clinical score, where most patients 
(87%) were classed as having mild symptoms. The low K&L scores were attributed to 
a lack of osteophytes amongst the patient pre-operative radiographs and their 
prominence in the K&L score over joint space narrowing (390). Knee joint space 
narrowing has shown to have greater correlation than osteophyte prominence with 
pain scores (391). 
 
The comorbidities of diabetes and hypertension are reported as they showed the 
highest prevalence in the cohort. Comorbidities only present in very small numbers 
of patients were not reported due to their incidence being too small to attribute 
meaningful analysis, for example in 2 or less participants. No participants were 
diagnosed with any excluding comorbidities. 
 
Across lifestyle factors, several notable observations were made. The majority of 
participants had an occupational history in manual labour (65%). The majority of 
participants either consumed alcohol within NHS recommended volumes or 
completely abstained (77%), and the vast majority of participants were not current 
smokers (94%) however some had previously been smokers and had stopped (29%). 
Lastly, the previous regular activity and sporting levels of the participants was skewed 
towards the higher end, with 49% of participants having previously taken part in 
regular high-level activity classified by a Tegner Activity Scale level of 7 and above. 
This level is defined as those who had regularly participated in competitive individual 
sports such as running or tennis, or in recreational field sports such as football, rugby, 
or hockey. Higher levels encompassed competitive impact or contact sports, and 
individual or team sports at national and international elite level. 
 
The other demographic cohort categories correlated with routine expectations of the 
clinical demographic based on National Joint Registry data.  The patient history of a 
56% rate of previous contralateral knee arthroplasty was notable as high in the 
cohort. This may have affected the recent level of activity of those patients in the 
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cohort, and also provided them with a comparison of expectations based on their 
previous experience. It may also have had a positive influence on the study 
recruitment rate due to the uncertainty surrounding a first arthroplasty not being 
present. 
 
Study Sub-cohort Demographics 
 
Study participants elected to provide different commitment levels and volumes of 
data categorised by the study sub-cohorts. These were self-selecting and allowed for 
the maximum possible volume of data collection while respecting the different 
individual levels of perceived research burden alongside the routine clinical service 
burden. It was important to establish that the different cohorts were not distinctly 
different when the demographic factors were examined. 
 
The data collection categories spanned all three sub-cohorts to varying extents. 
PROMs data were collected from all participants and analysed together, functional 
data were available for some time-points from both the Enhanced and Routine 
cohorts, and the extra time-point and additional functional data were only collected 
from the Enhanced cohort participants. 
 
A comparison of characteristics between the cohorts was necessary to identify any 
overt skewing of the cohort demographics, while keeping an awareness that the 
entire cohort was itself a sample of the population. This is addressed in the following 
sections. 
 
Enhanced Sub-cohort Demographics 
 
The enhanced sub-cohort attended more clinics and provided more data compared 
to the rest of the cohort. While by nature a smaller sub-cohort, a comparison of 
demographic factors was made to those from the overall cohort to determine 
representation. These are displayed, along with comparison to the other sub-cohorts, 
in Table 19. 
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Table 19 - Sub-cohort demographic factors frequency table with the MAKRO study. P values for similarity between 
sub-cohorts measured by One-Way ANOVA are shown for each sub-cohort compared to the entire cohort and also 
for the entire group. 
Characteristic  Cohort 
All Enhanced Routine WEL  
n 63 30 13 20  
p value (One-Way ANOVA) Group: 
p=0.98 
Indiv. to All 
(p=0.99) 
Indiv. to All 
(p=0.92) 
Indiv. to All 
(p=0.74) 
Biometrics n (%) n (%) n (%) n (%) 
Sex 
    
 
Male 31 (49) 15 (50) 9 (69) 7 (35)  
Female 32 (51) 15 (50) 4 (31) 13 (65) 
Age pre-op 
    
 
40-50 4 (6) 0 2 (15) 2 (10)  
50-60 15 (24) 9 (20) 3 (23) 3 (15)  
60-70 24 (38) 15 (50) 2 (15) 7 (35)  
70-80 15 (24) 4 (13) 5 (38) 6 (30)  
80-90 5 (8) 2 (7) 1 (8) 2 (10) 
BMI pre-op 
    
 
20-24.9 6 (10) 2 (7) 3 (23) 1 (5)  
25-29.9 15 (24) 5 (17) 3 (23) 7 (35)  
30-34.9 21 (33) 13 (43) 2 (15) 6 (30)  
35-39.9 14 (22) 8 (27) 3 (23) 3 (15)  
40-44.9 6 (9.5) 1 (3) 2 (15) 3 (15)  
45-49.9 1 (1.5) 1 (3) 0 0 
BEI pre-op 
    
 
10-14.9 1 (2) 0 1 (8) 0  
15-19.9 1 (2) 0 1 (8) 0  
20-24.9 2 (3.5) 0 1 (8) 1 (5)  
25-29.9 7 (12.5) 3 (10) 1 (8) 3 (15)  
30-34.9 7 (12.5) 5 (17) 1 (8) 1 (5)  
35-39.9 14 (25) 8 (28) 4 (31) 2 (10)  
40-44.9 10 (18) 6 (21) 2 (15) 2 (10)  
45-49.9 8 (14) 4 (14) 1 (8) 3 (15)  
50+ 6 (11) 3 (10) 1 (8) 2 (10) 
Kellgren and Lawrence Osteoarthritis Score for Op-knee 
   
 
1 22 (35) 10 (33) 7 (54) 5 (25)  
2 33 (52) 16 (53) 3 (23) 14 (70)  
3 5 (8) 2 (7) 2 (15) 1 (5)  
4 3 (5) 2 (7) 1 (8) 0 
Lifestyle 
    
Scottish Index of Multiple Deprivation Quintile 
    
 
1 8 (13) 2 (7) 2 (15) 4 (20)  
2 19 (30) 7 (23) 5 (38) 7 (35)  
3 12 (19) 6 (20) 1 (8) 5 (25)  
4 14 (22) 8 (27) 2 (15) 4 (20)  
5 10 (16) 7 (23) 3 (23) 0 
Occupation category 
    
 
Sedentary desk work 20 (32) 8 (27) 3 (23) 9 (45)  
Manual labour work 41 (65) 22 (73) 10 (77) 9 (45) 
Alcohol intake per week (units) 
    
 
Nil 16 (26) 4 (13) 4 (31) 8 (40)  
Consumption within NHS guidelines (1-14) 31 (51) 19 (63) 6 (46) 6 (30)  
Consumption above NHS guidelines (15+) 14 (23) 7 (23) 2 (15) 5 (25) 
Tobacco Smoking History 
    
 
Current 3 (5) 2 (7) 0 12 (60)  
Previous 18 (29) 7 (23) 4 (31) 6 (30)  
Never 41 (65) 21 (70) 8 (62) 2 (10) 
Peak previous regular physical activity (Tegner) 
    
 
Low (level 0-3) 15 (25) 6 (20) 4 (31) 5 (25)  
Medium (level 4-6) 16 (26) 7 (23) 3 (23) 6 (30)  
High (level 7-10) 30 (49) 17 (57) 5 (38) 8 (40) 
Comorbidities 
    
 
Diabetes 9 (10) 3 (10) 2 (15) 4 (20)  
Hypertension 22 (35) 11 (37) 3 (23) 8 (40) 
Long term pharamaceutical use pre-op 
    
 
Paracetamol 46 (73) 20 (67) 9 (69) 17 (85)  
NSAIDs 16 (25) 8 (27) 4 (31) 4 (20)  
Opiates (including minor and major) 27 (43) 14 (47) 4 (31) 9 (45) 
Previous Lower Limb Arthroplasty 
    
 
Contralateral Knee 35 (56) 19 (63) 7 (54) 9 (45)  
Contralateral Hip 8 (13) 3 (10) 5 (38) 0  
Ipsilateral Hip 7 (11) 2 (7) 4 (31) 1 (5)  
Contralateral Ankle 3 (5) 2 (7) 1 (8) 0  
Ipsilateral Ankle 4 (6) 2 (7) 2 (15) 0 
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As can be observed in the comparison of the two demographic cohort factors tables, 
the demographic distribution is well preserved in the Enhanced sub-cohort. Similar 
observations were made between all cohorts, with demographic percentage 
representations tested with one-way analysis of variance statistical tests (p=0.98). 
 
Surgical Operations and Recovery Period Study Flow 
 
Participants’ samples and data were collected in adherence to the protocol. Each sub-
cohort encompassed different data collection structures and are therefore separated 




The Enhanced sub-cohort’s successful data collection is displayed by category in 
Figure 27. Subsequent time-points and associated data categories are on the left of 
the figure, and the breakdown of any missed data is detailed on the right of the figure. 
 
The initial recruited cohort of 35 was reduced to 30 due to a withdrawal and surgery 
deferrals outside of the study time-window. 3 patient samples were not taken, one 
due to the surgeon deciding not to do so based upon the stature of the patient, and 
2 attributed to last minute changes in the operating list which were not conveyed to 
the researcher. 
 
Following the first missed sample, changes were made in the biopsy collection 
protocol to create a greater presence within the clinical environment, such as 
checking informal surgical lists with clinical secretaries, and providing contact details 
to multiple theatre staff members in the case of a change of surgical time or date. 
While further samples were subsequently missed in other sub-cohorts, the change of 
protocol greatly reduced the number of these cases. 
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Figure 27 - MAKRO Study Enhanced Sub-cohort CONSORT-Style Screening and Recruitment Flow Chart. 
 
A small number of patients were unable to attend certain time-points. Unattended 
appointments were rescheduled as soon as possible or, if not possible, postal 
questionnaires would be sent. At the 12-month time-point, one participant had 
moved out of area, and one was prematurely withdrawn rather than offered an 
alternative appointment when they called to say they could not attend. 
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Routine Sub-cohort 
 
The Routine sub-cohort had a similar minor reduction in participant numbers but due 
to different reasons. 3 patients had their TKA surgical operation cancelled altogether, 
1 patient planned to move out of area and so was transferred to the WEL sub-cohort, 
and 2 biopsy samples were not collected (Figure 28). 
 
The questionnaire-only time-points at 12-weeks and 6-months post-op provided a 
reduced return rate than those filled out in the clinic. Routine cohort participants 
returned 65% of questionnaires at this time-point, whereas Enhanced cohort 
participants completed 97% of their questionnaires. Participants who failed to return 
questionnaires were contacted by phone to ensure that they had received them and 
were asked if they had any concerns with the forms. Some were uncontactable and 
others stated that the questionnaire had not arrived. Repeat questionnaires were 
sent in these latter cases, however this did not always guarantee a returned form set. 
 
 
Figure 28- MAKRO Study Routine Sub-cohort CONSORT-Style Screening and Recruitment Flow Chart.  
Chapter 5: Results - The MAKRO Study 
  129 / 309   
Two patients were unable to attend their 6-week follow-up appointment. Both filled 
in postal questionnaires as a substitute but did not record direct functional data. 
 
At the end of the study, three patients repeatedly did not attend their hospital 
appointments. Due to the time-limited nature of the study, and the burden on the 
clinic frameworks, the patients were classed as lost data after 3 missed 
appointments. 
 
West and East Lothian (WEL) Sub-cohort 
 
The West and East Lothian (WEL) sub-cohort experienced a single participant 
reduction due to a withdrawal, and gained a participant due to a transfer from the 
Routine cohort (Figure 29). Biopsy samples were not taken in 2 participants, and 
follow-up questionnaire data return rate was similar to that observed in the Routine 




Figure 29- MAKRO Study West and East Lothian (WEL) Sub-cohort CONSORT-Style Screening and Recruitment Flow 
Chart.  
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Defining Variables for Analysis 
 
Demographic and Clinical Baseline Factors 
 
Out of the tabled demographic, lifestyle, and clinical baseline factors, almost all were 
used for subsequent investigations. Those criteria not used in analysis were excluded 
due to low numbers of participants. These comprised of the history of previous 
arthroplasty in joints other than the contralateral knee. This was decided due to the 
statistical implications and confounding factors arising from the inclusion of criteria 
with less than 3 participants per categorical variable. As such, the arthroplasty history 
for contralateral knee arthroplasty was the only arthroplasty history considered in 
further analyses. Though up to 8 participants had a history of other previous 
arthroplasties, due to the modelling methodology, which was dictated by the sample 
number of multiple factors, this reduced the viable sample numbers to below 3. 
 
To allow for structured statistical analysis of demographic and clinical baseline 
factors, ordinal data categories were created from discrete and continuous 
demographic variables. These were performed either in line with widely used and 
defined demographic or clinical cut-offs, or with justified threshold levels. This was 
performed for patient age by 5-year banding, BMI by 5-unit banding, BEI for 5-unit 
banding, alcohol use by current NHS recommendations (no intake; up to 14 units per 
week; 14-28 units per week; and 28 units per week or more), smoking history, and 
peak previous activity level by modified Tegner Activity Scale categories. This data 
binning facilitated straight forward analysis, particularly for the ordinal categories. 
 
For demographic data variables, the main categorical variables in the cohort were 
defined as sex, pre-op age group, pre-op BMI group pre-op, pre-op BEI group, 
Kellgren and Lawrence osteoarthritic score of op-knee, alcohol use group, smoking 
history, Scottish Index of Multiple Deprivation (SIMD) quintile, occupation category, 
peak activity level, comorbidity of diabetes, comorbidity of hypertension, long term 
use of paracetamol, long term use of NSAIDs, long term use of opiates, and whether 
the patient had previously undergone contralateral knee arthroplasty. 
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Demographic and clinical baseline factor correlations 
 
To assess for variable collinearity, and potential statistical bias, the demographic and 
clinical baseline factors were initially compared using correlation coefficients. Due to 
the categorical nature of many of the variables, Spearman Rho methodology was 
used. Some statistically significant weak correlations were observed, alongside two 
strong correlations, and one moderate correlation. The full correlation matrix can be 
found in Appendix C: Additional Data. 
 
Patient sex was found to strongly correlate with bioelectrical impedance, where the 
established biological propensity to higher body fat in females influenced results 
leading to higher BEI values (r = 0.65). Additionally, a moderate correlation was 
observed between sex and peak physical activity in life assessed by the modified 
Tegner Activity Scale (r = 0.47). Males were more likely than females to record a high 
score with this variable. Lastly, a strong correlation was observed between BMI and 
BEI data (r = 0.64), logically present due to the likelihood of higher body fat in those 
of shorter stature with higher body weight. For context, only a non-significant, very 
weak correlation was observed between sex and BMI (r = 0.10). Significance 
determines the likelihood that a result was found by chance when performing a 
statistical test. A probability-value (p-value) set at a level of 0.05 to determine a 
significant finding indicates that there is a 1 in 20 chance of the result being due to 
chance, and therefore a false positive. 
 
A further comparison of Variation Inflation Factors (VIFs) was made between the four 
discussed variables to check further for covariation. VIFs assesses collinearity which 
can artificially overfit a regression modelling result to indicate a stronger relationship 
is present when it is not. All were found to be below 2, a low value, which allayed 
concern for mutual inclusion in subsequent multivariate analyses. 
 
VIF evaluation was subsequently performed within all multiple variable models to 
assess for collinearity and to prevent potential bias and model overfit. 
 
  
Chapter 5: Results - The MAKRO Study 
  132 / 309   
PROMs, Functional, and Laboratory Factors 
 
Cohort data contained over 180 categories of data per patient. This only 
encompassed summary PROMs and functional scores, with the number of categories 
much higher including raw data. To allow structured statistical analysis, definitive 
data variables were selected. 
 
All data were combined from sub-cohorts for analysis. However, some categories 
were only obtained from a single sub-cohort by design. The cohort demographic 
similarities allowed reasonable comparison across the entire study cohort. 
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MAKRO Study Patient Data 
 
The patient data results from the longitudinal cohort study provided insight into 
temporal trends of the patients early functional outcome metrics. The relationship 
between the metrics could be examined, and the time-points which showed greatest 
metric variance were selected for further investigation. 
 
The interrogation of study results sought to answer the following research questions: 
 
 How do functional outcome metrics change over time during early surgical 
recovery following total knee arthroplasty? 
 Do different functional outcome metrics change at different rates post-TKA? 
 Which outcome time-points during early recovery post-TKA are best to 





Chapter 5: Results - The MAKRO Study 
  134 / 309   
Biometric, Functional and Patient Reported Outcomes Data 
 
Evaluating and understanding the temporal trajectory of each functional outcomes 
metric recorded provided information as to the recovery efficacy of the cohort. 
Additionally, it highlighted measurements which significantly changed within the 
duration of the study. The following research question was therefore addressed: 
 
 How do functional outcome metrics change over time during early surgical 
recovery following total knee arthroplasty? 
 
Summary graphical figures are displayed in-line for each metric’s results with figures 
and tables. Supplementary figures are located in appendices where stated in 
Appendix C: Additional Data. Time-points are summarised in figure captions as weeks 
following surgery or specifically as follows: pre-assessment clinic (PAC), 6-weeks post-
op (6W), 12-weeks post-op (12W), 6-months post-op (6M), and 12-months post-op 
(12M). 
 
Patient biometric data, functional data and PROMs data from the MAKRO cohort 
study are displayed in Table 20. Study temporal data are displayed in probability-
tables to show significant changes per metric over time in Table 21 and as graphical 
figures with 95% confidence intervals in Figure 30. Data for categories only measured 
in the Enhanced sub-cohort show lower numbers compared to those from the full 
cohort, therefore some response numbers varied by time-point. 
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Table 20 - Biometric, functional and patient reported outcomes summary results. 
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Table 21 – Probability tables showing statistical differences in metric between study time-point for patient 
biometric functional and PROMs data. Comparisons performed with omnibus One-way ANOVAs and, if statistically 
significantly different (alpha 0.05), interrogated with inter-time-point post-hoc pairwise comparison using t-tests 
with pooled standard deviations and Bonferroni-Holm (Holm) corrections for multiple comparisons. Sample n 
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Figure 30 – Time-course data series for biometrics, functional assessments, and PROMs scores with individual 
dimension representations. Dual boxplot and Loess (local regression) smooth fit curves in figures to show trends 
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over study time-course. Shaded areas represent 95% confidence intervals. Week zero represents TKA intervention. 
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Patient Biometrics 
 
Participant BMI and BEI values were relatively high across all time-points, with 
average BMI values classified as obese across all time-points. A ceiling effect was 
present for BEI values over 50% due to measurement device limitations discovered 
during the study. This affected 10% of baseline measurements. As described in the 
literature due to higher propensity to body fat, higher BEI values were observed in 
female participants compared to males across all time-points. This was not present 
for BMI values. 
 
BMI was found to be similar across all time-points (p=0.77). A similar trend was also 
found with BEI measurements (p=0.66). 
 
Patient op-knee range of motion showed variation between patients but typically 
improved following TKA. Patient Range of Movement (ROM) in the operated knee 
was found to be significantly different between time-points and was investigated 
further to determine where differences occurred during the study. Patient ROM 
initially decreased following their operation but had improved by 6-months post-op. 
No further ROM change was observed by 12-months post-op. 
 
Directly Measured Functional Outcomes 
 
During the study, the rate of change in ability of the control leg was noted in the 
majority of patients. Some had bilateral pain at their pre-op time-point, and some 
developed contralateral pain throughout the duration of the study. This pain 
reflected elements of their effort guarding while performing assessments, 
particularly the leg extensor power assessment. As such, this confirmed the selection 
of normalised power to body weight ratio over normalisation against control leg data. 
This body weight normalisation, controls for sex and patient stature (291). This 
created a constant which was reproducible by patient and time-point to allow 
sequential comparisons. 
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While pain was clearly present for the operative knee both in the preoperative 
assessment due to osteoarthritic pain, and then in the early post-operative window 
due to operative tissue damage, this was a constant across the entire patient cohort. 
 
Patient leg extensor power to weight ratio was found to differ significantly across the 
study, with similar values observed 6-weeks following surgery but with improved 
values achieved by 12-weeks post-op. The values then remained similar for the 
remainder of the study (Table 21). 
 
Patients’ Aggregated Locomotor Function (ALF) score was found to differ over time 
(Table 21). A lower ALF score reflected a quicker performance following an 
intervention and therefore a combination of relative comfort, agility and confidence 
in locomotion. Changes were observed between 6-weeks and 12-weeks following 
surgery which then stabilised. The total time taken to perform the functional activity 
battery ranged from 93.34 seconds, observed in one patient at 6-weeks post-op, to 
11.68 seconds, observed in another at 12-months post-op. A cluster effect was 
observed between 20 and 30 seconds, with patients scoring higher or lower 
noticeably exhibiting phenotypic functional issues or functional agility respectively. 
This indicated a potential sensitivity measurement range aspect of the functional 
assessment. 
 
The average daily step count of participants was calculated as a mean from the 
exported 4-day raw data from Xaomi Mi Band activity monitors provided to those 
allocated to the Enhanced sub-cohort. Cohort mean step count reduced from 3850 
to 2960 steps by 6-weeks following surgery, which then increased to 4700 steps by 
6-months and remained stable. All values are lower than recommended health 
targets (238) but do show a 22% primary outcome improvement over baseline when 
examined in this way. 
 
The average daily step count was found to be significantly different over time (Table 
21), however, when investigated using pairwise comparisons with corrections for 
multiple comparisons, no time-point changes were deemed different with the stated 
alpha. Similar values were observed between pre-op, 6-weeks, and 12-weeks post-
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op (p=1.00). The difference between 6-weeks and 6-months following surgery 
showed the largest non-significant different (p=0.06), which remained similar by 12-
months (p=1.00).  
 
The results for the average heart rate (p=0.78) and average nightly sleep duration 
(p=0.91), tested within the Enhanced cohort using the activity monitors, were found 
to be statistically similar across all time-points. 
 
Patient Reported Outcome Measures 
 
Patient EQ-5D index scores differed across time-points and were found to show the 
greatest improvements between pre-assessment and 6-weeks post-op. Further 
changes were observed by 6-months post-op which remained unchanged 6 months 
later (p=0.49). 
 
The EQ-5D’s Health VAS was found to change over time. Improvement was observed 
by 6-months post-op (mean change from 70.619.3 at PAC to 83.515.3 at 6 months, 
p=0.005). The Pain VAS also changed over time but showed positive changes earlier 
at 12-weeks post-op (mean change 50.822.3 at PAC to 67.930.3 at 12 weeks, 
p=0.004). For both, no further changes were observed after 6-months post-op 
(p0.861). 
 
FJS scores for the patient cohort positively changed over the course of the study, with 
step-wise significant changes observed from pre-op to 6-weeks post-op (p=0.002) 
and again from 6-weeks- to 12-weeks post-op (p=0.022), after which scores 
plateaued (p0.555). 
 
The Knee Injury and Osteoarthritis Outcome Score was analysed in its five separate 
dimension sub-scores and subsequently in its single index form. All six of the score 
totals were found to vary across the study time-points, however they showed 
differing rates of improvement. 5 of 6 of the KOOS scores initially improved by 6-
weeks after surgery (p<0.001), with the sport and recreation dimension initially 
continuing to show similar values (p=0.843). The symptoms and pain dimensions sub-
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scores improved at 12-weeks post-op to levels not seen until 6-months post-op in the 
activities of daily living, sport and recreation, and the quality of life sub-scores. The 
combined index score showed that all improvement had been achieved by 12-weeks 
post-op with no subsequent score increase (p0.230). 
 
The Oxford Knee Score was found to differ across time-points, specifically between 
pre-op and 6-weeks post-op (21.38.2 to 27.99.5, p<0.001), and then again to its 
maximum level by 12-weeks post-op (34.98.2, p<0.001). 
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Patient knee ROM has a threshold which dictates a combination of factors. A knee 
fixed in flexion and unable to extend fully can prove a tiresome burden due to 
constant muscular effort, and a knee lacking flexion past 80-90 degrees can be a large 
obstacle to performing ADLs such as climbing stairs, rising from a chair, and using a 
motor vehicle. With a larger total ROM, the likelihood of full extension and flexion 
past the stated threshold is increased and therefore reflected in the functional 
benefits of doing so. These factors were subsequently used as categorical variables 
during further tertiary analyses. 
 
Directly Measured Functional Outcomes 
 
While the four-day average step count allowed for snapshot data per time-point, the 
exact timing of the clinics may have influenced the activity of the patients. Research 
clinic assessments were scheduled on Wednesdays and Thursdays defined by clinic 
access schedule meaning that recording of activity occurred from day-of-clinic 
through to a Sunday or Monday night. While the recording period was thus 
standardised to include the weekend, the difference between weekday and weekend 
may have influenced the activity level either positively or negatively. Additionally, 
some clinic appointments occurred just prior to personal or national holidays, such 
as sedentary beach and sun-based vacations as well as family gatherings in late 
December, which would have provided uncharacteristic activity levels when 
compared to normal habits. The structure of the clinics didn’t allow for flexibility 
here, so all results are taken as representative. 
 
From discussions during clinic visits with patients, it became apparent that an 
element of habitual activity may have been observed during latter time-points. A 
patient may have possessed the ability to perform more steps but had no reason to 
do so. Once they had achieved their goal of reaching a local destination such as a 
shop, or a friend or family member’s residence, they had no reason to venture 
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further. A comparison of pre-operative daily step counts to those at 6-months and 
12-months post-op are displayed in Figure 31. 
 
 
Figure 31 - Individual plots of average daily step count recorded following the preoperative assessment clinic, the 
6-months post-op assessment, and the 12-months post-op assessment. 
A small number of time-point step-count outliers were present within the cohort. The 
most apparent was a participant’s change from roughly 800 daily steps pre-op to 
more than 13,000 steps 12 months following TKA, which was related to a return to 
manual labour work. Conversely, all major step-count reductions, such as a drop to 
zero, were related to other pathology. 
 
Several patients commented that while they had accomplished roughly the same 
distance as at 6-months post-op, by 12-months post-op they were doing so at a faster 
walking pace. As the factor of walking speed or cadence was frequently mentioned 
by patients is likely to be a relevant factor across all time-points.  
 
Investigations into sleep quality, for example determined through the extent of 
restlessness, disruptions or irregular circadian rhythms, may provide future insight 
into aspects of sleep disruption due to pain or other factors. However, the use of 
analgesic pharmaceuticals may counter this effect. 
 
Within the aggregated locomotor function data, comprising a timed-up-and-go with 
a stair-set climb and descend, and an 8-meter walk, the steep stair descent 
component proved the greatest obstacle to some study participants. For those 
experiencing functional difficulty, the activity of steep stair descent with the weight-
loaded knee in a compromised position would lead to them descending one stair at 
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a time, whilst favouring the non-operated knee, and using the bannisters to support 
themselves. This was likely to be due to the greater flexion required when descending 
stairs and the reduction in strength that this produces which subsequently 
accentuated any strength deficits that they had (392). This added the most time to 
their scores compared to their performance in the other areas of the test battery. 
Patient Reported Outcome Measures 
 
Overall, the study PROM data were in in-line with established databases of post-TKA 
responses which validated the results (Table 22). These are compared to local studies 
with similar case-mix (166,393), and to larger databases collected throughout the UK 
and Europe (394,395). 
 
Table 22 - Comparative headline PROMs data from study and published databases with time-points. Hamilton and 
Giesinger collected data at 12-months post-TKA, Baker collated data collected between 6-months and 12-month 
post-TKA. 
 
Data (Mean (StDev)) 
Category Study data Hamilton 2015 Giesinger 2015 Hamilton 2012 Baker 2012 
OKS Pre-op 21.3 (8.2) 19.7 (7.4) - 19.1 (7.5) 18.9 (7.8) 
OKS Post-op (6-12M) 37.9 (8.4) 37.8 (7.9) - 37.8 (7.9) 34 (11.7) 
EQ-5D Pre-op 0.40 (0.30) - - - 0.41 (0.27) 
EQ-5D Post-op (6-12M) 0.80 (0.20) - 0.85 (0.21) - 0.71 (0.27) 
 
The lower post-operative scores from the Baker et al. study likely reflects the 
different data collection time-window which included responses between 6-months 
post-op and 12-months post-op with responses from over 23000 patients. 
 
Within the study data, the differences between the PROM tools’ scores reflects the 
slight variances in their focuses. Particularly within the EQ-5D VAS scores, this could 
implicate the perceived value that pain contributes to overall health state. While pain 
had reduced, overall perceived health improvement was not seen for a further 3 
months which reflects the diverse contributions to the overall health state. 
 
Notable in the KOOS results was the sports and recreation sub-scores low final 
outcome level compared to the other sub-scores. The nature of post-operative 
clinical advice provision and the mechanical limitations and of the knee 
endoprosthesis dissuaded activities such as running and jumping which contributed 
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to the sub-score. The lack of ability to perform these and similar activities dictated a 
low sub-score in this dimension. 
 
The differently observed recovery trajectories within the KOOS reflected the nature 
of the TKA procedure and the different targets of the sub-scores. The operation 
intends to remove symptoms and associated pain, however the true benefits from 
the translational functional elements take longer to appear. The pain from the 
operative trauma has disappeared within 3-months following the operation but the 
full improved strength and endurance take longer to appear. These are reflected in 
the higher scores in those sub-scores within the latter time-points. 
 
The study data showed that some functional outcomes changed over time during 
early surgical recovery in the study cohort. Other recorded metrics remained similar 
through this period, particularly biometric data. 
 
These data were examined for their individual temporal trends during early surgical 
recovery. 
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Comparison of Measured Outcome Temporal Trends 
 
Differences in Recovery Rates by Chosen Metric 
 
Having evaluated the metric trends in isolation, next comparing them to the other 
study metrics provided answers to two of the study research questions: 
 
 Do different functional outcome metrics change at different rates post-TKA?  
 Which outcome time-points during early recovery post-TKA are best to 
investigate the associated effects relating to patient background and baseline 
muscle physiology? 
 
The difference in measured recovery rate differed by chosen outcome measurement 
within the study population. This occurred across outcome metric categories as well 
as between similar tools. Some measurements show significant sustained 
improvement by 6-weeks post-operation, while others initially worsened before 
improvements were observed by 12-weeks or 6-months post-op. Notably the 
operated knee ROM and the daily step count were worse than pre-op by 6-weeks of 
recovery time (Table 23). 
 
The significant improvements in PROMs scores by 6-weeks post-op contrasts sharply 
with patients’ direct functional measurements scores. While the PROM 
questionnaires capture more than just functional aspects of recovery, notably pain 
levels and some basic flexibility aspects, functional outcomes factor highly into index 
score weighting. 
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Table 23 – Rate of variation of different outcomes by time-point post-operation. Arrows represent an improvement 
or worsening in metric trend compared the previous time-point. Asterisks denote statistical significance (alpha = 
0.05). Colours are distinct for each arrow type to allow for ease of recognition. 
 Time-point post-operation 
 6-weeks 12-weeks 6-months 12-months 
Functional - Clinic Measured     
ROM ↓* ↑ ↑ → 
Power (leg extensor ratio) → ↑ ↑ → 
ADL performance (ALF score) → ↑ → → 
Functional - Community Measured     
Average daily step count ↓ → → → 
Patient Reported     
EQ-5D Index ↑* ↑* ↑ → 
EQ-5D Health VAS → → ↑ → 
EQ-5D Pain VAS → ↑ ↑ → 
FJS ↑* ↑* ↑ → 
KOOS Symptoms D. ↑* ↑ → → 
KOOS Pain D. ↑* ↑ → → 
KOOS ADL D. ↑* ↑ → → 
KOOS Sport & Rec.D. → ↑ → → 
KOOS QOL D. ↑* ↑ → → 
KOOS5 Index ↑* ↑ → → 
OKS ↑* ↑* → → 
 
6-week recovery data show that patients think that they have much improved at this 
stage of recovery compared to pre-operation. When compared to the directly 
measured functional outcomes at this time-point, the measured aspects provide a 
different picture. Patient operated knee joint ROM and average daily step count had 
decreased, while patient strength and function had remained similar. 
 
Subsequently, there is a division in the progression of outcome measurements. Some 
functional and patient reported metrics reach their maximum values by 12-weeks of 
recovery, however others continue to show improvement through until 6-months or 
even 12-months following the operation (Table 24). The variation in maximum 
progression time-point is distinct even within score sub-dimensions such as the KOOS 
dimensions. 
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Table 24 – Final time-point at which each outcome measurement subsequently plateaus and does not 
meaningfully improve. Improvement fit trend defined by local regression curve. 
 
Time-point post-operation 
6-weeks 12-weeks 6-months 12-months 
Functional - Clinic Measured 
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Compared to preoperative values, by 12 weeks post-op, patients had achieved 82% 
of final (12 months post-op) KOOS5 PROM score, 63% of final leg power, 63% of final 
ADL performance measured by ALF, and 5% of final daily step count. The values 
further increased by 6 months post-op with KOOS5 score increased to 92% of final 
score, leg power at 94% final, ADL at 116% final, and daily step count at 110% of final 
value. This is visualised in the time-course graphs displayed in Figure 30 earlier. 
 
These findings highlighted the utility of using a combination of diverse metrics to 
evaluate patient functional outcome and showed that patient evaluated outcome 
alone may not fully represent early functional outcome. They also emphasise the 
critical nature of the follow up time points chosen for clinical trials. 
 
Interestingly, while patients may have the physiological ability to extend their range 
and increase their step count based on improved strength and perceived ability, it 
seems that they choose not to do so based on established lifestyle and activity habits. 
The weaker correlation at 12 weeks between ALF and step count was notable as it 
may reflect the improvement in strength and ability to perform representative ADLs 
quickly when assessed in clinic, but that the endurance is still lacking for activities 
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such as walking distance. This endurance may have recovered by the 6-month time 
point resulting in the improved correlation with the other functional metrics. 
 
While not directly measured in this study, complimentary step count data such as 
step cadence or speed may further elucidate the picture in comparing walking ability 
and endurance between pre- and post-op function. Movement quality may have 
improved substantially, though it seems distance has not. Different sensitivity to 
recovery was observed across the range of functional outcome measurements. This 
reinforces the importance of multiple tool use in the design of clinical studies (188), 
to reflect the differing aspects of function, and that careful analysis is required due 
to the variation in metrics at different time-points. 
 
Patients are able to demonstrate greater functional ability in tests of maximal 
capacity following total knee arthroplasty, but they demonstrate habitual levels of 
activity, consistent with pre-operative values suggestion that activity behaviour 
modification may be required to utilise the physical benefit of knee arthroplasty. 
 
Once the arthritic pain is removed by surgical intervention, a patient may not 
suddenly double their daily step count, even though they have the capacity to do so. 
Additionally, a time period is required for the unstructured training adaption to gain 
skeletal muscle endurance for those activities to feel habitual, non-tiring, and 
comparatively effortless following a long pre-operative period of disuse. However, 
the genotype and phenotype of the patient muscle is key to determining the 
physiological propensity for this to be able to happen. An understanding of patient 
baseline physiology is therefore necessary to help clarify the causative factors within 
the study cohort. 
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Definitive Variables and Time-points for Multivariate Modelling Analysis 
 
Functional Variables for Multivariate Analysis 
 
Functionally assessed outcomes were examined to choose best representative 
results for multiple analysis comparisons. The primary decision for these selections 
came from the OARSI metrics recommendations, as with the initial choice of metrics, 
and the percentage of study data capture also factored into the final selection. 
 
The categories were also to be selected to avoid overfit which would have resulted 
from collinearity or including categories that measured very similar aspects of 
function with parallel results. The initial data categories were already selected to 
measure different aspects of function. 
 
Patient functional variables were compared to examine correlations (Table 25). Full 
matrices are located in Appendix C: Additional Data. Pearson correlation coefficients 
of pooled results from all time-points showed moderate correlations between ROM 
to Leg Power (r=0.464; p<0.001) and ALF score (r=-0.431; p<0.001), but not to Daily 
Step Count. Leg power showed correlations with Daily Step Count (r=0.291; p=0.001) 
and ALF score (r=-0.570; p<0.001). ALF score also showed moderate correlations 
Daily Step Count (r=-0.427; p<0.001). 
 
Table 25 - Pearson correlation coefficients showing associations between all functional metric results collated from 
all time-points. 
 
Total op-knee ROM Leg Power Ratio ALF Score 








Daily Step Count 0.093 0.291 -0.427 
0.291 0.001 <0.000 
Cell Contents: Pearson correlation 
P-Value 
 
When the factors were investigated at individual time-points, the data provided a 
similar picture.  Associations become notably stronger at latter time-points as 
patients recovered from TKA (Appendix C: Additional Data). 
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The associations broadly indicate that improved function in one parameter likely 
translates to improved ability in another. Daily step count and knee range of motion 
were least associated. Extreme restrictions in ROM (e.g. flexion block <80 and fixed 
flexion >10) lead to impaired locomotion in some patient but other participants 
remained fairly active in the community, measured by step count, despite limitations 
in movement range. 
 
The chosen categories for multivariate modelling analysis were directly measured 
functional power evaluated by Nottingham Leg Rig controlled by body weight, timed 
ADL surrogate performance by Aggregated Locomotor Function score, and average 
daily step count recorded by electronic activity monitor. These were termed the 
primary surgical outcome metrics and were therefore examined during multivariate 
modelling. Knee range of movement was not included as a primary functional 
outcome metric due to it being categorised for modelling purposes as a biometric 
measurement similar to BMI. Instead it was included as a predictive metric during 
modelling. 
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PROMs Variables for Multivariate Analysis 
 
The patient reported factors similarly required representative selection for use in 
multiple analysis comparisons. While each PROM tool had a unique question set, 
length and focus, an evaluation of collinearity was performed to measure the scoring 
overlap. 
 
PROM collinearity was assessed with a correlation matrix and a regression model to 
assess Variation Inflation Factors (VIF). Moderate correlation was observed in the VIF 
responses (VIF 3-5) and strong correlation coefficients were observed across all 
PROMs tools (r>0.70). These results indicated that a single PROM tool should be 
selected to prevent multicollinearity leading to model overfit.  
 
With one generic health score and three knee specific scores, the different 
specificities were apparent in the correlations data. The knee scores correlated more 
strongly with each other than with the EQ5D Index score. Due to the nature of the 
insight desired from the PROM, a knee specific score was more valuable regarding 
TKA outcome. Additionally, the highest response rate was necessary to maximise 
model power. 
 
The KOOS5 score was therefore chosen over the other PROMs scores due to its 
specificity in the TKA population and its response rate being highest amongst all other 
PROMs tools in the study. The KOOS tool was also the longest of all the study 
questionnaires and therefore was the most sensitive to variation in response. 
 
The KOOS5 Index score was found to correlate strongly with the EQ-5D and very 
strongly with the FJS and OKS PROMs tools at each time-point (Appendix C: Additional 
Data), making it a highly representative candidate of all the PROM data collected 
throughout the study period. 
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Definitive time-points for multivariate analysis 
 
Multivariate modelling comparisons required definitive time-points. A very early 
outcome and one representing final study endpoint were to be selected. 12-months 
post-op was chosen as primary study endpoint from the study outset due to the study 
duration. Patient functionally measured and patient reported data both displaying 
plateau effects by 12-months post-op. 
 
The study data were evaluated using time-point data levels instead of inter-time-
point variable change due to the large pre-op variation in functional performance and 
PROMs data. Both changes (delta) in metrics and absolute levels are routinely 
compared in the orthopaedic PROMs literature (396). Categorising a patient by their 
12-month outcome scores was selected to reflect real-world function rather than to 
control these values by their performance pre-op, as the initial values were likely 
affected by a large number of additional factors. Similarly, to control the values by 
patients’ 6-weeks data missed a key early window into their recovery where much 
recovery has taken place. Patients have uniform limited mobility in the first days 
following TKA, but some go on to achieve relative normality within 6 weeks while 
others remain disabled. The underlying causes are complex, with pain and control of 
pain playing a major role. For example, activity inhibiting pain varied, as did analgesic 
use as shown by patients’ Oxford Knee Score and VAS responses, and discussion their 
about analgesic use in clinic. These factors are investigated further within the 
multiple comparisons. 
 
Very early recovery outcome variation was defined as the 12-weeks post-op time-
point. This time-point was identified as showing large outcome variation within the 
cohort and the chosen primary outcome metrics, which allowed for further 
investigation of how a variety of background and physiological factors may influence 
this early stage and the rate of recovery following TKA. The 12-week time-point was 
selected over the nearest alternative time-points of 6-weeks post-op and 6-months 
post-op due to the respective excluding factors of residual surgical pain and the 
plateauing of metrics. Due to the nature of the patient cohort stratification, any 
functional factors were investigated within the Enhanced sub-cohort at this stage, 
but PROMs data were obtained from the whole study cohort.  
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Patient Biometric Data and Functional Outcomes: Results and Discussion 
 
Patient biometric data were compared with the main functional outcomes to 
examine further trends. This was performed using Pearson correlation coefficients. 




Total sleep duration, categorised sleep duration, and sleep quality measured from 
activity monitor light sleep to deep sleep ratio were compared to KOOS5 score, Leg 
Power Ratio, ALF score, and Step count at the defined very early (12 weeks post-op) 
and early (12 months post-op) TKA functional outcome assessments. Overview data 
for the metrics at 12-months post-op are tabled in Table 26, and data from 12-weeks 
can be found in Appendix C: Additional Data. 
Table 26 - Correlation coefficients of sleep data from 12-months post-op compared to functional outcome data. 
  KOOS5 Index 
(12M) 




Daily Step Count 
(12M) 
Total Sleep at 12 
months post-op 
-0.068 -0.249 0.223 -0.528 
0.748 0.230 0.284 0.007 
Total Light Sleep at 12 
month post-op 
0.209 0.306 <0.001 -0.224 
0.316 0.137 0.998 0.281 
Total Deep Sleep at 12 
months post-op 
0.219 0.063 -0.322 -0.208 
0.293 0.763 0.116 0.319 
Total Light Sleep/ Total 
Deep Sleep at 12 
months post-op 
-0.235 -0.148 0.511 -0.131 
0.259 0.481 0.009 0.532 
 
No significant correlations were identified between duration of light or deep sleep 
and functional outcomes at either time-point (p>0.05). Total sleep duration was 
correlated with ALF score at 12-weeks post-op (r=0.45; p=0.029), inferring longer 
sleep duration was associated with slower ALF performance during very early 
outcomes. Total sleep was also negatively correlated with daily step count at both 
12-week (r=-0.49; p=0.015) and  12-month time-points (r=-0.53; p=0.007). This 
showed longer sleep was correlated with lower daily step count.  The ratio of light 
sleep to deep sleep was correlated with a higher ALF score at 12-months post-op 
(r=0.51; p=0.009). This indicated a lack of deep sleep, or a disturbed and shallow 
sleep, being associated with slower times in ALF battery performance. An 
examination of pain scores showed no significant effect on the metric (p>0.05). 
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These preliminary results show sleep duration, depth and inferred quality provide a 
relevant metric to be examined in relation to patient function outcomes. Future 
examination of sleep factors in TKA outcomes with specialised PROM tools such as 
the Pittsburgh Sleep Quality Index (397) or Epworth scale (398) may identify clearer 
factors such as sleep deficiency, sleep latency, and the resulting psychometric and 
physiological effects (399). 
 
Knee and Thigh Circumference 
 
Knee and thigh circumferences were measured at 6-months post-op to explore 
aspects of Arthrogenic Muscle Inhibition (AMI), where local swelling can impair knee 
function by reducing the efficacy of innervation (Table 27). 
 
Mean knee circumference was measured as larger in op-knee at 6-months post-op 
compared to contralateral knee but found to be statistically similar using paired t-
tests (p=0.078). Thigh circumference was also but found to be statistically similar 
between sides (p=0.139). 
 
Table 27 - Knee and thigh circumference measurement data taken at 6-months post-op in the Enhanced cohort. 
Variable n m StDev 
Operated Knee Circumference (cm) 20 44.15 4.31 
Contralateral Knee Circumference (cm) 20 43.05 3.64 
Operated leg Mid-thigh Circumference (cm) 20 50.53 6.48 
Contralateral leg Mid-thigh Circumference (cm) 20 49.38 5.49 
Op. Knee Circ. / Conta. Knee Circ. 20 1.02 0.06 
Op. Leg Mid-thigh Circ. / Contra. Leg Mid-thigh Circ. 20 1.02 0.06 
 
Single time-point investigation of knee and thigh circumference with functional 
outcomes identified skeletal muscle bulk, continued knee swelling, and assessed 
differences between legs using Pearson correlation coefficients identified a single 
significant correlation between larger operated knee vs contralateral knee 
circumference as associated with longer ALF performance times (r=0.48; p=0.033) 
(Table 28). 
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Table 28 -Correlations between knee and thigh circumference measurements and functional outcomes data at 6-
months post-op. 
  KOOS5 Index (6M) Leg Power Ratio (NLR 6M) ALF Score (6M) Daily Step Count (6M) 
Operated Knee 
Circ. / 
Contra. Knee Circ. 
-0.257 -0.198 0.477 -0.065 
0.274 0.417 0.033 0.797 
Operated Knee 
Mid-thigh Circ. / 
Contra. Knee 
Mid-thigh Circ. 
0.084 -0.244 0.042 -0.091 
0.726 0.314 0.859 0.720 
Operated Knee 
Circ. 
0.012 -0.151 0.096 0.247 
0.961 0.536 0.687 0.323 
Operated Knee 
Mid-thigh Circ 
0.054 -0.268 -0.024 0.102 
0.821 0.267 0.921 0.688 
Contra. Knee Circ. 0.199 -0.042 -0.212 0.299 
0.401 0.865 0.369 0.229 
Contra. Knee 
Mid-thigh Circ. 
0.005 -0.163 -0.039 0.164 
0.984 0.504 0.869 0.514 
 
Comparably larger prosthetic knee at 6-months post-op can be related to implant size 
as well as remaining swelling from surgical trauma. At 6-months post-op, concern 
about infection had been allayed, with a visual inspection of the knee during research 
clinics to confirm this. The physiological impact on the local tissue resulting from 
differential swelling likely include elements of arthrogenic muscle inhibition (AMI), 
which leads to functional impairment as assessed during ALF testing (126). Future 
examination with nerve conduction studies would elucidate this effect further. 
 
Change in Activity Level 
 
Patient reported activity level was assessed using the modified Tegner activity scale 
to determine previous peak activity, activity level at time of surgical pre-assessment, 
and at 12-month post TKA (Table 29).  
 
Table 29 - Activity level data measured by modified Tegner Activity Level. 
Variable n m StDev 
Life Peak Tegner 61 6.3 2.8 
Full Cohort Tegner at PAC 60 1.3 0.8 
Paired Cohort (to 12M data) Tegner at PAC 36 1.4 0.8 
Tegner at 12-months post-TKA 36 2.0 1.3 
 
Recreational activity level significantly improved by 12-months post-op (p=0.005). 
The mean activity level change from 1 to 2 represented an improvement from an 
ability to walk on even ground and any vocational work restricted to desk-work, to 
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an ability to walk sustained on uneven ground and participate in golf, bowls, curling 
or similar sporting activities, and to undertake vocational work involving light labour 
such as that required by a shop assistant or school teacher. 
 
Examination of Pearson correlations between 12-month reported activity level and 
12-month functional outcomes identified strong correlations with activity level and 
KOOS5 score (r=0.639; p<0.001), leg power (r=0.711; p<0.001), and ALF score (r=-
0.754; p<0.001). Comparison with daily step count were non-significant (Table 30). 
 
Table 30 – The correlations between final functional outcome metrics and return to activities in the community 
with Pearson correlation coefficient. Both r and p values are presented. 
  KOOS5 Index (12M) Leg Power Ratio (NLR 12M) ALF Score (12M) Daily Step Count (12M) 
Activity level 
(Tegner) 12M 
0.639 0.711 -0.754 0.306 
<0.001 <0.001 <0.001 0.137 
 
Same time point general-to-specific predictive modelling was examined to determine 
the greatest contributions of clinic and self-reported tools influencing wider activity 
level as measured by Tegner (Table 31). The hierarchical investigation determined 
that clinic based ALF score was the greatest influence (p<0.01), with leg power also 
contributing (p=0.03). Combined they predicted 60% of reported Tegner score. 
 
Table 31 - Primary functional outcome factors as model contributors to activity score (Tegner) 12 months post-op. 
The second model also includes pre-operative Tegner activity level as a predictive factor. 
Response Metric Ranked contributing factors 






Activity Level (Tegner) 12 months 
following TKA 
ALF Score at 12 months post-op (<0.01; -0.06) 
Leg Power controlled by body weight at 12 months 
post-op (0.03; 0.75) 
0.60 <0.001 
(32) 
Activity Level (Tegner) 12 months 
following TKA 
ALF Score at 12 months post-op (<0.01; -0.06) 
Activity Level (Tegner) pre-op (0.02; 0.40) 
Leg Power controlled by body weight at 12 months 




Further examination of sex, age, peak life activity level, and analgesic use found no 
significant influences. Introducing the known pre-op activity level into the model, 
with a cohort real activity range varying from an inability to move around up to an 
ability to walk on a flat, even surface, provided another 6% of prediction to the 
model. 
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The results highlight two directly measured clinic-based outcomes that can strongly 
predict a return to greater levels of activity in the community at 1 year following TKA. 
Therefore, the targeting of post-operative rehabilitation to improve these functions 
should correlate with a more favourable achievement of desired activity levels. 
Furthermore, the lack of correlation with step count indicates additional evidence 




Analgesic medication is routinely used to combat musculoskeletal pain and its 
limitation of function. The comparison of patient managed analgesia and surgical 
outcomes can indicate if all patients with positive outcomes are pain free or if they 
achieve function despite continuing pain. 
 
Table 32 -The response data of analgesic medication use pre-op and at 12-months post-op 
Variable  Response n % using 
Paracetamol use pre-op 63 73.0 
NSAID use pre-op 63 25.4 
Opiate use pre-op 63 42.9 
Paracetamol use 12-months post-op 36 33.3 
NSAID use 12-months post-op 36 5.6 
Opiate use 12-months post-op 36 25.0 
 
Pre-op and final time-point (12-months post-op) data was collected on patient 
analgesia use in three categories: paracetamol, NSAIDs, and opiates (Table 32). This 
was recorded categorically. Use reductions were observed across all three categories, 
with the response rate for the latter time-point at 57%. Final time-point analgesic 
usage data and EQ-5D pain scores, to provide insight into pain levels, were then 
compared to functional outcomes using Pearson correlation coefficients (Table 33). 
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Table 33 – Correlation assessment between final functional outcome metrics and final time-point (12 months post-
op) analgesia use and PROM pain score with Pearson correlation coefficient. Both r and p values are presented. 
  KOOS5 Index (12M) Leg Power Ratio (NLR) 
(12M) 
ALF Score (12M) Daily Step Count (12M) 
Paracet. use 12 
months post-op 
-0.273 -0.152 0.245 0.284 
0.108 0.385 0.156 0.169 
NSAIDs use 12 
months post-op 
0.039 -0.060 0.063 0.106 
0.824 0.730 0.721 0.614 
Opiates use 12 
months post-op 
-0.130 -0.257 0.267 -0.178 
0.451 0.136 0.121 0.393 
EQ5D Pain VAS 
12M post-op 
0.557 0.238 -0.426 -0.204 
0.000 0.231 0.027 0.402 
 
No correlations were identified with analgesia use and functional outcome score. 
Lower pain level as measured by EQ-5D VAS was correlated with higher KOOS5 Score 
(r=0.557; p<0.001) and faster ALF performance (r=-0.426; p=0.027). The relationship 
between pain level and medication use at this time-point was also examined with 
Pearson correlation coefficients. 
 
Table 34 - Correlation assessment between final functional outcome metrics and final time-point (12 months post-
op) analgesia use with Pearson correlation coefficient. Both r and p values are presented. 
  Paracet. use 12 
months post-op 
NSAIDs use 12 months 
post-op 
Opiates use 12 months 
post-op 
EQ5D Pain VAS 12M post-op -0.666 0.082 -0.370 
0.000 0.684 0.057 
 
No association was identified between pain score and NSAID use. Correlations were 
found between pain score and paracetamol use (r=-0.666; p<0.001) and opiate use 
(r=-0.370; p=0.057) (Table 34). Further investigation of the correlation with opiate 
use was made with general-to-specific regression modelling due to the p-value of the 
correlation being marginally above the 0.05 alpha. This was found to be a non-
significant (p=0.611) association. The same methodology found paracetamol use 
alone predicted 42% of pain score at final time-point, with 38 points (EQ-5D Pain VAS 
score) higher pain for those making use of paracetamol (p<0.001). 
 
The results show that while patients’ use of some pain medication, namely 
paracetamol, strongly correlated with their reported pain levels, their use of opiates 
and particularly NSAIDs did not.  
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Knee ROM 
 
As previously discussed, restricted knee joint range of movement can limit functional 
ability.  
Patient ROM data was previously examined and shown to initially reduce following 
surgery and then significantly improve again by final time-point. Comparison of 
patient data on fixed flexion and flexion block prior to surgery and at final-time point 
can be compared to 12-month functional outcomes can identify relationships. 
 
Limited range of movement was defined as inability to extend the leg less than 5 
degrees from fully straightened, and as an inability to flex the knee past 90 degrees 
of flexion which corresponded with previously defined ROM limitations (400). Data 
were analysed using Pearson correlation coefficients (Table 35). 
 
Table 35 - Range of motion limitations by pre-operative and final time-point. 
Variable  Response n % with ROM limitation 
Flexion Block – PAC 58 10.3 
Flexion Block – 12-months post-op 36 11.1 
Fixed flexion – PAC 58 50.0 
Fixed Flexion – 12 months post-op 36 33.3 
 
A moderate and significant correlation was observed in those who had pre-op fixed 
flexion who still had fixed flexion 12-months following their operation (Table 36). 
 
Table 36 - Correlation assessment between patients’ pre-op and 12-month post-op knee range of movement 
limitations with Pearson correlation coefficient. Both r and p values are presented. 
 
Fixed Flexion Pre-Op Fixed Flexion 12-
months Post-Op 
Flexion <90 degrees 
Pre-Op 










Flexion <90 degrees 12-
months post-op 
-0.177 0.313 0.213 
0.302 0.064 0.212 
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Table 37 - Correlation assessment between final functional outcome metrics and knee range of movement 
limitations with Pearson correlation coefficients.* indicates that no participants of the enhanced cohort, who 








ALF Score (12M) Daily Step 
Count (12M) 
Fixed Flexion Pre-Op 0.158 0.038 0.035 -0.180 
0.296 0.828 0.840 0.389 
Fixed Flexion 12-months 
Post-Op 
-0.368 -0.321 0.479 -0.183 
0.027 0.060 0.003 0.381 
Flexion <90 degrees Pre-
Op 
-0.077 -0.321 0.193 * 
0.605 0.061 0.266 * 
Flexion <90 degrees 12-
months post-op 
-0.485 -0.230 0.161 0.478 
0.003 0.184 0.356 0.016 
 
No relationship was found between pre-op values and final outcomes. Weak and 
moderate correlations were identified between final study time-point ROM 
limitations and selected final functional outcomes (Table 37). A reduction in PROM 
scores was observed due to fixed flexion (r=-0.368; p=0.027) and flexion block (r=-
0.485; p=0.003). ALF scores were significantly increased by fixed flexion (r=0.479; 
p=0.004). Increased step count was found to correlate with flexion block, however 
this was no longer present once outliers were removed. 3 participants of 25 who 
recorded 12-month step count data had limited flexion. Two of these participants 
were the only individuals to record above 10000 step per day.  
 
Additionally, pre-op ROM limitations were found to significantly increase pre-op ALF 
timed score (r=0.28, p=0.03) and to reduce patient reported function (r=-0.38, 
p=0.03) (Table in Appendix C: Additional Data). 
 
The negative impact of patient ROM issues on patient reported outcome at final time-
point shows the negative effect of fixed flexion limitation on subjective symptoms, 
and on ADL function as measured by ALF score. 
 
Patient ROM limitations show negative effects on concurrent final outcomes, with a 
fuller range of movement achieving close to straight extension and flexion past 90 
degrees linked to better functional outcomes at 12-month following TKA. 
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Chapter 5 Summary 
 
This chapter identified the recruitment and data collection flow of the MAKRO study, 
including its correspondence with expected demographic and functional composition 
as compared to previous research and national databases. Demographic factors were 
also identified for subsequent use in multivariate analyses. 
 
Most outcome metrics were shown to change over time, with the notable exception 
of step count activity which indicated a return to pre-operative habitual activity level 
by 12-months post-TKA. Patient PROMs and direct functional assessments recovered 
at different rates following TKA and showed maximal level plateauing at different 
postoperative time-points. Moderate correlations were observed between direct 
functional assessments and strong correlations were observed between PROM tools. 
As such, multiple direct measurements and a single PROM tool were selected for use 
in multivariate analyses. The 12-weeks and 12-months postoperative time-points 
showed the greatest data variation and therefore possibility for differential insight 
based upon patient background and baseline muscle physiology. 
 
The effect of sleep, arthrogenic muscle inhibition, and knee range of movement 
limitations were examined in relation to functional performance. The relationship 
between analgesic use, activity levels and function were also explored, with 
suggestions that targeted rehabilitation maximising ALF-related ADL performance 
and leg extensor power lead to maximum return to activity post-TKA. 
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Chapter 6: Results - Laboratory Patient Physiological Data 
 
Laboratory data are presented separately in their respective methodology before 
they are analysed together. Histological results are followed by molecular results. 
This section aims to answer the following research questions: 
 
 What is the variation in patient muscle physiological factors at time of 
surgery? 
 How do patient muscle physiological factors at time of surgery relate to each 
other? 
 
Samples were collected from 58 study participants and were all examined using the 





Final summary data were collated from the replicates to provide single continuous 
variables in each measurement category. As a result, each sample and therefore 
participant had a measured number of type 1 and type 2 skeletal muscle fibres, and 
also a measurement of the mean lesser diameter per fibre type. 
 
Skeletal Muscle Fibre Types and Fibre Size 
 
Skeletal muscle fibre type data showed a larger number of type 2 fibres than type 1 
fibres (p<0.001) with a mean ratio of Type 1:Type 2 of 0.700.29, providing a mean 
vastus medialis fibre type distribution of 41% type 1 fibres and 59% type 2 fibres 
(Table 38). 
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Table 38 - Histological data for study skeletal muscle biopsies. 
 
Figure 32 - Histogram count (bin-width 0.1) 
for skeletal muscle fibre type ratio. Mean 
ratio value 0.70 (41% type 1, 59% type 2). 
n=58. 
 
Study results correspond to the literature for fibre type proportions within the 
quadriceps muscle group (401). Similarly, in correspondence with previous findings, 
a higher percentage of type 2 fibres were found in males (60%) compared to females 
(58%) (402). These findings can differ depending on the biopsy depth within a muscle 
group (401), but the parametric nature of the data likely show that the adherence to 
the sampling procedure instructions was sufficient standardisation (Figure 32). 
Further demographic comparative investigations are present later in this results 
section. 
 
Fibre lesser diameter measurements were identified as marginally larger in Type 2 
fibres but were found to be statistically similar when assessed with paired t-tests 
(p=0.962).Both fibre types showed a normal distribution amongst the population 
(Figure 34).  
  
Variable N m StDev 
Number of Type 1 skeletal 
muscle fibres 
58 20.78 7.44 
Number of Type 2 skeletal 
muscle fibres 
58 32.28 10.72 
Ratio of Type 1/Type 2 skeletal 
muscle fibres 
58 0.70 0.29 
Lesser diameter of Type 1 
skeletal muscle fibres (m) 
58 60.27 11.45 
Lesser diameter of Type 2 
skeletal muscle fibres (m) 
58 60.32 11.95 
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Mean diameter histological results are similar to previous findings for this muscle 
group in the literature, though here performed in a comparably older population 
(402). 
 
The relationship between fibre diameters was found to strongly correlate when 
examined with Pearson correlation coefficents (r=0.769; p<0.001). When data were 
displayed by scatterplot, the larger overall average diameter of the type 2 fibres was 
represented in the linear regression equation y-axis-intercept (+15.8) (Figure 33). 
 
 
Figure 35 – Individual fibre diameter compared to individual fibre 
type count ratios. Type 1 fibres showed no relationship with ratio 
(R2(adj)=0.02). Type 2 fibres showed a weak relationship with 
ratio (R2(adj)=0.10). By the nature of the ratio metric, diameter 
values from single individuals share x coordinates. 
Figure 34 - Histogram distribution (bin-width 5m) of 
fibre type diameters by fibre type. Mean values: Type 1 
– 60.27m, Type 2 – 60.32m. n=58. 
Figure 33 - Type 1 versus type 2 skeletal muscle fibre 
diameter. y = 15.79 + 0.74 · x, R2(adj)=0.58, n=58. 
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A comparison of fibre type diameter to count ratios found that type 2 diameter 
weakly influenced the likely ratio, while type 1 fibre diameter had less bearing on the 
relative number observed (Figure 35). This is likely due to different underlying stimuli 
behind isolated fibre type hypertrophy. While there were a higher overall percentage 
of type 2 fibres observed per individual, the fibre diameters were not equally 
correlated to the number of fibres observed. 
 
Using Pearson correlation coefficients, a weak correlation of fibre type diameter was 
found with sex (r=0.354; p<0.001), with male participants showing larger diameters. 
Older individuals possessed smaller fibre diameters (r=-0.312; p=0.001). This was 
more pronounced in type 2 (r=-0.369; p=0.004) compared to in type 1 fibres (r=-
0.252; p=0.056). No correlation was identified between fibre count ratio and sex 
(p=0.516) or with age (p=0.099) The findings regarding sex and age correlate with 
previous trends in the literature (42,43,402). 
 
Similarly analysed, no association was identified between fibre type proportion (r=-
0.151; p=0.305) or type 2 fibre diameter data (r=0.170; p=0.249) and fixed flexion 
ROM block. However, a weak correlation was identified between type 1 fibre 
diameter and fixed flexion (r=0.291; p0.045) showing an association between an 
inability to fully straighten the knee joint and a larger diameter of type 1 skeletal 
muscle fibres in vastus medialis. 
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Real-time polymerase chain reaction (qPCR) – Relative Gene Expressions 
 
Molecular Results Quality Steps 
 
Molecular target gene relative expression values (Cq) were calculated in line with 
the described protocol providing results for each target gene per patient. Molecular 
data sample numbers varied per gene of interest (GOI) due to the multiple quality 
checks on the raw data (Table 39). 
 
Table 39 - Sample numbers for qPCR method positive relative expression level data. HK = housekeeping reference 
genes. GOI = Gene of interest. Some exclusion categories overlap due to quality control steps. The final n for each 
positively expressed gene target should be noted as the “n Included” row, which is highlighted. 
GOI: MyoD1 Pax7 Myf5 Myog CDKN2A IL6 TNF 
n patients 58 58 58 58 58 58 58 
n excluded HK 9 9 9 9 9 9 9 
n GOI negative 6 0 0 0 39 25 10 
n GOI excluded 19 11 43 20 3 12 17 
n Included 34 46 16 39 8 16 20 
 
Nine samples were excluded from all target genes of interest (GOI) analysis due to 
housekeeping gene data resulting in an inability to normalise the expression data. 
The housekeeping exclusions were due to negative findings, exclusions based upon 
melt curve anomalies indicating incorrect product amplification, and from replicate 
exclusions. Each housekeeping gene required two out of three replicates to be 
consistent to be included, and each sample required a minimum of two included 
housekeeping genes to calculate a housekeeping mean to be used to calculate Cq. 
 
The myogenesis GOI panel (MyoD1, Pax7, Myf5, and Myog) had low to no exclusion 
due to negative expression. This was only observed with MyoD1 in 6 samples. The 
inflammatory and senescence GOI panels showed higher exclusion due to no 
identified expression. No expression was found in 39 samples of CDKN2A, 25 samples 
of IL6, and 10 samples of TNF. 
 
GOI exclusions from quality control steps were similar across all GOI panels once 
negative samples were removed. Remaining sample numbers with GOI relative 
expression data allowing quantitative analysis are tabled under “n Included” in Table 
39. Despite Cq being an exponential result metric, due to the molecular method is 
it derived from, it is commonly treated as a continuous variable for analysis purposes.  
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Myogenesis Genes of Interest 
 
The Cq values of the myogenesis panel and co-expression correlations were 
examined. Lower Cq values represent higher expression. Cq values can be 
negative. 
 
Table 41 - Delta cycle threshold values for the 
myogenesis genes of interest. Cq = 
difference between GOI in mean cycle 
threshold and housekeeping mean cycle 
threshold value. N.B. a lower Cq value infers 






Results for the myogenesis GOIs showed highest expression in Pax7 and Myog, with 
present but lower expression of MyoD1 and Myf5 (Table 41). The samples with no 
detectable GOI expression were not included in this quantitative analysis. 
 
Correlations were assessed between the myogenesis GOI expression using Pearson 
correlation coefficients (Table 40). Correlations were observed between Pax7 and 
MyoD (r=0.539; p=0.001), and with Myog relative expression levels (r=0.799; 
p<0.001). MyoD and Myog relative expression also correlated (r=0.0486; p=0.005). 
No correlations were found with Myf5 (p>0.736). 
 
The cohort displayed the average physiological phenotype of a reasonably high 
presence of MuSCs (represented by Pax7), low division and differentiation of MuSCs 
into myoblasts (MyoD1 and Myf5), and a high presence of terminally differentiating, 
or recently created or repaired muscle fibres (Myog). 
 
The observed relative expression correlations logically result from the presence of 
MuSCs and levels of MuSC activity. The lower correlation between MyoD when 
compared to Pax7 and Myog, suggests that the level of MuSC activation varies within 





 Cq m StDev 
MyoD1 34 10.7 2.4 
Pax7 46 3.0 2.1 
Myf5 16 10.5 3.5 
Myog 39 1.3 2.1 
Table 40 - Correlation matrix displaying Pearson 
correlation coefficients between the myogenesis genes 
of interest positive expression. P-values are also 
displayed for each comparison. 
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myogenesis GOIs is likely due to the large difference in inclusion sample numbers but 
may relate to the shorter duration that Myf5 is expressed during MuSC turnover (25). 
Myf5 expression level results were only obtained for <50% of sample numbers of the 
other myogenesis GOIs, with melting curve anomalies from non-specific 
amplification accounting for all exclusions. 
 
Senescence and Inflammatory Genes of Interest 
 
Positively expressed senescence and inflammatory GOIs amongst the cohort showed 
low relative expression (Table 43) with Cq values above 10 cycles. Additionally, no 
detectable expression of CDKN2A was identified in 80% of the cohort, no IL6 in 51%, 
and no TNF in 20%. exclusions in the quality control steps compared to the 
myogenesis GOIs grouping. 
 
Table 43- Delta cycle threshold values for the 
senescence and inflammation genes of interest. 
Cq = difference between GOI in mean cycle 
threshold and housekeeping mean cycle 
threshold value. N.B. a lower Cq value infers a 






In the examination of panel GOI co-expression Spearman Rho rank-based test for 
correlation coefficients were used. Low inclusions numbers and a lack of co-
expression resulted in non-parametric data. No correlation was observed between 
IL6 and TNF (p=0.160) (Table 42). Very strong correlations were identified between 
IL6, and between TNF (r=0.900) and CDK2NA (r=1.000), however the low sample 
numbers devalued this finding (respective overlaps for correlation calculation 
inclusions of n=3 and n=4 from a total of 58 patient samples). 
 
The results indicate that the study participants had either no detectable or very low 
levels of senescence or inflammation within their skeletal muscle biopsies. In their 
alternatively expressed role as endocrine markers, they also potentially suggest 
systemic presence of these factors, but the reflective extent of this could not be 







 Cq m StDev 
CDKN2A 39 8 10.9 3.6 
IL6 25 16 12.4 3.2 
TNF 10 20 11.8 3.6 
Table 42 - Correlation matrix displaying Spearman 
rho correlation coefficients between the 
senescence and inflammation genes of interest. P-
values are also displayed for each comparison. 
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Genes of interest cross-panel associations 
 
Gene of interest cross-panel associations were examined using Spearman Rho 
correlation coefficients. The myogenesis GOIs relative expression levels were 
compared to those of the senescence and inflammation panel GOIs. Multiple strong 
and very strong correlations were observed between the two panels (Table 44). 
 
Table 44 - Correlation matrix displaying Spearman rho correlation coefficients between the two genes of interest 
panels. P-values are also displayed for each comparison. 
 
 
Pax7 and Myog were found to correlate with IL6 relative expression (Pax7 – r=0.725, 
p=0.002; Myog – r=0.814, p<0.001). No correlation was found between IL6 and Myf5 
(p=0.622). A moderate but slightly non-significant correlation was identified between 
IL6 and MyoD (r=0.468, p=0.078). 
 
TNF relative expression showed positive correlations with Pax7 (r=0.609; p=0.006), 
Myf5 (r=0.806; p=0.005), and Myog (r=0.637; p=0.005). No correlation was found 
between TNF and MyoD (p=0.165). CDKN2A showed no correlation with the 
myogenesis GOIs (p>0.097). 
 
In addition to its primary association with inflammation, IL6 has a parallel role as a 
local myokine in response to muscular physical activity (136). Increased IL6 
expression in line with MuSC presence and terminal differentiation may be related to 
upregulation of this local function in response to certain stimuli, such as the Janus 
kinase / signal transducer and activator of transcription (JAK/STAT) pathway, or 
within certain groups (403). 
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Due to the association of TNF with skeletal muscle damage, the MuSC fibre repair 
response would be activated under these conditions. The stronger correlation with 
Myf5 over MyoD, while typically co-expressed at this stage in the repair cycle, may 
indicate preferential prolonged expression under conditions resulting in higher TNF 
expression. No associations were found between the myogenesis panel and the 
senescence marker CDK2NA. 
 
Molecular Relative Gene Expression by Fibre Size 
 
The relationship between the molecular relative gene expression results and the 
histological morphometry results were examined for associations by correlation 
coefficients. 
 
The myogenesis panel of GOIs relative expression levels were compared to the 
immunofluorescence data results using Pearson correlation coefficients (Table 45). 
 
Table 45 - Correlation matrix displaying Pearson correlation coefficients between the myogenesis GOI qPCR panel 
and sample fibre diameter and fibre ratios. As a lower Cq value conveys higher relative gene expression, 
correlation directions should be interpreted inversely. P-values are also displayed for each comparison. 
 
 
No meaningful correlations were observed. Comparisons were also made to 
determine inflammatory and senescent correlations with muscle morphological 
results using Spearman rho correlation coefficients due to their results distribution 
(Table 46). No correlations were observed. 
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Table 46 - Correlation matrix displaying Spearman correlation coefficients between the inflammatory and 
senescent GOI qPCR panel and sample fibre diameter and fibre ratios. As a lower Cq value conveys higher relative 




While analysing the histological sections to determine skeletal muscle fibre 
characteristics, an observation was made that could theoretically influence the qPCR 
results. Individual fibres ranged from ~30m to ~90m in diameter but the 
anatomical location of MuSCs remained constant. A larger average fibre diameter 
dictates a lower overall number of fibres for a finite volume of biopsy, and therefore 
less anatomical niche for MuSCs to reside. While the exact number of MuSCs per 
section was not able to be confirmed through immunofluorescence, the number per 
lysed sample for qPCR analysis may be influenced given standardised sizes across all 
samples prior to molecular analysis.  
 
Due to the comparison of fibre diameters with myogenesis panel expression levels 
showing no significant associations (Table 45), this effect can be confirmed as not 
present and not influencing results data. 
 
Laboratory Variables for Multivariate Analysis 
 
All laboratory summary variables were used in further comparisons due to their 
concise and distinctive natures. Data was transformed where relevant to ensure data 
inclusion. Sample relative expression molecular data were grouped into categorical 
bins to facilitate the inclusion of non-detect data during multivariate modelling (404).  
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Chapter 6 Summary 
 
Patient muscle anatomical immunofluorescent data showed correspondence with 
the accepted fibre type distribution for the quadriceps muscle group and sufficient 
standardisation of the biopsy methodology. This was presented for the first time in a 
comparably older population. Demographic correlations with fibre data were also 
explored, and a strong correlation was identified between fibre type diameters. 
 
Molecular gene expression analyses showed relatively high, but varied, myogenic 
expression which indicated differing muscle turnover activity and propensity 
between study participants. This presented as high presence of MuSCs and recently 
created or repaired muscle fibres but low numbers of actively differentiating cells. 
The results also showed overall low levels of senescent and inflammatory activity 
within the patient muscle biopsy samples. Cross-molecular-panel investigations 
identified correlations between inflammation and myogenesis markers but not with 
senescent markers. Separately, no associations were identified between fibre 
anatomy and molecular gene expression profiles. 
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Chapter 7: Results - The Relationship between Patient Factors, Patient 
Physiology and Surgical Functional Outcome 
 
Following the analysis of the individual metrics to determine their trends and 
associations over the course of the study, they could now be examined in a wider 
context.  
 
Baseline patient reported and functional measurements were initially compared to 
surgical outcomes. Low pre-op PROMs scores and functional performance have 
previous been shown to predict poor functional outcomes post-TKA (259,260,405). 
Patient demographic and lifestyle factors were next compared to patient surgical 
outcomes, followed by an examination of the relationship between patient 
physiology and surgical outcomes. An investigation into the associations of patient 
demographic and lifestyle choices on patient physiology at time of surgery follows. 
 
Figure 36 - Graphic overview of the multivariate modelling categories and predictive investigations. Arrow 
directions represent independent towards dependant variable comparisons.. 
The grouped variable comparisons are initially run as a combination of hypothesis 
driven multivariate regression models to determine contributing factors. These 
models are discussed in-section, with the full output displayed in Appendix C: 
Additional Data. For longitudinal factors, the comparisons are initially presented to 
evaluate the 12-month primary outcomes, followed by discussions of early recovery 
rates. 
 
As complex clinical outcomes resulting from a multitude of contributors, this allowed 
for the many parallel and potentially compounding factors to be assessed together. 
With the heterogeneity of the study cohort, it also allowed for an overview of the 
potential contributions that each independent variable has made to a dependent 
primary outcome.  
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7.1 - Functional and Patient Reported Predictive Factors of Functional Outcome 
 
Further Examination of Defined Baseline Time-point 
 
The use of linear regression analysis of the individual data categories identified 
predictive elements amongst the study data. Variables found to be significantly 
different over time using paired T-tests were further analysed in this way. The overall 
data trend found directly measured functional metrics to be better predictors of final 
same-metric outcomes than patient reported outcome measurements (Table 47). 
Functional metrics were also generally better pre-op predictors of final function, with 
PROMs variables generally showing greater predictions at 6-weeks post-op of final 
scores. Patient step count and the EQ-5D Index PROM indicated opposing findings. 
 
Table 47 – Comparison of intra-metric functional and PROMs factors as predictors of own final outcome score. 
Respective N tabled in Table 20 
Predictive Factors (early result as predictor of final result at 12-months post-op) 
Factor Initial Time-point % of Final Result Predicted 
by Initial Result 
(Linear Regression model, 
R-Sq(adj), alpha = 0.05) 
Functional Leg Power (weight adj.) Pre-op 43.7 
Leg Power (weight adj.) 6-weeks post-op 42.2 
Aggregated Locomotor Function 
score 
Pre-op 48.8 
Aggregated Locomotor Function 
score 
6-weeks post-op 43.4 
Step Count Pre-op 4.3 (n.s.) 
Step Count 6-weeks post-op 20.2 
PROMs EQ-5D Index Pre-op 17.7 
EQ-5D Index 6-weeks post-op 16.2 
Forgotten Joint Score Pre-op 4.1 (n.s.) 
Forgotten Joint Score 6-weeks post-op 21.3 
KOOS5 Index Pre-op 16.5 
KOOS5 Index 6-weeks post-op 27.7 
Oxford Knee Score Pre-op 11.5 
Oxford Knee Score 6-weeks post-op 27.0 
 
The results suggested that the best predictor of same-metric post-op outcome was 
pre-op Aggregated Locomotor Function (ALF) score which predicted a moderate 
48.8% of final ALF score. Moderate findings were also identified from 6-week ALF 
scores, and from pre-op and 6-week Leg Power scores. 
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Despite displaying weak predictions, PROMs data did show associations which may 
become relevant in multivariate modelling. 
Multivariate Functional and Patient Reported Predictions of Functional Surgical 
Outcomes 
 
The move from individual metric analyses to multivariate models addressed elements 
of the complicated nature of the recovery window. Patient functional performance 
and PROMs scores pre-op were modelled as predictors of final (12-months post-op) 
and early (12-weeks post-op) outcome. The intra-metric results previously 
highlighted the trend whereby patients with higher scores pre-op had more 
favourable final outcomes. While 6-week results were also examined as predictors, 
this section primarily focuses on the use of pre-op markers as predictors of surgical 
outcomes. Pre-op scores for the functional metrics and for the PROM tools were used 
as potential factors influencing early and final primary metric study outcomes (Table 
48). 
 
Table 48 – Functional and PROMs variables modelled as predictors of primary metric outcomes. 
Category Variable in model 
Functional Nottingham Leg Rig Power Ratio (W/kg) 
Aggregated Locomotor Function Score (seconds) 
Average daily step count (steps) 




Knee Injury and Osteoarthritis Outcome Score Index (KOOS5) 
EQ-5D Index 
Oxford Knee Score 
Forgotten Joint Score 
 
General-to-specific regression modelling techniques were used (386). The 
multivariate model output describes contributing factors to outcome metrics (Table 
49). Output significance and coefficients are displayed for contributing factors which 
denote contribution rank and metric influence. Model significance is also displayed 
along with the degrees of freedom (d.f. or ) per model (calculated from 𝑑. 𝑓. = 𝑛 −
𝑘 − 1; n=sample number, k=number of model parameters). ‘Best’ models were 
identified as those with significant outputs with the strongest R-Sq Adj. values. 
 
Models were identified using combined baseline functional and PROMs scores to 
moderately and strongly predict post-TKA outcomes at 12-weeks post-op (Table 49) 
Chapter 7: Results - The Relationship between Patient Factors, Patient Physiology and 
Surgical Functional Outcome 
  179 / 309   
for leg power (R2=0.73; p<0.001), ALF score (R2=0.54; p=0.001), and step count 
(R2=0.57, p<0.001). Predictive models were identified for the 12-month post-TKA leg 
power (R2=0.58; p<0.001), and daily step count (R2=0.28; p=0.005). No predictive 
model was identified for KOOS PROM score (p=0.495). 
 
Table 49 - General-to-specific modelling results table for pre-op functional and patient-reported scores as 
predictors of early and final primary functional surgical outcomes. 




























Leg Power Pre-op 
(<0.01; +0.56) 
ALF Score Pre-op 
(<0.01; -0.02) 
KOOS5 Index Pre-op 
(0.01; -0.02) 





op (<0.01; +1.10) 
EQ-5D Index Pre-









ALF Score Pre-op 
(<0.01; +1.30) 
EQ-5D Index Pre-op 
(0.01; -31.0) 
KOOS5 Index Pre-op 
(0.01; +0.68) 
Daily Step Count Pre-
op (0.05; 0.00) 
0.54 0.001 
(17) 






op (0.02; -19.00) 







FJS Score Pre-op 
(<0.01; +130.0) 
ALF Score Pre-op 
(0.02; -120.0) 










ALF Score Pre-op 
(<0.01; -1.20) 
FJS Score Pre-op 
(0.02; +0.59) 
Daily Step Count Pre-
op (0.04; -0.00) 
0.36 0.006 
(21) 
ALF Score Pre-op -0.01 0.495 
(42) 
 
As a confirmatory measure that the correct predictive time-point metrics had been 
selected, 6-week PROM scores were also factored into parallel models due to their 
higher intra-metric prediction rates, alongside pre-op markers. All were found to be 
non-significant model parameters, leaving only baseline functional elements in the 
models. A likely factor in this finding was the higher identified intra-metric prediction 
rates that measured functional metrics contributed to the models compared to the 
patient reported factors. 
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For the moderate and strong prediction models created for Leg Power and ADLs, 
same-metric predictors featured prominently as discussed in the previous section. 
However, the prediction strength had greatly increased from the incorporation of 
baseline PROM scores. The most useful PROM tool predictors of in-clinic 
measurements were the EQ-5D Index and the KOOS5 Index tools which were 
identified as significant contributors in all models. For ALF score, baseline Daily Step 
Count was also found to contribute to the prediction models. 
 
Functional and Patient Reported Predictive Factors of Functional Outcome Summary 
 
Overall these results indicate that moderate and strong predictions of TKA post-
operative early and mid-term measured functional outcome can be identified using 
baseline clinic measurements of leg strength and ADL function combined with a TKA 
specific PROM tool and a general health questionnaire. These present a simple 
battery of pre-operative tests that can provide a good indication of TKA functional 
outcome. This predictive model agrees with recent commentary on the use of PROM 
tools in assessing outcome and the importance of combining with functional 
performance based metrics to provide a full clinical picture of outcome (215). 
 
The results correlate with previous findings by Fortin et al. that suggest that operating 
earlier on patients with OA, and not waiting until very late-stage disease progression 
and corresponding poorer function, serve to improve outcomes (255). However, the 
strength of the models (12-months: R2 range 0.28-0.69) show that there is still case 
variation which implies that other factors are also implicated. 
 
The models fail to identify predictive parameters of patient reported outcomes which 
are pertinent to determining a successful surgical outcome. The examination of wider 
contextualising patient background factors and physiology may elucidate closer 
associations.  
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7.2 - Patient Background Predictive Factors of Surgical Functional Outcome 
 
Patients’ clinical backgrounds and lifestyles were compared to their primary surgical 
outcomes following total knee arthroplasty. The variables included in these 
categories are tabled in Table 50 on the next page, alongside their data types and 
defined categorised bins. The data bins were required to allow the regression 
modelling to complete. 
 
Each primary surgical outcome (Leg power, ALF score, Daily step count, and KOOS5 
index PROM score) was compared as a dependent variable to the 17 independent 
variables, comprising patient demographic, comorbidities and lifestyle factors, using 
the general-to-specific modelling technique. The independent variables collectively 
formed the defined patient background factors. 
 
Following the modelling of the patient primary surgical outcomes with 12-month 
post-op values, the technique was used to investigate contributing factors to patient 
very early outcomes at 12-weeks post-op. This allowed for insight to be gained into 
factors which correlated with favourable very early surgical outcomes. Once again 
this was chosen as a metric level rather than difference due to the frequently 
observed obstructive nature of the baseline OA pain and the uniform traumatic 
nature of the TKA procedure. The previous individual metric analyses discussed the 
changes over time for each primary metric when examined in individual patients, 
alongside their intra-metric associations. 
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Table 50 - Patient background variables modelled as predictors of primary metric outcomes. Data types and bins 
are stated alongside relevant comments. 
 
Chapter 7: Results - The Relationship between Patient Factors, Patient Physiology and 
Surgical Functional Outcome 
  183 / 309   
The main contributing factors, overall coefficient of multiple determination (R2-
adjusted), and statistical significance, including degrees of freedom, of the models 
are displayed in (Table 51), with full model outputs displayed in Appendix C: 
Additional Data. 
 
Table 51 – General-to-specific modelling results table for patient background factors as predictors of early and 
final primary functional surgical outcomes. 


























Peak Tegner (Physical 
Activity) (0.02; +0.07) 







Drug Hx - Opiates 
(0.10; -0.36) 







Drug Hx - NSAIDs 
(0.12; -11.0) 
Drug Hx - 
Paracetamol (0.16; -
8.5) 




Alcohol Hx (0.02; 
+5.2) 
Manual Labour Job 
Hx (0.07; +6.9) 




effect – reduced 
time) 





Age Group (0.02; -
660) 
















Alcohol Hx (0.03; -
6.4) 
K&L OA Score (0.03; 
+6.7) (worse OA pre-
op) 
Comorbidity - 
Diabetes (0.11; -12.0) 
0.15 0.02 
(43) 
K&L OA Score 
(<0.01; +11.0) 
(worse OA pre-op) 






Drug Hx - Opiates 
(0.14; -7.9) 





Weak predictive models for the primary outcome metrics were identified from 
demographic, lifestyle and comorbid baseline factors. This included 12-week post op 
leg power (R2=0.19; p=0.03), step count (R2=0.23; p=0.03), and KOOS5 PROM score 
(R2=0.15; p=0.02). No model was created for ALF at 12-weeks post-op. Viable models 
were identified for all 12-month primary outcomes including leg power (R2=0.14; 
p=0.05), ALF score (R2=0.18; p=0.04), step count (R2=0.28; p=0.02), and PROM score 
(R2=0.31; p<0.001). 
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Across all primary outcome metrics, no grouping of contributing factors was found to 
significantly contribute more than 31% to the predictive models. While all weak 
contributions, they have sufficient statistical power to allow discussion. Binary 
factors, by their nature, were found to contribute more than ordinal factors to each 
model, which is important in model interpretation. Factors are therefore ranked in 
respect to their significance level which reflects stronger statistical influence. For the 
grouping of background factors to 12-month post-op endpoint primary outcomes, all 
models were found to be significant. For the secondary early outcome insights 
provided by the 12-week measurement models, the ALF model was the only non-
significant model. 
 
During the interpretation of the models, steps were taken to avoid type 1 statistical 
errors resulting from classifying correlations as causations. Each contributing factor 
was examined in the context of the initial hypotheses and literature base, in order to 
qualify it as fitting current understanding, challenging current understanding, or 
inconclusive findings. Particular care was taken in the interpretation of factors with 
small influence. For each model, the significance value associated with each 
coefficient gave insight into its weighting in each model. A lower p-value for a 
contributing factor inferred a greater contribution to the multiple determination 
coefficient. While the alpha level for a model to be considered representative was 
set as 0.05, the alpha for individual factor inclusion was set to 0.20. The use of a more 
conservative individual factor alpha led to single viable models or multivariate 
models with negligible multiple determination coefficients, and to the model p-value 
increasing in some cases. 
 
Patient Background as predictor of Power Output 
 
With an overall prediction of 14%, peak physical activity, and opiate and alcohol 
history contributed to the prediction of primary power outcome. Peak activity was a 
positive contributor and alcohol and opiates did so negatively. 
 
These findings correlate with the physiological lasting effect of training on the body 
following a long period of training. However, the nature of the duration of the effect 
requires further information as the information related to the peak regular activity 
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from any point in life. This may have been a few years prior or several decades. While 
opiates and alcohol were associated with lower normalised power output, the exact 
mechanism beyond associations cannot be confirmed in this study. However, the 
negative physiological impact of long-term use of these substances has been 
discussed in the literature review. 
 
The negative coefficient within the alcohol levels of the primary model allowed for 
compounding as consumption increased and therefore a reduction of 0.76 in power 
ratio for those with the largest intake which was substantial. While at a physiological 
level the effects of alcohol have been shown as inhibiting, the patient group with high 
alcohol intake presented within the cohort with multiple factors negatively effecting 
outcome. For example, they reported neglecting their post-op rehabilitation 
recommendations in follow-up appointments, particularly those regarding improving 
range of movement, and were susceptible to falls and knocks to the recently replaced 
knee which further reduced confidence. While using the Nottingham Leg Rig 
instrument to measure leg power, the elements of ROM and pain guarding could 
account for these reductions. However, across the cohort, the vast majority were 
uninhibited in this regard and did not guard, which infers that the physiological 
effects discriminating between patient groups even within NHS alcohol intake 
recommendations may be strong. The model indicated that even low-level use of 
alcohol was associated with poorer power output outcome. Alcohol intake remained 
unchanged over the course of the study, which was evaluated by patient interview 
during clinic visits. 
 
Long term pre-op use of opiates was detrimentally associated with primary leg power 
outcome. As the evidence of opiates use directly impacting on skeletal muscle 
physiology is inconclusive in the literature, this finding may be a surrogate for other 
factors, particularly at this stage in the study. Due to the existing chronic use of 
opiates in this patient group pre-op, there may have not been options for increasing 
dosage to manage pain post-op. This may have left patients with greater pain during 
early recovery resulting in less motivation to perform functional rehabilitation steps. 
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When examined during early recovery at 12-weeks post-op, peak activity was again 
present within the model, but this time with an influence from chronic NSAIDs use. 
Previous activity level played the main role in contributing 19% to the prediction of 
this early outcome. As discussed, the physiological elements are likely present here 
with the propensity to rebuild strength. These discussion points are extrapolated 
from an association of this specific pain relief use with outcome parameters. 
Alongside this, there may be psychological elements such as motivation and ability 
to tolerate pain. Those who had previously taken part in elite level sport were 
predicted to generate twice as much power (1.2W/kg) as those who had never 
participated in regular sporting activity (0.6W/kg). 
 
A history of NSAIDs use was found to increase the predicted early outcome of 
controlled power. While physiologically NSAIDs have been shown to be potentially 
detrimental to MuSC activity, a positive influence was found towards power output. 
While a pre-op metric, this showed a large association within the early functional 
results which was no longer present by final outcome. This contradicted the current 
theoretical projections of the effect of NSAIDs on muscle turnover as discussed in the 
literature review. Factors such as a change in medication during this early post-op 
time window may have removed NSAID intake from the prescribed schedule which 
cannot be clarified from the available study data. 
 
Patient Background as predictor of ADL Performance in Clinic 
 
Contributing to a model showing 18% prediction of timed functional performance 
were patient alcohol history, occupational history, SIMD quintile, and a history of 
opiate use. 
 
Patient alcohol intake showed the greatest impact on aggregated locomotor function 
score. Each grouped level of intake added 5.2 seconds to the timed performance, in 
a timed score with a cohort mean of 23.9 seconds. Those with a larger alcohol intake 
were much slower at performing the timed ADL representative activities with a likely 
underlying casual link.  
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Having an occupational history in manual labour also increased the time to complete 
the functional score.  While such an occupational history may be equated with long 
term regular physical activity in terms of musculoskeletal impact history, the extent 
would depend on the nature of the work that was performed. As a binary metric, an 
occupational history of this nature adds almost 7 seconds to final ALF score outcome, 
which, as stated, had a mean cohort time of 23.9 seconds. 
 
While not the strongest contributing factors, patient Scottish Index of Multiple 
Deprivation (SIMD) residential quintile and opiate history also affected ADL 
performance. A patient’s performance was found to improve (reduced time taken) 
by 2.1 seconds for each additional quintile they belonged to. Having a history of long-
term opiate use conversely increased total time by 5.5 seconds. As with previous 
models, the effect of long-term opiates is likely to be a surrogate for complex 
comorbidity and pain. 
 
The metric of the Scottish Index of Multiple Deprivation by definition includes 
multiple factors includes. These include income, employment, health, education and 
skills, housing, crime, and geographical access to service dimensions (389). The 
factors are compounded and averaged with specific weighting for each geographic 
area to determine a national rank which is then split by quintile. Poorer performance 
in these domains within a patient’s residential postcode was found to correlate with 
poorer ADL function for this outcome. In other words, higher deprivation correlated 
with a poorer outcome in this case. 
 
Using the defined methodology, no viable significant model was produced to predict 
the very early outcome of ALF timed functional score from patient background 
factors (p=0.21). 
 
Patient Background as predictor of Average Daily Step Count measured in the 
Community 
 
Patient daily step count could be 28% predicted through a combination of 
pharmaceutical, comorbidity and lifestyle factors. A history of paracetamol use was 
found to predict increased step count, whereas hypertension and a smoking history 
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correlated with lower step counts. As binary factors, these predicted changed of 
between 2300 and 3000 steps each which had large impacts in a time-point metric 
average of 4600 daily steps.  
 
For those with the physiological capability and relatively mild pain, the use of 
paracetamol could arguably overcome this to facilitate walking further distance. 
However, as a pre-op metric, this cannot be inferred at the final time-point. Despite 
this, the long-term use pre-operation may have enabled habitual activity of this 
nature. With single metric data inferring that habitual activity was a major trend in 
determining daily step count, having an established pre-op usual distance may have 
created a target for life-style continuation in a similar way. 
 
Pharmaceutical study data from the cohort suggested that regular paracetamol use 
at 12-months post-op had reduced to zero in 50% of patients who responded. 
Extrapolated across the cohort, this infers that the habitual nature was a prominent 
factor, given this extended effect. 
 
When examined to determine the factors influencing early outcome, age group and 
SIMD quintile were found to be relevant. Each modelled age banding reduced step 
count by 660 steps and each SIMD banding increased daily step count by 850 steps. 
 
Increased age correlates with many relevant aspects that influence daily step count. 
Whether a core stimulating factor such as vocationally required tasks in those who 
still work to the physiological elements of frailty which may limit a patient’s 
undertaking. Patients in the cohort who recorded the highest daily step counts had 
returned to work involving manual labour by 12 months post-op. While noticeably 
less impactful during weekend days, the weekday values and averaged nature of the 
metric resulted in an increase in these cases. However, as noted in the primary 
outcome model, while daily activity levels measured in this way were affected by 
commitments outside of the home environment, they were also affected by pre-
operative habit. A long history of manageable OA impairment in the study knee or a 
history of multiple musculoskeletal problems may have led to a reduction in habitual 
activity over a longer period of time. 
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As with ADL performance, a correlation was observed between residential 
deprivation and outcome metric, but in this instance only during early recovery. A 
higher SIMD score theoretically correlates with easier access to services such as 
community health care or more generally with local amenities. Many patients in the 
cohort were recovering at this stage in the Scottish springtime which can be greatly 
affected by local council authority willingness to grit pavements amongst other steps 
to increase safety at this time of year, pertinent to those with mobility problems. 
Lower local crime rates would encourage a wider range of local activity, such as 
evening walking, or motivation to spend time in a town centre area. Higher 
educational attainment led to patients self-referring for physical therapy when they 
believed it was required, observed during patient clinic discussions. This was not 
observed elsewhere within the cohort. 
 
Patient Background as predictor of Patient Reported Outcome (KOOS5 Index Score) 
 
Multiple factors contributed to the model predicting 31% of KOOS5 patient reported 
primary study outcome at 12-months post-op. These included pre-op OA severity 
measured by K&L Score, patient sex, peak physical activity, history of opiate use, and 
pre-op BMI. 
 
Patients reported better outcomes if they had worse radiographically evaluated OA 
prior to their knee replacement. For a percentage score, each level of pre-op OA 
severity increased the final outcome score by 11%. While testing for local 
physiological paracrine effect was not possible with the study investigations, 
established effects could in theory impact on muscle function. These were discussed 
in the literature review (24). However, with the diseased bone tissue removed, and 
12-months elapsed since surgery, these effects would likely have dissipated. Worse 
OA is associated with greater arthritic pain and impairment. The contrast between 
extreme and relieved symptoms following arthroplasty intervention may produce a 
great relief than in patients with milder symptoms. This may be reflected in patient 
reported outcome scored in this way. 
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Males showed lower reported PROMs than females by 9.7% within the cohort. Study 
results were inconsistent with previous reports in TKA cohorts of lower PROMs scores 
in females (8,406,407), with this phenomenon attributed to psychosocial and 
psychological elements. Within the study cohort, males showed higher pre-op K&L 
OA scores compared to females (mean score 2.00 compared to 1.66). The higher 
significance of the OA scores in the model likely influences the observed sex 
association as a controlling factor. 
 
Patients who had previously performed higher levels of regular physical activity 
marginally showed lower PROM scores. A possible explanation related to subjective 
evaluations of activity levels. Those who had previously experienced very high levels 
of activity were never going to experience these again with a prosthetic knee 
following TKA. For example, taking part in activities involving impact on the knee is 
greatly discouraged by clinical care staff as it has been shown to reduce the life of the 
implant (408,409). While reduced pain has improved their reported quality of life, 
they have not managed to reobtain access to activity levels that they previously 
enjoyed. This mismatch of expectations compared to reality following TKA has been 
shown to lead to reduced PROM scores (410–412). 
 
Once again long-term use of opiates was found to affect outcome negatively as an 
indicator of comorbidities and other chronic problems. Patient reported outcomes 
measured by KOOS5 index were modelled as reducing by 7.9 points in these cases. 
Pre-op BMI group similarly negatively affected outcome, with each banding reducing 
reported outcome by 3.3 points. Excess patient weight continued to be associated 
with negative outcomes by 12-months post-op. Evaluation of BMI group at 12-
months post-op to KOOS5 Index score showed that those who had subsequently lost 
weight (22 of 35 participants who were measured) during surgical recovery scored 
similarly to those who maintained similar or gained weight compared to before their 
operation. BMI reduction in these patients was 1.951.59kg/m2 which may not have 
been sufficient to trigger the physiological benefits of greater weight loss. 
 
Early patient reported outcome data showed similar positive correlations with OA 
score, as well as negative influences from alcohol and diabetes. 
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While not as pronounced as at 12-months post-op, pre-op OA score similarly 
influence PROMs during early recovery. For every alcohol use banding, patients 
incrementally decreased response by 6.4%, while patients with diabetes showed 12% 
modelled reductions with the KOOS5 Index metric. Contrastingly, in the directly 
measured early functional outcomes, both factors were not significant. The KOOS 
PROM tool utilises dimensions that cover wide areas of daily life in relation to knee 
function. Despite specifying this, aspects from the impact of chronic diabetes may 
influence patients’ reports in this case. The impact from marginal alcohol use is less 
clear and could likely involve aspects of the physiological changes directly impacting 
upon the local recovery process following surgical trauma. Insight from patient 
biopsy physiological may elucidate underlying effects. 
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Patient Background as a Predictor of Surgical Outcome Summary 
 
The multivariate models identified logical and statistically significant relationships 
between certain patient background factors and their subsequent early and the mid-
range outcomes following TKA. 
 
Previous peak activity level was the most determinant positive factor of power 
output prediction, with additional positive predictive contribution from chronic 
NSAIDs use. Alcohol use and opiate use were negative influences. Less residential 
deprivation (SIMD) was found to improve ADL performance, with alcohol use, a 
manual labour job history, and opiate use reducing performance. Activity in the 
community as assessed by daily step count was influenced by multiple factors. Age, 
hypertension, and smoking reduced the metric, whereas less deprivation and 
paracetamol were found to increase the average number of steps taken. Patient 
reported outcome was also affected by several factors; pre-op K&L score positively, 
and being male, having high previous activity levels, diabetes, being in a high BMI 
group, and using alcohol and opiates found to lower PROM score. 
 
Clinic-measured direct functional outcomes (Leg power output and ALF battery of 
ADL performance) were noticeably more influenced by lifestyle factors with all 
significant modelled predictors falling into this grouping. These included 
pharmaceutical use, occupational and activity histories, alcohol use, and residential 
deprivation. The community measured functional outcome of step count and patient 
reported outcome were affected by a broad range of background factors also 
including comorbidities and biometrics alongside the lifestyle factors. 
 
Additionally, the models only provided weak predictions (14-28%) of surgical 
outcomes which were much reduced in power than the previously examined 
functional and PROMs tool models as predictive parameters by themselves (up to 
73%). Further examination of other discussed factor groupings may provide stronger 
models to determine the more influential factors affecting the early and very-early 
post-TKA surgical outcomes of leg power output, ADL performance, daily step count, 
and PROM score as represented by KOOS5 index.  
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7.3 - Patient Skeletal Muscle Physiology Predictive Factors of Functional Surgical 
Outcome 
 
Patient physiological factors were compared to their primary surgical outcomes. 
Initially these were performed with correlation coefficients using raw data, and 
subsequently with general-to-specific multivariate regression modelling to ascertain 
contributions and potential predictive factors. The multivariate models were able to 
increase model sample numbers due to the creation of categorical bins for factors 
unrepresented by molecular Ct values. 
 
Examination of Individual Correlations between Physiology and Functional Surgical 
Outcomes 
 
Due to the differences in data distributions, histological data and qPCR data for 
myogenic genes of interest (GOIs) were compared to the primary outcome metrics 
using Pearson correlation coefficients. The inflammatory and senescence GOIs were 
compared using Spearman rho correlation coefficients due to their lower positive 
sample numbers (Table 52, Table 53). 
 
Table 53 – Correlation coefficient matric 
comparing endpoint primary outcome 
associations with physiological data. 
 
With a set alpha of 0.05, the only observed correlation between physiological data 
and 12-month defined surgical outcomes was between CDK2NA and 12-month post-
op ALF Score (r=0.900; p=0.037), with all others deemed non-significant. A further 
number of correlations were identified with alpha increased to 0.10. Weak 
correlations were observed between controlled maximum power output and two 
metrics; a larger number of type 2 fibres (r=-0.326; p=0.090) and a higher Pax7 
Table 52 - Correlation coefficient matric comparing 
early recovery primary outcome associations with 
physiological data. 
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relative expression level (r=-0.340; p=0.089). Higher explosive skeletal muscle power 
output, central to Nottingham Leg Rig quantified metric, is typically associated with 
type 2 muscle fibres and was observed in the cohort. The Pax7 results infer that a 
higher presence of MuSCs is correlated with higher power generation.  
 
Separately, higher IL6 expression appeared to correlate with a higher KOOS5 index 
score (r=-0.588; p=0.074), but on closer inspection this may have been affected by 
low sample numbers (n=9). The CDK2NA results had even lower positively expressing 
sample numbers (n=8). 
 
With low sample number metrics excluded (IL6 and Myf5 with daily step count), no 
correlations were observed at 12-weeks post-op for the majority of outcome metrics. 
However, a single correlation with alpha set at 0.10 was observed between type 1 
fibre diameter and power output at this early stage (r=0.381; p=0.080). 
 
The nature of the Cq values presented in their raw form prevented quantitative 
analysis of the samples which showed no detectable relative levels of expression of 
the gene of interest (GOI). As such, despite viable results for the majority of 
participants, the number of samples for some GOIs which could be analysed in this 
way was reduced by as much as 84%. In reality, a lack of detectable expression was 
as much of a result finding as that of positive expression. For example, the lack of an 
expressed senescence gene marker in a patient’s muscle biopsy was equal in data 
value to a positively expressed marker. A system to include these data for 
multivariate analyses was therefore established. 
 
Regression modelling using discrete bins later allowed for a larger number of samples 
to be included. Allocating arbitrary values to non-detects, such as 35 or 40 cycles for 
Cq, when examining raw data is discouraged as it can introduce bias (404). The use of 
ordinal categorised bins avoided this issue as it facilitated descriptive analysis of the 
relative genetic expression status. The study molecular methodology utilising 
multiple MIQE informed quality control steps such as triplicates, removal of outliers, 
analysis of melting curves, and the use of multiple reference genes served to qualify 
the data as robust.  
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To gain deeper insight into the nature of the patient surgical outcomes, multivariate 
modelling was necessary. This allowed for increased statistical power and more 
representative multivariate scenarios to be tested through clear statistical steps.   
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Modelling of Patient Baseline Muscle Physiology as predictor of Surgical Outcomes 
 
Molecular expression data raw values were classified into bins for modelling. Five 
bins were created; non-detects, very low expression (Cq>10), low expression (Cq 
5-10), medium expression (Cq 1-5), and high expression (Cq <1). The bins were 
allocated the numbers one to 5. As previously described, these classifications allowed 
for the inclusion of non-detect data thereby greatly increasing the sample numbers 
per GOI and the data utility. With a reference genes mean Cq of 29.92.9, this 
represented consistent and moderately high expression of mRNA. This allowed Cq 
values to be classified in this terminology. Due to the nature of the quality steps in 
the qPCR data processing, quality eliminations are classified the same as uniform 
qPCR product non-amplifications. 
 
General-to-specific multivariate regression modelling was used as previously 
described to compare ten physiological baseline patient variables to their primary 
surgical outcomes following total knee arthroplasty. The variables included in these 
categories are tabled (Table 54) alongside their data types, bins, and any relevant 
comments. Following modelling of the primary 12-months outcomes data, this was 
also performed for the early outcome time-point of 12-weeks post-op. A summary of 
the best model findings with the ranked main contributing factors, overall coefficient 
of multiple determination (R2-adjusted), and statistical significance, including 
degrees of freedom, are tabled in Table 55. Full model data can be found in Appendix 
C: Additional Data. 
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Table 54 - Patient physiological variables modelled as predictors of primary metric outcomes. Data types and bins 
are stated alongside relevant comments. 
Category Subcategory Variable Data 
Type 











month / 12 week 
value) 
Nottingham Leg 




Measurement of quadriceps 








Measurement of ADL 







Averaged over 4 days 
measured immediately 
following clinic visit. 






PROM score index 
encompassing 5 dimensions 











Mean total type 1 fibres 
divided by mean total type 2 
fibres. A higher value infers 
more type 1 were observed 
than type 2 for that patient.  













Pax7 Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes  
MyoD Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes  
Myf5 Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes  
Myog Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 





CDK2NA Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes  
IL6 Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes  
TNF Ordinal 5 bins based on the relative 
expression level of the gene 
(1, non-detect; 2, Ct >10; 3, 
Ct 5-10; 4, Ct 1-5; 5, Ct <1) 
Quantified using qPCR and 
controlled with technical 
replicates and reference 
(housekeeping) genes 
 
Three viable models were identified with baseline physiological predictors of 12-
month functional outcome scores. These were for leg power (R2=0.29; p=0.01), daily 
step count (R2=0.11; p=0.06), and KOOS5 PROM score (R2=0.14; p=0.01). While not 
substantial predictive models (≤29%), they do indicate significantly contributing 
factors which merit highlighting. The modelling of the early outcomes conversely 
found no significant model associations or contributions of physiological factors 
during this stage of recovery (p≥0.13). 
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Table 55 - General-to-specific modelling results table for peri-operative muscle physiological factors as predictors 
of early and final primary functional surgical outcomes. 


























Myf5 Expression (0.24; 
+0.18) 






Fibre Type Ratio 
(0.02; -0.90) (Higher 
power with more 








Myog Expression (0.17; 
+2.3) 























CDK2NA (0.12; +7.0) 











Physiological data are identified from time-of-surgery biopsies and were compared 
to surgical outcomes at 3 and 12 months following their arthroplasty procedure. 
Histological elements are considered to be relatively stable over time, with 
meaningful remodelling occurring in response to stimuli over periods of weeks and 
months, however gene expression levels can largely vary from day to day. As 
discussed in the literature review, selected GOIs represented gene panel trends and 
also cell type abundance which infer different aspects of regenerative potential or 
inhibition. Histological metrics and molecular genes of interest included in these 
models are also taken to reflect habitual undertakings as projections of future 
expression levels. While this cannot be confirmed without subsequent biopsy 
sampling to determine contemporaneous in vivo levels, it is a pragmatic option to 
gain insight in a research area with complex ethical and clinical considerations with 
patient interest and impact at the centre. 
 
Baseline Muscle Physiology as predictor Power Output 
 
Controlled leg power output at 12 months post-op was found to be 29% predicted by 
baseline MyoD and CDKN2A relative expression alongside quadriceps skeletal muscle 
fibre type proportions (Table 55). 
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Patient baseline MyoD expression was found to be the highest contributor to power 
with each subsequent expression banding adding 0.47W/kg to the body-weight-
controlled score. As an intermediate gene expression within the myogenesis fibre 
formation and repair process, this demonstration of higher relative expression in 
stronger patients indicates a longer-term propensity towards myogenesis. The 
identification of expression perioperatively had projected effects to 12-months 
outcomes. However, the lack of presence when modelling the 12-week post-op 
values queries this finding, but that no significant model was identified for 12-week 
power output may allay concern (p=0.30). As stated, the use of contemporaneous 
biopsies is required to confirm concurrent expression. 
 
Patients’ skeletal muscle fibre composition was found to influence power output 
strongly, with a higher proportion of type 2 compared to type 1 skeletal muscle fibres 
in vastus medialis indicating a higher power output. As the instrument takes 
measurement of explosive maximal power output, and type 2 fibres’ glycolytic fast-
twitch designation, this finding was intuitive. 
 
The relative expression of CDK2NA, an indicator of cell senescence, was found to 
negatively contribute to leg power output. As a proportion of cells within skeletal 
muscle contain this genetic expression, they are theoretically unable to function. This 
subsequently would impact upon factors such as muscle atrophy, leading to less 
recruitment, and therefore less muscle power output. 
 
Baseline Muscle Physiology as predictor of ADL Performance in Clinic 
 
No viable multivariate model predicting Aggregated Locomotor Function score 
outcomes was found representing physiological predictors of surrogate ADL 
performance (12-week p=0.31; 12-month p=0.72) (Table 55). 
 
Baseline Muscle Physiology as predictor Average Daily Step Count measured in the 
Community 
 
A single physiological variable was found to predict average daily step count as a 12-
month post-op primary outcome (Table 55). Myogenin relative expression, was 
identified as predicting 11% of step count (p=0.06). Higher expression was linked to 
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reduced step count at 12-months post-op. Caveated with an awareness of the 
model’s significance level (p=0.06), the finding suggests that those with recently 
formed or repaired myofibers at time-of-surgery are prone to lower daily step counts 
by 12-months post-operation. Study participants’ pre-op Myogenin expression levels 
and pre-op step count data indicated a non-significant marginal association of lower 
expression correlating with higher step counts. As previously discussed, elements of 
habitual activity play a greater part in this outcome metric than the small projected 
contribution from this gene alone. Future examination of this concept could provide 
further insight into this effect. 
 
Baseline Muscle Physiology as predictor Patient Background as predictor of Patient 
Reported Outcome 
 
Contrastingly to the step count findings, relative Myogenin expression at baseline 
was found to contribute positively to patient reported outcome at primary outcome 
(Table 55). Additionally, TNF expression was found to contributed negatively to this 
outcome metric. Combined they accounted for 14% of KOOS5 PROM score at 12-
months post-op. 
 
While the role of Myogenin in the model indicated the propensity of myogenic 
activity having a long-term positive effect, the nature of its expression across the 
models warranted further investigation, with a future repeat-biopsies study design a 
likely candidate. The finding of TNF inflammatory marker expression at time of 
surgery contributing to PROM scores the following year indicated underlying long-
term issues potentially related to inflammation and activity-limiting pain. The use of 
repeat biopsies and comparisons to time-point pain-scales in this regard may provide 
a clearer picture in future studies.  
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Summary of Physiological and Anatomical Predictive Models of Patient Surgical 
Outcomes 
 
Multivariate modelling of quadriceps skeletal muscle physiology and anatomy as a 
predictor of TKA surgical outcomes identified a small number of significant model 
outputs. Leg extensor power, daily step count activity, and patient reported outcome 
12-months post-op values were able to be predicted. Higher myogenin expression 
level positively influenced PROM score but reduced daily step count. Expression of 
markers of inflammation and senescence reduced PROM score and leg extensor 
power respectively. Positive influences on leg power were high MyoD expression and 
a larger proportion of type 2 ‘fast-twitch’ muscle fibres than type 1. 
 
The impact of background factors but lack of physiological predictors on the defined 
surgical outcomes (Leg Power, ADL performance (ALF), Step count, and PROMs 
(KOOS5)) during the early 12-weeks post-TKA recovery time-point indicates a trend 
which may underlie patient motivations at this stage. As background parameter 
predictive model findings at this time-point were weakly indicative (R2 range 0.15-
0.23) but significant (p≤0.03), psychosocial factors could play a larger role than 
variations in baseline physiological elements in determining patient early surgical 
outcome at 12-weeks post-op. The predictive strength of the background factor 
models suggest that, while very much relevant, other additional factors hold 
influence over the defined outcome metrics at this time-point. While some of these 
demographic, lifestyle, and comorbid factors are established in the literature base as 
effecting long-term outcomes, these study findings contribute to the understanding 
of their impact at this early 12-weeks post-TKA time-point. 
 
With the exception of muscle power output, the same can be said for the primary 12-
months post-op study outcomes. Across the range of representative outcome 
metrics, they are slightly more associated with the range of background factors (R2 
range 0.14-0.31) than with the measured individual physiological elements (R2 range 
0.11-0.29). As with 12-week modelling, the R2 predictive values from these 
parameter groupings indicate that either combined or tertiary factors are also 
involved. 
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To impact aspects of measured functional outcomes directly, these background 
factors must impact on skeletal muscle physiology. The predictive modelling of 
identified background factors on the selected skeletal muscle physiological can 
provide insight into this mechanism. While the study chose a selected number of core 
factors, these considerations excluded a number of other relevant factors which were 
not investigated. Examples include diet, adherence to recommended therapy, social 
support, and biomechanical habits, amongst other factors which have previously 
been suggested as relevant to post-TKA outcome (413–415). 
  
Insight into the multiple effects of background factors onto the physiological 
elements can therefore provide another broader picture of how these factors affect 
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7.4 - Patient Background as a Predictor of Patient Skeletal Muscle Physiological 
Profile 
 
Patient background factors including demographics, lifestyles and comorbidities 
were examined against quantified patient skeletal muscle physiology at time of 
surgery. While previously compared against the primary surgical outcomes at 12-
months following TKA, the physiological measurements can be said to have elements 
of plasticity over this timeframe. Examination of how patient background factors can 
influence this perioperative physiology provides insight into what becomes a ‘time-
zero’ for the recovery process. While the relationships of both these elements to 
primary outcome metrics have been examined, the insights from the direct 
comparisons may further elucidate the complexity of primary TKA patients’ 
physiological phenotypes. 
 
Variable categories were defined in previous sections and remain the same for these 
comparisons, with 17 background independent and 10 physiological dependent 
variables included. Comparisons were performed using general-to-specific 
multivariate regression analyses allowing for collinear and non-significant variables 
to be removed. Results of the best models for each physiological outcome marker 
are displayed in Table 56. The best models are defined as the first model to be 
significant below the set alpha (0.05) with the highest multiple coefficient of multiple 
determination. 
 
Patient Background and Genetic Markers of Myogenesis 
 
The multivariate modelling of patient background factors against myogenic 
expression produced three viable predictive models (R2=15-21%) (Table 56). These 
were for Pax7, MyoD, and Myog, with no viable model for Myf5. 
 
Patient age group featured as a positive influence in all three models. This showed 
that the older patients showed higher relative expression of each gene of interest. 
This is initially counter-intuitive as previous examination of correlation results in this 
study showed older individuals had smaller fibre diameters. Additionally, much 
previous work has shown greater propensity towards skeletal muscle atrophy and 
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sarcopenia in elderly patient population (416,417), particularly in regards to fibre 
diameter reduction and distribution, however this is not reflected in MuSC content 
(418). 
 
Table 56 - General-to-specific modelling results table for patient background factors as predictors of patient peri-
operative physiology. 
Baseline (Demographic, Lifestyle, and Comorbidity) Contributing Factors to Patient Physiology at Time of Surgery 
Outcome Metric Ranked contributing factors 









Age Group (0.01; +0.21) 
Dominant Leg Operated (0.04; -0.72) 
Comorbidity - Diabetes (0.06; -1.0) 





Drug Hx - NSAIDs (0.05; +0.47) 
Alcohol Hx (0.05; +0.22) 
Age Group (0.07; +0.09) 





Arthroplasty Hx Contra Knee (0.24; -0.27) 
Comorbidity - Hypertension (0.29; +0.26) 
Drug Hx - Paracetamol (0.46; +0.18) 
Drug Hx - NSAIDs (0.49; +0.19) 





Alcohol Hx (<0.01; +0.64) 





Age Groups (<0.01; +0.11) 





BMI Group (0.05; -0.13) 
Age Group (0.05; +0.07) 
SIMD Quintile (0.11; -0.10) 
Peak Physical Activity - Tegner Score (0.18; +0.04) 





Arthroplasty Hx Contra Knee (0.06; -0.36) 
Drug Hx - NSAIDs (0.07; +0.40) 




Fibre Type Ratio 
Drug Hx - Paracetamol (<0.01; -0.31) 
Sex (0.03; -0.17) 
Dominant Leg Operated upon (0.06; 0.14) 




Type 1 Fibre 
Diameter 
Age Group (<0.01; -2.0) 
Peak Physical Activity (Tegner Scale) (0.04; -1.3) 
Arthroplasty Hx Contra Knee (0.04; -1.3) 




Type 2 Fibre 
Diameter 
BEI Group (0.04; -2.8) 
SIMD Quintile (0.09; -2.5) 




Examination of the myogenesis process has shown that healthy elderly patients show 
increased expression of myogenic markers when compared to healthy middle-aged 
controls (419). Also previously observed in elderly individuals was the phenomenon 
where late myogenic marker expression is only reduced in patients with cancer 
cachexia and associated reduced oxidative defence (419). 
 
Study participants’ age ranged from 45 up to age 90, which represented the typical 
arthroplasty population, and provided a wide range for this effect to be observed. In 
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this cohort, data show consistent expression across the entire differentiation 
program in older patients, indicating an (expected) lack of cachexia and persistence 
of oxidative stress defence. 
 
Other inferences from the models towards Pax7 relative expression, a surrogate for 
MuSC abundance, include lower expression for those whose dominated leg was 
operated upon, lower expression for those with diabetes, and higher expression for 
those who had taken long term NSAID medication. 
 
Dominant leg surgery assumed that the leg was painful prior to surgery and likely 
more so than the contralateral leg. With a preferential limb inhibited by pain, the 
motivation for locomotor activity in general could arguably be reduced for the 
patient. On the other hand, with pain in a non-dominant leg, motivation for climbing 
a set of stairs with the dominant non-painful leg leading or other activities requiring 
relative limb confidence could be increased. Frequency of dominant limb TKA in the 
study population was 50%. 
 
The negative influence from diabetes could be related to activity levels, aspects of 
vascular circulation as previously discussed regarding patient outcomes, or a general 
marker of poor patient global health. 
 
The NSAID findings correlated with previous findings in studies where despite NSAID 
use in young athletes reducing myoblast fusion (420), they were found to improve 
myogenesis in the elderly (421). The ilSIRENTE study results, a large prospective 
cohort study of individuals in northern Italy, indicated that they have a protective 
effect against sarcopenia in the elderly (422). Underlying physiological mechanisms 
likely involve the upregulation of nuclear factor erytroid-2-related factor 2 (Nrf2), 
sirtuin (SIRT), and klotho factors, alongside the downregulation of the insulin-like 
growth factor 1 – protein kinase B – mammalian target of rapamycin 1 (IGF-1-Akt-
mTOR) pathway and the focal adhesion kinase – protein kinase B – mammalian target 
of rapamycin 1 (FAK-Akt-mTOR) pathway (51). NSAIDs were also implicated as a 
significant contributing factor in relative MyoD expression, which correlated with 
other previously suggested model findings (122). This occurred through the inhibition 
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of the nuclear factor κ-light-chain enhancer of activated B cells (NFB) transcription 
factor by reducing inflammatory cytokine expression (137,423,424). Both of these 
findings suggested that NSAIDs contribute a protective role to myogenesis and 
muscle health in the study TKA population. 
 
Additional contributing factors to MyoD expression levels were alcohol history and a 
history of arthroplasty in the contralateral knee. Increased alcohol positively 
contributed to MyoD expression in contrast to expectations behind the metabolic 
effects of alcohol on skeletal muscle. This indicated an association between higher 
intake and a higher propensity to differentiate into myoblasts and undertake 
myogenesis activity. The negative influence of the contralateral arthroplasty was not 
obvious however a recent previous arthroplasty, in the order of 1-2 years prior, may 
have created a longer period of disuse atrophy of the patient’s lower limbs than from 
the disuse from single leg end-stage osteoarthritis alone. The two factors may have 
specific individual actions as discussed or may be additional global markers of health 
status. 
 
Patient Background and Genetic Markers of Senescence and Inflammation 
 
The models for the senescence and inflammatory markers were all viable (p≤0.042) 
and ranged from 9% to 24% determination (Table 56). The prediction model for 
CDK2NA was the strongest (R2=0.24), followed by IL6 (R2=0.15), and then TNF 
(R2=0.09). 
 
Age group featured in all models as a positive influence on all the genes of interest, 
showing an increase of senescent and inflammatory marker with age in line with 
accepted correlations (425,426). Arthroplasty history in patients’ contralateral knee 
contributed negatively to CDKN2A and TNF expression with no clear underlying 
suggestive principle. These individuals therefore had less senescence and 
inflammation as indicated by these markers. 
 
The additional factors modelled as contributing to IL6 expression included BMI group 
(-ve), SIMD quintile (-ve), peak physical activity (+ve), and diabetes (+ve). As a marker 
of inflammation, the reduced association with weight increase contradicted current 
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understanding of IL6 expression increase with high fat diets (427). However, high BMI 
was not ubiquitously linked to high fat diets, with the effects from such diets on the 
autophagy pathway observed differently across muscle groups and across patient 
cohorts (428). Another physiological explanation could be IL6’s role as a myokine 
(136), or alternatively with a sedentary lifestyle and a possible fatty infiltration of 
tissue. Similarly, the positive influence of diabetes in the model reflected its 
association as a stressor on the body or general health marker. 
 
Findings showed that with less deprivation came lower IL6 expression. IL6 is 
connected to stresses and depression, with higher incidence in deprived areas, 
therefore these factors could provide the underlying influence in this element. The 
relationship with peak activity was unclear other than a possible tolerance to pain or 
habitual propensity towards active lifestyle and more frequent muscle use to the 
point of triggering a stress response. With these latter findings, it was important to 
consider the lower contribution of peak activity and diabetes to the model. 
 
With TNF expression, the final influencer was NSAID use, with an increase in this 
inflammatory marker found at time of surgery following long term use of the 
analgesic medicine class. While pharmacological inference suggests a reduction in 
this cytokine, the underlying use may be in response to multiple systemic 
inflammatory stimuli such as other joint problems. The model contributed a 
predicted 9% to the relationship in this case, which leaves much room for other 
influencing factors in this finding. 
 
Patient Background and Skeletal Muscle Fibre Morphometry 
 
Patient histological factors (fibre type proportion and fibre type diameters) were 
modelled to background factors with significant multiple determination coefficients 
identified varying between 11-26% (Table 56). Variables were identified that 
predicted skeletal muscle fibre type ratio by 26% (p=0.001), type 1 fibre diameter by 
20% (p=0.005), and type 2 diameter by 11% (p=0.046). 
 
Fibre type ratio, while macroscopically a reflection of previous activity and training 
stimuli in an individual, were significantly influenced by four background factors. 
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Historical paracetamol use was associated with a bias towards more type 2 fibres, 
whilst being female increased the observed proportion of type 1 fibres. If the 
operated knee was on the patient’s dominant leg then they showed a higher number 
of type 1 fibres, and living in a higher SIMD quintile area was also associated with a 
higher propensity to type 1 fibre typing. 
 
The effect of paracetamol on skeletal muscle, as with many analgesic agents, is 
contested in the literature. In this cohort the association of paracetamol and type 2 
fibres was an identified correlation of which the exact physiological pathways cannot 
be determined from this study (429,430). However, findings from recent resistance 
exercise studies suggest that over-the-counter dosage of paracetamol has positive 
effects on leg extensor power, implicating type 2 fast-twitch fibres, as measured in 
small groups of young male athletes (431,432). Observed physiological mechanisms 
implicate general reduced pain, reduced neuromuscular fatigue, and suppressed 
mTOR activity which leads to greater hypertrophy. The latter study observed this 
specifically within type 2 fibres. Confirmation of whether paracetamol use served as 
a general health indicative marker or whether specific pathways were implemented 
requires further future examination. 
 
Female patients’ propensity for a larger percentage of type 1 fibres compared to 
males indicated an association away from explosive glycolytic activities towards 
endurance oxidative stimuli. Muscle fibre types are known to differ between muscle 
groups in individuals and between sexes for the same muscle group. Previous findings 
for the quadriceps muscle grouping have also found a greater proportion of type 1 
muscle fibres in females compared to males (433). 
 
The principles underlying the associations with dominant leg and deprivation scores 
were unable to be determined from the data, with no clear physiological pathway. 
Social factors such as occupation showed no association with fibre ratio, however 
higher levels of recreational activity did show a non-significant propensity towards a 
higher type 2 fibre proportion. 
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Skeletal muscle fibre diameters were influenced by different variables. Type 1 fibre 
diameters were impacted negatively by patient age, peak activity, and previously 
contralateral TKA, and positively by NSAID use. Type 2 fibres were influenced 
negatively by BEI, and SIMD, and positively by BMI. 
 
Notable elements of these include the NSAID association and the positive effect 
within the cohort, however age was a more determinant factor. For example, 
younger study participants with a history of long term NSAIDs use showed larger type 
1 fibres compared to older participants. Having previous contralateral knee 
arthroplasty was not associated with patient age, and also not with NSAIDs use. 
 
Type 2 fibres showing decreased diameter with higher body fat corroborated 
elements of the active lifestyle element within the study cohort data. Females are 
genetically predisposed to higher body fat and showed a propensity towards a higher 
number of type 1 fibres, which may have influenced this finding. The negative impact 
of less deprivation on type 2 fibre diameter correlated with the fibre ratio findings 
where a phenotypic preference for type 1 fibres was identified.  
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Summary of Patient Background Characteristics as Predictors of Baseline Muscle 
Physiology 
 
Many different background factors have been implicated as contributing to 
physiological baseline factors. Some of these have provided influence within the 
grouped factor and others across multiple elements, with others showing small 
influence in single variables. 
 
While all are contributors to weak models (R2=0.09-0.26), the repeat significant 
appearance of multiple factors suggests causation rather than chance correlation, 
however this cannot be confirmed without future studies specifically targeting these 
sub-elements. 
 
Patient age has appeared as an influencing factor in multiple models, as has long-
term NSAIDs use. Factors such as previous arthroplasty, alcohol use, diabetes and 
geographic deprivation have also repeatedly influenced patient physiological factors. 
 
Patient age was positively associated with myogenic potential alongside systemic 
inflammation and senescence. Preoperative long-term NSAIDs use increased 
expression of markers of myogenesis, but also was found to be associated with higher 
inflammation. Previous arthroplasty, indicating a longer history of osteoarthritis, was 
associated with negative myogenesis markers and negative expression in markers of 
inflammation and senescence. Diabetes reduced the abundance of MuSC and also 
reduced inflammation, but potentially also muscular activity.  
 
The implicated physiological trends include analgesic medication marginally tipping 
the balance towards net growth from atrophy by inhibiting negative elements of 
autophagy protease and lysosome pathways and possibly preventing sarcopenia. 
Active lifestyles also promote myogenesis through promoted expression of Nrf2, 
SIRT, and Klotho, which facilitate protection against oxidative stress by reactive 
oxygen species. Some additional observed factors, such as the effects of alcohol and 
smoking, may implicate epigenetic effects. Evidence in the literature of a pathway 
effect is currently lacking, however observations regarding this effect may be 
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connected through the JAK/STAT pathway and its influence on myogenesis from local 
inflammatory factors such as IL6. 
 
Once again, all models provided weak but significant predictions of response factors. 
The observed factors also correlate with much in the literature and provide further 
human evidence of some effects mostly evidenced in model studies. The weakness 
of the models once again hints at the complex nature of the patient population and 
the large number of factors influencing surgical outcome. However, the multivariate 
models utilising functional factors as predictors of post-TKA surgical outcome remain 
‘best’ so far. 
 
The explored models provided insight into the relationship between patient factors, 
patient physiology, and surgical outcomes however they are not exhaustive. A 
multitude of other factors may affect patient’s functional outcome score at a certain 
time-point post-TKA. The models have explored the interactions and influences of 
significant factors that are known to impact TKA outcomes within a longitudinal study 
cohort. They have confirmed translated theories in a clinical cohort, identified 
influential hierarchies, and identified factors which have different effects in different 
demographic populations. Suggestions have also been made as to where further 
factors influencing TKA outcome may lie. 
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7.5 - Overarching Multivariate Prediction Models of Patient Surgical Outcome 
Post-TKA 
 
The preceding sections have explored how baseline clinical and functional scores are 
related to post-TKA outcomes. They have considered how patient background factors 
and characteristics influence surgical functional outcome. The relationship between 
patient skeletal muscle physiology and functional outcome has been examined. And 
they have investigated the interactions between these two areas in how patient 
background characteristics are associated with patient skeletal muscle physiology 
and the associated influential pathway mechanisms. 
 
Three multivariate prediction models of post-TKA functional outcome were created 
with varying levels of identified associations. These allowed statistical confirmation 
of subgroup influences and significance. All identified significant predictive factors 
could now be combined into an overarching predictive model which prevents the 
confounding issues of doing this from the beginning (overfit and loss of power). For 
primary 12-month post-TKA endpoint outcomes, the independent variables from 
each grouping which provided the most significant contributions (p<0.05) were 
utilised Table 57. 
 
Table 57 – Patient variables modelled as predictors of primary 12-month post-TKA endpoint metric outcomes. 
Inclusion based upon significance contribution (<0.05) during earlier section’s category-specific multivariate 
regression modelling. 
















Fibre Type Ratio 




Pre-op Leg Power 
Ratio, 
Pre-op EQ5D Index, 
Pre-op KOOS5 




ALF pre-op n/a 
 
General-to-specific multivariate regression modelling was used to determine the best 
combined predictive model for the four outcome categories (Table 58). All models 
created significant (p≤0.006) and viable predictive outputs (R2=0.26-0.73). Two 
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models with the combined variables created lower coefficients of determination than 
the subgroup analysis alone, one resulted in exclusions recreating a previous model, 
and one created a more predictive model. 
 
Table 58 - Overarching General-to-Specific Combined Multivariate Model Results Table of Contributing Factors to 
Functional Surgical Outcomes. Novel models with higher R2 values than those from previous separate sub-group 
models are highlighted in bold and underlined. Novel models with lower R2 values are only underlined. 






Ranked contributing factors 
(relationship direction; 


















Leg Power Pre-op (<0.01; 
+0.56) 
ALF Score Pre-op (<0.01; -
0.02) 
KOOS5 Index Pre-op (0.01; -
0.02) 




Leg Power Pre-op (<0.01; 
+1.10) 
EQ-5D Index Pre-op 
(<0.01; +1.20) 







ALF Score Pre-op (<0.01; 
+1.30) 
EQ-5D Index Pre-op (0.01; -
31.0) 
KOOS5 Index Pre-op (0.01; 
+0.68) 




ALF Score Pre-op (<0.01; 
+0.80) 





FJS Score Pre-op (<0.01; 
+100) 






ALF Score Pre-op (0.06; -
110) 
Smoking Hx (0.07; -2050) 







ALF Score Pre-op (<0.01; -
1.20) 
FJS Score Pre-op (0.02; 
+0.59) 




K&L OA Score (<0.01; 
+9.89) 





The combined model to predict Leg Power at primary 12-month post-TKA endpoint 
eliminated all but the functional variables due to multicollinearity and statistical non-
significance. This resulted in the same predictive model being created as the with the 
functional elements alone. This created a moderate prediction of 58% outcome with 
pre-op Leg Power, combined with EQ-5D and KOOS5 Index PROM scores as 
previously discussed. 
 
Prediction of ALF final outcome resulted in a lower coefficient of determination but 
using higher degrees of freedom meaning a more powerful predictive model. The 
initial functional predictive model achieved a strong prediction of 69% using data 
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from 22 study participants. The low number out of the whole cohort was determined 
by the predictive use of pre-op step count as a factor which was only measured in the 
enhanced sub-cohort. The cross-category strongly predicted 60% of final ALF 
outcome using pre-op ALF score combined with patient alcohol history in 33 study 
participants (p<0.001). 
 
Patient step count at 12-months post-op was predicted 39% with data from 25 
participants using paracetamol use history, comorbidity of hypertension, smoking 
history, and pre-op ALF score. The model created a higher R2 value than with the pre-
op background or functional metrics alone. These both predicted 28% final outcome 
using 25 and 24 participants’ data respectfully. 
 
The modelling of the combined panels to predict PROM score resulted in a lower 
prediction (26%) than using background factors alone (31%). 
 
Examination of combined panel predictors of early outcome at 12-weeks post-op 
with the same technique led to exclusions resulting in single sub-category models or 
with lower R2 values than the initial single category models. Patient age combined 
with pre-op FJS score predicted 49% of final step count in 24 patients compared to a 
57% prediction using functional factors alone in 23 patients. 
 
These findings seemed surprising but reflected the complex and varying nature of the 
combined data sets, with varying numbers of responses and some missing values due 
to the study cohort design. For example, while all patients who attended the pre-op 
research clinic provided leg power data, only enhanced cohort participants had 
provided step count data. They also reflected the step-wise process of the general-
to-specific modelling technique which utilised consistent conservative methodology. 
 
The only combined model that improved prediction was for primary endpoint daily 
step count. The improved power in the model predicting final ALF score reflects the 
influencing effect of patient alcohol history on ADL performance, however pre-op ALF 
score remained the greatest influence. 
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Combined Summary Comments on Multivariate Model Analyses 
 
The combined multivariate models provided further insight to the factors that 
influenced step count in the study cohort and identified multiple models which 
predicted ADL performance and KOOS5 PROM score that were not previously 
identified. However, the majority of these new models were not as strongly 
predictive as parameter sub-group models identified during earlier analysis. 
 
Overall, the range of multivariate regression models identified in this chapter 
provided insight into complex clinical outcomes and their underlying contributors. 
Baseline functional and patient reported metrics provided the strongest prediction 
of early and 12-month post-op outcomes, while background and physiological factors 
provided weak but significant predictions of responses. They all therefore provided 
meaningful suggestions as to where the associated influences are found in the TKA 
population. Summary tables of the directional influences of factors on outcomes can 
be found in Appendix C: Additional Data. 
 
Following on from the individual metrics discussion, the indications for predictive 
factors that influence patient 12-month post-TKA primary outcomes can be better 
explained when the compounding effects of multiple factors are examined. While 
this was not generally the case for individual physiological markers, the evidence for 
demographic factors and how they affect both patient baseline physiology and 
eventually TKA primary surgical outcome is compelling. Additionally, the 
identification of factors which impact upon early surgical outcome can be used to 
inform the clinical practice and potentially policy decisions such as regional service 
provision. 
 
Considering the impact on outcome of both measured and subjective function of 
patients is important to generate a full picture of whether a surgical intervention has 
provided benefit. While on the whole predictive factors during modelling for these 
categories overlapped, there were instances where they diverged. For example, in 
the case of peak previous activity level positively influencing relative power 
generation but lowering patient reported outcome. The occurred due to the 
converging differences in positive physiological gains versus the negative mismatch 
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of expectations of those with higher previous sporting activity. These are important 
factors in equally relevant outcome measurement methodologies, but opposing 
impacts when using each to make an evaluation of overall TKA outcome. 
 
Some traditional demographic factors that are well established and routinely utilised 
metrics showed little influence in primary patient outcomes but impacted on baseline 
physiology. Patient age was found to negatively associate with early step count 
outcome alone, despite being a positively influencing factor in the majority of 
baseline physiological myogenesis metrics. Similarly, patient BMI was found to only 
be significantly associated with patient reported function. These showed that within 
the cohort these traditional headline demographics are not that important in 
determining measured outcome, despite what they may present as in perioperative 
physiology. 
 
Patient pharmaceutical history also impacted outcomes and physiological factors. 
Non-steroidal anti-inflammatory medication improved early leg power and also 
baseline physiological factors. Paracetamol positively influenced daily step count 12-
months post-op. While long-term opiate use affected one 12-week post-op and one 
12-month post-op outcome, it was not found to be relevant when assessing any 
physiological phenotypes. NSAIDs use in the TKA population overall suggests a 
protective effect against reduced strength and physiological markers of sarcopenia 
through a defence against oxidative stress. 
 
Patient lifestyle aspects such as alcohol and tobacco use, activity levels, and 
deprivation levels also played substantial roles in contributing to TKA outcome 
scores. Alcohol use negatively impacted power output, reported outcome, and 
surrogate ADL performance, while smoking history negatively influenced daily step 
count at final time-point. Alcohol was also found to increase patient myogenic activity 
at baseline. Overall these two substances uphold their established positions as 
negative influences in health, here reflected in the arthroplasty cohort. Notable was 
the negative impact of any alcohol use when compared to teetotal study participants. 
The broad range of effects from activity levels has been commented upon, while the 
effects from lower deprivation levels ranged from improving reported function and 
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ADL performance to creating an associated baseline skeletal muscle morphological 
phenotype. Lower physiological stress levels in less deprived communities, higher 
levels of recreation, and ease of access to primary health rehabilitation and local 
social facilities are some of the factors identified which lead to this effect. 
 
Clinical Implications from Modelling Outputs 
 
To optimise patient outcome following TKA, the study results indicate that the best 
prediction of outcome can be made by pre-operative function, specifically leg power 
and surrogate ADL performance such as that assessed by the ALF test. Identifying a 
pathway to optimise these elements either through earlier intervention or 
prehabilitation would serve to increase these pre-operative values. Alcohol and 
tobacco use should be avoided during the first 6-months of recovery, as values 
plateau after this point. Consideration should be made of the prescription of NSAIDs 
to elderly patients to preserve muscle bulk and myogenic ability. 
 
Activity monitoring to gain insight into step count provided an outcome metric which 
was significantly influenced by a number of factors during the 12-months following 
TKA, however was ultimately a metric that was influenced by patient habitual activity. 
As such, it remains an extremely useful methodology assess patient metrics in the 
community, with newer devices offering increased functionality with every 
generation, but has limited scope as a post-operative functional assessment using 
daily step count alone. As stated, extrapolations of this metric to include cadence and 
paired heart rate amongst others, would serve to bolster this method in its functional 
outcome use. 
 
As a central observation, the vast majority of participants’ outcomes across the 
cohort were positive by study endpoint at 12 months post-op. Primary TKA in 
response to end-stage osteoarthritis is a very established and precise surgical 
intervention. It has well-honed, standardised techniques and robust clinical care 
pathways that can respond to rare complications. However, the identified factors in 
these models are relevant to consider in the fine tuning of these surgical outcomes 
when considering the patient demographic in future practise. 
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Chapter 8: General Concluding Discussion and Future Work 
 
General Concluding Discussion 
 
This thesis followed a primary total knee arthroplasty cohort through early recovery 
up to 1-year following surgery while assessing surgical outcome. Performed at a 
single University Hospital site, with concurrent clinical and laboratory assessments by 
a single researcher, it evaluated the relationship between patient background and 
muscle physiology and the relationship with functional and patient-reported surgical 
outcomes. 
 
A major underlying driver in the creation of the study was the statistic that one in five 
patients are dissatisfied with their surgical outcomes following primary TKA. This 
study targeted the early functional aspects of this finding and sought to elucidate the 
underpinning factors through the primary study aim: 
 
 “To identify preoperative and perioperative muscle factors and patient 
background characteristics affecting early functional outcome following 
primary knee arthroplasty.” 
 
This work has identified patient background factors which were seen to influence 
patient post-TKA outcomes and has examined the nature of the role of patient peri-
operative physiology in multifactorial determination of these outcomes. 
 
Concluding elements are structured by their relationship to the initially set-out 
hypotheses and aims. 
 
The relationship between outcome measurements 
 
This section addresses the hypothesis that: 
 
 “The pattern of recovery of different categories of outcome metrics vary 
during the early recovery stage in primary total knee arthroplasty population.” 
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A successful outcome following TKA (or indeed any musculoskeletal surgical 
intervention) has elements of pain reduction, achievement of reasonable pre-
operative expectations, and corresponding physical or functional improvement. The 
range of measurements performed in the cohort captured data across these 
parameters and provided insight into the relationship between metrics. 
 
The range of outcome measurements covered direct functional assessments, 
functional assessments in the community, and patient reported outcomes. Study 
findings indicated that some tools evaluated outcome over the course of the study 
as remaining similar to pre-operative patient values, while others demonstrated large 
improvement when similarly assessed. For those metrics that did show improved 
outcome, some did so at different time-points during surgical recovery. On average, 
maximum functional outcome was achieved by 6-months following the procedure. 
Maximum measured and patient-reported ADL scores were achieved by 12-weeks 
post-op, and full symptoms and pain continued to improve at every time-point up 
until 12-months post-op. Despite tool validation during development including 
typical comparisons with previously established tools, the tools are not always 
comparable across all clinical groups and recovery time-scales. 
 
Additionally, different motivating factors were identified in the directly measured 
functional outcomes. Functional outcomes measured in clinic can intrinsically have a 
competitive element. Whether from instructing a patient to try their hardest during 
a maximum power test, or by timing a battery of surrogate ADL activities. Passively 
measured outcomes in the community via activity monitoring potentially have an 
artificially motivating effect, akin to white coat syndrome (434,435), but this was less 
pronounced as reported by study participants given the neutral initial instructions. 
This difference identified the potential that while maximum leg power, ADL 
performance, and several PROM tools reported maximum results at 6-month post-
op, patient daily step count was not a maximum possible value whenever reported. 
It reflected necessary or habitual activity. ADLs by definition are activities that must 
be performed in daily life, but modern life provides adaptions to community activity 
levels that can act as crutches. For example, activity-averse choices such as driving to 
the local shop rather than walking. The motivations for these activities can also be 
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affected by factors ranging from city-planning isolation to seasonal weather changes. 
While the 3000-5500 daily steps of the cohort’s 12-month interquartile range 
represents substantial activity, it falls short of higher recommended targets (242). 
Patient and public healthy lifestyle education highlights recommended activities for 
continued cardiovascular health benefit (436,437), but the influence of these 
strategies doesn’t seem to be found in the current study population. The implications 
for the use of step count data in clinical functional outcomes measurements was 
therefore highly dependent on contextual study instruction and was likely further 
influenced by patient baseline habitual activity level. 
 
The difference between PROM and direct functional measurements in the first 3 
months of recovery suggests differential response to patient reported function 
measures that don’t necessarily relate to each other during this time-frame. Patients 
reported significantly improved function at 6-weeks following TKA which was not 
observed in the assessed function tests until later time-points. These findings provide 
important context in which early patient reported outcome data should be 
considered. For example, 6-weeks post-op is a well reported timeframe in clinical 
trials of orthopaedic devices. Studies using different tools at the same time-points 
cannot be reliably compared at these, despite the measurements sounding similar. 
These may include different functional ADL tests or different specialised PROMs 
tools, with all carrying some level of uncertainty when compared in this way. 
 
The observations from this study confirm the benefit of evaluating functional 
outcome with multiple measurement categories (188). The use of a battery of metrics 
allowed for clearer evaluation of the spectrum of outcome and for the identification 
of aspects which were potentially causing dissatisfaction with function following 
primary TKA. 
 
Core outcome sets or domains are used to standardise measurement across clinical 
studies and trials. OMERACT-OARSI are current working on updating a previously 
published set with results expected by 2021 (438,439). Defined outcome targets 
remain focussed on the mid-to-long term due to the contemporary longevity of 
prosthetics and the nature of OA as a chronic disease, but the recognition of 
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functional outcome variation at early time-points is still a relevant factor which 
should be considered by musculoskeletal researchers and developers of orthopaedic 
devices. 
 
Baseline predictors of surgical outcome following primary TKA 
 
This section addresses the hypothesis that: 
 
 “Patient background characteristics and muscle factors affect very early 
functional recovery following primary total knee arthroplasty.” 
 
Secondary hypotheses are also addressed as stated. 
 
A primary aim of the study was to identify factors that affect early surgical outcome 
post-TKA. This included various patient background factors, baseline local muscle 
physiology with a focus on muscle satellite cells, and other preoperative functional 
assessments and patient reported factors. When the baseline measurements were 
compared to the study’s 12-weeks post-op ‘early’ and 12-months post-op ‘final’ 
endpoints, they allowed predictive statistical modelling to determine contribution to 
these surgical outcomes. 
 
Regression modelling identified the strongest predictions of early surgical outcomes 
from a selection of pre-op functional and PROM scores, with weak but significant 
predictive factors identified amongst the physiological and background patient 
factors. The method also created optimal predictive models of post-operative 
functional and patient reported measurements by combining all available predictive 
variables, however these composite models offered little additional predictive 
accuracy beyond the initial functional and PROM score models. 
 
 “Patient background characteristics correlate with functional surgical 
outcomes following primary total knee arthroplasty.” 
 
The strongest pre-operative predictors of patient post-operative strength (leg 
extensor power) utilised pre-op same-metric measured function combined with pre-
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op patient reported health status (EQ-5D) and patient reported knee-specific tools 
(KOOS). As such, post-operative patient strength and ADL performance could be 
strongly predicted using pre-op values combined with EQ-5D and KOOS5 scores. This 
combination of metrics provides an important pre-operative measurement grouping 
that can be used to strongly predict 12-month outcome. Study findings also suggest 
that targeted rehabilitation maximising ALF-related ADL performance and leg 
extensor power contribute to maximum return to activity post-TKA, in conjunction 
with other factors. 
 
Wider background factors were also identified that determine post-TKA surgical 
outcome. Previously high peak activity, chronic use of NSAIDs and paracetamol were 
found to associate with better directly measured outcomes, with any alcohol use, 
smoking, comorbidities, residential deprivation, and opiate use found to negatively 
affect these. Patient reported metrics were most positively affected by preperative 
severity of OA (assessed by K&L score) indicating a greater symptom reduction. These 
metrics were negatively influenced by being male, having high previous activity 
levels, diabetes, being in a high BMI group, and using alcohol and opiates. As such, 
clinic-measured direct functional outcomes were noticeably more influenced by 
lifestyle factors, whereas the community measured functional outcomes of step 
count and patient reported outcome were affected by a broad range of background 
factors also including comorbidities and biometrics alongside the lifestyle factors. 
 
 “Patient background correlates with patient muscle physiology at time of 
surgery in patients undergoing primary total knee arthroplasty.” 
 
Amongst the background and baseline physiological factors, trends were observed 
that shed further light on the primary TKA clinical population phenotype. Long-term 
use of NSAIDs prior to surgery and patient age were found to have a positive influence 
on myogenic activity. Patients who reported a history of NSAIDs use had raised 
presence of MuSCs but also of inflammatory activity. With this observation, the 
protective effect of NSAIDs against sarcopenia was likely seen in the study population 
through protection against oxidative stress and possible regulation of myogenesis 
through the JAK/STAT pathway. Patient recreational substance use also influenced 
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outcome metrics with smoking history and alcohol use impacting on multiple 
variables. Patient residential deprivation was also found to negatively influence 
surgical outcomes. 
 
Study laboratory findings identified high presence of MuSCs and recently created or 
repaired muscle fibres amongst patients, but low numbers of actively differentiating 
cells. The results also showed overall low levels of senescent and inflammatory 
activity within the patient muscle biopsy samples. Cross-molecular-panel 
investigations identified correlations between inflammation and myogenesis 
markers but not with senescent markers. Additionally, no associations were 
identified between fibre anatomy and molecular gene expression profiles. 
 
 “Patient muscle physiology at time of surgery correlates with functional 
surgical outcomes following primary total knee arthroplasty.” 
 
Patient baseline physiological markers were only weakly predictive of post-TKA 
functional outcomes. Specifically, higher myogenin expression level positively 
influenced PROM score but reduced daily step count. Expression of markers of 
inflammation and senescence reduced PROM score and leg extensor power 
respectively. Positive influences on leg power were high MyoD expression and a 
larger proportion of type 2 ‘fast-twitch’ muscle fibres than type 1.   
 
Despite significant predictive contributions, these did not influence patient outcomes 
to the comparatively higher level of preoperative functional measurements or 
patient background factors. However, significant attribution to muscle physiological 
phenotype was identified from patient background factors. Additionally, the 
plasticity of the investigated physiological markers was identified as a likely factor in 
the relatively lower predictive nature of the surgical outcomes. Preoperative 
measurements, while significant predictors, did not provide the level of insight 
possible through serial contemporaneous biopsies. Future expansion of these 
investigations may lead to the identification of pre-operatively identifiable 
phenotypes that facilitate personalisation of the total knee arthroplasty procedure 
and recovery pathway. 
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The study findings provide a novel preoperative functional battery which strongly 
predicts early outcome following TKA. Encompassing this series of patient tests into 
the preoperative assessment process could help to identify patients at risk of poor 
outcome due to the functional factors. This stratifying step towards personalised 
medicine could, with the appropriate allocations of resources, continue the modern 
progress toward optimising recovery from total knee arthroplasty for all patients. 
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Future Work 
 
There are several areas warranting future investigation. These included patient 
background, clinical assessment, and laboratory areas which proved linked or 
influential towards patient surgical outcomes. These areas can be explored in greater 
depth with tighter controls using different study designs or methodologies. 
 
Patient background factors of age, comorbidities, pharmaceutical history, and 
deprivation were indicated as impactful on patient outcome. As a study which 
reflected the wider clinical population, the cohort allowed commentary on a number 
of relevant factors by design. Further investigations identified specific aspects of 
sleep, arthrogenic muscle inhibition, recreational activity levels, and ROM limitations 
which impacted on patient outcomes. Future studies examining all of these areas 
through the targeted recruitment of specific clinical cohort subpopulations can be 
used to elucidate the underlying effects. Generally, the robustness of study findings 
can always be improved through increasing study recruitment numbers whilst 
keeping tight controls on variables. While challenging to do both of these in a clinical 
cohort study, the expansion into a multisite longitudinal cohort study or performing 
recruitment over a longer time frame would allow for increased recruitment and also 
the targeting of the relevant TKA subpopulation with altered study inclusion and 
exclusion criteria. 
 
While the molecular genetic expression investigated at time of surgery yielded weak 
correlation with final surgical outcomes, the time duration between sampling and 
assessment likely influenced results. A study design including longitudinal biopsies in 
line with post-operative assessment time-points could provide explanation as to how 
myogenesis, inflammatory, and senescent expression profiles correlate 
contemporaneously with outcome assessments. However, as demonstrated in the 
initial design aspirations of this study, this provides significant ethical challenges due 
to the infection risk and potential disabling effects that repeat biopsies can have near 
recent surgical sites. Care must also be taken that repeat biopsies are representative 
of the target muscle locations while not becoming influenced by previous scar tissue 
or excess variation in site. 
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The associations of higher alcohol use and increased myogenesis activity seemed 
counterintuitive and is therefore an area requiring further investigation to 
understand. Similarly, the significant findings of lower deprivation’s association with 
reduced inflammation and a propensity towards an endurance muscular phenotype 
also warrants further study to clarify. 
 
The expansion into the use of different laboratory methodology could also provide 
further information. Creating an immunofluorescent histological panel to assess 
myogenesis would allow for specific anatomical questions to be addressed. For 
example, the association of MuSCs with fibre typing, or with vasculature. Similarly, 
the examination of inflammatory markers or senescent expression in this way could 
also provide further insight into locality of expression. The potential use of flow 
cytometric analysis could provide in depth information on the heterogeneity of the 
MuSC population would clarify further hypotheses about patient physiological 
phenotypes. It can also be used to identify co-expression which would allow 
identification of cell-subpopulations. Additionally, the use of metabolomic studies, 
with techniques such as ultra-high-performance liquid chromatography (UPLC), mass 
spectrometry (MS), and nuclear magnetic resonance (NMR), could identify clearer 
patient physiological profiles for use in evaluating groupings, outcomes, and 
associations. Examples of effects to examine include drug metabolite levels, dietary 
metabolites, and paracrine effects resulting from arthritic disease. These would 
provide clearer insight into the pharmacological and dietary local effects on skeletal 
muscle tissue affecting control of the knee joint, and additionally further clarify the 
impact of arthritic severity on muscle physiology. 
 
The study findings suggest a substantial role of muscle function in the determination 
of outcome following total knee arthroplasty. Insight has been delivered into the 
recovery process in the first year following operation, with significant differences 
identified between measurement tools. A battery of pre-operative assessments has 
been identified that strongly predicts functional outcome post-TKA. Targeted support 
can be provided to optimise these patient assessments. 
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Furthermore, patient background characteristics and analgesic use has been shown 
to substantially impact of this physiological patient profile. The role of specific gene 
expression and muscle micro-anatomy profiles in the quadriceps muscle group has 
next been shown to affect patient outcomes following TKA, which has set the scene 
for further work in this area of personalised predictions of post-TKA recovery efficacy 
using skeletal muscle physiology.  
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Appendices 
 
Appendix A: Clinical Study Documentation 
 
Study Methodology Development 
PROMs Development 
 
Table 59 - Total Knee Arthroplasty Prominent PROMs tools. Adapted from Ramkumar et al and Collins et al 
(197,198). 
PROM tool description  
ARS (Activity Rating Scale) 
BOAS (British Orthopaedic Association Score) 
Bristol Knee Score 
CPG (Chronic Pain Grade) 
EQ-5D (Generic Measure of Quality of Life, EuroQoL Group Index Score - 5 Domains) 
Feller 
FJS (Forgotten Joint Score) 
HAAS (High Activity Arthroplasty Score) 
HADS (Hospital Anxiety and Depression Scale) 
HFKS (High-Flexion Knee Score) 
Hospital for Special Surgery Knee Score 
Hungerford 
ICOAP (Intermittent and Constant OsteoArthritis Pain) 
IKS (International Knee Society) 
IPAQ (International Physical Activity Questionnaire) 
KKS (Korean Knee Score) 
KOOS (Knee injury and Osteoarthritis Outcome Score) 
KOOS-PS (Knee injury and Osteoarthritis Outcome Score-Physical Function) 
KOS-ADLS (Knee Outcome Survey - Activities of Daily Living Score) 
KSS (Knee Society Score) 
Lequesne 
MODEMS (Musculoskeletal Outcomes Data Evaluation and Management System)  
New KSS 
New Zealand Score (NZS) 
NHP (Nottingham Health Profile) 
NRS (Numerical Rating Scale) 
OKS (Oxford-12 Knee Score) 
OKS-D (German adaptation) 
PerF (Function) and PerP (Pain) 
POMS (Profile of Mood States) 
PSQ (patient satisfaction questionnaire) 
SAPS (Self-Administered Patient Satisfaction) 
SF-12 (Short-Form 12) 
SF-36 (Short Form-36) 
SF-6D (Short Form-6 Domains) 
SIP (Sickness Impact Profile) 
Tegner-Lysholm Knee Score 
UCLA (University of California, Los Angeles) 
VAS (Visual Analogue Scale) 
WOMAC (Western Ontario McMaster University Score) 
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PROMs Tool Split by Questionnaire Battery 
 
 
Figure 37 - MAKRO Study Questionnaire Battery Time-Points 
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Clinical Study Approvals, Notices, and Documentation 
NHS Health Research Authority Study Summary 
 
The published public summary of the MAKRO Study on the NHS Health Research 
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MAKRO Study Patient Consent Form  
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Specific biological tissues can be identified through histological stains and 
counterstains, but this can become complicated when specificity is required. 
Immunohistochemistry allows for the visualisation of specific antigens on target 
tissues. It is superior to histology in that it can identify different targets with different 
stains and can do so with much greater precision. It can identify colocalization of 
different antigens, for example in order to identify a sub-phenotype within a cell 
population. Primary antibodies raised against a target protein are incubated on a 
slide section, followed by an incubation period of a counterstain or a secondary 
antibody against the primary. 
 
Immunohistochemistry relies upon antigen-antibody interactions to identify certain 
structures or presence of certain protein expression. The antibody variable domain is 
the geometric and chemical complement of the antigen epitope which allows for 
highly targeted specificity (440). 
 
While immunohistochemistry is very effective for some uses, it is limited due to its 
restriction to light microscopy. When trying to visualise colocalization of multiple 
targets, a colour blend at a specific location can be difficult to identify when present 
in differing concentrations. For example, both targets may be present, but one may 
exist in higher abundance and obscure the other. While altering antibody 
concentrations can help with balance, it can never be definitive. A variation of the 
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Immunofluorescence Overview 
 
Immunofluorescence (IF) staining allows for the tagging of antigen targets with 
secondary fluorescent probes. Choosing probes with emission spectra at differing 
wavelengths allows for visualisation of each targets separately with fluorescence 
microscopy. Each desired target in the tissue has been labelled with different 
fluorophore, they can be separately imaged using a fluorescence microscope. The 
images can then be digitally combined into merged images that allow for accurate 
identification of colocalization of targets. Similarly, the technique can be used to 
identify anatomical landmarks which may help with identifying or categorizing 
structures. 
 
Haematoxylin and Eosin materials and staining protocol 
 
Haematoxylin and Eosin (H&E) Histology Stain for human muscle 
 
Perform in hood due to alcohols. Use gloves and lab coat.   
 
Summary 
Histological stain to identify general structure of the sample: fibre size and contours, 
position of nuclei, fibrosis, inflammation, nerves, blood vessels. 
For snap frozen or fixed samples in paraffin. 
 
 
Read all MSDS, Risk Assessment, and be aware of PPE and mechanical controls for this protocol before beginning. 
 
Equipment Instruments Materials 
 11 histology staining dishes 
 Rack for slides to fit in dishes 
 Sink with running cold tap water 
 Timer 
Disposable forceps 
Paper towel roll 
Coverslips 









 Eosin Y Stain 
(Aqueous) – RBC-
0100-00A. 
 Ethanol absolute – 
20821.330 
 Histochoice clearing 
agent – H2779. 
































Pour 200ml from stock bottle into 







50% - 100ml EtOH, 100ml dH2O 
70% - 140ml EtOH, 60ml dH2O 
80% - 160ml EtOH, 40ml dH2O 
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 95% - 190ml EtOH, 10ml dH2O 
100% - 200ml EtOH 
100% - 200ml EtOH 
NOTE: Use distilled Milli-Q water or equivalent in all protocol steps and for preparing all solutions. 
NOTE: All solutions and equipment coming into contact with cells must be sterile, and proper sterile 
technique should be used accordingly. Surgical equipment may be sterilized by simply soaking in 
70% ethanol; however, it is important to rinse in PBS before use since ethanol will “fix” the tissue. 
 
For those new to Histological techniques: 
a. Familiarise yourself with the work environment (e.g. get comfortable and practice technique).  
b. Be mindful of hood or biosafety cabinet function/use; airflow disturbance, contaminants, working sliding sash height, 
and substances that may compromise the HEPA filters. Be aware of the location of all instruments and materials within 
the cabinet. 
c. Familiarise yourself with the biochemistry theory behind the stains, and what correct staining should look like. 
 
Methods 
A. Can be perfomed on fixed or snap frozen tissue. (Separate in-depth guides are available for the 
following) 
 FIXED: 4% Paraformaldehyde (PFA) for 24 hrs then 70% EtOH until embedded in paraffin. Store at room 
temperature. 
 SNAP FROZEN: Isopentane (2-Methylbutane) cooled in liquid nitrogen (cool isopentane until solid – remove 
onto bench until partial liquid then snap freeze samples.) Store in -80°C freezer. Thaw sample once (repeat 
cycles = artefact). 
 
B. Prepare solutions. (See ‘Solutions’ section for more detail). 
 Harris Haematoxylin Stain   (100% from stock) 
 Eosin Y Stain (Aqueous)   (100% from stock) 
 Ethanol dilutions    (make up 200ml for Histo StainDish) 
 Histochoice clearing agent   (100% from stock) 
 Keep one Histological Staining Dish in sink for running tap water rinses. 
 
C. Sectioning. 
 Cut tissue as preferred – microtome (fixed and paraffine embedded) or cryostat (snap frozen – be careful with 
thawing). 
 Superfrost Plus slides preferred to prevent sections lifting during staining protocol. 
 Label slides with standard format in pencil: Date, Name, Experiment, Sample number etc. 
 
Staining. 
 Rack up slides to be stained. 
 Fixed in paraffin: 
i. Dewax paraffin sections – incubate slides at 60°C for 20 minutes. 
ii. Dewax – Histochoice wash for 3 minutes (repeat X2). 
iii. Rehydrate sections – 100% ethanol for 3 minutes (repeat X2). 
iv. Rehydrate sections – 70% ethanol for 3 minutes. 
Continue as below… 
 
  Perform all following steps in a hood (bar sink washes) 
 
 Snap frozen: 
i. Stain – Haematoxylin for 30 seconds. 
ii. Remove excess stain in running tap water ~2 mins. 
iii. Stain – Eosin for 30 seconds. 
iv. Remove excess stain in running tap water ~2 mins. 
v. Dehydrate – 50% EtOH – 30 seconds. 
vi. Dehydrate – 70% EtOH – 30 seconds. 
vii. Dehydrate – 80% EtOH – 30 seconds. 
viii. Dehydrate – 95% EtOH – 30 seconds. 
ix. Dehydrate – 100% EtOH – 30 seconds. 
x. Dehydrate – 100% EtOH – 30 seconds. 
xi. Clear – Histochoice – 30 seconds. 
xii. Clear – Histochoice – 30 seconds. 
 Mount with coverslip: 
i. Remove slides from rack and allowed to evaporate briefly on paper towel. 
ii. Add small drop of DPX mountant on to section. 
iii. Apply coverslip. 
iv. Leave to dry in hood before examining under microscopy. 
END  
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ATPase materials and staining protocol 
 
ATPase Histology Stain for human muscle fibre types 
 
Perform in hood due to odour and vapour. Use gloves and lab coat. Keep hood light off to protect from light. 
 
Summary 
Histological stain to identify different fibre types in human muscle tissue. Type 2 
fibres will become dark, and type 1 fibres will be lighter. 
 
 
Read all MSDS, Risk Assessment, and be aware of PPE and mechanical controls for this protocol before beginning. 
Fresh Snap Frozen muscle samples only. Will not work on fixed samples as is metabolic. 
 
Equipment Instruments Materials 
 11 histology staining dishes 
 Rack for slides to fit in dishes 
 Sink with running cold tap water 
 Timer 
 Dry incubator set to 37°C. 
Disposable forceps 
Paper towel roll 
Coverslips 






 Ethanol absolute – 
20821.330 
 Histochoice clearing 
agent – H2779. 
 DPX mountant – 
O6522. 
 Glycine – G8898 
 NaCl – S7653 
 ATP – A2383 
 NaOH - 221465 
 Ammonium 
Suphide - A1952 




























Dissolve glycine, NaCl, and CaCl2 in 
dH2O. 
Use pH meter. Adjust pH to 9.4 using 
gradual addition of 0.1M NaOH. 
Once at 9.4, add ATP. 
Leave incubating solution in 37°C 
incubator to acclimatise. 






Dissolve CoCl2 in dH2O with magnetic 
stirrer. 






Combine liquids. Perform in fume 












Pour 200ml from stock bottle into 








50% - 100ml EtOH, 100ml dH2O 
70% - 140ml EtOH, 60ml dH2O 
80% - 160ml EtOH, 40ml dH2O 
95% - 190ml EtOH, 10ml dH2O 
100% - 200ml EtOH 
100% - 200ml EtOH 
 
NOTE: Use distilled Milli-Q water or equivalent in all protocol steps and for preparing all solutions. 
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NOTE: All solutions and equipment coming into contact with cells must be sterile, and proper sterile 
technique should be used accordingly. Surgical equipment may be sterilized by simply soaking in 
70% ethanol; however, it is important to rinse in PBS before use since ethanol will “fix” the tissue. 
 
For those new to Histological techniques: 
a. Familiarise yourself with the work environment (e.g. get comfortable and practice technique).  
b. Be mindful of hood or biosafety cabinet function/use; airflow disturbance, contaminants, working sliding 
sash height, and substances that may compromise the HEPA filters. Be aware of the location of all 
instruments and materials within the cabinet. 





A. Must be performed on fresh, snap frozen muscle sample. Not on fixed tissue. 
 Collect tissue in advance.. 
 SNAP FROZEN: Isopentane (2-Methylbutane) cooled in liquid nitrogen (cool isopentane until 
solid – remove onto bench until partial liquid then snap freeze samples.) Store in -80°C freezer. 
Thaw sample once (repeat cycles = artefact). 
 
B. Prepare solutions. 
 See ‘Solutions’ section for more detail. 
 Ammonium sulphide [(NH4)2S] and Cobalt Chloride [CoCl2] can be made in advance. 
 Incubating solutions must be made up fresh. 
 If (NH4)2S is yellow then needs changed. Similarly with excess surface precipitate with CoCl2. 
 Keep one Histological Staining Dish in sink for running tap water rinses. 
 
C. Sectioning. 
 Cut tissue – cryostat (snap frozen – be careful with thawing). 
 Superfrost Plus slides preferred to prevent sections lifting during staining protocol. 
 Label slides with standard format in pencil: Date, Name, Experiment, Sample number etc. 
 
Staining. 
 Rack up slides to be stained. 
 
  Perform all relevant following steps in a hood. 
 
 Snap frozen: 
i. Incubating solution for 30 minutes at 37°C. 
ii. Remove excess stain in dH2O bath ~2 mins. 
iii. Stain – 2% Cobalt Chloride for 5 mins. 
iv. Remove excess stain in running tap water ~1 min. 
v. dH2O bath for ~1 min. 
vi. dH2O bath for ~1 min. 
vii. Stain – 1% Ammonium Sulphide for 1 min. (be aware of odour limitation) 
viii. Remove excess stain in running tap water ~4 mins. (be aware of odour limitation) 
ix. Dehydrate – 50% EtOH – 30 seconds. 
x. Dehydrate – 70% EtOH – 30 seconds. 
xi. Dehydrate – 80% EtOH – 30 seconds. 
xii. Dehydrate – 95% EtOH – 30 seconds. 
xiii. Dehydrate – 100% EtOH – 30 seconds. 
xiv. Dehydrate – 100% EtOH – 30 seconds. 
xv. Clear – Histochoice – 30 seconds. 
xvi. Clear – Histochoice – 30 seconds. 
 Mount with coverslip: 
i. Remove slides from rack and allowed to evaporate briefly on paper towel. 
ii. Add small drop of DPX mountant on to section. 
iii. Apply coverslip. 
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Representative Muscle Satellite Cell Immunofluorescence Materials and Protocol 
 
Pax7 Immunofluorescence Stain for human muscle satellite cells 
 
Summary 
Immunofluorescence stain to identify the Pax7 nuclear marker representing muscle 
satellite cells in human muscle tissue. Secondary fluorophore labelling provides 
identification in the TRITC channel. 
 
 
Equipment Instruments Materials 
 800W microwave 
 Pressure cooker (Nordic Ware 
Tender Cooker) 
 Slide staining rack 
 Histology staining dishes 
 Rack for slides to fit in dish 
 Sink with running cold tap water 
 Timer 
 Dry incubator set to 37°C. 
Disposable forceps 
Paper towel roll 
Coverslips 






 Pax7 (PAX7-s) 
primary antibody 
(DHSB) 
 Donkey anti-mouse 
TRITC (PA128625) 
(Fisher Scientific) 
 Vectashield with 
DAPI (H-1200) 
(Vector Labs) 







Antigen Retrieval Buffer 
Antigen unmasking solution (H-3300) 




Add unmasking solution to PBS and 
mix with magnetic stirrer. 
0.05% PBST 









A. Prepare solutions. 
 See ‘Solutions’ section for more detail. 
 Antigen retrieval buffer can be made in advance. 
 
B. Sectioning. 
 Cut tissue – cryostat (snap frozen – be careful with thawing). 
 Superfrost Plus slides preferred to prevent sections lifting during staining protocol. 
 Label slides with standard format in pencil: Date, Name, Experiment, Sample number etc. 
 
Staining. 
 Rack up slides to be stained. 
 Slides placed on histological staining tray for individual application and washing. 
 Post fix in methanol at -20°C  – 6 mins. 
 
 Antigen retrieval: 
i. Transfer slides to rack with spaces between slides. 
ii. Warm up Antigen Retrieval Buffer in pressure cooker inside microwave for 1 min full 
power (800W). 
iii. Remove Antigen Retrieval Buffer. 
iv. Immerse slide rack in Antigen Retrieval Buffer. 
v. Microwave for 5 mins full power. 
vi. Remove and let cool for 15 mins in sink. Release pressure, remove rack, and continue. 
 
 Immunofluorescent Staining 
i. Ring sections on slide with Hydrophobic ‘PAP’ pen. 
ii. PBST wash – 3 x 2 mins. 
iii. DAKO Protein BLOCK X090930 – 15 mins - ~80µl/slide – Room Temperature (RT). 
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- PRIMARY ANTIBODIES -   [75µl / section in dilutions as follows] 
Diluent – DAKO Ab Diluent s202230 
iv. Pax7 (1:6) 
 
v. Incubate Iα – +4°C – overnight 
 
vi. PBST – 3 x4 mins  
vii. DAKO Protein BLOCK – 15 mins - ~80µl/slide – Room Temperature (RT). 
 
- SECONDARY ANTIBODIES -  [75µl / section in dilutions as follows] 
Diluent – DAKO Ab Diluent s202230 
viii. DαM TRITC: (1:500) 
 
ix. Incubate IIα – +37°C – 60mins *DARK* 
 
x. PBST – 3 x4 mins *DARK* 
xi. PBS – 4 mins *DARK* 
 
 
 Mount with coverslip: 
i. Remove excess wash with kimwipe paper towel. 
ii. Add small drop of Vectashield with DAPI soft-mountant on to section. 
iii. Apply coverslip. Seal with transparent, translucent nail polish. 
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Muscle Heavy Chain 7 Immunofluorescence Materials and Protocol 
 




Immunofluorescence stain to identify muscle heavy chain 7 (MyH7) representing 
type 1 skeletal muscle fibres in human muscle tissue. Secondary fluorophore labelling 
provides identification in the TRITC channel. 
 
 
Equipment Instruments Materials 
 Slide staining rack 
 Timer 
 Dry incubator set to 37°C. 
Disposable forceps 
Paper towel roll 
Coverslips 






 MyH7 (SC53090) 
primary antibody 
(Santa Cruz) 
 Donkey anti-mouse 
TRITC (PA128625) 
(Fisher Scientific) 


















A. Prepare solutions. 
 See ‘Solutions’ section for more detail. 
 Antigen retrieval buffer can be made in advance. 
 
B. Sectioning. 
 Cut tissue – cryostat (snap frozen – be careful with thawing). 
 Superfrost Plus slides preferred to prevent sections lifting during staining protocol. 
 Label slides with standard format in pencil: Date, Name, Experiment, Sample number etc. 
 
Staining. 
 Rack up slides to be stained. 
 Slides placed on histological staining tray for individual application and washing. 
 Post fix in methanol at -20°C  – 6 mins. 
 
 Immunofluorescent Staining 
i. Ring sections on slide with Hydrophobic ‘PAP’ pen. 
ii. PBST wash – 3 x 2 mins. 
iii. DAKO Protein BLOCK X090930 – 15 mins - ~80µl/slide – Room Temperature (RT). 
 
 
- PRIMARY ANTIBODIES -   [75µl / section in dilutions as follows] 
Diluent – DAKO Ab Diluent s202230 
iv. MyH7 (1:500) 
 
v. Incubate Iα – +4°C – overnight 
 
vi. PBST – 3 x4 mins  
vii. DAKO Protein BLOCK – 15 mins - ~80µl/slide – Room Temperature (RT). 
 
- SECONDARY ANTIBODIES -  [75µl / section in dilutions as follows] 
Diluent – DAKO Ab Diluent s202230 
viii. DαM TRITC: (1:750) 
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ix. Incubate IIα – +37°C – 60mins *DARK* 
 
x. PBST – 3 x4 mins *DARK* 
xi. PBS – 4 mins *DARK* 
 
 
 Mount with coverslip: 
i. Remove excess wash with kimwipe paper towel. 
ii. Add small drop of Vectashield with DAPI soft-mountant on to section. 
iii. Apply coverslip. Seal with transparent, translucent nail polish. 
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Cytometry 
Flow Cytometry Materials and Protocol (Methodology Development) 
 
Flow cytometry protocol for human skeletal muscle cells 
 
Summary 
Flow cytometry procedure for identification of human muscle tissue.  
 
 




A. Prepare solutions. 
 See ‘Solutions’ section for more detail. 
 Antigen retrieval buffer can be made in advance. 
 
B. Thaw muscle sample and preparation for digestion. 
 Thaw sample to room temperature (RT). 
 Human skeletal muscle tissue sample size ~3mm3. 
 Trim sample of excess fat, tendon, connective tissue, fascia – and mechanically mince with 
scalpel. 
 
C. Sample Digestion 
 Add 0.1% Collagenase XI II (1mg/ml) in DMEM with high glucose, 10% FBS, 1% Pen/Strep for 
70 mins at +37°C. 
 Intermittent slow manual needle trituration (18G). 
 Spin 700rpm/250g for 5 mins. 
 Discard supernatant. 
 
D. Wash and Re-Suspend Digest in PBS 
 Add 1X PBS to resuspend. 
 Spin 700rpm/250g for 5 min. 
 Discard supernatant. 
 
E. Resuspend in PBS. 
 Add 1X PBS to resuspend. 
 Chill Eppendorf at +5°C on wet ice. 
 
F. Check for Live/Dead stain with Propidium Iodide. 
 Add Propidium Iodide. 







  253 / 309   
Molecular 
RNA Extraction Methodology 
 
RNeasy Plus Universal Mini Kit – RNA Extraction Method 
 
RNeasy Plus Universal Mini Procedure: 
 
Reagents / Equipment required: 
 Chloroform 
 Ethanol (70% and 96–100% - ‘molecular grade’)[not 
denatured] 
 Sterile, RNase-free pipet tips 
 For stabilization of RNA in tissues: liquid nitrogen 
and dry ice 
 1.5 ml or 2 ml microcentrifuge tubes 
 Microcentrifuge(s) (with rotor for 2 ml tubes) for 
centrifugation at 4°C and at room temperature (15–
25°C) 
 Equipment for tissue disruption and 
homogenization 
 
Starting material: No more than 30mg tissue. 
 
Prep materials: 
- All autoclaved consumables ready. 
o (Tips, eppendorfs; 0.5, 1.5, 2.0ml, 
homogenizer tips). 
- Dry ice bucket with stored samples. 
- Wet ice bucket. 
- All QIAGEN kit contents ready and laid out. Add 
EtOH for first use. 
Step  Instruction Technical notes 
1 Remove tissue from storage  
 
 
2 Cut up tissue if too large 30mg maximum, will clog otherwise and vastly 
reduce yield and quality. 
Don’t let thaw. 
Disposable scalpel on dry ice cooled glass tray 
and cut into small pieces. 
3 Disrupt and homogenize tissue: 
- Place into 900ul QIAzol 
- Use fresh homogenizer tip until 
uniformly homogenous. 
Homogenize on ice in separate ice bucket so 
‘splash’ doesn’t contaminate other samples in 
run. 




5 Add 100ul gDNA Eliminator Solution 
- Shake 15 secs 
 
6 Add 180ul chloroform  
- Shake 15 secs 
 




8 Centrifgue at 12000g for 15 mins at 4C  
 Continued on next page..  
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After centrifugation, the sample separates into 3 phases: an upper, colorless, aqueous 
phase containing RNA; a white interphase; and a lower, red, organic phase. For tissues with 
an especially high fat content, an additional, clear phase may be visible below the red, 
organic phase. The volume of the aqueous phase should be approximately 600 μl.  
9. Transfer the upper, aqueous phase (usually 600 μl) to a new microcentrifuge tube (not 
supplied). 
 
10. Add 1 volume (usually 600 μl) of 70% ethanol, and mix thoroughly by pipetting up and 
down. Do not centrifuge. Proceed immediately to step 11.  
Note: The volume of lysate may be less than 600 μl due to loss during homogenization and 
centrifugation.  
Precipitates may be visible after addition of ethanol. Resuspend precipitates completely by 
vigorous shaking, and proceed immediately to step 11.  
11. Transfer up to 700 μl of the sample to an RNeasy Mini spin column placed in a 2 ml 
collection tube (supplied). Close the lid gently, and centrifuge for 15 s at ≥8000 x g (≥10,000 
rpm) at room temperature (15–25°C). Discard the flow-through.*  
Reuse the collection tube in step 12.  
12. Repeat step 11 using the remainder of the sample. Discard the flow- through.*  
Reuse the collection tube in step 13.  
13. Add 700 μl Buffer RWT to the RNeasy spin column. Close the lid gently, and centrifuge for 
15 s at ≥8000 x g (≥10,000 rpm) to wash the membrane. Discard the flow-through.* 
Reuse the collection tube in step 14.  
After centrifugation, carefully remove the RNeasy spin column from the collection tube so 
that the column does not contact the flow-through. Be sure to empty the collection tube 
completely.*  
Note: Buffer RWT is supplied as a concentrate. Ensure that ethanol is added to Buffer RWT 
before use (see “Things to do before starting”, page 17).  
14. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 15 
s at ≥8000 x g (≥10,000 rpm) to wash the membrane. Discard the flow-through. 
Reuse the collection tube in step 15.  
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to Buffer RPE 
before use (see “Things to do before starting”, page 17).  
15. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 2 
min at ≥8000 x g (≥10,000 rpm) to wash the membrane.  
The long centrifugation dries the spin column membrane, ensuring that no ethanol is 
carried over during RNA elution. Residual ethanol may interfere with downstream 
reactions.  
Note: After centrifugation, carefully remove the RNeasy spin column from the collection 
tube so that the column does not contact the flow-through. Otherwise, carryover of ethanol 
will occur.  
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16. Optional: Place the RNeasy spin column in a new 2 ml collection tube (supplied), and 
discard the old collection tube with the flow- through. Close the lid gently, and centrifuge at 
full speed for 1 min.  
Perform this step to eliminate any possible carryover of Buffer RPE, or if residual flow-
through remains on the outside of the RNeasy spin column after step 15.  
17. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 μl 
RNase-free water directly to the spin column membrane. Close the lid gently. To elute the 
RNA, centrifuge for 1 min at ≥8000 x g (≥10,000 rpm).  
18. Repeat step 17 using another volume of RNase-free water, or using the eluate from step 17 
(if high RNA concentration is required). Reuse the collection tube from step 17.  
If using the eluate from step 17, the RNA yield will be 15–30% less than that obtained using 
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Trizol – RNA Extraction Method 
 
Working with RNA: 
 
- Always use gloves 
- Before starting, clean all working areas and tools (pipettes, forcepts, bottles 
etc) with 70/75% EtOH.and Trigene. 
- Autoclave all necessary consumables (tips etc.) 1-2 days in advance. 
- Always use filtertips for pipetting and be sure to wlays change tips between 
each sample. 
- Do not have RNA samples at room temperature for too long (except when 
they are in Trizol). Always have the tubes on wet ice, then dry ice before 
storage. 
- Be paranoid, RNases are everywhere – especially on skin to protect you from 
viruses. 
 
RNA protocol background: 
 
Trizol Reagent: A mono-phasic solution of phenol and gunanidine isothiocynate that 
disrupts cells and dissolves cell components while maintaining RNA integrity. 
Working with this solution can be carried out in 15-30°C. 
 
Chloroform: Used for phase separation into 3 phases: aqueous phase (containing 
RNA), inter-phase (containing protein) and organic phase (containing DNA). 
 
2-propanol/isopropanol: Use for precipitating the RNA from the acquired aqueous 
phase. 
 
75% EtOH: Used for washing the RNA pellet from phenol and isopropanol residues. 
 
Materials: 
- Scalpel per sample 
- Well plates or similar sterile area that can be chilled on dry ice during cutting 
up sample 
- Tips – P1000, P200, P10 
- Pipettes, gloves, lab coat etc. 
- Vortex 
- Centrifuge that can be cooled to 4°C 
- Ice buckets – one for wet ice, one for dry ice. 




- RNAse free water (‘molecular grade’) 
- Trizol (Life Tech/Thermo Fisher – 15596026) 
- Chloroform 
- Isopropanol molecular grade (Fisher Scientific – BP2618) 
- Molecular grade ethanol 
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Make up: 
o 75% EtOH 
RNA Extractions Procedure: 
 
1. Pre-cooling steps 
– Switch on cooling centrifuge so can reach target temperature. 
– Put all sterile cutting tools on dry ice (in packaging) so can reach low 
temp and not prematurely thaw sample. 
 
2. Homogenization 
– Collect samples. Approximate to similar sizes. Keep on dry ice. 
– Cut up samples as small as possible using scalpel. Be aware that 
sample fragments may contaminate neighbouring areas. Transfer to 
2ml sterile Eppendorf. 
– Different tools for each sample. 
– Transfer samples in eppendorfs to wet ice bucket. 
– Add 1ml of Trizol to the preweighed frozen sample and homogenize it 
directly for 1-2 mins. (Keep the first samples on ice while working 
through next coming samples). 
– Phenol waste into separate purple bin. 
– Incubate the sample(s) at room temperature for 5 mins. Triturate 15-
20x while incubating. 
 
3. Phase separation  
– Add 200ul chloroform (1:5), cap the tube securely and shake the tube 
vigourously for at least 15 secs. Incubate the sample at room 
temperature for 3 mins. 
– Centrifuge the sample at 12000g for 15 mins at 4°C. 
 
4. Precipitation 
– Carefully move the aqueous phase (about 600ul to a clean 1.5ml 
Eppendorf tube and add 500ul isopropanol. 
– Can also remove protein phase for later analysis. 
– Invert and vortex the sample briefly. [Now leave at RT for 10 mins if going 
to incubate o/n] 
 
Can now leave overnight or while preparing other samples at -20°C. Extending the 
precipitation stage can help increase RNA yield. 
 
– Put 75% EtOH and RNase free water on Dry/Wet ice so cold for later 
steps. 
– Incubate it at room temperature for 10 mins. 
– Centrifuge the sample at 12000g for 10 mins at 4°C. Place and remove 
the Eppendorf carefully orientated so aware of location of pellet. 
 
5. RNA wash 
– Pour out the suspension in one quick inversion without losing the 
pellet. Can hold upside down while drip dries but do not shake. Dab 
on kim-wipe. 
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– Add 1ml of cold 75% EtOH cooled on wet ice. 
– Vortex the sample briefly so the pellet is dislodged and centrifuge at 
7500g for 5 mins at 4°C. 
 
6. Dissolving RNA: 
– Pour out the suspension in one quick inversion without losing the 
pellet. 
– Air-dry the pellet for 2-15 min to completely remove remaining EtOH. 
Can also use kim-wipe to absorb EtOH from inside Eppendorf. Do not 
touch near or on pellet. 
– Add 30ul of DEPC/RNase free cold water and dissolve the pellet by 
triturating and vortexing. 
– Keep on wet ice. 
– Analyse with Nanodrop if required. Record ratios and weight yield. 
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RNA Analysis 
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Genomic DNA Elimination Protocol 
 (Protocol from Primer Design DNase kit – PrimerDesign Handbook HB12.01.03) 
 
Starting material: 
- RNA samples (e.g. from Trizol extactions) 




– Sterilise all necessary equipment. 
– Switch on heat blocks so can reach target temperature. 
i. One to 30°C, one to 55°C. 
ii. Check temperature with thermometer or probe. 
– Remove kit from freezer and leave on wet ice to warm up. 
– Remove samples from -80°C freezer and leave on wet ice to warm up. 
 
Kit to be used in following ratio: 
5µl 10X Precision DNase reaction buffer for every 50µl of RNA 
1µl Precision DNase enzyme can eliminate DNA from up to 100µl of RNA solution 
 
2. Combine 10X Precision DNase reaction buffer with Precision DNase enzyme 
in Eppendorf. 
 
3. Add to each sample, triturate briefly and vortex briefly 
 
4. Incubate for 10-30 [15] minutes at 30°C. (DNase Treatment) 
– Longer than 30 minutes degrades RNA 
 
5. Incubate for 5 minutes at 55°C. (DNase inactivation) 
 
6. Transfer to wet ice 
 
7. Proceed to Reverse Transcription step or store DNase treated RNA at < -20°C 
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Reverse Transcription Protocol 
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Quantitative Polymerase Chain Reaction 
GeNorm Reference Gene Selection Protocol – Methodology Development 
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Real-Time Polymerase Chain Reaction: Genes of Interest 
 














  265 / 309   







  266 / 309   
Appendix C: Additional Data 
 
Correlation Matrices 
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Biometric Data and Functional Outcome Matrices 
 
Comparison of 12-week post-op Sleep Data and Functional Outcomes 
 
  KOOS5 Index (12W) Leg Power Ratio (NLR 12W) ALF Score (12W) Daily Step Count (12W) 
Total Sleep at 12 weeks post-
op 
-0.380906 -0.278152 0.446539 -0.490387 
0.0663 0.1882 0.0287 0.0150 
Total Light Sleep at 12 weeks 
post-op 
0.234888 0.036572 0.102528 -0.023157 
0.2692 0.8653 0.6336 0.9145 
Total Deep Sleep at 12 weeks 
post-op 
-0.141470 0.228142 -0.175680 -0.106889 
0.5096 0.2836 0.4116 0.6191 
Total Light Sleep/ Total Deep 
Sleep at 12 weeks post-op 
0.205182 -0.104914 0.101075 -0.019747 
0.3361 0.6256 0.6384 0.9270 
 
Comparison of pre-op ROM and Functional Outcomes 
 
 
KOOS5 Index (PAC) Leg Power Ratio (NLR PAC) ALF Score (PAC) Daily Step Count (PAC) 
Fixed Flexion Pre-Op -0.168394 -0.09505 0.007118 0.359116 
0.2148 0.4819 0.9585 0.0658 
Fixed Flexion 12-months Post-
Op 
-0.057665 -0.18515 0.186885 0.076558 
0.7421 0.287 0.2899 0.7101 
Flexion <90 degrees Pre-Op -0.00512 -0.108214 0.282523 0.050123 
0.9699 0.423 0.0349 0.8039 
Flexion <90 degrees 12-
months post-op 
-0.37599 -0.308164 0.209054 0.011066 
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Multivariate Regression Raw Model Outputs 
 
Baseline Functional and PROM Contributing Factors to Surgical Outcomes 
 
12-week Leg Power 
Call: 
    
lm(formula = datTert$Leg.Power.Ratio..NLR.12W. ~ datTert$NLR_RatPAC +  
    datTert$ALF_PAC + datTert$KOOS5_PAC + datTert$EQ5D_InPAC) 
 
Residuals: 
    
Min 1Q Median 3Q Max 
-0.49622 -0.16336 -0.01235 0.13871 0.41386 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.7305 0.295723 5.852 1.23E-05 
datTert$NLR_RatPAC 0.565393 0.142492 3.968 0.000824 
datTert$ALF_PAC -0.027007 0.006843 -3.947 0.000866 
datTert$KOOS5_PAC -0.019103 0.007137 -2.677 0.014916 
datTert$EQ5D_InPAC 0.630489 0.296622 2.126 0.046874      
Residual standard error: 0.2526 on 19 degrees of freedom 
 
  (39 observations deleted due to missingness) 
  
Multiple R-squared:  0.7737, Adjusted R-squared:  0.726  
  
F-statistic: 16.24 on 4 and 19 DF,  p-value: 6.195e-06 
  
 
12-month Leg Power 
Call: 
    
lm(formula = datTert$Leg.Power.Ratio..NLR.12M. ~ datTert$NLR_RatPAC +  
    datTert$KOOS5_PAC + datTert$EQ5D_InPAC) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-0.90774 -0.16222 0.03238 0.28505 0.65083 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 0.904304 0.231076 3.913 0.000556 
datTert$NLR_RatPAC 1.068084 0.183372 5.825 3.36E-06 
datTert$KOOS5_PAC -0.022321 0.009172 -2.434 0.021849 
datTert$EQ5D_InPAC 1.189578 0.359453 3.309 0.002657      
Residual standard error: 0.4128 on 27 degrees of freedom 
 
  (32 observations deleted due to missingness) 
  
Multiple R-squared:  0.626, Adjusted R-squared:  0.5844  
   
F-statistic: 15.06 on 3 and 27 DF,  p-value: 5.901e-06 
  
 
12-week ALF Timed Functional Score 
Call: 
    
lm(formula = datTert$ALF.Score..12W. ~ datTert$ALF_PAC + datTert$STEP_PAC +  
    datTert$KOOS5_PAC + datTert$EQ5D_InPAC) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-9.431 -5.701 -2.757 3.378 24.64 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) -24.51 1.12E+01 -2.182 0.043451 
datTert$ALF_PAC 1.26 2.62E-01 4.829 0.000157 
datTert$STEP_PAC 0.00 9.35E-04 2.156 0.045745 
datTert$KOOS5_PAC 0.68 2.49E-01 2.74 0.013967 
datTert$EQ5D_InPAC -31.31 1.09E+01 -2.884 0.010305      
Residual standard error: 8.836 on 17 degrees of freedom 
  
  (41 observations deleted due to missingness) 
  
Multiple R-squared:  0.6301, Adjusted R-squared:  0.543  
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12-month ALF Timed Functional Score 
Call: 
    
lm(formula = datTert$ALF.Score..12M. ~ datTert$ALF_PAC + datTert$STEP_PAC +  
    datTert$KOOS5_PAC + datTert$EQ5D_InPAC) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-6.817 -3.19 -1.003 1.809 15.386 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) -21.66 7.87E+00 -2.753 0.0136 
datTert$ALF_PAC 1.17 1.78E-01 6.591 4.58E-06 
datTert$STEP_PAC 0.00 6.88E-04 2.122 0.0488 
datTert$KOOS5_PAC 0.47 1.72E-01 2.758 0.0134 
datTert$EQ5D_InPAC -18.79 7.40E+00 -2.539 0.0212      
Residual standard error: 5.998 on 17 degrees of freedom 
 
  (41 observations deleted due to missingness) 
  
Multiple R-squared:  0.7515, Adjusted R-squared:  0.693  
   
F-statistic: 12.85 on 4 and 17 DF,  p-value: 5.358e-05 
  
 
12-week Daily Step Count 
Call: 
    
lm(formula = datTert$Daily.Step.Count..12W. ~ datTert$ALF_PAC +  
 
    datTert$KOOS5_PAC + datTert$FJS_PAC) 
   
Residuals: 
    
Min 1Q Median 3Q Max 
-2815.8 -642.3 96.6 474 3585.1 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 7945.2 1586.59 5.008 7.81E-05 
datTert$ALF_PAC -116.63 44.89 -2.598 0.0176 
datTert$KOOS5_PAC -78.7 30.81 -2.554 0.0194 
datTert$FJS_PAC 128.21 24.91 5.146 5.74E-05      
Residual standard error: 1541 on 19 degrees of freedom 
  
  (40 observations deleted due to missingness) 
  
Multiple R-squared:  0.6249, Adjusted R-squared:  0.5657  
   
F-statistic: 10.55 on 3 and 19 DF,  p-value: 0.000264 
  
 
12-month Daily Step Count 
Call: 
    
lm(formula = datTert$Daily.Step.Count..12M. ~ datTert$ALF_PAC) 
 
Residuals: 
    
Min 1Q Median 3Q Max 
-3124.7 -1595.8 -728.4 884.4 7577.4 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 9217.92 1557.63 5.918 5.90E-06 
datTert$ALF_PAC -168.81 54.09 -3.121 0.00498      
Residual standard error: 2423 on 22 degrees of freedom 
 
  (39 observations deleted due to missingness) 
  
Multiple R-squared:  0.3068, Adjusted R-squared:  0.2753    
  
F-statistic: 9.738 on 1 and 22 DF,  p-value: 0.004979   
  
 
12-week KOOS5 PROM Score 
Call: 
    
lm(formula = datTert$KOOS5.Index..12W. ~ datTert$ALF_PAC + datTert$STEP_PAC +  
    datTert$FJS_PAC) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-32.817 -8.526 -0.22 12.076 22.355 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 98.324381 12.45167 7.896 1.01E-07 
datTert$ALF_PAC -1.190705 0.358201 -3.324 0.00322 
datTert$STEP_PAC -0.003406 0.001595 -2.135 0.04472 
datTert$FJS_PAC 0.592219 0.242146 2.446 0.02335      
Residual standard error: 15.27 on 21 degrees of freedom 
  
  (38 observations deleted due to missingness) 
  
Multiple R-squared:   0.44, Adjusted R-squared:   0.36  
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12-month KOOS5 PROM Score 
Call: 
    
lm(formula = datTert$KOOS5.Index..12M. ~ datTert$ALF_PAC) 
 
Residuals: 
    
Min 1Q Median 3Q Max 
-53.842 -9.595 0.734 16.175 40.504 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 72.3599 7.0675 10.238 5.53E-13 
datTert$ALF_PAC -0.1412 0.205 -0.689 0.495      
Residual standard error: 20.61 on 42 degrees of freedom 
 
  (19 observations deleted due to missingness) 
  
Multiple R-squared:  0.01116, Adjusted R-squared:  -0.01238    
  
F-statistic: 0.4741 on 1 and 42 DF,  p-value: 0.4949 
  
 
Baseline Demographic, Lifestyle, and Comorbidity Contributing Factors to Surgical 
Outcome 
 
12-week Leg Power 
Call: 
    
lm(formula = datReg$Leg.Power.Ratio..NLR.12W. ~ datReg$DHx.NSAIDs +  
    datReg$Peak.Phys..Act..Tegner) 
   
Residuals: 
    
Min 1Q Median 3Q Max 
-1.10677 -0.26178 -0.01102 0.35984 0.65815 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 0.44464 0.2114 2.103 0.0457 
datReg$DHx.NSAIDs 0.30715 0.19509 1.574 0.128 
datReg$Peak.Phys..Act..Tegner 0.07381 0.02903 2.543 0.0176                
Residual standard error: 0.4219 on 25 degrees of freedom 
 
  (35 observations deleted due to missingness) 
  
Multiple R-squared:  0.2494, Adjusted R-squared:  0.1893  
 
F-statistic: 4.153 on 2 and 25 DF,  p-value: 0.02772 
    
 
12-month Leg Power 
Call: 
    
lm(formula = datReg$Leg.Power.Ratio..NLR.12M. ~ datReg$DHx.Opiates +  
    datReg$Alcohol.Hx + datReg$Peak.Phys..Act..Tegner) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-1.21201 -0.36588 -0.01828 0.33264 1.46933 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.31956 0.36299 3.635 0.000995 
datReg$DHx.Opiates -0.34643 0.20685 -1.675 0.104037 
datReg$Alcohol.Hx -0.1926 0.12638 -1.524 0.137646 
datReg$Peak.Phys..Act..Tegner 0.07894 0.0358 2.205 0.035023      
Residual standard error: 0.561 on 31 degrees of freedom 
 
  (28 observations deleted due to missingness) 
  
Multiple R-squared:  0.2175, Adjusted R-squared:  0.1418  
 
F-statistic: 2.873 on 3 and 31 DF,  p-value: 0.05211 
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12-week ALF Timed Functional Score 
Call: 
    
lm(formula = datReg$ALF.Score..12W. ~ datReg$DHx.Paracetamol +  
 
    datReg$DHx.NSAIDs + datReg$DHx.Opiates) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-20.257 -8.355 -0.475 3.149 43.521 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 31.308 5.161 6.067 2.89E-06 
datReg$DHx.Paracetamol -8.488 5.843 -1.453 0.159 
datReg$DHx.NSAIDs -10.979 6.713 -1.635 0.115 
datReg$DHx.Opiates 6.989 5.605 1.247 0.224           
Residual standard error: 14.31 on 24 degrees of freedom 
 
  (35 observations deleted due to missingness) 
  
Multiple R-squared:  0.1674, Adjusted R-squared:  0.06328  
 
F-statistic: 1.608 on 3 and 24 DF,  p-value: 0.2137 
    
 
12-month ALF Timed Functional Score 
Call: 
    
lm(formula = datReg$ALF.Score..12M. ~ datReg$DHx.Opiates + datReg$Man..Lab..Job.Hist. +  
    datReg$Alcohol.Hx + datReg$SIMD.Quint) 
  
     
Residuals: 
    
Min 1Q Median 3Q Max 
-13.837 -5.708 -1.196 5.8 18.715 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 11.751 7.313 1.607 0.1186 
datReg$DHx.Opiates 5.533 3.757 1.473 0.1512 
datReg$Man..Lab..Job.Hist. 6.878 3.712 1.853 0.0738 
datReg$Alcohol.Hx 5.187 2.098 2.472 0.0193 
datReg$SIMD.Quint -2.05 1.384 -1.481 0.149           
Residual standard error: 9.409 on 30 degrees of freedom 
 
  (28 observations deleted due to missingness) 
  
Multiple R-squared:  0.2796, Adjusted R-squared:  0.1835  
 
F-statistic: 2.911 on 4 and 30 DF,  p-value: 0.03796 
    
 
12-week Daily Step Count 
Call: 
    
lm(formula = datReg$Daily.Step.Count..12W. ~ datReg$Age.Groups +  
    datReg$SIMD.Quint) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-2767.2 -1264 -214 768.9 6425 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 3440.9 1676.8 2.052 0.0528 
datReg$Age.Groups -657.7 261.1 -2.519 0.0199 
datReg$SIMD.Quint 850.1 400.2 2.124 0.0457      
Residual standard error: 2012 on 21 degrees of freedom 
  
  (39 observations deleted due to missingness) 
  
Multiple R-squared:  0.2936, Adjusted R-squared:  0.2263  
 
F-statistic: 4.363 on 2 and 21 DF,  p-value: 0.02602 
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12-month Daily Step Count 
Call: 
    
lm(formula = datReg$Daily.Step.Count..12M. ~ datReg$Co.morb..Hyp..Ten. +  
    datReg$DHx.Paracetamol + datReg$Smoking.Hx) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-3160.9 -1907.5 -453.8 878 6128.6 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 4293 831.2 5.165 4.07E-05 
datReg$Co.morb..Hyp..Ten. -2303.3 1028.3 -2.24 0.036 
datReg$DHx.Paracetamol 2975.6 1084.5 2.744 0.0122 
datReg$Smoking.Hx -2307.3 1071.2 -2.154 0.043      
Residual standard error: 2366 on 21 degrees of freedom 
  
  (38 observations deleted due to missingness) 
  
Multiple R-squared:  0.3697, Adjusted R-squared:  0.2797  
 
F-statistic: 4.106 on 3 and 21 DF,  p-value: 0.01934 
    
 
12-week KOOS5 PROM Score 
Call: 
    
lm(formula = datReg$KOOS5.Index..12W. ~ datReg$K.L.OA.Score +  
 
    datReg$Co.morb..Diab. + datReg$Alcohol.Hx) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-33.243 -10.967 -1.043 10.407 46.293 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 63.916 8.611 7.423 3.16E-09 
datReg$K.L.OA.Score 6.654 3.025 2.199 0.0333 
datReg$Co.morb..Diab. -11.987 7.394 -1.621 0.1123 
datReg$Alcohol.Hx -6.361 2.795 -2.276 0.0279      
Residual standard error: 16.26 on 43 degrees of freedom 
 
  (16 observations deleted due to missingness) 
  
Multiple R-squared:  0.2009, Adjusted R-squared:  0.1452  
 
F-statistic: 3.604 on 3 and 43 DF,  p-value: 0.02079 
    
 
12-month KOOS5 PROM Score 
Call: 
    
lm(formula = datReg$KOOS5.Index..12M. ~ datReg$Sex + datReg$BMI.Groups +  
    datReg$K.L.OA.Score + datReg$DHx.Opiates + datReg$Peak.Phys..Act..Tegner) 
Residuals: 
    
Min 1Q Median 3Q Max 
-33.849 -9.291 1.231 10.384 33.339 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 76.129 10.004 7.61 2.30E-09 
datReg$Sex -9.725 5.621 -1.73 0.09113 
datReg$BMI.Groups -3.287 2.221 -1.48 0.146544 
datReg$K.L.OA.Score 11.435 3.195 3.579 0.000905 
datReg$DHx.Opiates -7.943 5.309 -1.496 0.142294 
datReg$Peak.Phys..Act..Tegner -1.652 1.007 -1.641 0.108431      
Residual standard error: 16.58 on 41 degrees of freedom 
 
  (16 observations deleted due to missingness) 
  
Multiple R-squared:  0.3881, Adjusted R-squared:  0.3134  
 
F-statistic:   5.2 on 5 and 41 DF,  p-value: 0.0008715 
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Baseline Physiological Contributing Factors to Surgical Outcomes 
 
12-week Leg Power 
Call: 
    
lm(formula = datReg$Leg.Power.Ratio..NLR.12W. ~ datReg$Fib..Type.Ratio +  
    datReg$Myf5.Group) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-0.84526 -0.36122 -0.01384 0.3204 0.84332 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.0426 0.3441 3.03 0.00719 
datReg$Fib..Type.Ratio -0.3607 0.3472 -1.039 0.31268 
datReg$Myf5.Group 0.1816 0.1501 1.21 0.2419      
Residual standard error: 0.4967 on 18 degrees of freedom 
 
  (42 observations deleted due to missingness) 
  
Multiple R-squared:  0.1244, Adjusted R-squared:  0.02712  
 
F-statistic: 1.279 on 2 and 18 DF,  p-value: 0.3025 
  
 
12-month Leg Power 
Call: 
    
lm(formula = datReg$Leg.Power.Ratio..NLR.12M. ~ datReg$Fib..Type.Ratio +  
    datReg$MyoD.Group + datReg$CDK2NA.Group) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-1.2158 -0.25987 0.05412 0.24891 0.80398 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.4519 0.3869 3.753 0.0011 
datReg$Fib..Type.Ratio -0.9053 0.3532 -2.563 0.01773 
datReg$MyoD.Group 0.4709 0.1618 2.911 0.00811 
datReg$CDK2NA.Group -0.4165 0.232 -1.795 0.08639      
Residual standard error: 0.5271 on 22 degrees of freedom 
 
  (37 observations deleted due to missingness) 
  
Multiple R-squared:  0.3793, Adjusted R-squared:  0.2946  
 
F-statistic:  4.48 on 3 and 22 DF,  p-value: 0.01337 
  
 
12-week ALF Timed Functional Score 
Call: 
    
lm(formula = datReg$ALF.Score..12W. ~ datReg$Myog.Group + datReg$TNF.Group) 
Residuals: 
    
Min 1Q Median 3Q Max 
-13.386 -6.396 -1.657 1.423 41.154 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 23.763 6.095 3.899 0.000772 
datReg$Myog.Group 2.28 1.609 1.417 0.170453 
datReg$TNF.Group -4.306 3.563 -1.209 0.239642      
Residual standard error: 12.1 on 22 degrees of freedom 
  
  (38 observations deleted due to missingness) 
  
Multiple R-squared:  0.1002, Adjusted R-squared:  0.01836  
 
F-statistic: 1.224 on 2 and 22 DF,  p-value: 0.3132 
  
 
12-month ALF Timed Functional Score 
Call: 
    
lm(formula = datReg$ALF.Score..12M. ~ datReg$Fib..Type.Ratio +  
 
    datReg$MyoD.Group + datReg$Myf5.Group) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-16.694 -5.659 -2.415 4.504 28.098 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 19.649 7.186 2.734 0.0121 
datReg$Fib..Type.Ratio 6.612 6.885 0.96 0.3473 
datReg$MyoD.Group -2.059 3.059 -0.673 0.5078 
datReg$Myf5.Group 1.847 2.424 0.762 0.4541      
Residual standard error: 10.14 on 22 degrees of freedom 
 
  (37 observations deleted due to missingness) 
  
Multiple R-squared:  0.05833, Adjusted R-squared:  -0.07008  
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12-week Daily Step Count 
Call: 
    
lm(formula = datReg$Daily.Step.Count..12W. ~ datReg$CDK2NA.Group) 
Residuals: 
    
Min 1Q Median 3Q Max 
-2647.9 -1061.6 -272.1 367.6 7909.4 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 5065 1352 3.747 0.00137 
datReg$CDK2NA.Group -1023 1095 -0.935 0.36176      
Residual standard error: 2341 on 19 degrees of freedom 
  
  (42 observations deleted due to missingness) 
  
Multiple R-squared:  0.04394, Adjusted R-squared:  -0.006375  
 
F-statistic: 0.8733 on 1 and 19 DF,  p-value: 0.3618 
  
 
12-month Daily Step Count 
Call: 
    
lm(formula = datReg$Daily.Step.Count..12M. ~ datReg$Myog.Group) 
 
Residuals: 
    
Min 1Q Median 3Q Max 
-4362.4 -1112.2 -215.4 1231 7140.6 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 6901.2 1185 5.824 8.83E-06 
datReg$Myog.Group -644.5 330.9 -1.948 0.0649      
Residual standard error: 2633 on 21 degrees of freedom 
  
  (40 observations deleted due to missingness) 
  
Multiple R-squared:  0.153, Adjusted R-squared:  0.1127  
 
F-statistic: 3.794 on 1 and 21 DF,  p-value: 0.06493 
  
 
12-week KOOS5 PROM Score 
Call: 
    
lm(formula = datReg$KOOS5.Index..12W. ~ datReg$CDK2NA.Group +  
    datReg$IL6.Group) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-37.86 -10.72 2.34 13.64 25.09 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 63.971 9.591 6.67 6.90E-08 
datReg$CDK2NA.Group 6.972 4.385 1.59 0.12 
datReg$IL6.Group -7.333 5.617 -1.306 0.2      
Residual standard error: 17.8 on 38 degrees of freedom 
  
  (22 observations deleted due to missingness) 
  
Multiple R-squared:  0.1018, Adjusted R-squared:  0.05448  
 
F-statistic: 2.152 on 2 and 38 DF,  p-value: 0.1302 
  
 
12-month KOOS5 PROM Score 
Call: 
    
lm(formula = datReg$KOOS5.Index..12M. ~ datReg$Myog.Group + datReg$TNF.Group) 
Residuals: 
    
Min 1Q Median 3Q Max 
-48.155 -8.287 -0.817 10.725 33.073 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 65.774 7.217 9.114 1.66E-11 
datReg$Myog.Group 4.299 1.612 2.667 0.0108 
datReg$TNF.Group -7.106 3.577 -1.986 0.0535      
Residual standard error: 17.65 on 42 degrees of freedom 
 
  (18 observations deleted due to missingness) 
  
Multiple R-squared:  0.1827, Adjusted R-squared:  0.1437  
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lm(formula = datReg$Pax7.Group ~ datReg$Age.Groups + datReg$Dominant.Leg.Operated +  
    datReg$Co.morb..Diab. + datReg$DHx.NSAIDs) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-2.6765 -0.7889 0.1727 0.9077 1.8919 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 2.78776 0.48709 5.723 6.62E-07 
datReg$Age.Groups 0.20791 0.08201 2.535 0.0146 
datReg$Dominant.Leg.Operated -0.71921 0.33893 -2.122 0.039 
datReg$Co.morb..Diab. -1.00705 0.51606 -1.951 0.0569 
datReg$DHx.NSAIDs 0.6808 0.39682 1.716 0.0927      
Residual standard error: 1.231 on 48 degrees of freedom 
    
  (10 observations deleted due to missingness) 
    
Multiple R-squared:  0.2668, Adjusted R-squared:  0.2057  
 
F-statistic: 4.367 on 4 and 48 DF,  p-value: 0.004309 




    
lm(formula = datReg$MyoD.Group ~ datReg$Age.Groups + datReg$Arth..Hx.Contra..Knee +  
    datReg$DHx.NSAIDs + datReg$Alcohol.Hx) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-1.41793 -0.54738 -0.03453 0.45262 1.58835 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.01372 0.37948 2.671 0.0102 
datReg$Age.Groups 0.08766 0.04738 1.85 0.0702 
datReg$Arth..Hx.Contra..Knee -0.35141 0.2079 -1.69 0.0972 
datReg$DHx.NSAIDs 0.47184 0.23157 2.038 0.0469 
datReg$Alcohol.Hx 0.22339 0.11153 2.003 0.0506      
Residual standard error: 0.7262 on 50 degrees of freedom 
    
  (8 observations deleted due to missingness) 
    
Multiple R-squared:  0.2102, Adjusted R-squared:  0.147  
 
F-statistic: 3.326 on 4 and 50 DF,  p-value: 0.01717 




    
lm(formula = datReg$Myf5.Group ~ datReg$Co.morb..Hyp..Ten. +  
 
    datReg$Arth..Hx.Contra..Knee + datReg$DHx.Paracetamol + datReg$DHx.NSAIDs +  
    datReg$Man..Lab..Job.Hist.) 
   
Residuals: 
    
Min 1Q Median 3Q Max 
-0.70502 -0.50294 -0.2987 0.06062 2.31177 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.26433 0.28165 4.489 4.22e-05 *** 
datReg$Co.morb..Hyp..Ten. 0.25541 0.23859 1.07 0.29 
datReg$Arth..Hx.Contra..Knee -0.2692 0.22739 -1.184 0.242 
datReg$DHx.Paracetamol 0.18365 0.24567 0.748 0.458 
datReg$DHx.NSAIDs 0.18529 0.26331 0.704 0.485 
datReg$Man..Lab..Job.Hist. 0.06875 0.23423 0.294 0.77      
Residual standard error: 0.7906 on 50 degrees of freedom 
    
  (7 observations deleted due to missingness) 
    
Multiple R-squared:  0.06852, Adjusted R-squared:  -0.02463  
 
F-statistic: 0.7356 on 5 and 50 DF,  p-value: 0.6003 
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Myog 
Call: 
    
lm(formula = datReg$Myog.Group ~ datReg$Age.Groups + datReg$Alcohol.Hx) 
Residuals: 
    
Min 1Q Median 3Q Max 
-3.3506 -1.3336 0.2453 1.2104 2.5169 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 0.71148 0.68912 1.032 0.30655 
datReg$Age.Groups 0.24544 0.09838 2.495 0.01575 
datReg$Alcohol.Hx 0.64035 0.23413 2.735 0.00847      
Residual standard error: 1.535 on 53 degrees of freedom 
    
  (7 observations deleted due to missingness) 
    
Multiple R-squared:  0.2075, Adjusted R-squared:  0.1776  
 
F-statistic: 6.939 on 2 and 53 DF,  p-value: 0.002105 




    
lm(formula = datReg$CDK2NA.Group ~ datReg$Age.Groups + datReg$Arth..Hx.Contra..Knee) 
Residuals: 
    
Min 1Q Median 3Q Max 
-0.86213 -0.29944 -0.13563 0.08945 1.47548 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 0.84929 0.18981 4.474 3.99E-05 
datReg$Age.Groups 0.11254 0.03208 3.508 0.000917 
datReg$Arth..Hx.Contra..Knee -0.27635 0.13255 -2.085 0.041828      
Residual standard error: 0.4868 on 54 degrees of freedom 
    
  (6 observations deleted due to missingness) 
    
Multiple R-squared:  0.2677, Adjusted R-squared:  0.2406  
 
F-statistic: 9.872 on 2 and 54 DF,  p-value: 0.0002219 




    
lm(formula = datReg$IL6.Group ~ datReg$Age.Groups + datReg$BMI.Groups +  
    datReg$Co.morb..Diab. + datReg$Peak.Phys..Act..Tegner + datReg$SIMD.Quint) 
Residuals: 
    
Min 1Q Median 3Q Max 
-0.6876 -0.3769 -0.1353 0.1461 1.2673 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.38064 0.42082 3.281 0.00195 
datReg$Age.Groups 0.07632 0.03809 2.004 0.05088 
datReg$BMI.Groups -0.13185 0.06425 -2.052 0.04574 
datReg$Co.morb..Diab. 0.32226 0.24406 1.32 0.19309 
datReg$Peak.Phys..Act..Tegner 0.03942 0.02919 1.351 0.18322 
datReg$SIMD.Quint -0.10257 0.06207 -1.653 0.1051      
Residual standard error: 0.5341 on 47 degrees of freedom 
    
  (10 observations deleted due to missingness) 
    
Multiple R-squared:  0.236, Adjusted R-squared:  0.1547  
 
F-statistic: 2.903 on 5 and 47 DF,  p-value: 0.02302 




    
lm(formula = datReg$TNF.Group ~ datReg$Age.Groups + datReg$Arth..Hx.Contra..Knee +  
    datReg$DHx.NSAIDs) 
    
Residuals: s: 
   
Min 1Q Median 3Q Max 
-0.9965 -0.5121 -0.2324 0.4389 1.8395 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 1.23738 0.27153 4.557 3.01E-05 
datReg$Age.Groups 0.07195 0.04435 1.622 0.1106 
datReg$Arth..Hx.Contra..Knee -0.36469 0.1897 -1.922 0.0598 
datReg$DHx.NSAIDs 0.39935 0.21425 1.864 0.0678      
Residual standard error: 0.6962 on 54 degrees of freedom 
    
  (5 observations deleted due to missingness) 
    
Multiple R-squared:  0.1398, Adjusted R-squared:  0.09201  
 
F-statistic: 2.925 on 3 and 54 DF,  p-value: 0.04194 
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Fibre Type Ratio 
Call: 
    
lm(formula = datReg$Fib..Type.Ratio ~ datReg$Sex + datReg$Dominant.Leg.Operated +  
    datReg$DHx.Paracetamol + datReg$SIMD.Quint) 
  
Residuals: 
    
Min 1Q Median 3Q Max 
-0.67821 -0.15617 -0.00434 0.11051 0.73845 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 0.81524 0.1199 6.8 2.25E-08 
datReg$Sex -0.16818 0.07311 -2.3 0.026235 
datReg$Dominant.Leg.Operated 0.14298 0.07275 1.965 0.055691 
datReg$DHx.Paracetamol -0.31422 0.0877 -3.583 0.000845 
datReg$SIMD.Quint 0.04666 0.02824 1.652 0.105577      
Residual standard error: 0.2529 on 44 degrees of freedom 
    
  (14 observations deleted due to missingness) 
    
Multiple R-squared:  0.3247, Adjusted R-squared:  0.2633  
 
F-statistic:  5.29 on 4 and 44 DF,  p-value: 0.001443 
    
 
Type 1 Fibre Diameter 
Call: 
    
lm(formula = datReg$Type.1.Fib..Diam. ~ datReg$Age.Groups + datReg$Arth..Hx.Contra..Knee +  
    datReg$DHx.NSAIDs + datReg$Peak.Phys..Act..Tegner) 
 
Residuals: 
    
Min 1Q Median 3Q Max 
-21.2617 -5.8431 -0.6311 6.2054 24.5262 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 80.2624 7.3178 10.968 2.66E-14 
datReg$Age.Groups -2.0478 0.7363 -2.781 0.00788 
datReg$Arth..Hx.Contra..Knee -7.1156 3.3728 -2.11 0.04047 
datReg$DHx.NSAIDs 6.237 3.4098 1.829 0.07401 
datReg$Peak.Phys..Act..Tegner -1.3479 0.6209 -2.171 0.03523      
Residual standard error: 10.48 on 45 degrees of freedom 
    
  (13 observations deleted due to missingness) 
    
Multiple R-squared:  0.2697, Adjusted R-squared:  0.2048  
 
F-statistic: 4.155 on 4 and 45 DF,  p-value: 0.005996 
    
 
Type 2 Fibre Diameter 
Call: 
    
lm(formula = datReg$Type.2.Fib..Diam. ~ datReg$BMI.Groups + datReg$BEI.Groups +  
    datReg$SIMD.Quint) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-23.717 -6.753 -1.978 6.043 27.413 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 74.725 8.209 9.103 2.15E-11 
datReg$BMI.Groups 3.581 2.274 1.575 0.123 
datReg$BEI.Groups -2.822 1.324 -2.131 0.0391 
datReg$SIMD.Quint -2.471 1.456 -1.697 0.0973      
Residual standard error: 12.32 on 41 degrees of freedom 
    
  (18 observations deleted due to missingness) 
    
Multiple R-squared:  0.1751, Adjusted R-squared:  0.1148  
 
F-statistic: 2.902 on 3 and 41 DF,  p-value: 0.04627 
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Overarching Combined Multivariate Model Contributing Factors to Functional Surgical 
Outcomes 
12-month ALF Timed Functional Score 
Call: 
    
lm(formula = datTert$ALF.Score..12M. ~ datTert$Alcohol.Hx + datTert$ALF_PAC) 
Residuals: 
    
Min 1Q Median 3Q Max 
-8.8339 -2.9548 -0.9338 2.1901 24.2291 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) -8.1582 4.7311 -1.724 0.09493 
datTert$Alcohol.Hx 4.3411 1.3649 3.181 0.00341 
datTert$ALF_PAC 0.7982 0.1259 6.338 5.45E-07      
Residual standard error: 6.41 on 30 degrees of freedom 
  
  (30 observations deleted due to missingness) 
  
Multiple R-squared:  0.6288, Adjusted R-squared:  0.6041  
   
F-statistic: 25.41 on 2 and 30 DF,  p-value: 3.497e-07 
  
 
12-week Daily Step Count 
Call: 
    
lm(formula = datTert$Daily.Step.Count..12W. ~ datTert$Age.Groups +  
    datTert$FJS_PAC) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-3824.2 -859.4 -7.8 937.2 3594.3 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 4945.29 978.6 5.053 5.28E-05 
datTert$Age.Groups -532.82 204.63 -2.604 0.016577 
datTert$FJS_PAC 99.79 23.55 4.237 0.000369      
Residual standard error: 1628 on 21 degrees of freedom 
 
  (39 observations deleted due to missingness) 
  
Multiple R-squared:  0.5373, Adjusted R-squared:  0.4932    
  
F-statistic: 12.19 on 2 and 21 DF,  p-value: 0.0003061 
  
 
12-month Daily Step Count 
Call: 
    
lm(formula = datTert$Daily.Step.Count..12M. ~ datTert$DHx.Paracetamol +  
    datTert$Co.morb..Hyp..Ten. + datTert$Smoking.Hx + datTert$ALF_PAC) 
Residuals: 
    
Min 1Q Median 3Q Max 
-3414.7 -1474.3 -223.1 1284 5724 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 7690.96 1864.49 4.125 0.000576 
datTert$DHx.Paracetamol 2199.14 1183.17 1.859 0.078634 
datTert$Co.morb..Hyp..Ten. -2047.83 1005.21 -2.037 0.055803 
datTert$Smoking.Hx -2045.83 1068.52 -1.915 0.07072 
datTert$ALF_PAC -110.12 56.03 -1.965 0.064157      
Residual standard error: 2216 on 19 degrees of freedom 
 
  (39 observations deleted due to missingness) 
  
Multiple R-squared:  0.4991, Adjusted R-squared:  0.3937  
   
F-statistic: 4.734 on 4 and 19 DF,  p-value: 0.00806 
  
 
12-month KOOS5 PROM Score 
Call: 
    
lm(formula = datTert$KOOS5.Index..12M. ~ datTert$K.L.OA.Score +  
 
    datTert$Myog.Group) 
    
Residuals: 
    
Min 1Q Median 3Q Max 
-41.347 -10.914 1.665 11.213 31.837 
Coefficients: 
    
 
Estimate Std. Error t value Pr(>|t|) 
(Intercept) 41.251 7.117 5.796 7.79E-07 
datTert$K.L.OA.Score 9.887 2.917 3.389 0.00153 
datTert$Myog.Group 3.179 1.475 2.156 0.03688      
Residual standard error: 16.36 on 42 degrees of freedom 
 
  (18 observations deleted due to missingness) 
  
Multiple R-squared:  0.2979, Adjusted R-squared:  0.2645  
  
F-statistic:  8.91 on 2 and 42 DF,  p-value: 0.0005949 
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Indicative Directional Model Factor Contributions Charts 
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Appendix D: Conference Paper Abstracts 
 
British Orthopaedic Research Society (BORS) 2018 
University of Leeds, United Kingdom 
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European Orthopaedic Research Society (EORS) 2018 
Galway, Ireland 
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Orthopaedic Research Society (ORS) 2019 
Austin, TX, United States of America 
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International Combined Meeting of Orthopaedic Research Societies (ICORS) 2019 
Montréal, Canada 





  286 / 309   
References 
 
1.  Simpson AHR, Hamilton DF, Beard DJ, Barker KL, Wilton T, Hutchison JD, et al. Targeted 
rehabilitation to improve outcome after total knee replacement (TRIO): study protocol for a 
randomised controlled trial. Trials [Internet]. 2014;15(1):44. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3911957&tool=pmcentrez&ren
dertype=abstract 
2.  Hamilton DF, Lane J V, Gaston P, Patton JT, Macdonald D, Simpson AHRW, et al. What 
determines patient satisfaction with surgery? A prospective cohort study of 4709 patients 
following total joint replacement. BMJ Open [Internet]. 2013 Apr 9;3(4):e002525. Available 
from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2012-002525 
3.  Stevens-Lapsley JE, Balter JE, Kohrt WM, Eckhoff DG. Quadriceps and hamstrings muscle 
dysfunction after total knee arthroplasty. Clin Orthop Relat Res. 2010;468(9):2460–8.  
4.  Rodriguez-Merchan EC, Oussedik S. Total Knee Arthroplasty: A Comprehensive Guide 
[Internet]. Rodríguez-Merchán EC, Oussedik S, editors. Vol. 10. Cham: Springer International 
Publishing; 2015. 1 p. Available from: 
https://books.google.com/books?id=yujV5S_TP_UC&pgis=1 
5.  Minns Lowe CJ, Barker KL, Dewey M, Sackley CM. Effectiveness of physiotherapy exercise after 
knee arthroplasty for osteoarthritis: systematic review and meta-analysis of randomised 
controlled trials. BMJ [Internet]. 2007;335(7624):812. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2034713&tool=pmcentrez&ren
dertype=abstract 
6.  Mizner RL, Snyder-Mackler L. Altered loading during walking and sit-to-stand is affected by 
quadriceps weakness after total knee arthroplasty. J Orthop Res. 2005;23(5):1083–90.  
7.  Lamb SE, Frost H. Recovery of mobility after knee arthroplasty: Expected rates and influencing 
factors. J Arthroplasty. 2003;18(5):575–82.  
8.  Lungu E, Desmeules F, Dionne CE, Belzile EL, Vendittoli P-A. Prediction of poor outcomes six 
months following total knee arthroplasty in patients awaiting surgery. BMC Musculoskelet 
Disord [Internet]. 2014;15:299. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4247215&tool=pmcentrez&ren
dertype=abstract 
9.  Sakuma K, Yamaguchi A. Molecular and Cellular Mechanism of Muscle Regeneration. Skelet 
Muscle-From Myogenes to Clin relations. 2012;3–30.  
10.  Bareja A, Billin AN. Satellite cell therapy - from mice to men. Skelet Muscle [Internet]. 
2013;3(1):2. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3579761&tool=pmcentrez&ren
dertype=abstract 
11.  Fleck SJ, Kraemer WJ. Designing Resistance Training Programs. 2004.  
12.  Chang NC, Chevalier FP, Rudnicki MA. Satellite Cells in Muscular Dystrophy – Lost in Polarity. 
Trends Mol Med [Internet]. 2016 Jun;22(6):479–96. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S1471491416300065 
13.  Silverstein P. Smoking and wound healing. Am J Med. 1992;93(1 SUPPL. 1):22–4.  
14.  Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res [Internet]. 2010;89(3):219–29. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20139336 
15.  Kwok IHY, Paton B, Haddad FS. Does Pre-Operative Physiotherapy Improve Outcomes in 
Primary Total Knee Arthroplasty? - A Systematic Review. J Arthroplasty [Internet]. 
2015;30(9):1657–63. Available from: http://dx.doi.org/10.1016/j.arth.2015.04.013 
16.  Pu Q, Abduelmula A, Masyuk M, Theiss C, Schwandulla D, Hans M, et al. The dermomyotome 
ventrolateral lip is essential for the hypaxial myotome formation. BMC Dev Biol [Internet]. 
2013;13(1):1. Available from: BMC Developmental Biology 
17.  Zhao P, Hoffman EP. Embryonic Myogenesis Pathways in Muscle Regeneration. Dev Dyn. 
2004;229(2):380–92.  
18.  Asfour HA, Allouh MZ, Said RS. Myogenic regulatory factors: The orchestrators of myogenesis 
after 30 years of discovery. Exp Biol Med. 2018;243(2):118–28.  
19.  Hernández-Hernández JM, García-González EG, Brun CE, Rudnicki MA. The Myogenic 
Regulatory Factors, Determinants of Muscle Development, Cell Identity and Regeneration. 
Semin Cell Dev Biol [Internet]. 2017; Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29127045 
References 
  287 / 309   
20.  Netter FH. Musculoskeletal System, Volume 6, Part III - Biology and Systemic Diseases. 2nd ed. 
Iannotti JP, Parker R, editors. 2013.  
21.  Herzog W, Schappacher G, DuVall M, Leonard TR, Herzog JA. Residual Force Enhancement 
Following Eccentric Contractions: A New Mechanism Involving Titin. Physiology [Internet]. 
2016;31(4):300–12. Available from: 
http://physiologyonline.physiology.org/lookup/doi/10.1152/physiol.00049.2014 
22.  Herzog W, Powers K, Johnston K, Duvall M. A new paradigm for muscle contraction. Front 
Physiol. 2015;6(MAY):1–11.  
23.  Eckels EC, Tapia-Rojo R, Rivas-Pardo JA, Fernández JM. The Work of Titin Protein Folding as a 
Major Driver in Muscle Contraction. Annu Rev Physiol [Internet]. 2018;80(1):327–51. Available 
from: http://www.annualreviews.org/doi/10.1146/annurev-physiol-021317-121254 
24.  Yin H, Price F, Rudnicki MA. Satellite Cells and the Muscle Stem Cell Niche. Physiol Rev 
[Internet]. 2013;93(1):23–67. Available from: 
http://physrev.physiology.org/cgi/doi/10.1152/physrev.00043.2011 
25.  Bentzinger CF, Wang YX, Rudnicki MA. Building muscle: molecular regulation of myogenesis. 
Cold Spring Harb Perspect Biol [Internet]. 2012;4(2):a008342–a008342. Available from: 
http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a008342%5Cnpapers3://p
ublication/doi/10.1101/cshperspect.a008342 
26.  Wang YX, Dumont N a, Rudnicki M a. Muscle stem cells at a glance. J Cell Sci [Internet]. 
2014;127(21):4543–8. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4215708&tool=pmcentrez&ren
dertype=abstract 
27.  Chang NC, Chevalier FP, Rudnicki MA. Satellite Cells in Muscular Dystrophy – Lost in Polarity. 
Trends Mol Med [Internet]. 2016;22(6):479–96. Available from: 
http://www.sciencedirect.com/science/article/pii/S1471491416300065 
28.  Chang NC, Rudnicki MA. Chapter Six - Satellite Cells: The Architects of Skeletal Muscle. In: 
Rendl M, editor. Stem Cells in Development and Disease [Internet]. Academic Press; 2014. p. 
161–81. (Current Topics in Developmental Biology; vol. 107). Available from: 
http://www.sciencedirect.com/science/article/pii/B9780124160224000068 
29.  Yin H, Price F, Rudnicki MA. Satellite Cells and the Muscle Stem Cell Niche. Physiol Rev 
[Internet]. 2013;93(1):23–67. Available from: 
http://physrev.physiology.org/cgi/doi/10.1152/physrev.00043.2011 
30.  Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen JL, Christensen LR, et al. The effects of 
heavy resistance training and detraining on satellite cells in human skeletal muscles. J Physiol 
[Internet]. 2004 Aug;558(3):1005–12. Available from: 
http://doi.wiley.com/10.1113/jphysiol.2004.065904 
31.  Murach KA, Fry CS, Kirby TJ, Jackson JR, Lee JD, White SH, et al. Starring or Supporting Role? 
Satellite Cells and Skeletal Muscle Fiber Size Regulation. Physiology [Internet]. 2018;33(1):26–
38. Available from: http://www.physiology.org/doi/10.1152/physiol.00019.2017 
32.  Scott W, Stevens J, Binder-Macleod S. Human Skeletal Muscle Fiber Type Classifications. Phys 
Ther [Internet]. 2001 Nov 1; Available from: 
https://academic.oup.com/ptj/article/81/11/1810/2857618/Human-Skeletal-Muscle-Fiber-
Type-Classifications 
33.  Schiaffino S. Fibre types in skeletal muscle : a personal account. 2010;(Table 1):451–63.  
34.  Talbot J, Maves L. Skeletal muscle fiber type: using insights from muscle developmental 
biology to dissect targets for susceptibility and resistance to muscle disease. Wiley Interdiscip 
Rev Dev Biol [Internet]. 2016 Jul;5(4):518–34. Available from: 
http://doi.wiley.com/10.1002/wdev.230 
35.  Miller MS, Bedrin NG, Ades PA, Palmer BM, Toth MJ. Molecular determinants of force 
production in human skeletal muscle fibers: effects of myosin isoform expression and cross-
sectional area. Am J Physiol Physiol [Internet]. 2015 Mar 15;308(6):C473–84. Available from: 
http://www.physiology.org/doi/10.1152/ajpcell.00158.2014 
36.  Murach KA, Englund DA, Dupont-Versteegden EE, McCarthy JJ, Peterson CA. Myonuclear 
domain flexibility challenges rigid assumptions on satellite cell contribution to skeletal muscle 
fiber hypertrophy. Front Physiol. 2018;9(MAY):1–7.  
37.  Rossi G, Messina G. Comparative myogenesis in teleosts and mammals. Cell Mol Life Sci 
[Internet]. 2014 Aug 25;71(16):3081–99. Available from: 
http://link.springer.com/10.1007/s00018-014-1604-5 
38.  Wilson JM, Loenneke JP, Jo E, Wilson GJ, Zourdos MC, Kim J-S. The effects of endurance, 
References 
  288 / 309   
strength, and power training on muscle fiber type shifting. J strength Cond Res [Internet]. 2012 
Jun;26(6):1724–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21912291 
39.  Goldspink G, Williams P, Simpson H. Gene expression in response to muscle stretch. Clin 
Orthop Relat Res. 2002;(403 SUPPL.):146–52.  
40.  Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev 
Biochem. 2006;75:19–37.  
41.  Schiaffino S, Reggiani C. Fiber Types in Mammalian Skeletal Muscles. Physiol Rev [Internet]. 
2011;91(4):1447–531. Available from: 
http://physrev.physiology.org/cgi/doi/10.1152/physrev.00031.2010 
42.  Klitgaard H, Zhou M, Schiaffino S, Betto R, Salviati G, Saltin B. Ageing alters the myosin heavy 
chain composition of single fibres from human skeletal muscle. Acta Physiol Scand [Internet]. 
1990 Sep;140(1):55–62. Available from: http://doi.wiley.com/10.1111/j.1748-
1716.1990.tb08975.x 
43.  Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 
[Internet]. 1995 Nov;50 Spec No:11–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/7493202 
44.  Renault V, Thorne L-E, Eriksson P-O, Butler-Browne G, Mouly V. Regenerative potential of 
human skeletal muscle during aging. Aging Cell. 2002;1(2):132–9.  
45.  Charville GW, Cheung TH, Yoo B, Santos PJ, Lee GK, Shrager JB, et al. Ex vivo expansion and in 
vivo self-renewal of human muscle stem cells. Stem Cell Reports [Internet]. 2015;5(4):621–32. 
Available from: http://dx.doi.org/10.1016/j.stemcr.2015.08.004 
46.  Perdiguero E, Cornelison D. Muscle Stem Cells [Internet]. Perdiguero E, Cornelison D, editors. 
New York, NY: Springer New York; 2017. (Methods in Molecular Biology; vol. 1556). Available 
from: http://link.springer.com/10.1007/978-1-4939-6771-1 
47.  Dellavalle A, Maroli G, Covarello D, Azzoni E, Innocenzi A, Perani L, et al. Pericytes resident in 
postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat 
Commun [Internet]. 2011;2:499. Available from: 
http://www.nature.com/doifinder/10.1038/ncomms1508 
48.  Tedesco FS, Moyle LA, Perdiguero E. Muscle Interstitial Cells: A Brief Field Guide to Non-
satellite Cell Populations in Skeletal Muscle. In 2017. p. 129–47. Available from: 
http://link.springer.com/10.1007/978-1-4939-6771-1_7 
49.  Cossu G, Previtali SC, Napolitano S, Cicalese MP, Tedesco FS, Nicastro F, et al. Intra-arterial 
transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. 
EMBO Mol Med [Internet]. 2015 Dec 1;7(12):1513–28. Available from: 
http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201505636 
50.  Formicola L, Marazzi G, Sassoon DA. The extraocular muscle stem cell niche is resistant to 
ageing and disease. Front Aging Neurosci [Internet]. 2014;6:328. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25520657 
51.  Gao Y, Arfat Y, Wang H, Goswami N. Muscle atrophy induced by mechanical unloading: 
Mechanisms and potential countermeasures. Front Physiol. 2018;9(MAR).  
52.  Mackey AL, Kjaer M. The breaking and making of healthy adult human skeletal muscle in vivo. 
Skelet Muscle [Internet]. 2017;7(1):24. Available from: 
https://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-017-0142-x 
53.  Schmidt AH, Bosse MJ, Frey KP, O’Toole R V., Stinner DJ, Scharfstein DO, et al. Predicting acute 
compartment syndrome (PACS): The role of continuous monitoring. J Orthop Trauma. 
2017;31(4):S40–7.  
54.  Corona BT, Rivera JC, Owens JG, Wenke JC, Rathbone CR. Volumetric muscle loss leads to 
permanent disability following extremity trauma. J Rehabil Res Dev [Internet]. 
2015;52(7):785–92. Available from: 
http://www.rehab.research.va.gov/jour/2015/527/pdf/JRRD-2014-07-0165.pdf 
55.  Khan NAJ, Khalid S, Ullah S, Malik MU, Makhoul S. Necrotizing Autoimmune Myopathy: A Rare 
Variant of Idiopathic Inflammatory Myopathies. J Investig Med High Impact Case Reports 
[Internet]. 2017 Apr 14;5(2):232470961770903. Available from: 
http://journals.sagepub.com/doi/10.1177/2324709617709031 
56.  Wongrakpanich S, Kallis C, Prasad P, Rangaswami J, Rosenzweig A. The Study of 
Rhabdomyolysis in the Elderly: An Epidemiological Study and Single Center Experience. Aging 
Dis [Internet]. 2018;9(1):1. Available from: 
http://www.aginganddisease.org/EN/10.14336/AD.2017.0304 
57.  Prieto S, Grau JM. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 
References 
  289 / 309   
[Internet]. 2010 Mar;9(5):A330–4. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1568997209001840 
58.  Dalakas MC. Inflammatory Muscle Diseases. Longo DL, editor. N Engl J Med [Internet]. 2015 
Apr 30;372(18):1734–47. Available from: http://www.nejm.org/doi/10.1056/NEJMra1402225 
59.  Ermann J, Fathman CG. Autoimmune diseases: genes, bugs and failed regulation. Nat 
Immunol. 2001 Sep 1;2(9):759–61.  
60.  Patil N, Nett M, Tria A, Scuderi G. Surgical Approaches in TKA: Standard and MIS Techniques. 
In: Scott WN, editor. Surgery of the Knee. 5th ed. Churchill Livingstone; 2011. p. 1029–42.  
61.  Hoppenfeld S, de Boer P, Buckley R. Surgical Exposures in Orthopaedics: The Anatomic 
Approach. 4th ed. Lippincott Williams & Wilkins (LWW); 2009. 852–854 p.  
62.  Koh IJ, Kim MW, Kim MS, Jang SW, Park DC, In Y. The Patient’s Perception Does Not Differ 
Following Subvastus and Medial Parapatellar Approaches in Total Knee Arthroplasty: A 
Simultaneous Bilateral Randomized Study. J Arthroplasty [Internet]. 2016;31(1):112–7. 
Available from: http://dx.doi.org/10.1016/j.arth.2015.08.004 
63.  Tomek IM, Kantor SR, Cori LAA, Scoville JM, Grove MR, Morgan TS, et al. Early patient 
outcomes after primary total knee arthroplasty with quadriceps-sparing subvastus and medial 
parapatellar techniques: A randomized, double-blind clinical trial. J Bone Jt Surg - Am Vol. 
2014;96(11):907–15.  
64.  Järvinen TAH, Järvinen TLN, Kääriäinen M, Kalimo H, Järvinen M. Muscle Injuries. Am J Sports 
Med [Internet]. 2005;33(5):745–64. Available from: 
http://journals.sagepub.com/doi/10.1177/0363546505274714 
65.  Ebhardt HA, Degen S, Tadini V, Schilb A, Johns N, Greig CA, et al. Comprehensive proteome 
analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study. J Cachexia 
Sarcopenia Muscle. 2017;8(4):567–82.  
66.  Shewan LG. An analysis of the types of recently published research in the field of cachexia. Eur 
J Prev Cardiol. 2017;24(16):1759–73.  
67.  Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular 
pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle [Internet]. 
2015 Sep;6(3):197–207. Available from: http://doi.wiley.com/10.1002/jcsm.12043 
68.  Warren S, Bradt RK. The immediate causes of death in cancer. Am J Med Sci. 1932;184(5):610–
5.  
69.  von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic 
illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia 
Muscle. 2016;7(5):507–9.  
70.  Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: Understanding the 
molecular basis. Nat Rev Cancer [Internet]. 2014;14(11):754–62. Available from: 
http://dx.doi.org/10.1038/nrc3829 
71.  Calvani R, Marini F, Cesari M, Tosato M, Picca A, Anker SD, et al. Biomarkers for physical frailty 
and sarcopenia. Aging Clin Exp Res. 2017;29(1):29–34.  
72.  Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia 
Sarcopenia Muscle. 2016;7(5):512–4.  
73.  Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women 
and men. Muscle and Nerve. 2004;29(1):120–7.  
74.  Fry CS, Lee JD, Mula J, Kirby TJ, Jackson JR, Liu F, et al. Inducible depletion of satellite cells in 
adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. Nat 
Med [Internet]. 2014 Dec 15;21:76. Available from: https://doi.org/10.1038/nm.3710 
75.  McCarthy JJ, Mula J, Miyazaki M, Erfani R, Garrison K, Farooqui AB, et al. Effective fiber 
hypertrophy in satellite cell-depleted skeletal muscle. Development [Internet]. 2011 Sep 
1;138(17):3657–66. Available from: http://dev.biologists.org/cgi/doi/10.1242/dev.068858 
76.  Snijders T, Nederveen JP, McKay BR, Joanisse S, Verdijk LB, van Loon LJC, et al. Satellite cells in 
human skeletal muscle plasticity. Front Physiol [Internet]. 2015;6(October):1–21. Available 
from: http://journal.frontiersin.org/Article/10.3389/fphys.2015.00283/abstract 
77.  McCarthy JJ, Dupont-Versteegden EE, Fry CS, Murach KA, Peterson CA. Methodological issues 
limit interpretation of negative effects of satellite cell depletion on adult muscle hypertrophy. 
Development [Internet]. 2017 Apr 15;144(8):1363–5. Available from: 
http://dev.biologists.org/lookup/doi/10.1242/dev.145797 
78.  Snijders T, Verdijk LB, Smeets JSJ, McKay BR, Senden JMG, Hartgens F, et al. The skeletal 
muscle satellite cell response to a single bout of resistance-type exercise is delayed with aging 
in men. Age (Omaha) [Internet]. 2014 Aug;36(4):9699. Available from: 
References 
  290 / 309   
https://doi.org/10.1007/s11357-014-9699-z 
79.  Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, et al. Serum 
concentrations of myostatin and myostatin-interacting proteins do not differ between young 
and sarcopenic elderly men. Journals Gerontol - Ser A Biol Sci Med Sci. 2011;66 A(6):620–6.  
80.  Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, 
ageing and disease. Nat Rev Mol Cell Biol [Internet]. 2016 Mar 9;17(5):267–79. Available from: 
http://www.nature.com/doifinder/10.1038/nrm.2016.7 
81.  Feige P, Rudnicki MA, Tapley B, Turvey ST. Quick guide Muscle stem cells. 2018;589–90.  
82.  Shamim B, Hawley JA, Camera DM. Protein Availability and Satellite Cell Dynamics in Skeletal 
Muscle. Sport Med [Internet]. 2018; Available from: https://doi.org/10.1007/s40279-018-
0883-7 
83.  McGlory C, van Vliet S, Stokes T, Mittendorfer B, Phillips SM. The impact of exercise and 
nutrition on the regulation of skeletal muscle mass. J Physiol. 2019;597(5):1251–8.  
84.  Goncalves-Mendes N, Walrand S, Domingues-Faria C, Vasson M-P, Boirie Y. Skeletal muscle 
regeneration and impact of aging and nutrition. Ageing Res Rev [Internet]. 2015;26:22–36. 
Available from: http://dx.doi.org/10.1016/j.arr.2015.12.004 
85.  Angulo J, El Assar M, Rodríguez-Mañas L. Frailty and sarcopenia as the basis for the phenotypic 
manifestation of chronic diseases in older adults. Mol Aspects Med [Internet]. 2016;50:1–32. 
Available from: http://dx.doi.org/10.1016/j.mam.2016.06.001 
86.  Frontera WR, Suh D, Krivickas LS, Hughes VA, Goldstein R, Roubenoff R. Skeletal muscle fiber 
quality in older men and women. Am J Physiol Physiol. 2017;279(3):C611–8.  
87.  D’Antona G, Pellegrino MA, Adami R, Rossi R, Naccari Carlizzi C, Canepari M, et al. The effect 
of ageing and immobilization on structure and function of human skeletal muscle fibres. J 
Physiol. 2003;552(2):499–511.  
88.  Grosicki GJ, Standley RA, Murach KA, Raue U, Minchev K, Coen PM, et al. Improved single 
muscle fiber quality in the oldest-old. J Appl Physiol. 2016;121(4):878–84.  
89.  Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, Van Loon LJC. Satellite cells in human skeletal 
muscle; From birth to old age. Age (Omaha). 2014;36(2):545–57.  
90.  Agyapong-Badu S, Warner M, Samuel D, Stokes M. Measurement of ageing effects on muscle 
tone and mechanical properties of rectus femoris and biceps brachii in healthy males and 
females using a novel hand-held myometric device. Arch Gerontol Geriatr [Internet]. 
2016;62:59–67. Available from: 
http://www.sciencedirect.com/science/article/pii/S0167494315300637 
91.  Miller MS, Callahan DM, Tourville TW, Slauterbeck JR, Kaplan A, Fiske BR, et al. Moderate-
intensity resistance exercise alters skeletal muscle molecular and cellular structure and 
function in inactive older adults with knee osteoarthritis. J Appl Physiol [Internet]. 2017 
Apr;122(4):775–87. Available from: 
http://www.physiology.org/doi/10.1152/japplphysiol.00830.2016 
92.  Heuts PHTG, Vlaeyen JWS, Roelofs J, De Bie RA, Aretz K, Van Weel C, et al. Pain-related fear 
and daily functioning in patients with osteoarthritis. Pain. 2004;110(1–2):228–35.  
93.  Güney-Deniz H, Irem Kınıklı G, Çağlar Ö, Atilla B, Yüksel İ. Does kinesiophobia affect the early 
functional outcomes following total knee arthroplasty? Physiother Theory Pract. 
2017;33(6):448–53.  
94.  Filardo G, Roffi A, Merli G, Marcacci T, Ceroni FB, Raboni D, et al. Patient kinesiophobia affects 
both recovery time and final outcome after total knee arthroplasty. Knee Surgery, Sport 
Traumatol Arthrosc [Internet]. 2016 Oct 19;24(10):3322–8. Available from: 
http://link.springer.com/10.1007/s00167-015-3898-8 
95.  Filardo G, Merli G, Roffi A, Marcacci T, Berti Ceroni F, Raboni D, et al. Kinesiophobia and 
depression affect total knee arthroplasty outcome in a multivariate analysis of psychological 
and physical factors on 200 patients. Knee Surgery, Sport Traumatol Arthrosc. 
2017;25(11):3417–23.  
96.  Katzel LI, Ryan AS, Goldberg AP, Blumenthal JB, Watson JM, Prior SJ. Sarcopenia Is Associated 
With Lower Skeletal Muscle Capillarization and Exercise Capacity in Older Adults. Journals 
Gerontol Ser A [Internet]. 2016;71(8):1096–101. Available from: 
https://doi.org/10.1093/gerona/glw017 
97.  Gueugneau M, Coudy-Gandilhon C, Meunier B, Combaret L, Taillandier D, Polge C, et al. Lower 
skeletal muscle capillarization in hypertensive elderly men. Exp Gerontol [Internet]. 
2016;76:80–8. Available from: 
http://www.sciencedirect.com/science/article/pii/S0531556516300134 
References 
  291 / 309   
98.  Barnouin Y, McPhee JS, Butler-Browne G, Bosutti A, De Vito G, Jones DA, et al. Coupling 
between skeletal muscle fiber size and capillarization is maintained during healthy aging. J 
Cachexia Sarcopenia Muscle [Internet]. 2017 Aug;8(4):647–59. Available from: 
http://doi.wiley.com/10.1002/jcsm.12194 
99.  Lorenzi M, Bonassi S, Lorenzi T, Giovannini S, Bernabei R, Onder G. A review of telomere length 
in sarcopenia and frailty. Biogerontology [Internet]. 2018;19(3–4):209–21. Available from: 
https://doi.org/10.1007/s10522-018-9749-5 
100.  Kadi F, Ponsot E. The biology of satellite cells and telomeres in human skeletal muscle: Effects 
of aging and physical activity. Scand J Med Sci Sport. 2010;20(1):39–48.  
101.  García-Prat L, Sousa-Victor P, Muñoz-Cánoves P. Functional dysregulation of stem cells during 
aging: A focus on skeletal muscle stem cells. FEBS J. 2013;280(17):4051–62.  
102.  Hamblen DL, Simpson H. Adams’s Outline of Orthopaedics. Elsevier Health Sciences; 2009.  
103.  Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can We 
Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? 
A Focus on Epidemiology and Phenotype of Osteoarthritis. Drugs and Aging. 2015;32(3):179–
87.  
104.  Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthr Cartil [Internet]. 
2019;27(3):359–64. Available from: https://doi.org/10.1016/j.joca.2018.11.001 
105.  Sherwood J. Osteoarthritis year in review 2018: biology. Osteoarthr Cartil [Internet]. 
2019;27(3):365–70. Available from: https://doi.org/10.1016/j.joca.2018.10.005 
106.  Ikeda S, Tsumura H, Torisu T. Age-related quadriceps-dominant muscle atrophy and incident 
radiographic knee osteoarthritis. J Orthop Sci [Internet]. 2005;10(2):121–6. Available from: 
http://www.sciencedirect.com/science/article/pii/S0949265815327378 
107.  Taniguchi M, Fukumoto Y, Kobayashi M, Kawasaki T, Maegawa S, Ibuki S, et al. Quantity and 
Quality of the Lower Extremity Muscles in Women with Knee Osteoarthritis. Ultrasound Med 
Biol [Internet]. 2015 Oct;41(10):2567–74. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0301562915003634 
108.  Hart HF, Ackland DC, Pandy MG, Crossley KM. Quadriceps volumes are reduced in people with 
patellofemoral joint osteoarthritis. Osteoarthr Cartil [Internet]. 2012;20(8):863–8. Available 
from: http://www.sciencedirect.com/science/article/pii/S1063458412007972 
109.  NJR Editorial Board. NJR 15th Annual Report [Internet]. 2018. Available from: 
www.njrcentre.org.uk 
110.  UN Department of Economic and Social Affairs / Population Division. World Population 
Prospects 2015. 2015.  
111.  Martinez R. @HlthAnalysis [Internet]. Twitter. [cited 2019 Feb 5]. Available from: 
https://twitter.com/hlthanalysis 
112.  Krishnasamy P, Hall M, Robbins SR. The role of skeletal muscle in the pathophysiology and 
management of knee osteoarthritis. 2018;(January):22–33.  
113.  Grimsholm O, Guo Y, Ny T, Forsgren S. Expression patterns of neurotrophins and neurotrophin 
receptors in articular chondrocytes and inflammatory infiltrates in knee joint arthritis. Cells 
Tissues Organs [Internet]. 2008;188(3):299–309. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18349525 
114.  Kumar D, Karampinos DC, MacLeod TD, Lin W, Nardo L, Li X, et al. Quadriceps intramuscular 
fat fraction rather than muscle size is associated with knee osteoarthritis. Osteoarthr Cartil 
[Internet]. 2014 Feb;22(2):226–34. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1063458413010388 
115.  Harasymowicz NS, Clement ND, Azfer A, Burnett R, Salter DM, Simpson AHWR. Regional 
Differences Between Perisynovial and Infrapatellar Adipose Tissue Depots and Their Response 
to Class II and Class III Obesity in Patients With Osteoarthritis. Arthritis Rheumatol [Internet]. 
2017 Jul;69(7):1396–406. Available from: http://doi.wiley.com/10.1002/art.40102 
116.  Pucci S, Greggi C, Polidoro C, Piro MC, Celi M, Feola M, et al. Clusterin silencing restores 
myoblasts viability and down modulates the inflammatory process in osteoporotic disease. J 
Transl Med [Internet]. 2019 Dec 10;17(1):118. Available from: https://translational-
medicine.biomedcentral.com/articles/10.1186/s12967-019-1868-5 
117.  Connor JR, Kumar S, Sathe G, Mooney J, O’Brien SP, Mui P, et al. Clusterin expression in adult 
human normal and osteoarthritic articular cartilage. Osteoarthr Cartil [Internet]. 2001 
Nov;9(8):727–37. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1063458401904753 
118.  Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L. Lower serum clusterin 
References 
  292 / 309   
levels in patients with erosive hand osteoarthritis are associated with more pain. BMC 
Musculoskelet Disord [Internet]. 2018 Dec 27;19(1):264. Available from: 
https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-018-2179-3 
119.  Fandridis E, Apergis G, Korres DS, Nikolopoulos K, Zoubos AB, Papassideri I, et al. Increased 
expression levels of apolipoprotein J/clusterin during primary osteoarthritis. In Vivo [Internet]. 
2011;25(5):745–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21753128 
120.  Ferrer I, Carmona M, Blanco R, Moreno D, Torrejón-Escribano B, Olivé M. Involvement of 
Clusterin and the Aggresome in Abnormal Protein Deposits in Myofibrillar Myopathies and 
Inclusion Body Myositis. Brain Pathol. 2006;15(2):101–8.  
121.  Mackey AL, Rasmussen LK, Kadi F, Schjerling P, Helmark IC, Ponsot E, et al. Activation of 
satellite cells and the regeneration of human skeletal muscle are expedited by ingestion of 
nonsteroidal anti-inflammatory medication. FASEB J. 2016;30(6):2266–81.  
122.  Mackey AL. Does an NSAID a day keep satellite cells at bay? J Appl Physiol [Internet]. 2013 Sep 
15;115(6):900–8. Available from: 
http://www.physiology.org/doi/10.1152/japplphysiol.00044.2013 
123.  Mikkelsen UR, Schjerling P, Helmark IC, Reitelseder S, Holm L, Skovgaard D, et al. Local NSAID 
infusion does not affect protein synthesis and gene expression in human muscle after 
eccentric exercise. Scand J Med Sci Sport. 2011;21(5):630–44.  
124.  Mizner R, Petterson S, Stevens J, Vandenborne K, Snyder-Mackler L. Early Quadriceps Strength 
Loss After Total Knee Arthroplasty. J Bone Jt Surg. 2005;87 A(5):1047–53.  
125.  Hopkins JT, Ingersoll CD. Arthrogenic muscle inhibition: A limiting factor in joint rehabilitation. 
J Sport Rehabil. 2000;9(2):135–59.  
126.  Rice DA, McNair PJ. Quadriceps Arthrogenic Muscle Inhibition: Neural Mechanisms and 
Treatment Perspectives. Semin Arthritis Rheum [Internet]. 2010;40(3):250–66. Available from: 
http://dx.doi.org/10.1016/j.semarthrit.2009.10.001 
127.  Callaghan MJ, Parkes MJ, Hutchinson CE, Felson DT. Factors associated with arthrogenous 
muscle inhibition in patellofemoral osteoarthritis. Osteoarthr Cartil [Internet]. 
2014;22(6):742–6. Available from: http://dx.doi.org/10.1016/j.joca.2014.03.015 
128.  Meier W, Mizner R, Marcus R, Dibble L, Peters C, Lastayo PC. Total Knee Arthroplasty: Muscle 
Impairments, Functional Limitations, and Recommended Rehabilitation Approaches. J Orthop 
Sport Phys Ther. 2008;38(5):246–56.  
129.  Hamilton DF, Loth FC, MacDonald DJ, MacFarlane GJ, Beard DJ, Simpson AHRW, et al. Exploring 
variation in patient access of post-discharge physiotherapy following total hip and knee 
arthroplasty under a choice based system in the UK: An observational cohort study. BMJ Open. 
2019;9(2):1–8.  
130.  Memtsoudis SG, Della Valle AG, Besculides MC, Gaber L, Laskin R. Trends in Demographics, 
Comorbidity Profiles, In-Hospital Complications and Mortality Associated With Primary Knee 
Arthroplasty. J Arthroplasty [Internet]. 2009 Jun;24(4):518–27. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0883540308003173 
131.  Poultsides LA, Ma Y, Valle AG Della, Chiu Y-L, Sculco TP, Memtsoudis SG. In-Hospital Surgical 
Site Infections after Primary Hip and Knee Arthroplasty — Incidence and Risk Factors. J 
Arthroplasty [Internet]. 2013;28(3):385–9. Available from: 
http://www.sciencedirect.com/science/article/pii/S0883540312005049 
132.  Teng S, Huang P. The effect of type 2 diabetes mellitus and obesity on muscle progenitor cell 
function. Stem Cell Res Ther [Internet]. 2019;10(1):103. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30898146%0Ahttps://stemcellres.biomedcentral.co
m/articles/10.1186/s13287-019-1186-0 
133.  Lebrasseur NK, Kirkland JL. Cellular Senescence and the Biology of Aging , Disease , and Frailty. 
2015;83:11–8.  
134.  Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. 
2012;15(1):12–22.  
135.  Sousa-Victor P, Gutarra S, García-Prat L, Rodriguez-Ubreva J, Ortet L, Ruiz-Bonilla V, et al. 
Geriatric muscle stem cells switch reversible quiescence into senescence. Nature [Internet]. 
2014;506(7488):316–21. Available from: 
http://www.nature.com/doifinder/10.1038/nature13013 
136.  Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle : a 
double-edged sword ? 2013;280:4131–48.  
137.  Brzeszczyńska J, Meyer A, McGregor R, Schilb A, Degen S, Tadini V, et al. Alterations in the in 
vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of 
References 
  293 / 309   
sarcopenia. J Cachexia Sarcopenia Muscle [Internet]. 2017;(September). Available from: 
http://doi.wiley.com/10.1002/jcsm.12252 
138.  Peterson JM, Bakkar N, Guttridge DC. NF-κB Signaling in Skeletal Muscle Health and Disease. 
In 2011. p. 85–119. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/B9780123859402000048 
139.  Hall DT, Ma JF, Marco S Di, Gallouzi I-E. Inducible nitric oxide synthase (iNOS) in muscle wasting 
syndrome, sarcopenia, and cachexia. Aging (Albany NY) [Internet]. 2011 Aug;3(8):702–15. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21832306 
140.  Chen SL, Dowhan DH, Hosking BM, Muscat GE. The steroid receptor coactivator, GRIP-1, is 
necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes 
Dev [Internet]. 2000 May 15;14(10):1209–28. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10817756 
141.  Boldrin L, Muntoni F, Morgan JE. Are Human and Mouse Satellite Cells Really the Same ? The 
Journal of Histochemistry & Cytochemistry. Histochemistry. 2010;58(11):941–55.  
142.  Bareja A, Holt JA, Luo G, Chang C, Lin J, Hinken AC, et al. Human and Mouse Skeletal Muscle 
Stem Cells: Convergent and Divergent Mechanisms of Myogenesis. PLoS One [Internet]. 
2014;9(2):1–12. Available from: https://doi.org/10.1371/journal.pone.0090398 
143.  Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload 
exercise precede hypertrophy and are not lost on detraining. Proc Natl Acad Sci [Internet]. 
2010;107(34):15111–6. Available from: 
http://www.pnas.org/cgi/doi/10.1073/pnas.0913935107 
144.  Gundersen K. Muscle memory and a new cellular model for muscle atrophy and hypertrophy. 
J Exp Biol [Internet]. 2016 Jan;219(2):235–42. Available from: 
http://jeb.biologists.org/lookup/doi/10.1242/jeb.124495 
145.  Harrison BC, Allen DL, Leinwand LA. IIb or not IIb? Regulation of myosin heavy chain gene 
expression in mice and men. Skelet Muscle [Internet]. 2011;1(1):5. Available from: 
http://skeletalmusclejournal.biomedcentral.com/articles/10.1186/2044-5040-1-5 
146.  Dungan CM, Murach KA, Frick KK, Jones SR, Crow SE, Englund DA, et al. Elevated Myonuclear 
Density During Skeletal Muscle Hypertrophy In Response to Training Is Reversed During 
Detraining. Am J Physiol Physiol [Internet]. 2019 Mar 6;ajpcell.00050.2019. Available from: 
https://www.physiology.org/doi/10.1152/ajpcell.00050.2019 
147.  Brook MS, Wilkinson DJ, Phillips BE, Perez-Schindler J, Philp A, Smith K, et al. Skeletal muscle 
homeostasis and plasticity in youth and ageing: Impact of nutrition and exercise. Acta Physiol. 
2016;216(1):15–41.  
148.  Koopman R, van Loon LJC. Regulation of Protein Metabolism in Exercise and Recovery: Aging , 
exercise , and muscle protein metabolism. J Appl Physiol. 2009;(106):2040–8.  
149.  Wall BT, Gorissen SH, Pennings B, Koopman R, Groen BBL, Verdijk LB, et al. Aging is 
accompanied by a blunted muscle protein synthetic response to protein ingestion. PLoS One. 
2015;10(11):1–13.  
150.  Ceccarelli G, Benedetti L, Arcari ML, Carubbi C, Galli D. Muscle stem cell and physical activity: 
what point is the debate at? Open Med [Internet]. 2017;12(1):144–56. Available from: 
http://www.degruyter.com/view/j/med.2017.12.issue-1/med-2017-0022/med-2017-
0022.xml 
151.  Mori N, Kimura S, Onodera T, Iwasaki N, Nakagawa I, Masuda T. Use of a pneumatic tourniquet 
in total knee arthroplasty increases the risk of distal deep vein thrombosis: A prospective, 
randomized study. Knee [Internet]. 2016 Oct;23(5):887–9. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0968016016000697 
152.  Harsten A, Bandholm T, Kehlet H, Toksvig-Larsen S. Tourniquet versus no tourniquet on knee-
extension strength early after fast-track total knee arthroplasty; a randomized controlled trial. 
Knee [Internet]. 2015 Mar;22(2):126–30. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0968016014003135 
153.  Liu D, Graham D, Gillies K, Gillies RM. Effects of Tourniquet Use on Quadriceps Function and 
Pain in Total Knee Arthroplasty. Knee Surg Relat Res [Internet]. 2014 Dec 30;26(4):207–13. 
Available from: http://www.jksrr.org/journal/view.html?doi=10.5792/ksrr.2014.26.4.207 
154.  Wernbom M, Apro W, Paulsen G, Nilsen TS, Blomstrand E, Raastad T. Acute low-load 
resistance exercise with and without blood flow restriction increased protein signalling and 
number of satellite cells in human skeletal muscle. Eur J Appl Physiol [Internet]. 2013 
Dec;113(12):2953–65. Available from: https://doi.org/10.1007/s00421-013-2733-5 
155.  Muyskens JB, Hocker AD, Turnbull DW, Shah SN, Lantz BA, Jewett BA, et al. Transcriptional 
References 
  294 / 309   
profiling and muscle cross-section analysis reveal signs of ischemia reperfusion injury following 
total knee arthroplasty with tourniquet. Physiol Rep [Internet]. 2016;4(1):e12671. Available 
from: http://physreports.physiology.org/content/4/1/e12671.abstract 
156.  O’Reilly SC, Muir KR, Doherty M. Occupation and knee pain: a community study. Osteoarthr 
Cartil [Internet]. 2000 Mar;8(2):78–81. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1063458499902741 
157.  Rossignol M. Primary osteoarthritis of hip, knee, and hand in relation to occupational 
exposure. Occup Environ Med [Internet]. 2005 Nov 1;62(11):772–7. Available from: 
http://oem.bmj.com/cgi/doi/10.1136/oem.2005.020057 
158.  Franklin J, Ingvarsson T, Englund M, Lohmander S. Association between occupation and knee 
and hip replacement due to osteoarthritis: a case-control study. Arthritis Res Ther [Internet]. 
2010;12(3):R102. Available from: http://arthritis-
research.biomedcentral.com/articles/10.1186/ar3033 
159.  McWilliams DF, Leeb BF, Muthuri SG, Doherty M, Zhang W. Occupational risk factors for 
osteoarthritis of the knee: a meta-analysis. Osteoarthr Cartil [Internet]. 2011 Jul;19(7):829–
39. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1063458411000677 
160.  Gignac MAM, Irvin E, Cullen K, Van Eerd D, Beaton DE, Mahood Q, et al. Men and women’s 
occupational activities and the risk of developing osteoarthritis of the knee, hip or hands: A 
systematic review and recommendations for future research. Arthritis Care Res (Hoboken) 
[Internet]. 2019 Feb 14; Available from: http://doi.wiley.com/10.1002/acr.23855 
161.  Liebs TR, Herzberg W, Rüther W, Russlies M, Hassenpflug J. Quality-Adjusted Life Years Gained 
by Hip and Knee Replacement Surgery and Its Aftercare. Arch Phys Med Rehabil. 
2016;97(5):691–700.  
162.  Evans JT, Walker RW, Evans JP, Blom AW, Sayers A, Whitehouse MR. How long does a knee 
replacement last? A systematic review and meta-analysis of case series and national registry 
reports with more than 15 years of follow-up. Lancet [Internet]. 2019 Feb;393(10172):655–
63. Available from: http://dx.doi.org/10.1016/S0140-6736(18)32531-5 
163.  Dalury DF, Pomeroy DL, Gorab RS, Adams MJ. Why are total knee arthroplasties being revised? 
J Arthroplasty [Internet]. 2013;28(8 SUPPL):120–1. Available from: 
http://dx.doi.org/10.1016/j.arth.2013.04.051 
164.  Greidanus N V., Peterson RC, Masri BA, Garbuz DS. Quality of Life Outcomes in Revision Versus 
Primary Total Knee Arthroplasty. J Arthroplasty [Internet]. 2011;26(4):615–20. Available from: 
http://dx.doi.org/10.1016/j.arth.2010.04.026 
165.  Nichols CI, Vose JG. Clinical Outcomes and Costs Within 90 Days of Primary or Revision Total 
Joint Arthroplasty. J Arthroplasty [Internet]. 2016;31(7):1400-1406.e3. Available from: 
http://dx.doi.org/10.1016/j.arth.2016.01.022 
166.  Hamilton DF, Burnett R, Patton JT, Howie CR, Moran M, Simpson  a HRW, et al. Implant design 
influences patient outcome after total knee arthroplasty: a prospective double-blind 
randomised controlled trial. Bone Joint J [Internet]. 2015;97-B(1):64–70. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25568415 
167.  Guerra ML, Singh PJ, Taylor NF. Early mobilization of patients who have had a hip or knee joint 
replacement reduces length of stay in hospital: A systematic review. Clin Rehabil. 
2015;29(9):844–54.  
168.  Soffin EM, Yadeau JT. Enhanced recovery after surgery for primary hip and knee arthroplasty: 
A review of the evidence. Br J Anaesth. 2016;117:iii62–72.  
169.  Hamilton DF, Mcleish JA, Gaston P. Muscle ‘regenerative potential’ determines physical 
recovery following total knee replacement. Bone Jt J. 2013;2(4):70–8.  
170.  Katz B. The Terminations of the Afferent Nerve Fibre in the Muscle Spindle of the Frog. Philos 
Trans R Soc B Biol Sci [Internet]. 1961 Feb 2;243(703):221–40. Available from: 
http://rstb.royalsocietypublishing.org/cgi/doi/10.1098/rstb.1961.0001 
171.  Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493–5.  
172.  Dumont NA, Bentzinger CF, Sincennes M-C, Rudnicki MA. Satellite Cells and Skeletal Muscle 
Regeneration. Compr Physiol [Internet]. 2015;5(3):1027–59. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26140708 
173.  Cornelison DDW. “Known Unknowns”: Current Questions in Muscle Satellite Cell Biology 
[Internet]. 1st ed. Vol. 126, Current Topics in Developmental Biology. Elsevier Inc.; 2018. 177–
203 p. Available from: http://dx.doi.org/10.1016/bs.ctdb.2017.08.006 
174.  Mashinchian O, Pisconti A, Le Moal E, Bentzinger CF. The Muscle Stem Cell Niche in Health and 
Disease [Internet]. 1st ed. Vol. 126, Current Topics in Developmental Biology. Elsevier Inc.; 
References 
  295 / 309   
2018. 177–203 p. Available from: http://dx.doi.org/10.1016/bs.ctdb.2017.08.003 
175.  Velentgas P, Dreyer N, Wu A. Outcome Definition and Measurement. Dev a Protoc Obs Comp 
Eff Res A User’s Guid [Internet]. 2013;83–92. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK126190/pdf/Bookshelf_NBK126190.pdf 
176.  Krumholz HM, Lin Z, Normand S-LT. Measuring hospital clinical outcomes. BMJ [Internet]. 
2013;346. Available from: https://www.bmj.com/content/346/bmj.f620 
177.  Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-Reported 
Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An 
ISPOR COA Emerging Good Practices Task Force Report. Value Heal [Internet]. 
2017;20(7):838–55. Available from: http://dx.doi.org/10.1016/j.jval.2017.05.015 
178.  Boudreau JD, Cassell EJ, Fuks A. The Clinical Method and Subjectivity in Medicine [Internet]. 
Vol. 1. Oxford University Press; 2018. 1–10 p. Available from: 
http://www.oxfordscholarship.com/view/10.1093/oso/9780199370818.001.0001/oso-
9780199370818 
179.  L’Abbé KA. Meta-Analysis in Clinical Research. Ann Intern Med [Internet]. 1987 Aug 
1;107(2):224. Available from: http://annals.org/article.aspx?doi=10.7326/0003-4819-107-2-
224 
180.  Bergner M. Quality of Life, Health Status, and Clinical Research. Med Care [Internet]. 
1989;27(3):S148--S156. Available from: http://www.jstor.org/stable/3765660 
181.  Wood-Dauphinee S. Assessing Quality of Life in Clinical Research: From Where Have We Come 
and Where Are We Going? J Clin Epidemiol [Internet]. 1999;52(4):355–63. Available from: 
http://www.sciencedirect.com/science/article/pii/S0895435698001796 
182.  Beauchamp TL. The Belmont Report. Oxford Textb Clin Res ethics. 2008;149–55.  
183.  NHMRC. A Model Framework for Consumer and Community Participation in Health and 
Medical Research. National Health and Medical Research Council. 2004. 
https://www.nhmrc.gov.au/_files_nhmrc/publications.  
184.  Harris DA, Kieburtz K, Venuto C, Dorsey ER, Venkataraman V. Novel Methods and Technologies 
for 21st-Century Clinical Trials. JAMA Neurol. 2015;72(5):582.  
185.  Appari A, Johnson ME. Information security and privacy in healthcare: current state of 
research. Int J Internet Enterp Manag [Internet]. 2010;6(4):279. Available from: 
http://www.inderscience.com/link.php?id=35624 
186.  McCusker K, Gunaydin S. Research using qualitative, quantitative or mixed methods and 
choice based on the research. Perfus (United Kingdom). 2015;30(7):537–42.  
187.  Brockow T, Cieza A, Kuhlow H, Sigl T, Franke T, Harder M, et al. Identifying the concepts 
contained in outcome measures of clinical trials on musculoskeletal disorders and chronic 
widespread pain using the International Classification of Functioning, Disability and Health as 
a reference. J Rehabil Med. 2004;36(SUPPL. 44):30–6.  
188.  Mizner RL, Petterson SC, Clements KE, Zeni JA, Irrgang JJ, Snyder-Mackler L. Measuring 
Functional Improvement After Total Knee Arthroplasty Requires Both Performance-Based and 
Patient-Report Assessments. A Longitudinal Analysis of Outcomes. J Arthroplasty [Internet]. 
2011;26(5):728–37. Available from: http://dx.doi.org/10.1016/j.arth.2010.06.004 
189.  Doward LC, McKenna SP. Defining patient-reported outcomes. Value Heal [Internet]. 
2004;7(SUPPL. 1):S4–8. Available from: http://dx.doi.org/10.1111/j.1524-4733.2004.7s102.x 
190.  Kyte DG, Calvert M, van der Wees PJ, ten Hove R, Tolan S, Hill JC. An introduction to patient-
reported outcome measures (PROMs) in physiotherapy. Physiother (United Kingdom) 
[Internet]. 2015;101(2):119–25. Available from: 
http://dx.doi.org/10.1016/j.physio.2014.11.003 
191.  Schwartzenberger J, Presson A, Lyle A, O’Farrell A, Tyser AR. Remote Collection of Patient-
Reported Outcomes Following Outpatient Hand Surgery: A Randomized Trial of Telephone, 
Mail, and E-Mail. J Hand Surg Am [Internet]. 2017;42(9):693–9. Available from: 
http://dx.doi.org/10.1016/j.jhsa.2017.05.002 
192.  Coons SJ, Gwaltney CJ, Hays RD, Lundy JJ, Sloan JA, Revicki DA, et al. Recommendations on 
evidence needed to support measurement equivalence between electronic and paper-based 
patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force 
report. Value Heal [Internet]. 2009;12(4):419–29. Available from: 
http://dx.doi.org/10.1111/j.1524-4733.2008.00470.x 
193.  Griffiths-Jones W, Norton MR, Fern ED, Williams DH. The equivalence of remote electronic and 
paper patient reported outcome (PRO) Collection. J Arthroplasty. 2014;29(11):2136–9.  
194.  Zbrozek A, Hebert J, Gogates G, Thorell R, Dell C, Molsen E, et al. Validation of electronic 
References 
  296 / 309   
systems to collect patient-reported outcome (PRO) data - Recommendations for clinical trial 
teams: Report of the ISPOR ePRO systems validation good research practices task force. Value 
Heal [Internet]. 2013;16(4):480–9. Available from: 
http://dx.doi.org/10.1016/j.jval.2013.04.002 
195.  Coons SJ, Eremenco S, Lundy JJ, O’Donohoe P, O’Gorman H, Malizia W. Capturing Patient-
Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO 
Measurement in Clinical Trials. Patient [Internet]. 2015;8(4):301–9. Available from: 
http://dx.doi.org/10.1007/s40271-014-0090-z 
196.  Gagnier JJ. Patient reported outcomes in orthopaedics. J Orthop Res. 2017;35(10):2098–108.  
197.  Ramkumar PN, Harris JD, Noble PC. Patient-reported outcome measures after total knee 
arthroplasty. Bone Joint Res [Internet]. 2015 Jul;4(7):120–7. Available from: 
http://online.boneandjoint.org.uk/doi/10.1302/2046-3758.47.2000380 
198.  Collins NJ, Roos EM. PROMs for Osteoarthritis. In: El Miedany Y, editor. Patient Reported 
Outcome Measures in Rheumatic Diseases [Internet]. Cham: Springer International Publishing; 
2016. p. 249–85. Available from: https://doi.org/10.1007/978-3-319-32851-5_10 
199.  Scott CEH, Turnbull GS, MacDonald D, Breusch SJ. Activity levels and return to work following 
total knee arthroplasty in patients under 65 years of age. Bone Joint J [Internet]. 2017;99-
B(8):1037–46. Available from: 
http://www.bjj.boneandjoint.org.uk/lookup/doi/10.1302/0301-620X.99B8.BJJ-2016-1364.R1 
200.  Hamilton DF, Lane J V., Gaston P, Patton JT, MacDonald D, Simpson AHRW, et al. What 
determines patient satisfaction with surgery? A prospective cohort study of 4709 patients 
following total joint replacement. BMJ Open. 2013;3(4):1–7.  
201.  Scott CEH, MacDonald DJ, Howie CR. ‘Worse than death’ and waiting for a joint arthroplasty. 
Bone Joint J [Internet]. 2019;101-B(8):941–50. Available from: 
https://online.boneandjoint.org.uk/doi/10.1302/0301-620X.101B8.BJJ-2019-0116.R1 
202.  Scott CEH, Clement ND, MacDonald DJ, Hamilton DF, Gaston P, Howie CR, et al. Five-year 
survivorship and patient-reported outcome of the Triathlon single-radius total knee 
arthroplasty. Knee Surgery, Sport Traumatol Arthrosc [Internet]. 2015;23(6):1676–83. 
Available from: http://dx.doi.org/10.1007/s00167-014-2922-8 
203.  Hamilton DF, Giesinger JM, Patton JT, MacDonald DJ, Simpson AHRW, Howie CR, et al. Making 
the Oxford Hip and Knee Scores meaningful at the patient level through normative scoring and 
registry data. Bone Joint Res. 2015;4(8):137–44.  
204.  Giesinger JM, Loth FL, MacDonald DJ, Giesinger K, Patton JT, Simpson AHRW, et al. Patient-
reported outcome metrics following total knee arthroplasty are influenced differently by 
patients’ body mass index. Knee Surgery, Sport Traumatol Arthrosc [Internet]. 
2018;26(11):3257–64. Available from: http://dx.doi.org/10.1007/s00167-018-4853-2 
205.  Katz JN, Bierbaum BE, Losina E. Case mix and outcomes of total knee replacement in 
orthopaedic specialty hospitals. Med Care. 2008;46(5):476–80.  
206.  Giesinger JM, Giesinger K, Federico B, Howie CD, Hamilton DF. Differences in case mix and 
outcomes between Swiss and Scottish total knee arthroplasty patients. Knee Surgery, Sport 
Traumatol Arthrosc [Internet]. 2019;4–11. Available from: 
http://link.springer.com/10.1007/s00167-019-05597-x 
207.  Franklin PD, Miozzari H, Christofilopoulos P, Hoffmeyer P, Ayers DC, Lübbeke A. Important 
patient characteristics differ prior to total knee arthroplasty and total hip arthroplasty 
between Switzerland and the United States. BMC Musculoskelet Disord [Internet]. 2017 Dec 
11;18(1):14. Available from: 
http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-016-1372-5 
208.  Clement ND, Macdonald D, Burnett R, Simpson AHRW, Howie CR. A patient’s perception of 
their hospital stay influences the functional outcome and satisfaction of total knee 
arthroplasty. Arch Orthop Trauma Surg [Internet]. 2017 May;137(5):693–700. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28331990 
209.  Dressendorfer R, Pitts D. Total Knee Replacement: Physical Therapy. EBSCO Clinical Review. 
2015.  
210.  Konan S, Hossain F, Patel S, Haddad FS. Measuring function after hip and knee surgery. Bone 
Joint J. 2014;96-B(11):1431–5.  
211.  Dobson F, Hinman RS, Roos EM, Abbott JH, Stratford P, Davis AM, et al. OARSI recommended 
performance-based tests to assess physical function in people diagnosed with hip or knee 
osteoarthritis. Osteoarthr Cartil [Internet]. 2013;21(8):1042–52. Available from: 
http://dx.doi.org/10.1016/j.joca.2013.05.002 
References 
  297 / 309   
212.  Dobson F, Hinman RS, Hall M, Marshall CJ, Sayer T, Anderson C, et al. Reliability and 
measurement error of the Osteoarthritis Research Society International (OARSI) 
recommended performance-based tests of physical function in people with hip and knee 
osteoarthritis. Osteoarthr Cartil [Internet]. 2017;25(11):1792–6. Available from: 
https://doi.org/10.1016/j.joca.2017.06.006 
213.  Mizner RL, Petterson SC, Snyder-Mackler L. Quadriceps Strength and the Time Course of 
Functional Recovery After Total Knee Arthroplasty. J Orthop Sport Phys Ther [Internet]. 2005 
Jul;35(7):424–36. Available from: http://www.jospt.org/doi/10.2519/jospt.2005.35.7.424 
214.  Stevens-Lapsley JE, Schenkman ML, Dayton MR. Comparison of Self-Reported Knee Injury and 
Osteoarthritis Outcome Score to Performance Measures in Patients After Total Knee 
Arthroplasty. PM R [Internet]. 2011;3(6):541–9. Available from: 
http://dx.doi.org/10.1016/j.pmrj.2011.03.002 
215.  Hossain FS, Konan S, Patel S, Rodriguez-Merchan EC, Haddad FS. The assessment of outcome 
after total knee arthroplasty: are we there yet? Bone Joint J. 2015;97-B(1):3–9.  
216.  Hamilton DF, Giesinger JM, Giesinger K. It is merely subjective opinion that patient-reported 
outcome measures are not objective tools. Bone Joint Res. 2017;6(12):665–6.  
217.  Hodgkiss AM, McCarthy HD. Thigh circumference measurement as a potential marker of leg 
skeletal muscle mass – cross sectional study in a U.S. population age 39–69 years. Proc Nutr 
Soc. 2017;76(OCE1):E14.  
218.  Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement 
of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 
2018;9(2):269–78.  
219.  O’Sullivan K, Sainsbury D, O’Connor R. Measurement of thigh muscle size using tape or 
ultrasound is a poor indicator of thigh muscle strength. Isokinet Exerc Sci. 2009;17(3):145–53.  
220.  Arangio GA, Chen C, Kalady M, Reed JF. Thigh Muscle Size and Strength After Anterior Cruciate 
Ligament Reconstruction and Rehabilitation. J Orthop Sport Phys Ther [Internet]. 1997 
Nov;26(5):238–43. Available from: http://www.jospt.org/doi/10.2519/jospt.1997.26.5.238 
221.  Gonzalez MC, Heymsfield SB. Bioelectrical impedance analysis for diagnosing sarcopenia and 
cachexia: what are we really estimating? J Cachexia Sarcopenia Muscle. 2017;8(2):187–9.  
222.  Vargas Luna FM, Balleza-Ordaz M, Huerta Franco MR, Riu P. Electrical Impedance Signal 
Analysis for Medical Diagnosis. In: Simini F, Bertemes-Filho P, editors. Bioimpedance in 
Biomedical Applications and Research [Internet]. Cham: Springer International Publishing; 
2018. p. 65–85. Available from: https://doi.org/10.1007/978-3-319-74388-2_5 
223.  Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by 
bioelectrical impedance analysis. J Appl Physiol. 2017;89(2):465–71.  
224.  Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older 
persons is associated with functional impairment and physical disability. J Am Geriatr Soc 
[Internet]. 2002;50(5):889–96. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12028177 
225.  Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gómez JM, et al. Bioelectrical 
impedance analysis - Part I: Review of principles and methods. Clin Nutr. 2004;23(5):1226–43.  
226.  DERE D. Effect of body mass index on functional recovery after total knee arthroplasty in 
ambulatory overweight or obese women with osteoarthritis. ACTA Orthop Traumatol Turc 
[Internet]. 2014;48(2):117–21. Available from: 
http://www.aott.org.tr/index.php/aott/article/view/2751/3443 
227.  Bonnefoy-Mazure A, Martz P, Armand S, Hoffmeyer P, Sagawa Y, Suva D, et al. Knee kinematic 
recovery one year after total knee arthroplasties: The influence of BMI. Osteoarthr Cartil 
[Internet]. 2016;24(2016):S101. Available from: http://dx.doi.org/10.1016/j.joca.2016.01.206 
228.  Majumder S, Mondal T, Deen M. Wearable Sensors for Remote Health Monitoring. Sensors 
[Internet]. 2017 Jan 12;17(12):130. Available from: http://www.mdpi.com/1424-
8220/17/1/130 
229.  Al Ameen M, Liu J, Kwak K. Security and Privacy Issues in Wireless Sensor Networks for 
Healthcare Applications. J Med Syst [Internet]. 2012 Feb;36(1):93–101. Available from: 
https://doi.org/10.1007/s10916-010-9449-4 
230.  Avancha S, Baxi A, Kotz D. Privacy in Mobile Technology for Personal Healthcare. ACM Comput 
Surv [Internet]. 2012 Dec;45(1):3:1--3:54. Available from: 
http://doi.acm.org/10.1145/2379776.2379779 
231.  Wright SP, Hall Brown TS, Collier SR, Sandberg K. How consumer physical activity monitors 
could transform human physiology research. Am J Physiol Regul Integr Comp Physiol 
References 
  298 / 309   
[Internet]. 2017;ajpregu.00349.2016. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28052867 
232.  Berlin AA, Gabriel KJ. Distributed MEMS: new challenges for computation. IEEE Comput Sci Eng 
[Internet]. 1997;4(1):12–6. Available from: http://ieeexplore.ieee.org/document/590851/ 
233.  Gabriel KJ, Behi F, Mahadevan R, Walker JA, Mehregany M. Silicon-Based Micromechanical 
Structures And Devices. In: Vukobratovich D, editor. 1989. p. 137. Available from: 
http://proceedings.spiedigitallibrary.org/proceeding.aspx?doi=10.1117/12.962935 
234.  Kim Y, Barry VW, Kang M. Validation of the ActiGraph GT3X and activPAL Accelerometers for 
the Assessment of Sedentary Behavior. Meas Phys Educ Exerc Sci [Internet]. 2015;19(3):125–
37. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-
84939803959&partnerID=tZOtx3y1 
235.  El-Amrawy F, Nounou MI. Are currently available wearable devices for activity tracking and 
heart rate monitoring accurate, precise, and medically beneficial? Healthc Inform Res. 
2015;21(4):315–20.  
236.  Grant PM, Ryan CG, Tigbe WW, Granat MH. The validation of a novel activity monitor in the 
measurement of posture and motion during everyday activities. Br J Sports Med [Internet]. 
2006;40(12):992–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16980531 
237.  Gill JMR, Hawari NSA, Maxwell DJ, Louden D, Mourselas N, Bunn C, et al. Validation of a Novel 
Device to Measure and Provide Feedback on Sedentary Behavior. Med Sci Sports Exerc. 
2018;50(3):525–32.  
238.  Tudor-Locke C, Williams JE, Reis JP, Pluto D. Utility of Pedometers for Assessing Physical 
Activity. Sport Med [Internet]. 2002;32(12):795–808. Available from: 
http://link.springer.com/10.2165/00007256-200232120-00004 
239.  Wang R, Blackburn G, Desai M, Phelan D, Gillinov L, Houghtaling P, et al. Accuracy of wrist-
worn heart rate monitors. JAMA Cardiol. 2017;2(1):104–6.  
240.  Luna IE, Kehlet H, Peterson B, Wede HR, Hoevsgaard SJ, Aasvang EK. Early patient-reported 
outcomes versus objective function after total hip and knee arthroplasty. Bone Jt J. 
2017;99B(9):1167–75.  
241.  John D, Morton A, Arguello D, Lyden K, Bassett D. “What Is a Step?” Differences in How a Step 
Is Detected among Three Popular Activity Monitors That Have Impacted Physical Activity 
Research. Sensors (Basel) [Internet]. 2018 Apr 15;18(4). Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29662048 
242.  Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many 
steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act 
[Internet]. 2011;8(1):80. Available from: http://www.ijbnpa.org/content/8/1/80 
243.  Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical 
Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. 
Diabetes Care [Internet]. 2016 Nov 1;39(11):2065 LP – 2079. Available from: 
http://care.diabetesjournals.org/content/39/11/2065.abstract 
244.  Webber SC, Strachan SM, Pachu NS. Sedentary behavior, cadence, and physical activity 
outcomes after knee arthroplasty. Med Sci Sports Exerc. 2017;49(6):1057–65.  
245.  Van der Walt N, Salmon LJ, Gooden B, Lyons MC, O’Sullivan M, Martina K, et al. Feedback From 
Activity Trackers Improves Daily Step Count After Knee and Hip Arthroplasty: A Randomized 
Controlled Trial. J Arthroplasty [Internet]. 2018;33(11):3422–8. Available from: 
https://doi.org/10.1016/j.arth.2018.06.024 
246.  Wang R, Blackburn G, Desai M, Phelan D, Gillinov L, Houghtaling P, et al. Accuracy of Wrist-
Worn Heart Rate Monitors. JAMA Cardiol [Internet]. 2016;313(6):625–6. Available from: 
http://jamanetwork.com/journals/jamacardiology/article-abstract/2566167 
247.  Benowitz NL, Jacob P, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and 
caffeine in humans*. Clin Pharmacol Ther [Internet]. 1995 Dec;58(6):684–91. Available from: 
http://doi.wiley.com/10.1016/0009-9236(95)90025-X 
248.  Manning BT, Kearns SM, Bohl DD, Edmiston T, Sporer SM, Levine BR. Prospective Assessment 
of Sleep Quality Before and After Primary Total Joint Replacement. Orthopedics [Internet]. 
2017 Jul 1;40(4):e636–40. Available from: 
http://www.healio.com/doiresolver?doi=10.3928/01477447-20170411-01 
249.  Gong L, Wang ZH, Fan D. Sleep Quality Effects Recovery After Total Knee Arthroplasty (TKA) - 
A Randomized, Double-Blind, Controlled Study. J Arthroplasty [Internet]. 2015;30(11):1897–
901. Available from: http://dx.doi.org/10.1016/j.arth.2015.02.020 
250.  Lyden K, Kozey SL, Staudenmeyer JW, Freedson PS. A comprehensive evaluation of commonly 
References 
  299 / 309   
used accelerometer energy expenditure and MET prediction equations. Eur J Appl Physiol. 
2011;111(2):187–201.  
251.  Kennedy DM, Hanna SE, Stratford PW, Wessel J, Gollish JD. Preoperative Function and Gender 
Predict Pattern of Functional Recovery After Hip and Knee Arthroplasty. J Arthroplasty. 
2006;21(4):559–66.  
252.  Kortram K, Bezstarosti H, Metsemakers W-J, Raschke MJ, Van Lieshout EMM, Verhofstad MHJ. 
Risk factors for infectious complications after open fractures; a systematic review and meta-
analysis. Int Orthop [Internet]. 2017 Oct 25;41(10):1965–82. Available from: 
http://link.springer.com/10.1007/s00264-017-3556-5 
253.  Shim J, Mclernon DJ, Hamilton D, Simpson HA, Beasley M, Macfarlane GJ. Development of a 
clinical risk score for pain and function following total knee arthroplasty: Results from the TRIO 
study. Rheumatol Adv Pract. 2018;2(2):1–9.  
254.  Desmeules F, Dionne CE, Belzile ÉL, Bourbonnais R, Champagne F, Frémont P. Determinants of 
pain, functional limitations and health-related quality of life six months after total knee 
arthroplasty: results from a prospective cohort study. Sport Med Arthrosc Rehabil Ther 
Technol [Internet]. 2013;5(1):2. Available from: https://doi.org/10.1186/2052-1847-5-2 
255.  Fortin PR, Clarke AE, Joseph L, Liang MH, Tanzer M, Ferland D, et al. Outcomes of total hip and 
knee replacement: Preoperative functional status predicts outcomes at six months after 
surgery. Arthritis Rheum. 1999;42(8):1722–8.  
256.  Cabilan CJ, Hines S, Munday J. The effectiveness of prehabilitation or preoperative exercise for 
surgical patients: a systematic review. JBI Database Syst Rev Implement Reports [Internet]. 
2015 Jan;13(1):146–87. Available from: https://insights.ovid.com/crossref?an=01938924-
201513010-00014 
257.  Volpato HBB, Szego P, Lenza M, Milan SL, Talerman C, Ferretti M. Femoral quadriceps 
neuromuscular electrical stimulation after total knee arthroplasty: a systematic review. 
Einstein (Sao Paulo). 2016;14(1):77–98.  
258.  Lowry V, Ouellet P, Vendittoli P-A, Carlesso LC, Wideman TH, Desmeules F. Determinants of 
pain, disability, health-related quality of life and physical performance in patients with knee 
osteoarthritis awaiting total joint arthroplasty. Disabil Rehabil [Internet]. 2017;0(0):1–11. 
Available from: https://www.tandfonline.com/doi/full/10.1080/09638288.2017.1355412 
259.  Judge A, Arden NK, Cooper C, Kassim Javaid M, Carr AJ, Field RE, et al. Predictors of outcomes 
of total knee replacement surgery. Rheumatology [Internet]. 2012 Oct 1;51(10):1804–13. 
Available from: https://academic.oup.com/rheumatology/article-
lookup/doi/10.1093/rheumatology/kes075 
260.  Lingard EA, Katz JN, Wright EA, Sledge CB, Kinemax Outcomes Group. Predicting the outcome 






261.  Sullivan M, Tanzer M, Stanish W, Fallaha M, Keefe FJ, Simmonds M, et al. Psychological 
determinants of problematic outcomes following Total Knee Arthroplasty. Pain [Internet]. 
2009 May;143(1):123–9. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006396-
200905000-00020 
262.  Duivenvoorden T, Vissers MM, Verhaar JAN, Busschbach JJV, Gosens T, Bloem RM, et al. 
Anxiety and depressive symptoms before and after total hip and knee arthroplasty: a 
prospective multicentre study. Osteoarthr Cartil [Internet]. 2013 Dec;21(12):1834–40. 
Available from: https://linkinghub.elsevier.com/retrieve/pii/S1063458413009400 
263.  Khatib Y, Madan A, Naylor JM, Harris IA. Do Psychological Factors Predict Poor Outcome in 
Patients Undergoing TKA? A Systematic Review. Clin Orthop Relat Res [Internet]. 
2015;473(8):2630–8. Available from: http://dx.doi.org/10.1007/s11999-015-4234-9 
264.  Rakel BA, Blodgett NP, Zimmerman BM, Logsden-Sackett N, Clark C, Noiseux N, et al. Predictors 
of postoperative movement and resting pain following total knee replacement. Pain [Internet]. 
2012 Nov;153(11):2192–203. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006396-
201211000-00009 
265.  Woytowicz EJ, Westlake KP, Whitall J, Sainburg RL. Handedness results from complementary 
References 
  300 / 309   
hemispheric dominance, not global hemispheric dominance: evidence from mechanically 
coupled bilateral movements. J Neurophysiol [Internet]. 2018 Aug;120(2):729–40. Available 
from: https://www.physiology.org/doi/10.1152/jn.00878.2017 
266.  Mannen EM, Ali AA, Dennis DA, Haas BD, Rullkoetter PJ, Shelburne KB. Influence of 
Component Geometry on Patellar Mechanics in Posterior-Stabilized Rotating Platform Total 
Knee Arthroplasty. J Arthroplasty [Internet]. 2019 Jan; Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0883540319300403 
267.  Li Y, Kakar RS, Fu Y-C, Mahoney OM, Kinsey TL, Simpson KJ. Knee strength, power and stair 
performance of the elderly 5 years after unicompartmental knee arthroplasty. Eur J Orthop 
Surg Traumatol [Internet]. 2018 Oct;28(7):1411–6. Available from: 
https://doi.org/10.1007/s00590-018-2198-7 
268.  Driban JB, Hootman JM, Sitler MR, Harris KP, Cattano NM. Is Participation in Certain Sports 
Associated With Knee Osteoarthritis? A Systematic Review. J Athl Train [Internet]. 2017 Jun 
2;52(6):497–506. Available from: http://natajournals.org/doi/10.4085/1062-6050-50.2.08 
269.  Roberts WO. Running causes knee osteoarthritis: myth or misunderstanding. Br J Sports Med 
[Internet]. 2018 Feb;52(3):142–142. Available from: 
http://bjsm.bmj.com/lookup/doi/10.1136/bjsports-2017-098227 
270.  Madaleno FO, Santos BA, Araújo VL, Oliveira VC, Resende RA. Prevalence of knee osteoarthritis 
in former athletes: a systematic review with meta-analysis. Brazilian J Phys Ther [Internet]. 
2018 Nov;22(6):437–51. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1413355517306275 
271.  Matharu GS, Mouchti S, Twigg S, Delmestri A, Murray DW, Judge A, et al. The effect of smoking 
on outcomes following primary total hip and knee arthroplasty: a population-based cohort 
study of 117,024 patients. Acta Orthop [Internet]. 2019;3674:1–9. Available from: 
https://www.tandfonline.com/doi/full/10.1080/17453674.2019.1649510 
272.  Smith TO, Penny F, Fleetcroft R. Smoking and alcohol behaviours in people following hip and 
knee arthroplasty: Data from the Osteoarthritis Initiative. Orthop Traumatol Surg Res 
[Internet]. 2016;102(2):239–45. Available from: http://dx.doi.org/10.1016/j.otsr.2015.12.005 
273.  Kong L, Cao J, Zhang Y, Ding W, Shen Y. Risk factors for periprosthetic joint infection following 
primary total hip or knee arthroplasty: a meta-analysis. Int Wound J. 2017;14(3):529–36.  
274.  Jørgensen CC, Kehlet H. Outcomes in smokers and alcohol users after fast-track hip and knee 
arthroplasty. Acta Anaesthesiol Scand. 2013;57(5):631–8.  
275.  Zwart A, Dekker J, Lems W, Roorda L, Esch M, Leeden M. Factors associated with upper leg 
muscle strength in knee osteoarthritis: A scoping review. J Rehabil Med [Internet]. 
2018;50(2):140–50. Available from: 
https://www.medicaljournals.se/jrm/content/abstract/10.2340/16501977-2284 
276.  Dell’isola A, Wirth W, Steultjens M, Eckstein F, Culvenor AG. Knee extensor muscle weakness 
and radiographic knee osteoarthritis progression. Acta Orthop [Internet]. 2018;89(4):406–11. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29714070 
277.  Zietek P, Dziedziejko V, Safranow K, Zietek J, Stępień-Słodkowska M, Bialecka M, et al. TNF-α 
concentrations in pre-operative synovial fluid for predicting early post-operative function and 
pain after fast-track total knee arthroplasty. Knee. 2016;23(6):1044–8.  
278.  Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN. Inflammatory predictors of 
ongoing pain 2 years following knee replacement surgery. Knee [Internet]. 2013;20(5):316–8. 
Available from: http://dx.doi.org/10.1016/j.knee.2012.10.015 
279.  Cremeans-Smith JK, Greene K, Delahanty DL. Physiological indices of stress prior to and 
following total knee arthroplasty predict the occurrence of severe post-operative pain. Pain 
Med (United States). 2016;17(5):970–9.  
280.  Muyskens JB, Foote DM, Bigot NJ, Strycker LA, Smolkowski K, Kirkpatrick TK, et al. Cellular and 
morphological changes with EAA supplementation before and after total knee arthroplasty. J 
Appl Physiol [Internet]. 2019 Jul 25;japplphysiol.00869.2018. Available from: 
https://www.physiology.org/doi/10.1152/japplphysiol.00869.2018 
281.  Dreyer HC, Strycker LA, Senesac HA, Hocker AD, Smolkowski K, Shah SN, et al. Essential amino 
acid supplementation in patients following total knee arthroplasty. J Clin Invest [Internet]. 
2013 Nov 1;123(11):4654–66. Available from: http://www.jci.org/articles/view/70160 
282.  Turnbull GS, Scott CEH, MacDonald DJ, Breusch SJ. Gender and preoperative function predict 
physical activity levels after revision total knee arthroplasty. J Arthroplasty [Internet]. 2019; 
Available from: https://www.sciencedirect.com/science/article/pii/S0883540319300853 
283.  DH Research and Development Directorate (England), National Institute for Social Care and 
References 
  301 / 309   
Health Research (Wales), Chief Scientist Office (Scotland), R&D Division, Public Health Agency 
(Northern Ireland). Governance Arrangements for Research Ethics Committees. DoH 
[Internet]. 2011;(May). Available from: 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Pub
licationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4005727 
284.  (CIOMS) C for IO of MS and WHO (WHO). International Ethical Guidelines for Health-related 
Research Involving Humans Fourth Edition. Geneva [Internet]. Biomedical Research. 2016. 
Available from: http://www.sciencedirect.com/science/article/B6VC6-45F5X02-
9C/2/e44bc37a6e392634b1cf436105978f01 
285.  Health Research Authority (HRA). Integrated Research Application System (IRAS) [Internet]. 
Available from: http://www.myresearchproject.org.uk/ 
286.  NHS Health Research Authority. Research Summary - MAKRO Study [Internet]. 2017. Available 
from: https://www.hra.nhs.uk/planning-and-improving-research/application-
summaries/research-summaries/muscular-assessed-knee-replacement-outcome-makro/ 
287.  UKCGC. UK Caldicott Guardian Council Information. 2019.  
288.  Flesch R. A new readability yardstick. J Appl Psychol [Internet]. 1948 Jun;32(3):221–33. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/18867058 
289.  El-Daly I, Ibraheim H, Rajakulendran K, Culpan P, Bates P. Are Patient-reported Outcome 
Measures in Orthopaedics Easily Read by Patients? Clin Orthop Relat Res. 2016;474(1):246–
55.  
290.  McCarthy CJ, Oldham JA. The reliability, validity and responsiveness of an aggregated 
locomotor function (ALF) score in patients with osteoarthritis of the knee. Rheumatology. 
2004;43(4):514–7.  
291.  Bassey EJ, Short AH. A new method for measuring power output in a single leg extension: 
feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol [Internet]. 1990;60(5):385–
90. Available from: http://link.springer.com/10.1007/BF00713504 
292.  Robertson S, Frost H, Doll H, O’Connor JJ. Leg extensor power and quadriceps strength: An 
assessment of repeatability in patients with osteoarthritic knees. Clin Rehabil. 
1998;12(2):120–6.  
293.  Simpson H, Kingdom U, Augat P. Experimental Research Methods in Orthopaedics and 
Trauma. 2015;  
294.  Aljehani M, Madara K, Snyder-Mackler L, Christiansen C, Zeni JA. The contralateral knee may 
not be a valid control for biomechanical outcomes after unilateral total knee arthroplasty. Gait 
Posture [Internet]. 2019 May;70:179–84. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0966636218305307 
295.  Dickstein R, Heffes Y, Shabtai EI, Markowitz E. Total Knee Arthroplasty in the Elderly: Patients’ 
Self-Appraisal 6 and 12 Months Postoperatively. Gerontology [Internet]. 1998;44(4):204–10. 
Available from: https://www.karger.com/Article/FullText/22011 
296.  Ministry of Justice; Hertfordshire Constabulary. Electronic Monitoring GPS Satellite Tagging 
handbook [Internet]. 2015. Available from: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/563633/Annex_N_-_GPS_handbook.pdf 
297.  Scottish Government. Electronic Monitoring in Scotland Working Group Final Report 




298.  International Electrotechnical Commission. Degrees of protection provided by enclosures (IP 
Code). 60529:1989+AMD1:1999+AMD2:2013, 2013.  
299.  El Gaafary M. A Guide to PROMs Methodology and Selection Criteria. In: El Miedany Y, editor. 
Patient Reported Outcome Measures in Rheumatic Diseases [Internet]. Cham: Springer 
International Publishing; 2016. p. 21–58. Available from: https://doi.org/10.1007/978-3-319-
32851-5_2 
300.  Voshaar MAHO, van de Laar MAFJ. PROMs and Quality of Care. In: El Miedany Y, editor. Patient 
Reported Outcome Measures in Rheumatic Diseases [Internet]. Cham: Springer International 
Publishing; 2016. p. 1–19. Available from: https://doi.org/10.1007/978-3-319-32851-5_1 
301.  Breakwell LM, Cole AA, Birch N, Heywood C. Should we all go to the PROM? The first two years 
of the British Spine Registry. Bone Jt J. 2015;97-B(7):871–4.  
302.  J.E. Ware CDS. The MOS 36-Item Short-Form Health Survey ( SF-36 ): I . Conceptual Framework 
References 
  302 / 309   
and Item Selection Author ( s ): John E . Ware , Jr . and Cathy Donald Sherbourne Published 
by : Lippincott Williams & Wilkins Stable URL : http://www.jstor.org/stable/3765916 Ac. Med 
Care. 1992;30(6):473–83.  
303.  Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-
36 health survey questionnaire: new outcome measure for primary care. BMJ [Internet]. 1992 
Jul 18;305(6846):160–4. Available from: 
http://www.bmj.com/cgi/doi/10.1136/bmj.305.6846.160 
304.  Ware. J. E. SF-36 Health Survey Update. Spine (Phila Pa 1976) [Internet]. 2000;25(24):3130–9. 
Available from: http://www.sf-36.org/tools/sf36.shtml%5CnSF-36 
305.  Charlson ME, Pompei P, Ales KL, MacKenzie RC. a New Method of Classifying Prognostic in 
Longitudinal Studies : Development. J Chronic Dis. 1987;40(5):373–83.  
306.  Group TE. EuroQol - a new facility for the measurement of health-related quality of life. Health 
Policy (New York) [Internet]. 1990;16(3):199–208. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/0168851090904219 
307.  Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of 
the knee. Rheumatology. 1999;38(9):807–13.  
308.  Behrend H, Giesinger K, Giesinger JM, Kuster MS. The “Forgotten Joint” as the Ultimate Goal 
in Joint Arthroplasty. J Arthroplasty [Internet]. 2011;27(3):430-436.e1. Available from: 
http://dx.doi.org/10.1016/j.arth.2011.06.035 
309.  Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation 
and comparison to the WOMAC in total knee replacement. Heal Qual Life Outcomes. 
2003;1:17.  
310.  Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about 
total knee replacement. J Bone Jt Surg. 2003;80(1):63–9.  
311.  Scott CEH, Howie CR, MacDonald D, Biant LC. Predicting dissatisfaction following total knee 
replacement. J Bone Joint Surg Br. 2010;92-B(9):1253–8.  
312.  Tegner Y, Lysholm J. Rating Systems in the Evaluation of Knee Ligament Injuries. Clin Orthop 
Relat Res [Internet]. 1985 Sep;(198):43–9. Available from: 
https://insights.ovid.com/crossref?an=00003086-198509000-00007 
313.  Fältström A, Hägglund M, Kvist J. Patient-reported knee function, quality of life, and activity 
level after bilateral anterior cruciate ligament injuries. Am J Sports Med. 2013;41(12):2805–
13.  
314.  Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life 
measures: Literature review and proposed guidelines. J Clin Epidemiol [Internet]. 1993 
Dec;46(12):1417–32. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/089543569390142N 
315.  Williamson A, Hoggart Mbbs B. ISSUES IN CLINICAL NURSING Pain: a review of three commonly 





316.  van Vliet M, Huisman M, Deeg DJH. Decreasing Hospital Length of Stay: Effects on Daily 
Functioning in Older Adults. J Am Geriatr Soc. 2017;65(6):1214–21.  
317.  Duchenne GBA. Recherches sur la paralysie musculaire pseudohypertrophique ou paralysie 
myo-sclérosique. Arch gén Méd. 1868;11:179–209.  
318.  Bergström J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical 
Research. Scand J Clin Lab Invest. 1975;35(7):609–16.  
319.  Lindgren PG. Percutaneous needle biopsy. A new technique. Acta Radiol - Ser Diagnosis. 
1982;23(6):653–6.  
320.  Parodi B. Biobanks: A Definition. In: Mascalzoni D, editor. Ethics, Law and Governance of 
Biobanking: National, European and International Approaches [Internet]. Dordrecht: Springer 
Netherlands; 2015. p. 15–9. Available from: https://doi.org/10.1007/978-94-017-9573-9_2 
321.  Gwathmey FW, Miller MD. Primary Anterior Cruciate Ligament Reconstruction. In: Operative 
Techniques: Knee Surgery [Internet]. Elsevier; 2018. p. 165–76. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/B9780323462921000198 
322.  Dubowitz V, Swery C, Oldfors A, Lane R. Muscle biopsy [Internet]. 2013. 1–6 p. Available from: 
http://neuromuscular.wustl.edu/lab/mbiopsy.htm#stain 
323.  Siri WE. Body composition from fluid spaces and density: analysis of methods. Nutrition 
References 
  303 / 309   
[Internet]. 1956;9(5):480–91; discussion 480, 492. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/8286893 
324.  Bruce A, Andersson M, Arvidsson B, Isaksson B. Body composition. Prediction of normal body 
potassium, body water and body fat in adults on the basis of body height, body weight and 
age. Scand J Clin Lab Invest [Internet]. 1980 Jan 8;40(5):461–73. Available from: 
http://www.tandfonline.com/doi/full/10.3109/00365518009101869 
325.  Deurenberg P, van der Kooy K, Leenen R, Weststrate JA, Seidell JC. Sex and age specific 
prediction formulas for estimating body composition from bioelectrical impedance: a cross-
validation study. Int J Obes [Internet]. 1991 Jan;15(1):17–25. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/2010255 
326.  Walker JM. Myogenesis - Methods and Protocols [Internet]. Vol. 531, Life Sciences. 2009. 588 
p. Available from: http://books.google.com/books?id=Ku2wPAAACAAJ 
327.  Meng H, Janssen PML, Grange RW, Yang L, Beggs AH, Swanson LC, et al. Tissue triage and 
freezing for models of skeletal muscle disease. J Vis Exp [Internet]. 2014;(89):e51586. Available 
from: http://www.jove.com/video/51586/tissue-triage-and-freezing-for-models-of-skeletal-
muscle-disease 
328.  Spencer LT. 7 - Microtomy for paraffin and frozen sections. In: Suvarna SK, Layton C, Bancroft 
JD, editors. Bancroft’s Theory and Practice of Histological Techniques (Eighth Edition) 
[Internet]. Eighth Edi. Content Repository Only!; 2019. p. 84–95. Available from: 
http://www.sciencedirect.com/science/article/pii/B9780702068645000074 
329.  Leidenfrost JG. De aquae communis nonnullis qualitatibus tractatus. In Ovenius; 1756.  
330.  Quéré D. Leidenfrost Dynamics. Annu Rev Fluid Mech. 2012;45(1):197–215.  
331.  Baumeister KJ, Asme M, Simon FF. Leidenfrost Temperature-Its Correlation for Lipid Metals, 
Cryogens, Hydrocarbons, and Water. 1973; Available from: 
http://heattransfer.asmedigitalcollection.asme.org/ 
332.  Guthrie GB, Huffman HM. Thermal Data. XVI. The Heat Capacity and Entropy of Isopentane. 
The Absence of a Reported Anomaly. J Am Chem Soc. 1943;65(6):1139–43.  
333.  Perkins RA, Roder HM, Friend DG, Nieto de Castro CA. The thermal conductivity and heat 
capacity of fluid nitrogen. Phys A Stat Mech its Appl [Internet]. 1991 May;173(3):332–62. 
Available from: http://linkinghub.elsevier.com/retrieve/pii/037843719190368M 
334.  Dechema. DETHERM web portal database [Internet]. 2018. Available from: 
http://detherm.cds.rsc.org/detherm/index.php 
335.  Yaws CL. Volume 2 - Organic Compounds C5 to C7. In: Handbook of Thermal Conductivity. 
1995. p. 70.  
336.  Behan WMH, Cossar DW, Madden HA, McKay IC. Validation of a simple, rapid, and economical 
technique for distinguishing type 1 and 2 fibres in fixed and frozen skeletal muscle. J Clin Pathol 
[Internet]. 2002;55(5):375–80. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1769641&tool=pmcentrez&ren
dertype=abstract 
337.  Kumar A, Accorsi A, Rhee Y, Girgenrath M. Do’s and Don’ts in the Preparation of Muscle 
Cryosections for Histological Analysis. J Vis Exp [Internet]. 2015;(99):1–7. Available from: 
http://www.jove.com/video/52793/do-s-don-ts-preparation-muscle-cryosections-for-
histological 
338.  Almeida CF, Fernandes SA, Ribeiro Junior AF, Keith Okamoto O, Vainzof M, Almeida CF, et al. 
Muscle Satellite Cells: Exploring the Basic Biology to Rule Them. Stem Cells Int [Internet]. 
2016;2016:1–14. Available from: http://www.hindawi.com/journals/sci/2016/1078686/ 
339.  McKay BR, Toth KG, Tarnopolsky MA, Parise G. Satellite cell number and cell cycle kinetics in 
response to acute myotrauma in humans: immunohistochemistry versus flow cytometry. J 
Physiol [Internet]. 2010;588(Pt 17):3307–20. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2976024&tool=pmcentrez&ren
dertype=abstract 
340.  Lindström M, Thornell LE. New multiple labelling method for improved satellite cell 
identification in human muscle: Application to a cohort of power-lifters and sedentary men. 
Histochem Cell Biol. 2009;132(2):141–57.  
341.  Capkovic KL, Stevenson S, Johnson MC, Thelen JJ, Cornelison DDW. Neural cell adhesion 
molecule (NCAM) marks adult myogenic cells committed to differentiation. Exp Cell Res 
[Internet]. 2008 Apr;314(7):1553–65. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0014482708000505 
342.  Wang C, Yue F, Kuang S. Muscle Histology Characterization Using H&amp;amp;E Staining and 
References 
  304 / 309   
Muscle Fiber Type Classification Using Immunofluorescence Staining. Bio-Protocol [Internet]. 
2017;7(10):1–12. Available from: http://www.bio-protocol.org/e2279 
343.  Feng X, Naz F, Juan AH, Orso SD, Sartorelli V. Identification of Skeletal Muscle Satellite Cells by 
Immunofluorescence with Pax7 and Laminin Antibodies. 2018;(April):8–13.  
344.  Nederveen JP, Joanisse S, Snijders T, Thomas AC, Kumbhare D, Parise G. The influence of 
capillarization on satellite cell pool expansion and activation following exercise-induced 
muscle damage in healthy young men. J Physiol [Internet]. 2018;6:1063–78. Available from: 
http://doi.wiley.com/10.1113/JP275155 
345.  Damas F, Libardi CA, Ugrinowitsch C, Vechin FC, Lixandrão ME, Snijders T, et al. Early- and later-
phases satellite cell responses and myonuclear content with resistance training in young men. 
PLoS One. 2018;13(1):1–12.  
346.  Pugh JK, Faulkner SH, Turner MC, Nimmo MA. Satellite cell response to concurrent resistance 
exercise and high-intensity interval training in sedentary, overweight/obese, middle-aged 
individuals. Eur J Appl Physiol [Internet]. 2017;0(0):0. Available from: 
http://link.springer.com/10.1007/s00421-017-3721-y 
347.  McKay BR, Ogborn DI, Baker JM, Toth KG, Tarnopolsky MA, Parise G. Elevated SOCS3 and 
altered IL-6 signaling is associated with age-related human muscle stem cell dysfunction. AJP 
Cell Physiol [Internet]. 2013;304(8):C717–28. Available from: 
http://ajpcell.physiology.org/cgi/doi/10.1152/ajpcell.00305.2012 
348.  Messi ML, Li T, Wang ZM, Marsh AP, Nicklas B, Delbono O. Resistance Training Enhances 
Skeletal Muscle Innervation Without Modifying the Number of Satellite Cells or their Myofiber 
Association in Obese Older Adults. Journals Gerontol - Ser A Biol Sci Med Sci. 
2016;71(10):1273–80.  
349.  Yamashita S, Okada Y. Application of heat-induced antigen retrieval to aldehyde-fixed fresh 
frozen sections. J Histochem Cytochem. 2005;53(11):1421–32.  
350.  Brown D, Lydon J, McLaughlin M, Stuart-Tilley  a, Tyszkowski R, Alper S. Antigen retrieval in 
cryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS). 
Histochem Cell Biol. 1996;105:261–7.  
351.  Costin-Kelly N. Histological analysis of a muscle biopsy. Biomed Sci [Internet]. 
2008;(December):1063–70. Available from: http://www.ibms.org/go/media/the-biomedical-
scientist/archive,2008,12,151 
352.  Fiacco E, Castagnetti F, Bianconi V, Madaro L, De Bardi M, Nazio F, et al. Autophagy regulates 
satellite cell ability to regenerate normal and dystrophic muscles. Cell Death Differ [Internet]. 
2016;1–11. Available from: http://www.nature.com/doifinder/10.1038/cdd.2016.70 
353.  Rubart M, Field LJ. CARDIAC REGENERATION: Repopulating the Heart. Annu Rev Physiol 
[Internet]. 2006 Jan;68(1):29–49. Available from: 
http://www.annualreviews.org/doi/10.1146/annurev.physiol.68.040104.124530 
354.  Benson RC, Meyer RA, Zaruba ME, McKhann GM. Cellular autofluorescence--is it due to 
flavins? J Histochem Cytochem [Internet]. 1979 Jan 5;27(1):44–8. Available from: 
http://journals.sagepub.com/doi/10.1177/27.1.438504 
355.  Jackson KA, Snyder DS, Goodell MA. Skeletal muscle fiber-specific green autofluorescence: 
potential for stem cell engraftment artifacts. Stem Cells [Internet]. 2004;22(2):180–7. 
Available from: papers3://publication/uuid/DD8ABC4C-5F82-40A4-90B7-0BD7F50269CB 
356.  Lichtman JW, Conchello J-A. Fluorescence microscopy. Nat Methods [Internet]. 2005 Dec 
18;2(12):910–9. Available from: http://www.nature.com/articles/nmeth817 
357.  Dobrucki JW, Kubitscheck U. Fluorescence Microscopy. In: Fluorescence Microscopy 
[Internet]. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2017. p. 85–132. 
Available from: http://doi.wiley.com/10.1002/9783527687732.ch3 
358.  Atzinger U. University of Arizona Spectra Database.  
359.  Abcam Plc. Abcam Technical Supplements [Internet]. 2018. Available from: 
www.abcam.com/technical 
360.  Mayeuf-louchart A, Hardy D, Thorel Q, Roux P, Gueniot L, Briand D, et al. MuscleJ : a high-
content analysis method to study skeletal muscle with a new Fiji tool. 2018;1–11.  
361.  Conboy MJ, Cerletti M, Wagers AJ, Conboy IM. Chapter 11 - Immuno-Analysis and FACS Sorting 
of Adult Muscle Fiber-Associated Stem/Precursor Cells. Vol. 621. 2010. 165–173 p.  
362.  Garcia SM, Tamaki S, Lee S, Wong A, Jose A, Dreux J, et al. High-Yield Purification, Preservation, 
and Serial Transplantation of Human Satellite Cells. Stem Cell Reports [Internet]. 
2018;10(3):1160–74. Available from: https://doi.org/10.1016/j.stemcr.2018.01.022 
363.  Crowley LC, Scott AP, Marfell BJ, Boughaba JA, Chojnowski G, Waterhouse NJ. Measuring Cell 
References 
  305 / 309   
Death by Propidium Iodide Uptake and Flow Cytometry. Cold Spring Harb Protoc [Internet]. 
2016 Jul 1;2016(7):pdb.prot087163. Available from: 
http://www.cshprotocols.org/lookup/doi/10.1101/pdb.prot087163 
364.  Rio DC, Ares M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI Reagent). Cold 
Spring Harb Protoc. 2010;5(6):1–4.  
365.  Simms D, Cizdziel PE, Chomczynski P. TRIzol: A new reagent for optimal single-step isolation of 
RNA. Focus (Madison). 1993;15(4):532–5.  
366.  Bonham MJ, Danielpour D. Improved purification and yields of RNA by RNeasy®. 
Biotechniques. 1996;21(1):57–60.  
367.  Wilfinger WW, Mackey K, Chomczynski P. Short Technical Reports: Effect of pH and Ionic 
Strength on the Spectro- photometric Assessment of Nucleic Acid Purity BioTechniques. 
Biotechniques. 1997;22(3):474–81.  




369.  Van Lieshout EMM. 39 Molecular Testing. In: Simpson H, Augat P, editors. Experimental 
Research Methods in Orthopedics and Trauma [Internet]. Stuttgart: Georg Thieme Verlag; 
2015. Available from: http://www.thieme-
connect.de/products/ebooks/lookinside/10.1055/b-0035-122039 
370.  Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol 
Aspects Med. 2006;27(2–3):126–39.  
371.  Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA 
integrity number for assigning integrity values to RNA measurements. BMC Mol Biol [Internet]. 
2006 Jan 31;7:3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16448564 
372.  Botling J, Edlund K, Segersten U, Tahmasebpoor S, Engström M, Sundström M, et al. Impact of 
Thawing on RNA Integrity and Gene Expression Analysis in Fresh Frozen Tissue. Diagnostic Mol 
Pathol [Internet]. 2009 Mar;18(1):44–52. Available from: 
https://insights.ovid.com/crossref?an=00019606-200903000-00006 
373.  National Centre for Biotechnology Infomation (US). NIH Gene Resource [Internet]. Available 
from: https://www.ncbi.nlm.nih.gov/gene/ 
374.  Pfaffl MW. Determination of most stable housekeeping genes, differentially regulated target 
genes and sample integrity : BestKeeper© - Excel spreadsheet tool using a Repeated Pair-wise 
Correlation and Regression Analysis. 2004;509–15.  
375.  Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate 
normalization of real-time quantitative RT-PCR data by geometric averaging of multiple 
internal control genes. Genome Biol [Internet]. 2002 Jun 18;3(7):RESEARCH0034. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/12184808 
376.  Andersen CL. Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A 
Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, 
Applied to Bladder and Colon Cancer Data Sets. Cancer Res [Internet]. 2004;64(15):5245–50. 
Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-04-0496 
377.  Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative 
quantification framework and software for management and automated analysis of real-time 
quantitative PCR data. Genome Biol [Internet]. 2007;8(2):R19. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17291332 
378.  Costin-Kelly N. Collecting and handling muscle biopsies. Biomed Sci. 2008;(June):491–5.  
379.  Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: 
minimum information for publication of quantitative real-time PCR experiments. Clin Chem 
[Internet]. 2009 Apr;55(4):611–22. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19246619 
380.  Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 
[Internet]. 2006;1(3):1559–82. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17406449 
381.  Farrar JS, Wittwer CT. High-Resolution Melting Curve Analysis for Molecular Diagnostics. In: 
Molecular Diagnostics [Internet]. Elsevier; 2017. p. 79–102. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/B9780128029718000067 
382.  Lee S, Lee DK. What is the proper way to apply the multiple comparison test? Korean J 
Anesthesiol. 2018;71(5):353–60.  
References 
  306 / 309   
383.  Chen SY, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. J Thorac 
Dis. 2017;9(6):1725–9.  
384.  Chan YH. Biostatistics 104: correlational analysis. Singapore Med J [Internet]. 2003 
Dec;44(12):614–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14770254 
385.  Akoglu H. User’s guide to correlation coefficients. Turkish J Emerg Med. 2018;18(3):91–3.  
386.  Campos J, Ericsson NR, Hendry DF. Board of Governors of the Federal Reserve System General-
to-specific Modeling: An Overview and Selected Bibliography General-to-specific Modeling: An 
Overview and Selected Bibliography. 2005;(838).  
387.  Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for 
improving the quality of reports of parallel-group randomised trials. Lancet (London, England) 
[Internet]. 2001 Apr 14;357(9263):1191–4. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11323066 
388.  National Joint Registry’s Steering Committee. National Joint Registry Reports [Internet]. 2018. 
Available from: http://www.njrreports.org.uk/knees-primary-procedures-patient-
characteristics 
389.  Scottish Government. Scottish Index of Multiple Deprivation [Internet]. National Statistics 
Scotland. 2016. Available from: https://www2.gov.scot/Topics/Statistics/SIMD 
390.  Brandt KD, Fife RS, Braunstein EM, Katz B. Radiographic grading of the severity of knee 
osteoarthritis: Relation of the Kellgren and Lawrence grade to a grade based on joint space 
narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. 
Arthritis Rheum. 1991;34(11):1381–6.  
391.  Neogi T, Felson D, Niu J, Nevitt M, Lewis CE, Aliabadi P, et al. Association between radiographic 
features of knee osteoarthritis and pain: Results from two cohort studies. BMJ. 
2009;339(7719):498–501.  
392.  Bjerke J, Öhberg F, Nilsson KG, Foss OA, Stensdotter AK. Peak Knee Flexion Angles During Stair 
Descent in TKA Patients. J Arthroplasty [Internet]. 2014;29(4):707–11. Available from: 
http://dx.doi.org/10.1016/j.arth.2013.07.010 
393.  Hamilton DF, Gaston P, Simpson AHRW. Is patient reporting of physical function accurate 
following total knee replacement? J Bone Jt Surg - Ser B. 2012;94 B(11):1506–10.  
394.  Giesinger JM, Hamilton DF, Jost B, Behrend H, Giesinger K. WOMAC, EQ-5D and Knee Society 
Score Thresholds for Treatment Success After Total Knee Arthroplasty. J Arthroplasty 
[Internet]. 2015;30(12):2154–8. Available from: http://dx.doi.org/10.1016/j.arth.2015.06.012 
395.  Baker PN, Petheram T, Jameson SS, Avery PJ, Reed MR, Gregg PJ, et al. Comparison of patient-
reported outcome measures following total and unicondylar knee replacement. J Bone Jt Surg 
- Ser B. 2012;94 B(7):919–27.  
396.  Ramkumar PN, Harris JD, Noble PC. Patient-reported outcome measures after total knee 
arthroplasty: A systematic review. Bone Jt Res. 2015;4(7):120–7.  
397.  Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A 
new instrument for psychiatric practice and research. Psychiatry Res [Internet]. 1989 
May;28(2):193–213. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/0165178189900474 
398.  Johns MW. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. 
Sleep [Internet]. 1991;14(6):540–5. Available from: https://doi.org/10.1093/sleep/14.6.540 
399.  Rosipal R, Lewandowski A, Dorffner G. In search of objective components for sleep quality 
indexing in normal sleep. Biol Psychol [Internet]. 2013 Sep;94(1):210–20. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0301051113001464 
400.  Yercan HS, Sugun TS, Bussiere C, Ait Si Selmi T, Davies A, Neyret P. Stiffness after total knee 
arthroplasty: Prevalence, management and outcomes. Knee. 2006;13(2):111–7.  
401.  Travnik L, Pernus F, Erzen I. Histochemical and morphometric characteristics of the normal 
human vastus medialis longus and vastus medialis obliquus muscles. J Anat [Internet]. 1995 
Oct;187 ( Pt 2:403–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7592003 
402.  Staron RS, Hagerman FC, Hikida RS, Murray TF, Hostler DP, Crill MT, et al. Fiber type 
composition of the vastus lateralis muscle of young men and women. J Histochem Cytochem. 
2000;48(5):623–9.  
403.  Moresi V, Adamo S, Berghella L. The JAK/STAT pathway in skeletal muscle pathophysiology. 
Front Physiol. 2019;10(APR).  
404.  McCall MN, McMurray HR, Land H, Almudevar A. On non-detects in qPCR data. Bioinformatics. 
2014;30(16):2310–6.  
405.  Bade MJ, Kittelson JM, Kohrt WM, Stevens-Lapsley JE. Predicting functional performance and 
References 
  307 / 309   
range of motion outcomes after total knee arthroplasty. Am J Phys Med Rehabil [Internet]. 
2014;93(7):579–85. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4350663&tool=pmcentrez&ren
dertype=abstract 
406.  Mackie A, Muthumayandi K, Shirley M, Deehan D, Gerrand C. Association between body mass 
index change and outcome in the first year after total knee arthroplasty. J Arthroplasty 
[Internet]. 2015;30(2):206–9. Available from: http://dx.doi.org/10.1016/j.arth.2014.09.003 
407.  Harris K, Lim CR, Dawson J, Fitzpatrick R, Beard DJ, Price AJ. The Oxford knee score and its 
subscales do not exhibit a ceiling or a floor effect in knee arthroplasty patients: an analysis of 
the National Health Service PROMs data set. Knee Surgery, Sport Traumatol Arthrosc 
[Internet]. 2017 Sep 30;25(9):2736–42. Available from: 
http://link.springer.com/10.1007/s00167-015-3788-0 
408.  Witjes S, Gouttebarge V, Kuijer PPFM, van Geenen RCI, Poolman RW, Kerkhoffs GMMJ. Return 
to Sports and Physical Activity After Total and Unicondylar Knee Arthroplasty: A Systematic 
Review and Meta-Analysis. Sport Med [Internet]. 2016 Feb;46(2):269–92. Available from: 
https://doi.org/10.1007/s40279-015-0421-9 
409.  Swanson EA, Schmalzried TP, Dorey FJ. Activity Recommendations After Total Hip and Knee 
Arthroplasty: A Survey of the American Association for Hip and Knee Surgeons. J Arthroplasty 
[Internet]. 2009;24(6, Supplement):120–6. Available from: 
http://www.sciencedirect.com/science/article/pii/S0883540309001892 
410.  Clement ND, MacDonald D, Patton JT, Burnett R. Post-operative Oxford knee score can be used 
to indicate whether patient expectations have been achieved after primary total knee 
arthroplasty. Knee Surgery, Sport Traumatol Arthrosc [Internet]. 2015 Jun 1;23(6):1578–90. 
Available from: http://link.springer.com/10.1007/s00167-014-2865-0 
411.  Barker KL, Hannink E, Pemberton S, Jenkins C. Knee Arthroplasty Patients Predicted Versus 
Actual Recovery: What Are Their Expectations About Time of Recovery After Surgery and How 
Long Before They Can Do the Tasks They Want to Do? Arch Phys Med Rehabil [Internet]. 
2018;99(11):2230–7. Available from: https://doi.org/10.1016/j.apmr.2018.03.022 
412.  de Achaval S, Kallen MA, Amick B, Landon G, Siff S, Edelstein D, et al. Patients’ expectations 
about total knee arthroplasty outcomes. Heal Expect. 2016;19(2):299–308.  
413.  Groen J-W, Stevens M, Kersten RFMR, Reininga IHF, van den Akker-Scheek I. After total knee 
arthroplasty, many people are not active enough to maintain their health and fitness: an 
observational study. J Physiother [Internet]. 2012;58(2):113–6. Available from: 
http://www.sciencedirect.com/science/article/pii/S1836955312700917 
414.  Lavernia CJ, Sierra RJ, Baerga L. Nutritional Parameters and Short Term Outcome in 
Arthroplasty. J Am Coll Nutr [Internet]. 1999;18(3):274–8. Available from: 
https://doi.org/10.1080/07315724.1999.10718863 
415.  Kremers HM, Kremers WK, Berry DJ, Lewallen DG. Social and Behavioral Factors in Total Knee 
and Hip Arthroplasty. J Arthroplasty [Internet]. 2015;30(10):1852–4. Available from: 
http://www.sciencedirect.com/science/article/pii/S0883540315003228 
416.  Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HHCM, van Loon LJC. Satellite cell 
content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol 
Endocrinol Metab [Internet]. 2007;292(1):E151–7. Available from: 
http://ajpendo.physiology.org/content/ajpendo/292/1/E151.full.pdf 
417.  Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related 
skeletal muscle wasting and weakness. Biogerontology. 2008;9(4):213–28.  
418.  Mackey AL, Karlsen A, Couppé C, Mikkelsen UR, Nielsen RH, Magnusson SP, et al. Differential 
satellite cell density of type I and II fibres with lifelong endurance running in old men. Acta 
Physiol. 2014;210(3):612–27.  
419.  Brzeszczynska J, Johns N, Schilb A, Degen S, Degen M, Langen R, et al. Loss of oxidative defense 
and potential blockade of satellite cell maturation in the skeletal muscle of patients with 
cancer but not in the healthy elderly. Aging (Albany NY). 2016;8(8):1690–702.  
420.  Paulsen G, Mikkelsen UR, Raastad T, Peake JM. Leucocytes, cytokines and satellite cells: what 
role do they play in muscle damage and regeneration following eccentric exercise? Exerc 
Immunol Rev. 2012;18:42–97.  
421.  Schoenfeld BJ. The use of nonsteroidal anti-inflammatory drugs for exercise-induced muscle 
damage: Implications for skeletal muscle development. Sport Med. 2012;42(12):1017–28.  
422.  Landi F, Marzetti E, Liperoti R, Pahor M, Russo A, Martone AM, et al. Nonsteroidal anti-
inflammatory drug (NSAID) use and sarcopenia in older people: Results from the ilsirente 
References 
  308 / 309   
study. J Am Med Dir Assoc [Internet]. 2013;14(8):626.e9-626.e13. Available from: 
http://dx.doi.org/10.1016/j.jamda.2013.04.012 
423.  Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle 
growth and atrophy. FEBS J. 2013;280(17):4294–314.  
424.  Guttridge DC. NF-kappa B-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle 
Decay and Cachexia. Science (80- ) [Internet]. 2000 Sep 29;289(5488):2363–6. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.289.5488.2363 
425.  Sousa-Victor P, Gutarra S, García-Prat L, Rodriguez-Ubreva J, Ortet L, Ruiz-Bonilla V, et al. 
Geriatric muscle stem cells switch reversible quiescence into senescence. Nature [Internet]. 
2014 Feb 12;506:316. Available from: https://doi.org/10.1038/nature13013 
426.  McCormick R, Vasilaki A. Age-related changes in skeletal muscle: changes to life-style as a 
therapy. Biogerontology [Internet]. 2018;19(6):519–36. Available from: 
https://doi.org/10.1007/s10522-018-9775-3 
427.  Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor 
and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Metab. 
2017;280(5):E745–51.  
428.  Herrenbruck AR, Bollinger LM. Role of skeletal muscle autophagy in high-fat-diet – induced 
obesity and exercise. 2019;0(0):1–9.  
429.  Mackey AL, Rasmussen LK, Kadi F, Schjerling P, Helmark IC, Ponsot E, et al. Activation of 
satellite cells and the regeneration of human skeletal muscle are expedited by ingestion of 
nonsteroidal anti-inflammatory medication. FASEB J [Internet]. 2016 Jun;30(6):2266–81. 
Available from: http://www.fasebj.org/doi/10.1096/fj.201500198R 
430.  Trappe TA, Carroll CC, Dickinson JM, LeMoine JK, Haus JM, Sullivan BE, et al. Influence of 
acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older 




431.  Morgan PT, Bowtell JL, Vanhatalo A, Jones AM, Bailey SJ. Acute acetaminophen ingestion 
improves performance and muscle activation during maximal intermittent knee extensor 
exercise. Eur J Appl Physiol [Internet]. 2018 Mar 13;118(3):595–605. Available from: 
http://link.springer.com/10.1007/s00421-017-3794-7 
432.  D’Lugos AC, Patel SH, Ormsby JC, Curtis DP, Fry CS, Carroll CC, et al. Prior acetaminophen 
consumption impacts the early adaptive cellular response of human skeletal muscle to 
resistance exercise. J Appl Physiol [Internet]. 2018 Apr 1;124(4):1012–24. Available from: 
https://www.physiology.org/doi/10.1152/japplphysiol.00922.2017 
433.  Haizlip KM, Harrison BC, Leinwand LA. Sex-based differences in skeletal muscle kinetics and 
fiber-type composition. Physiology (Bethesda) [Internet]. 2015;30(1):30–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25559153%0Ahttp://www.pubmedcentral.nih.gov/ar
ticlerender.fcgi?artid=PMC4285578 
434.  Snyder A, Colvin B, Gammack JK. Pedometer Use Increases Daily Steps and Functional Status 
in Older Adults. J Am Med Dir Assoc [Internet]. 2011;12(8):590–4. Available from: 
http://dx.doi.org/10.1016/j.jamda.2010.06.007 
435.  Harkin B, Webb TL, Chang BPI, Prestwich A, Conner M, Kellar I, et al. Does monitoring goal 
progress promote goal attainment? A meta-analysis of the experimental evidence. Psychol 
Bull [Internet]. 2016 Feb;142(2):198–229. Available from: 
http://doi.apa.org/getdoi.cfm?doi=10.1037/bul0000025 
436.  Barengo NC, Antikainen R, Borodulin K, Harald K, Jousilahti P. Leisure-Time Physical Activity 
Reduces Total and Cardiovascular Mortality and Cardiovascular Disease Incidence in Older 
Adults. J Am Geriatr Soc. 2017;65(3):504–10.  
437.  Sparling PB, Howard BJ, Dunstan DW, Owen N. Recommendations for physical activity in older 
adults. BMJ [Internet]. 2015 Jan 21;350(jan20 6):h100–h100. Available from: 
http://www.bmj.com/cgi/doi/10.1136/bmj.h100 
438.  Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, et al. The OMERACT-OARSI 
Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. J 
Rheumatol. 2019;jrheum.181194.  
439.  Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a 
core set of outcome measures for future phase III clinical trials in knee, hip, and hand 
osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802.  
References 
  309 / 309   
440.  Sanderson T, Wild G, Cull AM, Marston J, Zardin G. 19 - Immunohistochemical and 
immunofluorescent techniques. In: Suvarna SK, Layton C, Bancroft JD, editors. Bancroft’s 
Theory and Practice of Histological Techniques (Eighth Edition) [Internet]. Eighth Edi. Content 
Repository Only!; 2019. p. 337–94. Available from: 
http://www.sciencedirect.com/science/article/pii/B9780702068645000190 
 
